id	sid	tid	token	lemma	pos
dti-3019	1	1	dti	dti	PROPN
dti-3019	1	2	drug	drug	PROPN
dti-3019	1	3	target	target	NOUN
dti-3019	1	4	insights	insight	NOUN
dti-3019	1	5	2024	2024	NUM
dti-3019	1	6	;	;	PUNCT
dti-3019	1	7	18	18	NUM
dti-3019	1	8	:	:	SYM
dti-3019	1	9	8	8	NUM
dti-3019	1	10	-	-	SYM
dti-3019	1	11	19	19	NUM
dti-3019	1	12	issn	issn	PROPN
dti-3019	1	13	1177	1177	NUM
dti-3019	1	14	-	-	SYM
dti-3019	1	15	3928	3928	NUM
dti-3019	1	16	|	|	ADV
dti-3019	1	17	doi	doi	NOUN
dti-3019	1	18	:	:	PUNCT
dti-3019	1	19	10.33393	10.33393	NUM
dti-3019	1	20	/	/	SYM
dti-3019	1	21	dti.2024.3019	dti.2024.3019	NUM
dti-3019	1	22	review	review	NOUN
dti-3019	1	23	drug	drug	NOUN
dti-3019	1	24	target	target	NOUN
dti-3019	1	25	insights	insight	NOUN
dti-3019	1	26	issn	issn	VERB
dti-3019	1	27	1177	1177	NUM
dti-3019	1	28	-	-	SYM
dti-3019	1	29	3928	3928	NUM
dti-3019	1	30	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3019	1	31	©	©	PROPN
dti-3019	1	32	2024	2024	NUM
dti-3019	1	33	the	the	DET
dti-3019	1	34	authors	author	NOUN
dti-3019	1	35	.	.	PUNCT
dti-3019	2	1	this	this	DET
dti-3019	2	2	article	article	NOUN
dti-3019	2	3	is	be	AUX
dti-3019	2	4	published	publish	VERB
dti-3019	2	5	by	by	ADP
dti-3019	2	6	aboutscience	aboutscience	NOUN
dti-3019	2	7	and	and	CCONJ
dti-3019	2	8	licensed	license	VERB
dti-3019	2	9	under	under	ADP
dti-3019	2	10	creative	creative	ADJ
dti-3019	2	11	commons	common	NOUN
dti-3019	2	12	attribution	attribution	NOUN
dti-3019	2	13	-	-	PUNCT
dti-3019	2	14	noncommercial	noncommercial	ADJ
dti-3019	2	15	4.0	4.0	NUM
dti-3019	2	16	international	international	NOUN
dti-3019	2	17	(	(	PUNCT
dti-3019	2	18	cc	cc	NOUN
dti-3019	2	19	by	by	ADP
dti-3019	2	20	-	-	PUNCT
dti-3019	2	21	nc	nc	PROPN
dti-3019	2	22	4.0	4.0	NUM
dti-3019	2	23	)	)	PUNCT
dti-3019	2	24	.	.	PUNCT
dti-3019	3	1	commercial	commercial	ADJ
dti-3019	3	2	use	use	NOUN
dti-3019	3	3	is	be	AUX
dti-3019	3	4	not	not	PART
dti-3019	3	5	permitted	permit	VERB
dti-3019	3	6	and	and	CCONJ
dti-3019	3	7	is	be	AUX
dti-3019	3	8	subject	subject	ADJ
dti-3019	3	9	to	to	ADP
dti-3019	3	10	publisher	publisher	NOUN
dti-3019	3	11	’s	’s	PART
dti-3019	3	12	permissions	permission	NOUN
dti-3019	3	13	.	.	PUNCT
dti-3019	4	1	full	full	ADJ
dti-3019	4	2	information	information	NOUN
dti-3019	4	3	is	be	AUX
dti-3019	4	4	available	available	ADJ
dti-3019	4	5	at	at	ADP
dti-3019	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3019	4	7	the	the	DET
dti-3019	4	8	dark	dark	ADJ
dti-3019	4	9	side	side	NOUN
dti-3019	4	10	of	of	ADP
dti-3019	4	11	drug	drug	NOUN
dti-3019	4	12	repurposing	repurposing	NOUN
dti-3019	4	13	.	.	PUNCT
dti-3019	5	1	from	from	ADP
dti-3019	5	2	clinical	clinical	ADJ
dti-3019	5	3	trial	trial	NOUN
dti-3019	5	4	challenges	challenge	NOUN
dti-3019	5	5	to	to	ADP
dti-3019	5	6	antimicrobial	antimicrobial	ADJ
dti-3019	5	7	resistance	resistance	NOUN
dti-3019	5	8	:	:	PUNCT
dti-3019	5	9	analysis	analysis	NOUN
dti-3019	5	10	based	base	VERB
dti-3019	5	11	on	on	ADP
dti-3019	5	12	three	three	NUM
dti-3019	5	13	major	major	ADJ
dti-3019	5	14	fields	field	NOUN
dti-3019	5	15	iyad	iyad	PROPN
dti-3019	5	16	y.	y.	PROPN
dti-3019	5	17	natsheh1	natsheh1	PROPN
dti-3019	5	18	,	,	PUNCT
dti-3019	5	19	majd	majd	PROPN
dti-3019	5	20	m.	m.	PROPN
dti-3019	5	21	alsaleh1,2	alsaleh1,2	PROPN
dti-3019	5	22	,	,	PUNCT
dti-3019	5	23	ahmad	ahmad	PROPN
dti-3019	5	24	k.	k.	PROPN
dti-3019	5	25	alkhawaldeh1	alkhawaldeh1	PROPN
dti-3019	5	26	,	,	PUNCT
dti-3019	5	27	duaa	duaa	PROPN
dti-3019	5	28	k.	k.	PROPN
dti-3019	5	29	albadawi1	albadawi1	PROPN
dti-3019	5	30	,	,	PUNCT
dti-3019	5	31	maisa	maisa	NOUN
dti-3019	5	32	’	'	PUNCT
dti-3019	5	33	m.	m.	NOUN
dti-3019	5	34	darwish2,3	darwish2,3	PROPN
dti-3019	5	35	,	,	PUNCT
dti-3019	5	36	mohammed	mohammed	PROPN
dti-3019	5	37	jamal	jamal	PROPN
dti-3019	5	38	a.	a.	PROPN
dti-3019	5	39	shammout4	shammout4	PROPN
dti-3019	6	1	1department	1department	NUM
dti-3019	6	2	of	of	ADP
dti-3019	6	3	medical	medical	ADJ
dti-3019	6	4	applied	apply	VERB
dti-3019	6	5	sciences	science	NOUN
dti-3019	6	6	,	,	PUNCT
dti-3019	6	7	zarqa	zarqa	PROPN
dti-3019	6	8	university	university	PROPN
dti-3019	6	9	college	college	PROPN
dti-3019	6	10	,	,	PUNCT
dti-3019	6	11	al	al	PROPN
dti-3019	6	12	-	-	PUNCT
dti-3019	6	13	balqa	balqa	NOUN
dti-3019	6	14	applied	apply	VERB
dti-3019	6	15	university	university	NOUN
dti-3019	6	16	,	,	PUNCT
dti-3019	6	17	salt	salt	NOUN
dti-3019	6	18	jordan	jordan	PROPN
dti-3019	6	19	2department	2department	PROPN
dti-3019	6	20	of	of	ADP
dti-3019	6	21	biology	biology	NOUN
dti-3019	6	22	,	,	PUNCT
dti-3019	6	23	school	school	NOUN
dti-3019	6	24	of	of	ADP
dti-3019	6	25	science	science	NOUN
dti-3019	6	26	,	,	PUNCT
dti-3019	6	27	university	university	PROPN
dti-3019	6	28	of	of	ADP
dti-3019	6	29	jordan	jordan	PROPN
dti-3019	6	30	,	,	PUNCT
dti-3019	6	31	amman	amman	PROPN
dti-3019	6	32	jordan	jordan	PROPN
dti-3019	7	1	3national	3national	NUM
dti-3019	7	2	agricultural	agricultural	ADJ
dti-3019	7	3	research	research	NOUN
dti-3019	7	4	center	center	NOUN
dti-3019	7	5	,	,	PUNCT
dti-3019	7	6	amman	amman	PROPN
dti-3019	7	7	jordan	jordan	PROPN
dti-3019	7	8	4chemistry	4chemistry	PROPN
dti-3019	7	9	department	department	NOUN
dti-3019	7	10	,	,	PUNCT
dti-3019	7	11	faculty	faculty	NOUN
dti-3019	7	12	of	of	ADP
dti-3019	7	13	science	science	NOUN
dti-3019	7	14	,	,	PUNCT
dti-3019	7	15	applied	apply	VERB
dti-3019	7	16	science	science	NOUN
dti-3019	7	17	private	private	ADJ
dti-3019	7	18	university	university	NOUN
dti-3019	7	19	,	,	PUNCT
dti-3019	7	20	amman	amman	PROPN
dti-3019	7	21	jordan	jordan	PROPN
dti-3019	7	22	abstract	abstract	PROPN
dti-3019	7	23	drug	drug	NOUN
dti-3019	7	24	repurposing	repurposing	NOUN
dti-3019	7	25	is	be	AUX
dti-3019	7	26	a	a	DET
dti-3019	7	27	strategic	strategic	ADJ
dti-3019	7	28	endeavor	endeavor	NOUN
dti-3019	7	29	that	that	PRON
dti-3019	7	30	entails	entail	VERB
dti-3019	7	31	the	the	DET
dti-3019	7	32	identification	identification	NOUN
dti-3019	7	33	of	of	ADP
dti-3019	7	34	novel	novel	ADJ
dti-3019	7	35	therapeutic	therapeutic	ADJ
dti-3019	7	36	applications	application	NOUN
dti-3019	7	37	for	for	ADP
dti-3019	7	38	pharmaceuticals	pharmaceutical	NOUN
dti-3019	7	39	that	that	PRON
dti-3019	7	40	are	be	AUX
dti-3019	7	41	already	already	ADV
dti-3019	7	42	available	available	ADJ
dti-3019	7	43	in	in	ADP
dti-3019	7	44	the	the	DET
dti-3019	7	45	market	market	NOUN
dti-3019	7	46	.	.	PUNCT
dti-3019	8	1	despite	despite	SCONJ
dti-3019	8	2	the	the	DET
dti-3019	8	3	advantageous	advantageous	ADJ
dti-3019	8	4	nature	nature	NOUN
dti-3019	8	5	of	of	ADP
dti-3019	8	6	implementing	implement	VERB
dti-3019	8	7	this	this	DET
dti-3019	8	8	particular	particular	ADJ
dti-3019	8	9	strategy	strategy	NOUN
dti-3019	8	10	owing	owe	VERB
dti-3019	8	11	to	to	ADP
dti-3019	8	12	its	its	PRON
dti-3019	8	13	cost	cost	NOUN
dti-3019	8	14	-	-	PUNCT
dti-3019	8	15	effectiveness	effectiveness	NOUN
dti-3019	8	16	and	and	CCONJ
dti-3019	8	17	efficiency	efficiency	NOUN
dti-3019	8	18	in	in	ADP
dti-3019	8	19	reducing	reduce	VERB
dti-3019	8	20	the	the	DET
dti-3019	8	21	time	time	NOUN
dti-3019	8	22	required	require	VERB
dti-3019	8	23	for	for	ADP
dti-3019	8	24	the	the	DET
dti-3019	8	25	drug	drug	NOUN
dti-3019	8	26	discovery	discovery	NOUN
dti-3019	8	27	process	process	NOUN
dti-3019	8	28	,	,	PUNCT
dti-3019	8	29	it	it	PRON
dti-3019	8	30	is	be	AUX
dti-3019	8	31	essential	essential	ADJ
dti-3019	8	32	to	to	PART
dti-3019	8	33	bear	bear	VERB
dti-3019	8	34	in	in	ADP
dti-3019	8	35	mind	mind	NOUN
dti-3019	8	36	that	that	SCONJ
dti-3019	8	37	there	there	PRON
dti-3019	8	38	are	be	VERB
dti-3019	8	39	various	various	ADJ
dti-3019	8	40	factors	factor	NOUN
dti-3019	8	41	that	that	PRON
dti-3019	8	42	must	must	AUX
dti-3019	8	43	be	be	AUX
dti-3019	8	44	meticulously	meticulously	ADV
dti-3019	8	45	considered	consider	VERB
dti-3019	8	46	and	and	CCONJ
dti-3019	8	47	taken	take	VERB
dti-3019	8	48	into	into	ADP
dti-3019	8	49	account	account	NOUN
dti-3019	8	50	.	.	PUNCT
dti-3019	9	1	up	up	ADP
dti-3019	9	2	to	to	ADP
dti-3019	9	3	this	this	DET
dti-3019	9	4	point	point	NOUN
dti-3019	9	5	,	,	PUNCT
dti-3019	9	6	there	there	PRON
dti-3019	9	7	has	have	AUX
dti-3019	9	8	been	be	AUX
dti-3019	9	9	a	a	DET
dti-3019	9	10	noticeable	noticeable	ADJ
dti-3019	9	11	absence	absence	NOUN
dti-3019	9	12	of	of	ADP
dti-3019	9	13	comprehensive	comprehensive	ADJ
dti-3019	9	14	analyses	analysis	NOUN
dti-3019	9	15	that	that	PRON
dti-3019	9	16	shed	shed	VERB
dti-3019	9	17	light	light	NOUN
dti-3019	9	18	on	on	ADP
dti-3019	9	19	the	the	DET
dti-3019	9	20	limitations	limitation	NOUN
dti-3019	9	21	of	of	ADP
dti-3019	9	22	repurposing	repurpose	VERB
dti-3019	9	23	drugs	drug	NOUN
dti-3019	9	24	.	.	PUNCT
dti-3019	10	1	the	the	DET
dti-3019	10	2	primary	primary	ADJ
dti-3019	10	3	aim	aim	NOUN
dti-3019	10	4	of	of	ADP
dti-3019	10	5	this	this	DET
dti-3019	10	6	review	review	NOUN
dti-3019	10	7	is	be	AUX
dti-3019	10	8	to	to	PART
dti-3019	10	9	conduct	conduct	VERB
dti-3019	10	10	a	a	DET
dti-3019	10	11	thorough	thorough	ADJ
dti-3019	10	12	illustration	illustration	NOUN
dti-3019	10	13	of	of	ADP
dti-3019	10	14	the	the	DET
dti-3019	10	15	various	various	ADJ
dti-3019	10	16	challenges	challenge	NOUN
dti-3019	10	17	that	that	PRON
dti-3019	10	18	arise	arise	VERB
dti-3019	10	19	when	when	SCONJ
dti-3019	10	20	contemplating	contemplate	VERB
dti-3019	10	21	drug	drug	NOUN
dti-3019	10	22	repurposing	repurpose	VERB
dti-3019	10	23	from	from	ADP
dti-3019	10	24	a	a	DET
dti-3019	10	25	clinical	clinical	ADJ
dti-3019	10	26	perspective	perspective	NOUN
dti-3019	10	27	in	in	ADP
dti-3019	10	28	three	three	NUM
dti-3019	10	29	major	major	ADJ
dti-3019	10	30	fields	field	NOUN
dti-3019	10	31	—	—	PUNCT
dti-3019	10	32	cardiovascular	cardiovascular	ADJ
dti-3019	10	33	,	,	PUNCT
dti-3019	10	34	cancer	cancer	NOUN
dti-3019	10	35	,	,	PUNCT
dti-3019	10	36	and	and	CCONJ
dti-3019	10	37	diabetes	diabetes	NOUN
dti-3019	10	38	—	—	PUNCT
dti-3019	10	39	and	and	CCONJ
dti-3019	10	40	to	to	PART
dti-3019	10	41	further	far	ADV
dti-3019	10	42	underscore	underscore	VERB
dti-3019	10	43	the	the	DET
dti-3019	10	44	potential	potential	ADJ
dti-3019	10	45	risks	risk	NOUN
dti-3019	10	46	associated	associate	VERB
dti-3019	10	47	with	with	ADP
dti-3019	10	48	the	the	DET
dti-3019	10	49	emergence	emergence	NOUN
dti-3019	10	50	of	of	ADP
dti-3019	10	51	antimicrobial	antimicrobial	ADJ
dti-3019	10	52	resistance	resistance	NOUN
dti-3019	10	53	(	(	PUNCT
dti-3019	10	54	amr	amr	NOUN
dti-3019	10	55	)	)	PUNCT
dti-3019	10	56	when	when	SCONJ
dti-3019	10	57	employing	employ	VERB
dti-3019	10	58	repurposed	repurpose	VERB
dti-3019	10	59	antibiotics	antibiotic	NOUN
dti-3019	10	60	for	for	ADP
dti-3019	10	61	the	the	DET
dti-3019	10	62	treatment	treatment	NOUN
dti-3019	10	63	of	of	ADP
dti-3019	10	64	noninfectious	noninfectious	ADJ
dti-3019	10	65	and	and	CCONJ
dti-3019	10	66	infectious	infectious	ADJ
dti-3019	10	67	diseases	disease	NOUN
dti-3019	10	68	.	.	PUNCT
dti-3019	11	1	the	the	DET
dti-3019	11	2	process	process	NOUN
dti-3019	11	3	of	of	ADP
dti-3019	11	4	developing	develop	VERB
dti-3019	11	5	repurposed	repurposed	ADJ
dti-3019	11	6	medications	medication	NOUN
dti-3019	11	7	necessitates	necessitate	VERB
dti-3019	11	8	the	the	DET
dti-3019	11	9	application	application	NOUN
dti-3019	11	10	of	of	ADP
dti-3019	11	11	creativity	creativity	NOUN
dti-3019	11	12	and	and	CCONJ
dti-3019	11	13	innovation	innovation	NOUN
dti-3019	11	14	in	in	ADP
dti-3019	11	15	designing	design	VERB
dti-3019	11	16	the	the	DET
dti-3019	11	17	development	development	NOUN
dti-3019	11	18	program	program	NOUN
dti-3019	11	19	,	,	PUNCT
dti-3019	11	20	as	as	SCONJ
dti-3019	11	21	the	the	DET
dti-3019	11	22	body	body	NOUN
dti-3019	11	23	of	of	ADP
dti-3019	11	24	evidence	evidence	NOUN
dti-3019	11	25	may	may	AUX
dti-3019	11	26	differ	differ	VERB
dti-3019	11	27	for	for	ADP
dti-3019	11	28	each	each	DET
dti-3019	11	29	specific	specific	ADJ
dti-3019	11	30	case	case	NOUN
dti-3019	11	31	.	.	PUNCT
dti-3019	12	1	in	in	ADP
dti-3019	12	2	order	order	NOUN
dti-3019	12	3	to	to	PART
dti-3019	12	4	effectively	effectively	ADV
dti-3019	12	5	repurpose	repurpose	VERB
dti-3019	12	6	drugs	drug	NOUN
dti-3019	12	7	,	,	PUNCT
dti-3019	12	8	it	it	PRON
dti-3019	12	9	is	be	AUX
dti-3019	12	10	crucial	crucial	ADJ
dti-3019	12	11	to	to	PART
dti-3019	12	12	consider	consider	VERB
dti-3019	12	13	the	the	DET
dti-3019	12	14	clinical	clinical	ADJ
dti-3019	12	15	implications	implication	NOUN
dti-3019	12	16	and	and	CCONJ
dti-3019	12	17	potential	potential	ADJ
dti-3019	12	18	drawbacks	drawback	NOUN
dti-3019	12	19	that	that	PRON
dti-3019	12	20	may	may	AUX
dti-3019	12	21	arise	arise	VERB
dti-3019	12	22	during	during	ADP
dti-3019	12	23	this	this	DET
dti-3019	12	24	process	process	NOUN
dti-3019	12	25	.	.	PUNCT
dti-3019	13	1	by	by	ADP
dti-3019	13	2	comprehensively	comprehensively	ADV
dti-3019	13	3	analyzing	analyze	VERB
dti-3019	13	4	these	these	DET
dti-3019	13	5	challenges	challenge	NOUN
dti-3019	13	6	,	,	PUNCT
dti-3019	13	7	we	we	PRON
dti-3019	13	8	can	can	AUX
dti-3019	13	9	attain	attain	VERB
dti-3019	13	10	a	a	DET
dti-3019	13	11	deeper	deep	ADJ
dti-3019	13	12	comprehension	comprehension	NOUN
dti-3019	13	13	of	of	ADP
dti-3019	13	14	the	the	DET
dti-3019	13	15	intricacies	intricacy	NOUN
dti-3019	13	16	involved	involve	VERB
dti-3019	13	17	in	in	ADP
dti-3019	13	18	drug	drug	NOUN
dti-3019	13	19	repurposing	repurposing	NOUN
dti-3019	13	20	,	,	PUNCT
dti-3019	13	21	which	which	PRON
dti-3019	13	22	will	will	AUX
dti-3019	13	23	ultimately	ultimately	ADV
dti-3019	13	24	lead	lead	VERB
dti-3019	13	25	to	to	ADP
dti-3019	13	26	the	the	DET
dti-3019	13	27	development	development	NOUN
dti-3019	13	28	of	of	ADP
dti-3019	13	29	more	more	ADV
dti-3019	13	30	efficacious	efficacious	ADJ
dti-3019	13	31	and	and	CCONJ
dti-3019	13	32	safe	safe	ADJ
dti-3019	13	33	therapeutic	therapeutic	ADJ
dti-3019	13	34	approaches	approach	NOUN
dti-3019	13	35	.	.	PUNCT
dti-3019	14	1	keywords	keyword	NOUN
dti-3019	14	2	:	:	PUNCT
dti-3019	14	3	thalidomide	thalidomide	NOUN
dti-3019	14	4	,	,	PUNCT
dti-3019	14	5	levofloxacin	levofloxacin	PROPN
dti-3019	14	6	,	,	PUNCT
dti-3019	14	7	minocycline	minocycline	NOUN
dti-3019	14	8	,	,	PUNCT
dti-3019	14	9	doxycycline	doxycycline	NOUN
dti-3019	14	10	,	,	PUNCT
dti-3019	14	11	azithromycin	azithromycin	PROPN
dti-3019	14	12	,	,	PUNCT
dti-3019	14	13	hydroxychloroquine	hydroxychloroquine	PROPN
dti-3019	14	14	received	receive	VERB
dti-3019	14	15	:	:	PUNCT
dti-3019	14	16	january	january	PROPN
dti-3019	14	17	2	2	NUM
dti-3019	14	18	,	,	PUNCT
dti-3019	14	19	2024	2024	NUM
dti-3019	14	20	accepted	accept	VERB
dti-3019	14	21	:	:	PUNCT
dti-3019	14	22	april	april	PROPN
dti-3019	14	23	18	18	NUM
dti-3019	14	24	,	,	PUNCT
dti-3019	14	25	2024	2024	NUM
dti-3019	14	26	published	publish	VERB
dti-3019	14	27	online	online	ADV
dti-3019	14	28	:	:	PUNCT
dti-3019	14	29	may	may	AUX
dti-3019	14	30	10	10	NUM
dti-3019	14	31	,	,	PUNCT
dti-3019	14	32	2024	2024	NUM
dti-3019	14	33	corresponding	correspond	VERB
dti-3019	14	34	author	author	NOUN
dti-3019	14	35	:	:	PUNCT
dti-3019	14	36	majd	majd	PROPN
dti-3019	14	37	m.	m.	PROPN
dti-3019	14	38	alsaleh	alsaleh	PROPN
dti-3019	14	39	email	email	NOUN
dti-3019	14	40	:	:	PUNCT
dti-3019	14	41	majd.alsaleh@bau.edu.jo	majd.alsaleh@bau.edu.jo	NOUN
dti-3019	14	42	the	the	DET
dti-3019	14	43	unintentional	unintentional	ADJ
dti-3019	14	44	off	off	ADP
dti-3019	14	45	-	-	PUNCT
dti-3019	14	46	target	target	NOUN
dti-3019	14	47	effects	effect	NOUN
dti-3019	14	48	of	of	ADP
dti-3019	14	49	extant	extant	ADJ
dti-3019	14	50	medications	medication	NOUN
dti-3019	14	51	(	(	PUNCT
dti-3019	14	52	2	2	NUM
dti-3019	14	53	)	)	PUNCT
dti-3019	14	54	.	.	PUNCT
dti-3019	15	1	this	this	DET
dti-3019	15	2	novel	novel	ADJ
dti-3019	15	3	approach	approach	NOUN
dti-3019	15	4	includes	include	VERB
dti-3019	15	5	the	the	DET
dti-3019	15	6	use	use	NOUN
dti-3019	15	7	of	of	ADP
dti-3019	15	8	pharmaceuticals	pharmaceutical	NOUN
dti-3019	15	9	that	that	PRON
dti-3019	15	10	have	have	AUX
dti-3019	15	11	previously	previously	ADV
dti-3019	15	12	been	be	AUX
dti-3019	15	13	approved	approve	VERB
dti-3019	15	14	,	,	PUNCT
dti-3019	15	15	drugs	drug	NOUN
dti-3019	15	16	that	that	PRON
dti-3019	15	17	have	have	AUX
dti-3019	15	18	been	be	AUX
dti-3019	15	19	declared	declare	VERB
dti-3019	15	20	ineffective	ineffective	ADJ
dti-3019	15	21	in	in	ADP
dti-3019	15	22	clinical	clinical	ADJ
dti-3019	15	23	trials	trial	NOUN
dti-3019	15	24	,	,	PUNCT
dti-3019	15	25	and	and	CCONJ
dti-3019	15	26	drugs	drug	NOUN
dti-3019	15	27	that	that	PRON
dti-3019	15	28	have	have	AUX
dti-3019	15	29	been	be	AUX
dti-3019	15	30	removed	remove	VERB
dti-3019	15	31	from	from	ADP
dti-3019	15	32	the	the	DET
dti-3019	15	33	market	market	NOUN
dti-3019	15	34	for	for	ADP
dti-3019	15	35	a	a	DET
dti-3019	15	36	variety	variety	NOUN
dti-3019	15	37	of	of	ADP
dti-3019	15	38	reasons	reason	NOUN
dti-3019	15	39	(	(	PUNCT
dti-3019	15	40	3	3	NUM
dti-3019	15	41	)	)	PUNCT
dti-3019	15	42	.	.	PUNCT
dti-3019	16	1	by	by	ADP
dti-3019	16	2	venturing	venture	VERB
dti-3019	16	3	into	into	ADP
dti-3019	16	4	the	the	DET
dti-3019	16	5	realm	realm	NOUN
dti-3019	16	6	of	of	ADP
dti-3019	16	7	drug	drug	NOUN
dti-3019	16	8	repurposing	repurposing	NOUN
dti-3019	16	9	,	,	PUNCT
dti-3019	16	10	researchers	researcher	NOUN
dti-3019	16	11	can	can	AUX
dti-3019	16	12	unlock	unlock	VERB
dti-3019	16	13	a	a	DET
dti-3019	16	14	vast	vast	ADJ
dti-3019	16	15	reservoir	reservoir	NOUN
dti-3019	16	16	of	of	ADP
dti-3019	16	17	therapeutic	therapeutic	ADJ
dti-3019	16	18	potential	potential	NOUN
dti-3019	16	19	that	that	PRON
dti-3019	16	20	has	have	VERB
dti-3019	16	21	hitherto	hitherto	NOUN
dti-3019	16	22	remained	remain	VERB
dti-3019	16	23	untapped	untapped	ADJ
dti-3019	16	24	.	.	PUNCT
dti-3019	17	1	however	however	ADV
dti-3019	17	2	,	,	PUNCT
dti-3019	17	3	the	the	DET
dti-3019	17	4	question	question	NOUN
dti-3019	17	5	posed	pose	VERB
dti-3019	17	6	by	by	ADP
dti-3019	17	7	several	several	ADJ
dti-3019	17	8	readers	reader	NOUN
dti-3019	17	9	,	,	PUNCT
dti-3019	17	10	researchers	researcher	NOUN
dti-3019	17	11	,	,	PUNCT
dti-3019	17	12	and	and	CCONJ
dti-3019	17	13	patients	patient	NOUN
dti-3019	17	14	is	be	AUX
dti-3019	17	15	as	as	SCONJ
dti-3019	17	16	follows	follow	VERB
dti-3019	17	17	:	:	PUNCT
dti-3019	17	18	“	"	PUNCT
dti-3019	17	19	have	have	AUX
dti-3019	17	20	any	any	DET
dti-3019	17	21	drugs	drug	NOUN
dti-3019	17	22	that	that	PRON
dti-3019	17	23	have	have	AUX
dti-3019	17	24	been	be	AUX
dti-3019	17	25	repurposed	repurpose	VERB
dti-3019	17	26	actually	actually	ADV
dti-3019	17	27	received	receive	VERB
dti-3019	17	28	approval	approval	NOUN
dti-3019	17	29	for	for	ADP
dti-3019	17	30	their	their	PRON
dti-3019	17	31	new	new	ADJ
dti-3019	17	32	indications	indication	NOUN
dti-3019	17	33	?	?	PUNCT
dti-3019	17	34	”	"	PUNCT
dti-3019	17	35	at	at	ADP
dti-3019	17	36	first	first	ADV
dti-3019	17	37	,	,	PUNCT
dti-3019	17	38	one	one	PRON
dti-3019	17	39	may	may	AUX
dti-3019	17	40	find	find	VERB
dti-3019	17	41	oneself	oneself	PRON
dti-3019	17	42	engaged	engage	VERB
dti-3019	17	43	in	in	ADP
dti-3019	17	44	confident	confident	ADJ
dti-3019	17	45	mental	mental	ADJ
dti-3019	17	46	processes	process	NOUN
dti-3019	17	47	,	,	PUNCT
dti-3019	17	48	but	but	CCONJ
dti-3019	17	49	with	with	ADP
dti-3019	17	50	an	an	DET
dti-3019	17	51	impassive	impassive	ADJ
dti-3019	17	52	countenance	countenance	NOUN
dti-3019	17	53	,	,	PUNCT
dti-3019	17	54	while	while	SCONJ
dti-3019	17	55	seeking	seek	VERB
dti-3019	17	56	to	to	PART
dti-3019	17	57	recall	recall	VERB
dti-3019	17	58	enough	enough	ADJ
dti-3019	17	59	examples	example	NOUN
dti-3019	17	60	to	to	PART
dti-3019	17	61	confirm	confirm	VERB
dti-3019	17	62	the	the	DET
dti-3019	17	63	current	current	ADJ
dti-3019	17	64	reaction	reaction	NOUN
dti-3019	17	65	.	.	PUNCT
dti-3019	18	1	still	still	ADV
dti-3019	18	2	,	,	PUNCT
dti-3019	18	3	a	a	DET
dti-3019	18	4	memorable	memorable	ADJ
dti-3019	18	5	case	case	NOUN
dti-3019	18	6	,	,	PUNCT
dti-3019	18	7	such	such	ADJ
dti-3019	18	8	as	as	ADP
dti-3019	18	9	thalidomide	thalidomide	NOUN
dti-3019	18	10	,	,	PUNCT
dti-3019	18	11	will	will	AUX
dti-3019	18	12	spring	spring	VERB
dti-3019	18	13	to	to	ADP
dti-3019	18	14	mind	mind	NOUN
dti-3019	18	15	(	(	PUNCT
dti-3019	18	16	4	4	NUM
dti-3019	18	17	)	)	PUNCT
dti-3019	18	18	.	.	PUNCT
dti-3019	19	1	the	the	DET
dti-3019	19	2	drug	drug	NOUN
dti-3019	19	3	,	,	PUNCT
dti-3019	19	4	infamously	infamously	ADV
dti-3019	19	5	recognized	recognize	VERB
dti-3019	19	6	in	in	ADP
dti-3019	19	7	its	its	PRON
dti-3019	19	8	devastating	devastating	ADJ
dti-3019	19	9	original	original	ADJ
dti-3019	19	10	form	form	NOUN
dti-3019	19	11	as	as	ADP
dti-3019	19	12	a	a	DET
dti-3019	19	13	sedative	sedative	NOUN
dti-3019	19	14	and	and	CCONJ
dti-3019	19	15	curative	curative	ADJ
dti-3019	19	16	for	for	ADP
dti-3019	19	17	morning	morning	NOUN
dti-3019	19	18	sickness	sickness	NOUN
dti-3019	19	19	,	,	PUNCT
dti-3019	19	20	returned	return	VERB
dti-3019	19	21	to	to	ADP
dti-3019	19	22	the	the	DET
dti-3019	19	23	medical	medical	ADJ
dti-3019	19	24	world	world	NOUN
dti-3019	19	25	for	for	ADP
dti-3019	19	26	the	the	DET
dti-3019	19	27	treatment	treatment	NOUN
dti-3019	19	28	of	of	ADP
dti-3019	19	29	leprosy	leprosy	NOUN
dti-3019	19	30	and	and	CCONJ
dti-3019	19	31	,	,	PUNCT
dti-3019	19	32	subsequently	subsequently	ADV
dti-3019	19	33	,	,	PUNCT
dti-3019	19	34	multiple	multiple	ADJ
dti-3019	19	35	introduction	introduction	NOUN
dti-3019	19	36	drug	drug	NOUN
dti-3019	19	37	repurposing	repurposing	NOUN
dti-3019	19	38	,	,	PUNCT
dti-3019	19	39	otherwise	otherwise	ADV
dti-3019	19	40	referred	refer	VERB
dti-3019	19	41	to	to	ADP
dti-3019	19	42	as	as	ADP
dti-3019	19	43	drug	drug	NOUN
dti-3019	19	44	repositioning	repositioning	NOUN
dti-3019	19	45	,	,	PUNCT
dti-3019	19	46	is	be	AUX
dti-3019	19	47	a	a	DET
dti-3019	19	48	tactical	tactical	ADJ
dti-3019	19	49	attempt	attempt	NOUN
dti-3019	19	50	encompassing	encompass	VERB
dti-3019	19	51	the	the	DET
dti-3019	19	52	identification	identification	NOUN
dti-3019	19	53	of	of	ADP
dti-3019	19	54	novel	novel	ADJ
dti-3019	19	55	therapeutic	therapeutic	ADJ
dti-3019	19	56	applications	application	NOUN
dti-3019	19	57	for	for	ADP
dti-3019	19	58	already	already	ADV
dti-3019	19	59	existing	exist	VERB
dti-3019	19	60	pharmaceuticals	pharmaceutical	NOUN
dti-3019	19	61	.	.	PUNCT
dti-3019	20	1	it	it	PRON
dti-3019	20	2	presents	present	VERB
dti-3019	20	3	itself	itself	PRON
dti-3019	20	4	as	as	ADP
dti-3019	20	5	a	a	DET
dti-3019	20	6	highly	highly	ADV
dti-3019	20	7	advantageous	advantageous	ADJ
dti-3019	20	8	strategy	strategy	NOUN
dti-3019	20	9	due	due	ADP
dti-3019	20	10	to	to	ADP
dti-3019	20	11	its	its	PRON
dti-3019	20	12	cost	cost	NOUN
dti-3019	20	13	-	-	PUNCT
dti-3019	20	14	effective	effective	ADJ
dti-3019	20	15	nature	nature	NOUN
dti-3019	20	16	and	and	CCONJ
dti-3019	20	17	ability	ability	NOUN
dti-3019	20	18	to	to	PART
dti-3019	20	19	save	save	VERB
dti-3019	20	20	time	time	NOUN
dti-3019	20	21	in	in	ADP
dti-3019	20	22	the	the	DET
dti-3019	20	23	drug	drug	NOUN
dti-3019	20	24	discovery	discovery	NOUN
dti-3019	20	25	process	process	NOUN
dti-3019	20	26	,	,	PUNCT
dti-3019	20	27	all	all	PRON
dti-3019	20	28	while	while	SCONJ
dti-3019	20	29	mitigating	mitigate	VERB
dti-3019	20	30	the	the	DET
dti-3019	20	31	risks	risk	NOUN
dti-3019	20	32	of	of	ADP
dti-3019	20	33	failure	failure	NOUN
dti-3019	20	34	as	as	SCONJ
dti-3019	20	35	opposed	oppose	VERB
dti-3019	20	36	to	to	ADP
dti-3019	20	37	customary	customary	ADJ
dti-3019	20	38	approaches	approach	NOUN
dti-3019	20	39	(	(	PUNCT
dti-3019	20	40	1	1	NUM
dti-3019	20	41	)	)	PUNCT
dti-3019	20	42	.	.	PUNCT
dti-3019	21	1	drug	drug	NOUN
dti-3019	21	2	repurposing	repurposing	NOUN
dti-3019	21	3	is	be	AUX
dti-3019	21	4	an	an	DET
dti-3019	21	5	extremely	extremely	ADV
dti-3019	21	6	advantageous	advantageous	ADJ
dti-3019	21	7	technique	technique	NOUN
dti-3019	21	8	in	in	ADP
dti-3019	21	9	the	the	DET
dti-3019	21	10	field	field	NOUN
dti-3019	21	11	of	of	ADP
dti-3019	21	12	pharmaceutical	pharmaceutical	ADJ
dti-3019	21	13	research	research	NOUN
dti-3019	21	14	because	because	SCONJ
dti-3019	21	15	it	it	PRON
dti-3019	21	16	capitalizes	capitalize	VERB
dti-3019	21	17	on	on	ADP
dti-3019	21	18	https://doi.org/10.33393/dti.2024.3019	https://doi.org/10.33393/dti.2024.3019	PROPN
dti-3019	21	19	https://doi.org/dti.2022.2522	https://doi.org/dti.2022.2522	PROPN
dti-3019	22	1	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	NUM
dti-3019	22	2	natsheh	natsheh	NOUN
dti-3019	22	3	et	et	PROPN
dti-3019	22	4	al	al	PROPN
dti-3019	22	5	drug	drug	PROPN
dti-3019	22	6	target	target	NOUN
dti-3019	22	7	insights	insight	NOUN
dti-3019	22	8	2024	2024	NUM
dti-3019	22	9	;	;	PUNCT
dti-3019	22	10	18	18	NUM
dti-3019	22	11	:	:	SYM
dti-3019	22	12	9	9	NUM
dti-3019	22	13	©	©	ADP
dti-3019	22	14	2024	2024	NUM
dti-3019	22	15	the	the	DET
dti-3019	22	16	authors	author	NOUN
dti-3019	22	17	.	.	PUNCT
dti-3019	23	1	published	publish	VERB
dti-3019	23	2	by	by	ADP
dti-3019	23	3	aboutscience	aboutscience	NOUN
dti-3019	23	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3019	23	5	myeloma	myeloma	NOUN
dti-3019	23	6	(	(	PUNCT
dti-3019	23	7	5	5	NUM
dti-3019	23	8	)	)	PUNCT
dti-3019	23	9	.	.	PUNCT
dti-3019	24	1	it	it	PRON
dti-3019	24	2	is	be	AUX
dti-3019	24	3	worth	worth	ADJ
dti-3019	24	4	noting	note	VERB
dti-3019	24	5	that	that	SCONJ
dti-3019	24	6	the	the	DET
dti-3019	24	7	discovery	discovery	NOUN
dti-3019	24	8	of	of	ADP
dti-3019	24	9	thalidomide	thalidomide	NOUN
dti-3019	24	10	’s	’s	PART
dti-3019	24	11	efficacy	efficacy	NOUN
dti-3019	24	12	in	in	ADP
dti-3019	24	13	treating	treat	VERB
dti-3019	24	14	leprosy	leprosy	NOUN
dti-3019	24	15	,	,	PUNCT
dti-3019	24	16	specifically	specifically	ADV
dti-3019	24	17	erythema	erythema	VERB
dti-3019	24	18	nodosum	nodosum	NOUN
dti-3019	24	19	leprosum	leprosum	NOUN
dti-3019	24	20	,	,	PUNCT
dti-3019	24	21	was	be	AUX
dti-3019	24	22	a	a	DET
dti-3019	24	23	serendipitous	serendipitous	ADJ
dti-3019	24	24	occurrence	occurrence	NOUN
dti-3019	24	25	(	(	PUNCT
dti-3019	24	26	6	6	NUM
dti-3019	24	27	)	)	PUNCT
dti-3019	24	28	.	.	PUNCT
dti-3019	25	1	the	the	DET
dti-3019	25	2	story	story	NOUN
dti-3019	25	3	behind	behind	ADP
dti-3019	25	4	this	this	DET
dti-3019	25	5	accidental	accidental	ADJ
dti-3019	25	6	discovery	discovery	NOUN
dti-3019	25	7	is	be	AUX
dti-3019	25	8	recounted	recount	VERB
dti-3019	25	9	in	in	ADP
dti-3019	25	10	the	the	DET
dti-3019	25	11	book	book	NOUN
dti-3019	25	12	dark	dark	ADJ
dti-3019	25	13	remedy	remedy	NOUN
dti-3019	25	14	.	.	PUNCT
dti-3019	26	1	in	in	ADP
dti-3019	26	2	this	this	DET
dti-3019	26	3	tale	tale	NOUN
dti-3019	26	4	,	,	PUNCT
dti-3019	26	5	a	a	DET
dti-3019	26	6	physician	physician	NOUN
dti-3019	26	7	administered	administer	VERB
dti-3019	26	8	the	the	DET
dti-3019	26	9	only	only	ADJ
dti-3019	26	10	sedative	sedative	NOUN
dti-3019	26	11	available	available	ADJ
dti-3019	26	12	in	in	ADP
dti-3019	26	13	the	the	DET
dti-3019	26	14	hospital	hospital	NOUN
dti-3019	26	15	’s	’s	PART
dti-3019	26	16	pharmacy	pharmacy	NOUN
dti-3019	26	17	,	,	PUNCT
dti-3019	26	18	which	which	PRON
dti-3019	26	19	had	have	AUX
dti-3019	26	20	not	not	PART
dti-3019	26	21	been	be	AUX
dti-3019	26	22	previously	previously	ADV
dti-3019	26	23	attempted	attempt	VERB
dti-3019	26	24	,	,	PUNCT
dti-3019	26	25	to	to	ADP
dti-3019	26	26	a	a	DET
dti-3019	26	27	suffering	suffering	NOUN
dti-3019	26	28	leprosy	leprosy	NOUN
dti-3019	26	29	patient	patient	NOUN
dti-3019	26	30	.	.	PUNCT
dti-3019	27	1	astonishingly	astonishingly	ADV
dti-3019	27	2	,	,	PUNCT
dti-3019	27	3	the	the	DET
dti-3019	27	4	drug	drug	NOUN
dti-3019	27	5	had	have	VERB
dti-3019	27	6	a	a	DET
dti-3019	27	7	dramatic	dramatic	ADJ
dti-3019	27	8	and	and	CCONJ
dti-3019	27	9	unexpected	unexpected	ADJ
dti-3019	27	10	effect	effect	NOUN
dti-3019	27	11	on	on	ADP
dti-3019	27	12	the	the	DET
dti-3019	27	13	patient	patient	NOUN
dti-3019	27	14	’s	’s	PART
dti-3019	27	15	condition	condition	NOUN
dti-3019	27	16	(	(	PUNCT
dti-3019	27	17	7	7	NUM
dti-3019	27	18	)	)	PUNCT
dti-3019	27	19	.	.	PUNCT
dti-3019	28	1	this	this	PRON
dti-3019	28	2	is	be	AUX
dti-3019	28	3	a	a	DET
dti-3019	28	4	perfect	perfect	ADJ
dti-3019	28	5	example	example	NOUN
dti-3019	28	6	of	of	ADP
dti-3019	28	7	repurposing	repurpose	VERB
dti-3019	28	8	a	a	DET
dti-3019	28	9	medicine	medicine	NOUN
dti-3019	28	10	that	that	PRON
dti-3019	28	11	was	be	AUX
dti-3019	28	12	authorized	authorize	VERB
dti-3019	28	13	and	and	CCONJ
dti-3019	28	14	then	then	ADV
dti-3019	28	15	abandoned	abandon	VERB
dti-3019	28	16	(	(	PUNCT
dti-3019	28	17	and	and	CCONJ
dti-3019	28	18	the	the	DET
dti-3019	28	19	method	method	NOUN
dti-3019	28	20	in	in	ADP
dti-3019	28	21	which	which	PRON
dti-3019	28	22	it	it	PRON
dti-3019	28	23	was	be	AUX
dti-3019	28	24	abandoned	abandon	VERB
dti-3019	28	25	)	)	PUNCT
dti-3019	28	26	to	to	PART
dti-3019	28	27	treat	treat	VERB
dti-3019	28	28	a	a	DET
dti-3019	28	29	completely	completely	ADV
dti-3019	28	30	other	other	ADJ
dti-3019	28	31	ailment	ailment	NOUN
dti-3019	28	32	(	(	PUNCT
dti-3019	28	33	8)	8)	NUM
dti-3019	28	34	.	.	PUNCT
dti-3019	29	1	another	another	DET
dti-3019	29	2	example	example	NOUN
dti-3019	29	3	of	of	ADP
dti-3019	29	4	drug	drug	NOUN
dti-3019	29	5	repurposing	repurposing	NOUN
dti-3019	29	6	that	that	PRON
dti-3019	29	7	is	be	AUX
dti-3019	29	8	widely	widely	ADV
dti-3019	29	9	recognized	recognize	VERB
dti-3019	29	10	is	be	AUX
dti-3019	29	11	sildenafil	sildenafil	NOUN
dti-3019	29	12	,	,	PUNCT
dti-3019	29	13	which	which	PRON
dti-3019	29	14	is	be	AUX
dti-3019	29	15	also	also	ADV
dti-3019	29	16	commonly	commonly	ADV
dti-3019	29	17	known	know	VERB
dti-3019	29	18	as	as	ADP
dti-3019	29	19	viagra	viagra	NOUN
dti-3019	29	20	.	.	PUNCT
dti-3019	30	1	initially	initially	ADV
dti-3019	30	2	,	,	PUNCT
dti-3019	30	3	this	this	DET
dti-3019	30	4	medication	medication	NOUN
dti-3019	30	5	was	be	AUX
dti-3019	30	6	prescribed	prescribe	VERB
dti-3019	30	7	for	for	ADP
dti-3019	30	8	the	the	DET
dti-3019	30	9	treatment	treatment	NOUN
dti-3019	30	10	of	of	ADP
dti-3019	30	11	arterial	arterial	ADJ
dti-3019	30	12	narrowness	narrowness	NOUN
dti-3019	30	13	,	,	PUNCT
dti-3019	30	14	hypertension	hypertension	NOUN
dti-3019	30	15	,	,	PUNCT
dti-3019	30	16	and	and	CCONJ
dti-3019	30	17	heart	heart	NOUN
dti-3019	30	18	disease	disease	NOUN
dti-3019	30	19	in	in	ADP
dti-3019	30	20	both	both	DET
dti-3019	30	21	humans	human	NOUN
dti-3019	30	22	and	and	CCONJ
dti-3019	30	23	animals	animal	NOUN
dti-3019	30	24	.	.	PUNCT
dti-3019	31	1	however	however	ADV
dti-3019	31	2	,	,	PUNCT
dti-3019	31	3	it	it	PRON
dti-3019	31	4	was	be	AUX
dti-3019	31	5	fortuitously	fortuitously	ADV
dti-3019	31	6	discovered	discover	VERB
dti-3019	31	7	that	that	SCONJ
dti-3019	31	8	sildenafil	sildenafil	NOUN
dti-3019	31	9	has	have	VERB
dti-3019	31	10	beneficial	beneficial	ADJ
dti-3019	31	11	effects	effect	NOUN
dti-3019	31	12	on	on	ADP
dti-3019	31	13	erectile	erectile	ADJ
dti-3019	31	14	tissue	tissue	NOUN
dti-3019	31	15	dysfunction	dysfunction	NOUN
dti-3019	31	16	in	in	ADP
dti-3019	31	17	male	male	ADJ
dti-3019	31	18	genital	genital	ADJ
dti-3019	31	19	organs	organ	NOUN
dti-3019	31	20	(	(	PUNCT
dti-3019	31	21	9	9	NUM
dti-3019	31	22	)	)	PUNCT
dti-3019	31	23	.	.	PUNCT
dti-3019	32	1	following	follow	VERB
dti-3019	32	2	its	its	PRON
dti-3019	32	3	approval	approval	NOUN
dti-3019	32	4	by	by	ADP
dti-3019	32	5	the	the	DET
dti-3019	32	6	us	us	PROPN
dti-3019	32	7	food	food	NOUN
dti-3019	32	8	and	and	CCONJ
dti-3019	32	9	drug	drug	PROPN
dti-3019	32	10	administration	administration	PROPN
dti-3019	32	11	(	(	PUNCT
dti-3019	32	12	fda	fda	PROPN
dti-3019	32	13	)	)	PUNCT
dti-3019	32	14	in	in	ADP
dti-3019	32	15	1998	1998	NUM
dti-3019	32	16	,	,	PUNCT
dti-3019	32	17	sildenafil	sildenafil	PROPN
dti-3019	32	18	has	have	AUX
dti-3019	32	19	brought	bring	VERB
dti-3019	32	20	about	about	ADP
dti-3019	32	21	a	a	DET
dti-3019	32	22	significant	significant	ADJ
dti-3019	32	23	transformation	transformation	NOUN
dti-3019	32	24	in	in	ADP
dti-3019	32	25	the	the	DET
dti-3019	32	26	management	management	NOUN
dti-3019	32	27	of	of	ADP
dti-3019	32	28	erectile	erectile	ADJ
dti-3019	32	29	dysfunction	dysfunction	NOUN
dti-3019	32	30	(	(	PUNCT
dti-3019	32	31	ed	ed	NOUN
dti-3019	32	32	)	)	PUNCT
dti-3019	32	33	and	and	CCONJ
dti-3019	32	34	has	have	AUX
dti-3019	32	35	contributed	contribute	VERB
dti-3019	32	36	to	to	ADP
dti-3019	32	37	a	a	DET
dti-3019	32	38	deeper	deep	ADJ
dti-3019	32	39	comprehension	comprehension	NOUN
dti-3019	32	40	of	of	ADP
dti-3019	32	41	the	the	DET
dti-3019	32	42	underlying	underlie	VERB
dti-3019	32	43	scientific	scientific	ADJ
dti-3019	32	44	principles	principle	NOUN
dti-3019	32	45	behind	behind	ADP
dti-3019	32	46	ed	ed	NOUN
dti-3019	32	47	and	and	CCONJ
dti-3019	32	48	its	its	PRON
dti-3019	32	49	impact	impact	NOUN
dti-3019	32	50	on	on	ADP
dti-3019	32	51	men	man	NOUN
dti-3019	32	52	’s	’s	PART
dti-3019	32	53	overall	overall	ADJ
dti-3019	32	54	well	well	ADV
dti-3019	32	55	-	-	PUNCT
dti-3019	32	56	being	be	AUX
dti-3019	32	57	(	(	PUNCT
dti-3019	32	58	10	10	NUM
dti-3019	32	59	)	)	PUNCT
dti-3019	32	60	.	.	PUNCT
dti-3019	33	1	in	in	ADP
dti-3019	33	2	addition	addition	NOUN
dti-3019	33	3	to	to	ADP
dti-3019	33	4	its	its	PRON
dti-3019	33	5	application	application	NOUN
dti-3019	33	6	in	in	ADP
dti-3019	33	7	treating	treat	VERB
dti-3019	33	8	ed	ed	NOUN
dti-3019	33	9	,	,	PUNCT
dti-3019	33	10	sildenafil	sildenafil	PROPN
dti-3019	33	11	has	have	AUX
dti-3019	33	12	also	also	ADV
dti-3019	33	13	demonstrated	demonstrate	VERB
dti-3019	33	14	efficacy	efficacy	NOUN
dti-3019	33	15	in	in	ADP
dti-3019	33	16	addressing	address	VERB
dti-3019	33	17	pulmonary	pulmonary	ADJ
dti-3019	33	18	arterial	arterial	ADJ
dti-3019	33	19	hypertension	hypertension	NOUN
dti-3019	33	20	(	(	PUNCT
dti-3019	33	21	pah	pah	PROPN
dti-3019	33	22	)	)	PUNCT
dti-3019	33	23	(	(	PUNCT
dti-3019	33	24	11	11	NUM
dti-3019	33	25	)	)	PUNCT
dti-3019	33	26	.	.	PUNCT
dti-3019	34	1	early	early	ADJ
dti-3019	34	2	investigations	investigation	NOUN
dti-3019	34	3	and	and	CCONJ
dti-3019	34	4	clinical	clinical	ADJ
dti-3019	34	5	trials	trial	NOUN
dti-3019	34	6	have	have	AUX
dti-3019	34	7	explored	explore	VERB
dti-3019	34	8	the	the	DET
dti-3019	34	9	potential	potential	ADJ
dti-3019	34	10	favorable	favorable	ADJ
dti-3019	34	11	impacts	impact	NOUN
dti-3019	34	12	of	of	ADP
dti-3019	34	13	sildenafil	sildenafil	NOUN
dti-3019	34	14	on	on	ADP
dti-3019	34	15	various	various	ADJ
dti-3019	34	16	organs	organ	NOUN
dti-3019	34	17	,	,	PUNCT
dti-3019	34	18	including	include	VERB
dti-3019	34	19	the	the	DET
dti-3019	34	20	heart	heart	NOUN
dti-3019	34	21	,	,	PUNCT
dti-3019	34	22	liver	liver	NOUN
dti-3019	34	23	,	,	PUNCT
dti-3019	34	24	kidney	kidney	NOUN
dti-3019	34	25	,	,	PUNCT
dti-3019	34	26	brain	brain	NOUN
dti-3019	34	27	,	,	PUNCT
dti-3019	34	28	and	and	CCONJ
dti-3019	34	29	intestines	intestine	NOUN
dti-3019	34	30	(	(	PUNCT
dti-3019	34	31	12	12	NUM
dti-3019	34	32	)	)	PUNCT
dti-3019	34	33	.	.	PUNCT
dti-3019	35	1	nevertheless	nevertheless	ADV
dti-3019	35	2	,	,	PUNCT
dti-3019	35	3	further	further	ADJ
dti-3019	35	4	research	research	NOUN
dti-3019	35	5	is	be	AUX
dti-3019	35	6	necessary	necessary	ADJ
dti-3019	35	7	in	in	ADP
dti-3019	35	8	order	order	NOUN
dti-3019	35	9	to	to	PART
dti-3019	35	10	fully	fully	ADV
dti-3019	35	11	comprehend	comprehend	VERB
dti-3019	35	12	the	the	DET
dti-3019	35	13	effects	effect	NOUN
dti-3019	35	14	of	of	ADP
dti-3019	35	15	sildenafil	sildenafil	NOUN
dti-3019	35	16	on	on	ADP
dti-3019	35	17	different	different	ADJ
dti-3019	35	18	diseases	disease	NOUN
dti-3019	35	19	and	and	CCONJ
dti-3019	35	20	organs	organ	NOUN
dti-3019	35	21	(	(	PUNCT
dti-3019	35	22	13	13	NUM
dti-3019	35	23	)	)	PUNCT
dti-3019	35	24	.	.	PUNCT
dti-3019	36	1	despite	despite	SCONJ
dti-3019	36	2	the	the	DET
dti-3019	36	3	numerous	numerous	ADJ
dti-3019	36	4	obstacles	obstacle	NOUN
dti-3019	36	5	and	and	CCONJ
dti-3019	36	6	unsuccessful	unsuccessful	ADJ
dti-3019	36	7	attempts	attempt	NOUN
dti-3019	36	8	that	that	SCONJ
dti-3019	36	9	we	we	PRON
dti-3019	36	10	have	have	AUX
dti-3019	36	11	elaborated	elaborate	VERB
dti-3019	36	12	on	on	ADP
dti-3019	36	13	in	in	ADP
dti-3019	36	14	the	the	DET
dti-3019	36	15	preceding	precede	VERB
dti-3019	36	16	sections	section	NOUN
dti-3019	36	17	,	,	PUNCT
dti-3019	36	18	there	there	PRON
dti-3019	36	19	have	have	AUX
dti-3019	36	20	been	be	AUX
dti-3019	36	21	instances	instance	NOUN
dti-3019	36	22	of	of	ADP
dti-3019	36	23	drug	drug	NOUN
dti-3019	36	24	repurposing	repurposing	NOUN
dti-3019	36	25	that	that	PRON
dti-3019	36	26	have	have	AUX
dti-3019	36	27	achieved	achieve	VERB
dti-3019	36	28	success	success	NOUN
dti-3019	36	29	.	.	PUNCT
dti-3019	37	1	notable	notable	ADJ
dti-3019	37	2	examples	example	NOUN
dti-3019	37	3	include	include	VERB
dti-3019	37	4	the	the	DET
dti-3019	37	5	utilization	utilization	NOUN
dti-3019	37	6	of	of	ADP
dti-3019	37	7	zidovudine	zidovudine	PROPN
dti-3019	37	8	(	(	PUNCT
dti-3019	37	9	azidothymidine	azidothymidine	NOUN
dti-3019	37	10	,	,	PUNCT
dti-3019	37	11	azt	azt	PROPN
dti-3019	37	12	)	)	PUNCT
dti-3019	37	13	as	as	ADP
dti-3019	37	14	a	a	DET
dti-3019	37	15	therapeutic	therapeutic	ADJ
dti-3019	37	16	agent	agent	NOUN
dti-3019	37	17	against	against	ADP
dti-3019	37	18	human	human	ADJ
dti-3019	37	19	immunodeficiency	immunodeficiency	NOUN
dti-3019	37	20	virus	virus	NOUN
dti-3019	37	21	(	(	PUNCT
dti-3019	37	22	hiv	hiv	PROPN
dti-3019	37	23	)	)	PUNCT
dti-3019	37	24	(	(	PUNCT
dti-3019	37	25	14	14	NUM
dti-3019	37	26	)	)	PUNCT
dti-3019	37	27	and	and	CCONJ
dti-3019	37	28	the	the	DET
dti-3019	37	29	repurposing	repurposing	NOUN
dti-3019	37	30	of	of	ADP
dti-3019	37	31	tocilizumab	tocilizumab	NOUN
dti-3019	37	32	for	for	ADP
dti-3019	37	33	the	the	DET
dti-3019	37	34	treatment	treatment	NOUN
dti-3019	37	35	of	of	ADP
dti-3019	37	36	covid19	covid19	NOUN
dti-3019	37	37	(	(	PUNCT
dti-3019	37	38	15	15	NUM
dti-3019	37	39	)	)	PUNCT
dti-3019	37	40	.	.	PUNCT
dti-3019	38	1	the	the	DET
dti-3019	38	2	practice	practice	NOUN
dti-3019	38	3	of	of	ADP
dti-3019	38	4	repurposing	repurpose	VERB
dti-3019	38	5	drugs	drug	NOUN
dti-3019	38	6	has	have	AUX
dti-3019	38	7	demonstrated	demonstrate	VERB
dti-3019	38	8	its	its	PRON
dti-3019	38	9	effectiveness	effectiveness	NOUN
dti-3019	38	10	in	in	ADP
dti-3019	38	11	the	the	DET
dti-3019	38	12	development	development	NOUN
dti-3019	38	13	of	of	ADP
dti-3019	38	14	therapeutic	therapeutic	ADJ
dti-3019	38	15	strategies	strategy	NOUN
dti-3019	38	16	for	for	ADP
dti-3019	38	17	various	various	ADJ
dti-3019	38	18	diseases	disease	NOUN
dti-3019	38	19	and	and	CCONJ
dti-3019	38	20	holds	hold	VERB
dti-3019	38	21	promise	promise	NOUN
dti-3019	38	22	in	in	ADP
dti-3019	38	23	addressing	address	VERB
dti-3019	38	24	rare	rare	ADJ
dti-3019	38	25	and	and	CCONJ
dti-3019	38	26	difficult	difficult	ADJ
dti-3019	38	27	conditions	condition	NOUN
dti-3019	38	28	(	(	PUNCT
dti-3019	38	29	3	3	NUM
dti-3019	38	30	)	)	PUNCT
dti-3019	38	31	.	.	PUNCT
dti-3019	39	1	this	this	DET
dti-3019	39	2	approach	approach	NOUN
dti-3019	39	3	entails	entail	VERB
dti-3019	39	4	a	a	DET
dti-3019	39	5	combination	combination	NOUN
dti-3019	39	6	of	of	ADP
dti-3019	39	7	experimental	experimental	ADJ
dti-3019	39	8	and	and	CCONJ
dti-3019	39	9	computational	computational	ADJ
dti-3019	39	10	methods	method	NOUN
dti-3019	39	11	,	,	PUNCT
dti-3019	39	12	leveraging	leverage	VERB
dti-3019	39	13	existing	exist	VERB
dti-3019	39	14	safety	safety	NOUN
dti-3019	39	15	data	datum	NOUN
dti-3019	39	16	and	and	CCONJ
dti-3019	39	17	redirecting	redirect	VERB
dti-3019	39	18	the	the	DET
dti-3019	39	19	application	application	NOUN
dti-3019	39	20	of	of	ADP
dti-3019	39	21	drugs	drug	NOUN
dti-3019	39	22	based	base	VERB
dti-3019	39	23	on	on	ADP
dti-3019	39	24	validated	validated	ADJ
dti-3019	39	25	target	target	NOUN
dti-3019	39	26	molecules	molecule	NOUN
dti-3019	39	27	(	(	PUNCT
dti-3019	39	28	16	16	NUM
dti-3019	39	29	)	)	PUNCT
dti-3019	39	30	.	.	PUNCT
dti-3019	40	1	the	the	DET
dti-3019	40	2	utilization	utilization	NOUN
dti-3019	40	3	of	of	ADP
dti-3019	40	4	application	application	NOUN
dti-3019	40	5	programming	programming	NOUN
dti-3019	40	6	interfaces	interface	NOUN
dti-3019	40	7	(	(	PUNCT
dti-3019	40	8	apis	apis	PROPN
dti-3019	40	9	)	)	PUNCT
dti-3019	40	10	in	in	ADP
dti-3019	40	11	drug	drug	NOUN
dti-3019	40	12	repurposing	repurposing	NOUN
dti-3019	40	13	is	be	AUX
dti-3019	40	14	increasingly	increasingly	ADV
dti-3019	40	15	being	be	AUX
dti-3019	40	16	acknowledged	acknowledge	VERB
dti-3019	40	17	as	as	ADP
dti-3019	40	18	a	a	DET
dti-3019	40	19	promising	promising	ADJ
dti-3019	40	20	technique	technique	NOUN
dti-3019	40	21	for	for	ADP
dti-3019	40	22	expediting	expedite	VERB
dti-3019	40	23	the	the	DET
dti-3019	40	24	process	process	NOUN
dti-3019	40	25	of	of	ADP
dti-3019	40	26	drug	drug	NOUN
dti-3019	40	27	discovery	discovery	NOUN
dti-3019	40	28	and	and	CCONJ
dti-3019	40	29	development	development	NOUN
dti-3019	40	30	(	(	PUNCT
dti-3019	40	31	17	17	NUM
dti-3019	40	32	)	)	PUNCT
dti-3019	40	33	.	.	PUNCT
dti-3019	41	1	integrative	integrative	ADJ
dti-3019	41	2	approaches	approach	NOUN
dti-3019	41	3	that	that	PRON
dti-3019	41	4	extract	extract	VERB
dti-3019	41	5	data	datum	NOUN
dti-3019	41	6	from	from	ADP
dti-3019	41	7	multiple	multiple	ADJ
dti-3019	41	8	sources	source	NOUN
dti-3019	41	9	through	through	ADP
dti-3019	41	10	apis	apis	PROPN
dti-3019	41	11	offer	offer	VERB
dti-3019	41	12	the	the	DET
dti-3019	41	13	advantages	advantage	NOUN
dti-3019	41	14	of	of	ADP
dti-3019	41	15	adaptability	adaptability	NOUN
dti-3019	41	16	,	,	PUNCT
dti-3019	41	17	reusability	reusability	NOUN
dti-3019	41	18	,	,	PUNCT
dti-3019	41	19	and	and	CCONJ
dti-3019	41	20	transparency	transparency	NOUN
dti-3019	41	21	(	(	PUNCT
dti-3019	41	22	18	18	NUM
dti-3019	41	23	)	)	PUNCT
dti-3019	41	24	.	.	PUNCT
dti-3019	42	1	one	one	NUM
dti-3019	42	2	particular	particular	ADJ
dti-3019	42	3	study	study	NOUN
dti-3019	42	4	outlined	outline	VERB
dti-3019	42	5	a	a	DET
dti-3019	42	6	strategy	strategy	NOUN
dti-3019	42	7	for	for	ADP
dti-3019	42	8	ligand	ligand	NOUN
dti-3019	42	9	-	-	PUNCT
dti-3019	42	10	based	base	VERB
dti-3019	42	11	in	in	ADP
dti-3019	42	12	silico	silico	NOUN
dti-3019	42	13	drug	drug	NOUN
dti-3019	42	14	repurposing	repurposing	NOUN
dti-3019	42	15	utilizing	utilize	VERB
dti-3019	42	16	the	the	DET
dti-3019	42	17	analytical	analytical	ADJ
dti-3019	42	18	platform	platform	NOUN
dti-3019	42	19	knime	knime	NOUN
dti-3019	42	20	,	,	PUNCT
dti-3019	42	21	which	which	PRON
dti-3019	42	22	entailed	entail	VERB
dti-3019	42	23	targeted	target	VERB
dti-3019	42	24	data	datum	NOUN
dti-3019	42	25	retrieval	retrieval	NOUN
dti-3019	42	26	,	,	PUNCT
dti-3019	42	27	data	data	NOUN
dti-3019	42	28	curation	curation	NOUN
dti-3019	42	29	,	,	PUNCT
dti-3019	42	30	and	and	CCONJ
dti-3019	42	31	substructure	substructure	NOUN
dti-3019	42	32	searches	search	NOUN
dti-3019	42	33	in	in	ADP
dti-3019	42	34	drugbank	drugbank	NOUN
dti-3019	42	35	and	and	CCONJ
dti-3019	42	36	other	other	ADJ
dti-3019	42	37	databases	database	NOUN
dti-3019	42	38	(	(	PUNCT
dti-3019	42	39	19	19	NUM
dti-3019	42	40	)	)	PUNCT
dti-3019	42	41	.	.	PUNCT
dti-3019	43	1	another	another	DET
dti-3019	43	2	study	study	NOUN
dti-3019	43	3	developed	develop	VERB
dti-3019	43	4	a	a	DET
dti-3019	43	5	fully	fully	ADV
dti-3019	43	6	automated	automate	VERB
dti-3019	43	7	and	and	CCONJ
dti-3019	43	8	parameterfree	parameterfree	ADJ
dti-3019	43	9	virtual	virtual	ADJ
dti-3019	43	10	screening	screening	NOUN
dti-3019	43	11	server	server	NOUN
dti-3019	43	12	called	call	VERB
dti-3019	43	13	drugrep	drugrep	PROPN
dti-3019	43	14	,	,	PUNCT
dti-3019	43	15	which	which	PRON
dti-3019	43	16	conducted	conduct	VERB
dti-3019	43	17	molecular	molecular	ADJ
dti-3019	43	18	structure	structure	NOUN
dti-3019	43	19	construction	construction	NOUN
dti-3019	43	20	,	,	PUNCT
dti-3019	43	21	docking	docking	NOUN
dti-3019	43	22	,	,	PUNCT
dti-3019	43	23	similarity	similarity	NOUN
dti-3019	43	24	comparison	comparison	NOUN
dti-3019	43	25	,	,	PUNCT
dti-3019	43	26	and	and	CCONJ
dti-3019	43	27	binding	bind	VERB
dti-3019	43	28	affinity	affinity	NOUN
dti-3019	43	29	screening	screen	VERB
dti-3019	43	30	in	in	ADP
dti-3019	43	31	a	a	DET
dti-3019	43	32	completely	completely	ADV
dti-3019	43	33	autonomous	autonomous	ADJ
dti-3019	43	34	manner	manner	NOUN
dti-3019	43	35	(	(	PUNCT
dti-3019	43	36	20	20	NUM
dti-3019	43	37	)	)	PUNCT
dti-3019	43	38	.	.	PUNCT
dti-3019	44	1	these	these	DET
dti-3019	44	2	computational	computational	ADJ
dti-3019	44	3	tools	tool	NOUN
dti-3019	44	4	furnish	furnish	VERB
dti-3019	44	5	researchers	researcher	NOUN
dti-3019	44	6	with	with	ADP
dti-3019	44	7	user	user	NOUN
dti-3019	44	8	-	-	PUNCT
dti-3019	44	9	friendly	friendly	ADJ
dti-3019	44	10	interfaces	interface	NOUN
dti-3019	44	11	and	and	CCONJ
dti-3019	44	12	interactive	interactive	ADJ
dti-3019	44	13	predictions	prediction	NOUN
dti-3019	44	14	,	,	PUNCT
dti-3019	44	15	thereby	thereby	ADV
dti-3019	44	16	enhancing	enhance	VERB
dti-3019	44	17	the	the	DET
dti-3019	44	18	accessibility	accessibility	NOUN
dti-3019	44	19	and	and	CCONJ
dti-3019	44	20	efficiency	efficiency	NOUN
dti-3019	44	21	of	of	ADP
dti-3019	44	22	drug	drug	NOUN
dti-3019	44	23	repurposing	repurposing	NOUN
dti-3019	44	24	(	(	PUNCT
dti-3019	44	25	21	21	NUM
dti-3019	44	26	)	)	PUNCT
dti-3019	44	27	.	.	PUNCT
dti-3019	45	1	through	through	ADP
dti-3019	45	2	the	the	DET
dti-3019	45	3	optimization	optimization	NOUN
dti-3019	45	4	of	of	ADP
dti-3019	45	5	the	the	DET
dti-3019	45	6	therapeutic	therapeutic	ADJ
dti-3019	45	7	potential	potential	NOUN
dti-3019	45	8	of	of	ADP
dti-3019	45	9	already	already	ADV
dti-3019	45	10	existing	exist	VERB
dti-3019	45	11	drugs	drug	NOUN
dti-3019	45	12	,	,	PUNCT
dti-3019	45	13	drug	drug	NOUN
dti-3019	45	14	repurposing	repurposing	NOUN
dti-3019	45	15	enhances	enhance	VERB
dti-3019	45	16	the	the	DET
dti-3019	45	17	likelihood	likelihood	NOUN
dti-3019	45	18	of	of	ADP
dti-3019	45	19	attaining	attain	VERB
dti-3019	45	20	successful	successful	ADJ
dti-3019	45	21	outcomes	outcome	NOUN
dti-3019	45	22	and	and	CCONJ
dti-3019	45	23	offers	offer	VERB
dti-3019	45	24	a	a	DET
dti-3019	45	25	means	means	NOUN
dti-3019	45	26	to	to	PART
dti-3019	45	27	promptly	promptly	ADV
dti-3019	45	28	identify	identify	VERB
dti-3019	45	29	effective	effective	ADJ
dti-3019	45	30	treatments	treatment	NOUN
dti-3019	45	31	(	(	PUNCT
dti-3019	45	32	22	22	NUM
dti-3019	45	33	)	)	PUNCT
dti-3019	45	34	.	.	PUNCT
dti-3019	46	1	thinking	think	VERB
dti-3019	46	2	deeply	deeply	ADV
dti-3019	46	3	,	,	PUNCT
dti-3019	46	4	we	we	PRON
dti-3019	46	5	can	can	AUX
dti-3019	46	6	conclude	conclude	VERB
dti-3019	46	7	that	that	SCONJ
dti-3019	46	8	the	the	DET
dti-3019	46	9	development	development	NOUN
dti-3019	46	10	of	of	ADP
dti-3019	46	11	repurposed	repurpose	VERB
dti-3019	46	12	medications	medication	NOUN
dti-3019	46	13	necessitates	necessitate	VERB
dti-3019	46	14	the	the	DET
dti-3019	46	15	application	application	NOUN
dti-3019	46	16	of	of	ADP
dti-3019	46	17	creativity	creativity	NOUN
dti-3019	46	18	and	and	CCONJ
dti-3019	46	19	innovation	innovation	NOUN
dti-3019	46	20	in	in	ADP
dti-3019	46	21	designing	design	VERB
dti-3019	46	22	the	the	DET
dti-3019	46	23	development	development	NOUN
dti-3019	46	24	program	program	NOUN
dti-3019	46	25	,	,	PUNCT
dti-3019	46	26	as	as	SCONJ
dti-3019	46	27	the	the	DET
dti-3019	46	28	body	body	NOUN
dti-3019	46	29	of	of	ADP
dti-3019	46	30	evidence	evidence	NOUN
dti-3019	46	31	differs	differ	VERB
dti-3019	46	32	for	for	ADP
dti-3019	46	33	each	each	DET
dti-3019	46	34	individual	individual	ADJ
dti-3019	46	35	case	case	NOUN
dti-3019	46	36	not	not	PART
dti-3019	46	37	depending	depend	VERB
dti-3019	46	38	on	on	ADP
dti-3019	46	39	the	the	DET
dti-3019	46	40	chance	chance	NOUN
dti-3019	46	41	(	(	PUNCT
dti-3019	46	42	23	23	NUM
dti-3019	46	43	)	)	PUNCT
dti-3019	46	44	.	.	PUNCT
dti-3019	47	1	several	several	ADJ
dti-3019	47	2	research	research	NOUN
dti-3019	47	3	studies	study	NOUN
dti-3019	47	4	have	have	AUX
dti-3019	47	5	focused	focus	VERB
dti-3019	47	6	their	their	PRON
dti-3019	47	7	attention	attention	NOUN
dti-3019	47	8	on	on	ADP
dti-3019	47	9	investigating	investigate	VERB
dti-3019	47	10	and	and	CCONJ
dti-3019	47	11	understanding	understand	VERB
dti-3019	47	12	the	the	DET
dti-3019	47	13	potential	potential	ADJ
dti-3019	47	14	advantages	advantage	NOUN
dti-3019	47	15	and	and	CCONJ
dti-3019	47	16	positive	positive	ADJ
dti-3019	47	17	outcomes	outcome	NOUN
dti-3019	47	18	associated	associate	VERB
dti-3019	47	19	with	with	ADP
dti-3019	47	20	the	the	DET
dti-3019	47	21	practice	practice	NOUN
dti-3019	47	22	of	of	ADP
dti-3019	47	23	drug	drug	NOUN
dti-3019	47	24	repurposing	repurposing	NOUN
dti-3019	47	25	.	.	PUNCT
dti-3019	48	1	however	however	ADV
dti-3019	48	2	,	,	PUNCT
dti-3019	48	3	it	it	PRON
dti-3019	48	4	is	be	AUX
dti-3019	48	5	worth	worth	ADJ
dti-3019	48	6	noting	note	VERB
dti-3019	48	7	that	that	SCONJ
dti-3019	48	8	,	,	PUNCT
dti-3019	48	9	up	up	ADP
dti-3019	48	10	until	until	ADP
dti-3019	48	11	now	now	ADV
dti-3019	48	12	,	,	PUNCT
dti-3019	48	13	there	there	PRON
dti-3019	48	14	has	have	AUX
dti-3019	48	15	been	be	AUX
dti-3019	48	16	a	a	DET
dti-3019	48	17	lack	lack	NOUN
dti-3019	48	18	of	of	ADP
dti-3019	48	19	comprehensive	comprehensive	ADJ
dti-3019	48	20	reviews	review	NOUN
dti-3019	48	21	that	that	PRON
dti-3019	48	22	shed	shed	VERB
dti-3019	48	23	light	light	NOUN
dti-3019	48	24	on	on	ADP
dti-3019	48	25	the	the	DET
dti-3019	48	26	potential	potential	ADJ
dti-3019	48	27	drawbacks	drawback	NOUN
dti-3019	48	28	and	and	CCONJ
dti-3019	48	29	negative	negative	ADJ
dti-3019	48	30	aspects	aspect	NOUN
dti-3019	48	31	of	of	ADP
dti-3019	48	32	drug	drug	NOUN
dti-3019	48	33	repurposing	repurposing	NOUN
dti-3019	48	34	.	.	PUNCT
dti-3019	49	1	therefore	therefore	ADV
dti-3019	49	2	,	,	PUNCT
dti-3019	49	3	the	the	DET
dti-3019	49	4	main	main	ADJ
dti-3019	49	5	aim	aim	NOUN
dti-3019	49	6	of	of	ADP
dti-3019	49	7	this	this	DET
dti-3019	49	8	particular	particular	ADJ
dti-3019	49	9	review	review	NOUN
dti-3019	49	10	is	be	AUX
dti-3019	49	11	to	to	PART
dti-3019	49	12	provide	provide	VERB
dti-3019	49	13	an	an	DET
dti-3019	49	14	in	in	ADP
dti-3019	49	15	-	-	PUNCT
dti-3019	49	16	depth	depth	NOUN
dti-3019	49	17	analysis	analysis	NOUN
dti-3019	49	18	and	and	CCONJ
dti-3019	49	19	exploration	exploration	NOUN
dti-3019	49	20	of	of	ADP
dti-3019	49	21	the	the	DET
dti-3019	49	22	various	various	ADJ
dti-3019	49	23	challenges	challenge	NOUN
dti-3019	49	24	that	that	PRON
dti-3019	49	25	arise	arise	VERB
dti-3019	49	26	when	when	SCONJ
dti-3019	49	27	considering	consider	VERB
dti-3019	49	28	drug	drug	NOUN
dti-3019	49	29	repurposing	repurpose	VERB
dti-3019	49	30	from	from	ADP
dti-3019	49	31	a	a	DET
dti-3019	49	32	clinical	clinical	ADJ
dti-3019	49	33	perspective	perspective	NOUN
dti-3019	49	34	in	in	ADP
dti-3019	49	35	the	the	DET
dti-3019	49	36	fields	field	NOUN
dti-3019	49	37	of	of	ADP
dti-3019	49	38	cardiovascular	cardiovascular	ADJ
dti-3019	49	39	disease	disease	NOUN
dti-3019	49	40	,	,	PUNCT
dti-3019	49	41	cancer	cancer	NOUN
dti-3019	49	42	,	,	PUNCT
dti-3019	49	43	and	and	CCONJ
dti-3019	49	44	diabetes	diabetes	NOUN
dti-3019	49	45	.	.	PUNCT
dti-3019	50	1	additionally	additionally	ADV
dti-3019	50	2	,	,	PUNCT
dti-3019	50	3	the	the	DET
dti-3019	50	4	primary	primary	ADJ
dti-3019	50	5	objective	objective	NOUN
dti-3019	50	6	of	of	ADP
dti-3019	50	7	this	this	DET
dti-3019	50	8	analysis	analysis	NOUN
dti-3019	50	9	is	be	AUX
dti-3019	50	10	to	to	PART
dti-3019	50	11	underscore	underscore	VERB
dti-3019	50	12	the	the	DET
dti-3019	50	13	heightened	heightened	ADJ
dti-3019	50	14	risk	risk	NOUN
dti-3019	50	15	associated	associate	VERB
dti-3019	50	16	with	with	ADP
dti-3019	50	17	the	the	DET
dti-3019	50	18	development	development	NOUN
dti-3019	50	19	of	of	ADP
dti-3019	50	20	amr	amr	PROPN
dti-3019	50	21	that	that	PRON
dti-3019	50	22	arises	arise	VERB
dti-3019	50	23	from	from	ADP
dti-3019	50	24	the	the	DET
dti-3019	50	25	utilization	utilization	NOUN
dti-3019	50	26	of	of	ADP
dti-3019	50	27	antibiotics	antibiotic	NOUN
dti-3019	50	28	for	for	ADP
dti-3019	50	29	purposes	purpose	NOUN
dti-3019	50	30	other	other	ADJ
dti-3019	50	31	than	than	ADP
dti-3019	50	32	their	their	PRON
dti-3019	50	33	original	original	ADJ
dti-3019	50	34	intended	intended	ADJ
dti-3019	50	35	use	use	NOUN
dti-3019	50	36	,	,	PUNCT
dti-3019	50	37	whether	whether	SCONJ
dti-3019	50	38	it	it	PRON
dti-3019	50	39	be	be	VERB
dti-3019	50	40	for	for	ADP
dti-3019	50	41	treating	treat	VERB
dti-3019	50	42	various	various	ADJ
dti-3019	50	43	infectious	infectious	ADJ
dti-3019	50	44	diseases	disease	NOUN
dti-3019	50	45	or	or	CCONJ
dti-3019	50	46	noninfectious	noninfectious	ADJ
dti-3019	50	47	conditions	condition	NOUN
dti-3019	50	48	that	that	PRON
dti-3019	50	49	deviate	deviate	VERB
dti-3019	50	50	from	from	ADP
dti-3019	50	51	their	their	PRON
dti-3019	50	52	initial	initial	ADJ
dti-3019	50	53	approved	approve	VERB
dti-3019	50	54	indications	indication	NOUN
dti-3019	50	55	.	.	PUNCT
dti-3019	51	1	drug	drug	NOUN
dti-3019	51	2	repurposing	repurpose	VERB
dti-3019	51	3	challenges	challenge	NOUN
dti-3019	51	4	in	in	ADP
dti-3019	51	5	clinical	clinical	ADJ
dti-3019	51	6	view	view	NOUN
dti-3019	51	7	the	the	DET
dti-3019	51	8	process	process	NOUN
dti-3019	51	9	of	of	ADP
dti-3019	51	10	drug	drug	NOUN
dti-3019	51	11	repurposing	repurposing	NOUN
dti-3019	51	12	has	have	VERB
dti-3019	51	13	a	a	DET
dti-3019	51	14	number	number	NOUN
dti-3019	51	15	of	of	ADP
dti-3019	51	16	drawbacks	drawback	NOUN
dti-3019	51	17	.	.	PUNCT
dti-3019	52	1	one	one	NUM
dti-3019	52	2	key	key	ADJ
dti-3019	52	3	barrier	barrier	NOUN
dti-3019	52	4	is	be	AUX
dti-3019	52	5	the	the	DET
dti-3019	52	6	pharmaceutical	pharmaceutical	ADJ
dti-3019	52	7	industry	industry	NOUN
dti-3019	52	8	’s	’s	PART
dti-3019	52	9	restricted	restrict	VERB
dti-3019	52	10	focus	focus	NOUN
dti-3019	52	11	on	on	ADP
dti-3019	52	12	diseases	disease	NOUN
dti-3019	52	13	that	that	PRON
dti-3019	52	14	provide	provide	VERB
dti-3019	52	15	more	more	ADJ
dti-3019	52	16	financial	financial	ADJ
dti-3019	52	17	rewards	reward	NOUN
dti-3019	52	18	,	,	PUNCT
dti-3019	52	19	lowering	lower	VERB
dti-3019	52	20	the	the	DET
dti-3019	52	21	amount	amount	NOUN
dti-3019	52	22	of	of	ADP
dti-3019	52	23	repurposing	repurpose	VERB
dti-3019	52	24	chances	chance	NOUN
dti-3019	52	25	for	for	ADP
dti-3019	52	26	orphan	orphan	NOUN
dti-3019	52	27	diseases	disease	NOUN
dti-3019	52	28	and	and	CCONJ
dti-3019	52	29	neglected	neglect	VERB
dti-3019	52	30	tropical	tropical	ADJ
dti-3019	52	31	disorders	disorder	NOUN
dti-3019	52	32	(	(	PUNCT
dti-3019	52	33	24	24	NUM
dti-3019	52	34	)	)	PUNCT
dti-3019	52	35	.	.	PUNCT
dti-3019	53	1	furthermore	furthermore	ADV
dti-3019	53	2	,	,	PUNCT
dti-3019	53	3	there	there	PRON
dti-3019	53	4	are	be	VERB
dti-3019	53	5	legal	legal	ADJ
dti-3019	53	6	concerns	concern	NOUN
dti-3019	53	7	surrounding	surround	VERB
dti-3019	53	8	repurposed	repurposed	ADJ
dti-3019	53	9	medications	medication	NOUN
dti-3019	53	10	,	,	PUNCT
dti-3019	53	11	including	include	VERB
dti-3019	53	12	restricted	restrict	VERB
dti-3019	53	13	patent	patent	NOUN
dti-3019	53	14	coverage	coverage	NOUN
dti-3019	53	15	and	and	CCONJ
dti-3019	53	16	obstacles	obstacle	NOUN
dti-3019	53	17	encountered	encounter	VERB
dti-3019	53	18	during	during	ADP
dti-3019	53	19	the	the	DET
dti-3019	53	20	execution	execution	NOUN
dti-3019	53	21	of	of	ADP
dti-3019	53	22	clinical	clinical	ADJ
dti-3019	53	23	trials	trial	NOUN
dti-3019	53	24	,	,	PUNCT
dti-3019	53	25	both	both	PRON
dti-3019	53	26	of	of	ADP
dti-3019	53	27	which	which	PRON
dti-3019	53	28	decrease	decrease	VERB
dti-3019	53	29	the	the	DET
dti-3019	53	30	likelihood	likelihood	NOUN
dti-3019	53	31	of	of	ADP
dti-3019	53	32	success	success	NOUN
dti-3019	53	33	(	(	PUNCT
dti-3019	53	34	25	25	NUM
dti-3019	53	35	)	)	PUNCT
dti-3019	53	36	.	.	PUNCT
dti-3019	54	1	it	it	PRON
dti-3019	54	2	is	be	AUX
dti-3019	54	3	imperative	imperative	ADJ
dti-3019	54	4	to	to	PART
dti-3019	54	5	address	address	VERB
dti-3019	54	6	additional	additional	ADJ
dti-3019	54	7	challenges	challenge	NOUN
dti-3019	54	8	that	that	PRON
dti-3019	54	9	require	require	VERB
dti-3019	54	10	attention	attention	NOUN
dti-3019	54	11	,	,	PUNCT
dti-3019	54	12	such	such	ADJ
dti-3019	54	13	as	as	ADP
dti-3019	54	14	the	the	DET
dti-3019	54	15	generation	generation	NOUN
dti-3019	54	16	of	of	ADP
dti-3019	54	17	false	false	ADJ
dti-3019	54	18	-	-	PUNCT
dti-3019	54	19	positive	positive	ADJ
dti-3019	54	20	signals	signal	NOUN
dti-3019	54	21	during	during	ADP
dti-3019	54	22	data	data	NOUN
dti-3019	54	23	mining	mining	NOUN
dti-3019	54	24	and	and	CCONJ
dti-3019	54	25	the	the	DET
dti-3019	54	26	vulnerability	vulnerability	NOUN
dti-3019	54	27	of	of	ADP
dti-3019	54	28	hypothesis	hypothesis	NOUN
dti-3019	54	29	validation	validation	NOUN
dti-3019	54	30	to	to	PART
dti-3019	54	31	bias	bias	VERB
dti-3019	54	32	and	and	CCONJ
dti-3019	54	33	confounding	confound	VERB
dti-3019	54	34	(	(	PUNCT
dti-3019	54	35	26	26	NUM
dti-3019	54	36	)	)	PUNCT
dti-3019	54	37	.	.	PUNCT
dti-3019	55	1	moreover	moreover	ADV
dti-3019	55	2	,	,	PUNCT
dti-3019	55	3	the	the	DET
dti-3019	55	4	absence	absence	NOUN
dti-3019	55	5	of	of	ADP
dti-3019	55	6	clear	clear	ADJ
dti-3019	55	7	regulatory	regulatory	ADJ
dti-3019	55	8	guidance	guidance	NOUN
dti-3019	55	9	poses	pose	VERB
dti-3019	55	10	yet	yet	ADV
dti-3019	55	11	another	another	DET
dti-3019	55	12	hindrance	hindrance	NOUN
dti-3019	55	13	in	in	ADP
dti-3019	55	14	the	the	DET
dti-3019	55	15	field	field	NOUN
dti-3019	55	16	of	of	ADP
dti-3019	55	17	drug	drug	NOUN
dti-3019	55	18	repurposing	repurposing	NOUN
dti-3019	55	19	(	(	PUNCT
dti-3019	55	20	27	27	NUM
dti-3019	55	21	)	)	PUNCT
dti-3019	55	22	.	.	PUNCT
dti-3019	56	1	despite	despite	SCONJ
dti-3019	56	2	the	the	DET
dti-3019	56	3	inherent	inherent	ADJ
dti-3019	56	4	advantages	advantage	NOUN
dti-3019	56	5	of	of	ADP
dti-3019	56	6	this	this	DET
dti-3019	56	7	technique	technique	NOUN
dti-3019	56	8	,	,	PUNCT
dti-3019	56	9	such	such	ADJ
dti-3019	56	10	as	as	ADP
dti-3019	56	11	cheaper	cheap	ADJ
dti-3019	56	12	costs	cost	NOUN
dti-3019	56	13	and	and	CCONJ
dti-3019	56	14	faster	fast	ADJ
dti-3019	56	15	time	time	NOUN
dti-3019	56	16	frames	frame	NOUN
dti-3019	56	17	,	,	PUNCT
dti-3019	56	18	it	it	PRON
dti-3019	56	19	is	be	AUX
dti-3019	56	20	crucial	crucial	ADJ
dti-3019	56	21	to	to	PART
dti-3019	56	22	recognize	recognize	VERB
dti-3019	56	23	substantial	substantial	ADJ
dti-3019	56	24	failures	failure	NOUN
dti-3019	56	25	found	find	VERB
dti-3019	56	26	during	during	ADP
dti-3019	56	27	clinical	clinical	ADJ
dti-3019	56	28	trials	trial	NOUN
dti-3019	56	29	,	,	PUNCT
dti-3019	56	30	when	when	SCONJ
dti-3019	56	31	the	the	DET
dti-3019	56	32	repurposed	repurpose	VERB
dti-3019	56	33	medicine	medicine	NOUN
dti-3019	56	34	may	may	AUX
dti-3019	56	35	fail	fail	VERB
dti-3019	56	36	to	to	PART
dti-3019	56	37	exhibit	exhibit	VERB
dti-3019	56	38	a	a	DET
dti-3019	56	39	good	good	ADJ
dti-3019	56	40	balance	balance	NOUN
dti-3019	56	41	of	of	ADP
dti-3019	56	42	benefits	benefit	NOUN
dti-3019	56	43	and	and	CCONJ
dti-3019	56	44	risks	risk	NOUN
dti-3019	56	45	(	(	PUNCT
dti-3019	56	46	28	28	NUM
dti-3019	56	47	)	)	PUNCT
dti-3019	56	48	.	.	PUNCT
dti-3019	57	1	consequently	consequently	ADV
dti-3019	57	2	,	,	PUNCT
dti-3019	57	3	a	a	DET
dti-3019	57	4	comprehensive	comprehensive	ADJ
dti-3019	57	5	analysis	analysis	NOUN
dti-3019	57	6	of	of	ADP
dti-3019	57	7	these	these	DET
dti-3019	57	8	challenges	challenge	NOUN
dti-3019	57	9	and	and	CCONJ
dti-3019	57	10	limitations	limitation	NOUN
dti-3019	57	11	must	must	AUX
dti-3019	57	12	precede	precede	VERB
dti-3019	57	13	the	the	DET
dti-3019	57	14	pursuit	pursuit	NOUN
dti-3019	57	15	of	of	ADP
dti-3019	57	16	drug	drug	NOUN
dti-3019	57	17	repurposing	repurpose	VERB
dti-3019	57	18	strategies	strategy	NOUN
dti-3019	57	19	.	.	PUNCT
dti-3019	58	1	challenges	challenge	NOUN
dti-3019	58	2	in	in	ADP
dti-3019	58	3	cardiovascular	cardiovascular	ADJ
dti-3019	58	4	endeavor	endeavor	VERB
dti-3019	58	5	the	the	DET
dti-3019	58	6	clinical	clinical	ADJ
dti-3019	58	7	perspective	perspective	NOUN
dti-3019	58	8	on	on	ADP
dti-3019	58	9	drug	drug	NOUN
dti-3019	58	10	repurposing	repurposing	NOUN
dti-3019	58	11	has	have	AUX
dti-3019	58	12	faced	face	VERB
dti-3019	58	13	numerous	numerous	ADJ
dti-3019	58	14	challenges	challenge	NOUN
dti-3019	58	15	and	and	CCONJ
dti-3019	58	16	trials	trial	NOUN
dti-3019	58	17	that	that	PRON
dti-3019	58	18	have	have	AUX
dti-3019	58	19	not	not	PART
dti-3019	58	20	been	be	AUX
dti-3019	58	21	successful	successful	ADJ
dti-3019	58	22	.	.	PUNCT
dti-3019	59	1	despite	despite	SCONJ
dti-3019	59	2	the	the	DET
dti-3019	59	3	potential	potential	ADJ
dti-3019	59	4	benefits	benefit	NOUN
dti-3019	59	5	of	of	ADP
dti-3019	59	6	repurposing	repurpose	VERB
dti-3019	59	7	current	current	ADJ
dti-3019	59	8	the	the	DET
dti-3019	59	9	dark	dark	ADJ
dti-3019	59	10	side	side	NOUN
dti-3019	59	11	of	of	ADP
dti-3019	59	12	drug	drug	NOUN
dti-3019	59	13	repurposing10	repurposing10	NOUN
dti-3019	60	1	©	©	ADP
dti-3019	60	2	2024	2024	NUM
dti-3019	60	3	the	the	DET
dti-3019	60	4	authors	author	NOUN
dti-3019	60	5	.	.	PUNCT
dti-3019	61	1	drug	drug	NOUN
dti-3019	61	2	target	target	NOUN
dti-3019	61	3	insights	insight	NOUN
dti-3019	61	4	issn	issn	VERB
dti-3019	61	5	1177	1177	NUM
dti-3019	61	6	-	-	SYM
dti-3019	61	7	3928	3928	NUM
dti-3019	61	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-3019	61	9	drugs	drug	NOUN
dti-3019	61	10	for	for	ADP
dti-3019	61	11	unique	unique	ADJ
dti-3019	61	12	applications	application	NOUN
dti-3019	61	13	,	,	PUNCT
dti-3019	61	14	there	there	PRON
dti-3019	61	15	are	be	VERB
dti-3019	61	16	specific	specific	ADJ
dti-3019	61	17	limitations	limitation	NOUN
dti-3019	61	18	that	that	PRON
dti-3019	61	19	hinder	hinder	VERB
dti-3019	61	20	success	success	NOUN
dti-3019	61	21	in	in	ADP
dti-3019	61	22	this	this	DET
dti-3019	61	23	endeavor	endeavor	NOUN
dti-3019	61	24	.	.	PUNCT
dti-3019	62	1	these	these	DET
dti-3019	62	2	limitations	limitation	NOUN
dti-3019	62	3	encompass	encompass	VERB
dti-3019	62	4	a	a	DET
dti-3019	62	5	lack	lack	NOUN
dti-3019	62	6	of	of	ADP
dti-3019	62	7	resources	resource	NOUN
dti-3019	62	8	,	,	PUNCT
dti-3019	62	9	difficulties	difficulty	NOUN
dti-3019	62	10	with	with	ADP
dti-3019	62	11	accessing	access	VERB
dti-3019	62	12	data	datum	NOUN
dti-3019	62	13	,	,	PUNCT
dti-3019	62	14	and	and	CCONJ
dti-3019	62	15	concerns	concern	NOUN
dti-3019	62	16	regarding	regard	VERB
dti-3019	62	17	personnel	personnel	NOUN
dti-3019	62	18	,	,	PUNCT
dti-3019	62	19	all	all	PRON
dti-3019	62	20	of	of	ADP
dti-3019	62	21	which	which	PRON
dti-3019	62	22	can	can	AUX
dti-3019	62	23	impede	impede	VERB
dti-3019	62	24	the	the	DET
dti-3019	62	25	process	process	NOUN
dti-3019	62	26	of	of	ADP
dti-3019	62	27	drug	drug	NOUN
dti-3019	62	28	profiling	profiling	NOUN
dti-3019	62	29	(	(	PUNCT
dti-3019	62	30	29	29	NUM
dti-3019	62	31	)	)	PUNCT
dti-3019	62	32	.	.	PUNCT
dti-3019	63	1	within	within	ADP
dti-3019	63	2	the	the	DET
dti-3019	63	3	realm	realm	NOUN
dti-3019	63	4	of	of	ADP
dti-3019	63	5	cardiovascular	cardiovascular	ADJ
dti-3019	63	6	disease	disease	NOUN
dti-3019	63	7	,	,	PUNCT
dti-3019	63	8	repurposing	repurpose	VERB
dti-3019	63	9	anti	anti	ADJ
dti-3019	63	10	-	-	ADJ
dti-3019	63	11	inflammatory	inflammatory	ADJ
dti-3019	63	12	medicines	medicine	NOUN
dti-3019	63	13	has	have	AUX
dti-3019	63	14	proven	prove	VERB
dti-3019	63	15	to	to	PART
dti-3019	63	16	be	be	AUX
dti-3019	63	17	challenging	challenge	VERB
dti-3019	63	18	due	due	ADJ
dti-3019	63	19	to	to	ADP
dti-3019	63	20	unforeseen	unforeseen	ADJ
dti-3019	63	21	consequences	consequence	NOUN
dti-3019	63	22	and	and	CCONJ
dti-3019	63	23	the	the	DET
dti-3019	63	24	necessity	necessity	NOUN
dti-3019	63	25	for	for	ADP
dti-3019	63	26	prolonged	prolonged	ADJ
dti-3019	63	27	therapy	therapy	NOUN
dti-3019	63	28	(	(	PUNCT
dti-3019	63	29	30	30	NUM
dti-3019	63	30	)	)	PUNCT
dti-3019	63	31	.	.	PUNCT
dti-3019	64	1	in	in	ADP
dti-3019	64	2	a	a	DET
dti-3019	64	3	study	study	NOUN
dti-3019	64	4	conducted	conduct	VERB
dti-3019	64	5	by	by	ADP
dti-3019	64	6	ridker	ridker	NOUN
dti-3019	64	7	et	et	PROPN
dti-3019	64	8	al	al	PROPN
dti-3019	64	9	(	(	PUNCT
dti-3019	64	10	31	31	NUM
dti-3019	64	11	)	)	PUNCT
dti-3019	64	12	,	,	PUNCT
dti-3019	64	13	it	it	PRON
dti-3019	64	14	was	be	AUX
dti-3019	64	15	found	find	VERB
dti-3019	64	16	that	that	SCONJ
dti-3019	64	17	the	the	DET
dti-3019	64	18	repurposing	repurposing	NOUN
dti-3019	64	19	of	of	ADP
dti-3019	64	20	the	the	DET
dti-3019	64	21	therapeutic	therapeutic	ADJ
dti-3019	64	22	agent	agent	NOUN
dti-3019	64	23	canakinumab	canakinumab	NOUN
dti-3019	64	24	possesses	possess	VERB
dti-3019	64	25	the	the	DET
dti-3019	64	26	capacity	capacity	NOUN
dti-3019	64	27	to	to	PART
dti-3019	64	28	induce	induce	VERB
dti-3019	64	29	unfavorable	unfavorable	ADJ
dti-3019	64	30	outcomes	outcome	NOUN
dti-3019	64	31	,	,	PUNCT
dti-3019	64	32	which	which	PRON
dti-3019	64	33	encompasses	encompass	VERB
dti-3019	64	34	the	the	DET
dti-3019	64	35	occurrence	occurrence	NOUN
dti-3019	64	36	of	of	ADP
dti-3019	64	37	neutropenia	neutropenia	NOUN
dti-3019	64	38	as	as	ADV
dti-3019	64	39	well	well	ADV
dti-3019	64	40	as	as	ADP
dti-3019	64	41	an	an	DET
dti-3019	64	42	elevated	elevated	ADJ
dti-3019	64	43	susceptibility	susceptibility	NOUN
dti-3019	64	44	to	to	ADP
dti-3019	64	45	mortality	mortality	NOUN
dti-3019	64	46	specifically	specifically	ADV
dti-3019	64	47	attributed	attribute	VERB
dti-3019	64	48	to	to	ADP
dti-3019	64	49	infection	infection	NOUN
dti-3019	64	50	or	or	CCONJ
dti-3019	64	51	sepsis	sepsis	NOUN
dti-3019	64	52	,	,	PUNCT
dti-3019	64	53	as	as	SCONJ
dti-3019	64	54	illustrated	illustrate	VERB
dti-3019	64	55	in	in	ADP
dti-3019	64	56	figure	figure	NOUN
dti-3019	64	57	1	1	NUM
dti-3019	64	58	.	.	PUNCT
dti-3019	65	1	another	another	DET
dti-3019	65	2	instance	instance	NOUN
dti-3019	65	3	exemplified	exemplify	VERB
dti-3019	65	4	in	in	ADP
dti-3019	65	5	figure	figure	NOUN
dti-3019	65	6	1	1	NUM
dti-3019	65	7	arises	arise	NOUN
dti-3019	65	8	when	when	SCONJ
dti-3019	65	9	etanercept	etanercept	NOUN
dti-3019	65	10	is	be	AUX
dti-3019	65	11	employed	employ	VERB
dti-3019	65	12	as	as	ADP
dti-3019	65	13	a	a	DET
dti-3019	65	14	repurposed	repurposed	ADJ
dti-3019	65	15	therapeutic	therapeutic	ADJ
dti-3019	65	16	agent	agent	NOUN
dti-3019	65	17	for	for	ADP
dti-3019	65	18	the	the	DET
dti-3019	65	19	management	management	NOUN
dti-3019	65	20	of	of	ADP
dti-3019	65	21	cardiovascular	cardiovascular	ADJ
dti-3019	65	22	ailments	ailment	NOUN
dti-3019	65	23	.	.	PUNCT
dti-3019	66	1	the	the	DET
dti-3019	66	2	clinical	clinical	ADJ
dti-3019	66	3	trials	trial	NOUN
dti-3019	66	4	were	be	AUX
dti-3019	66	5	terminated	terminate	VERB
dti-3019	66	6	prematurely	prematurely	ADV
dti-3019	66	7	due	due	ADJ
dti-3019	66	8	to	to	ADP
dti-3019	66	9	the	the	DET
dti-3019	66	10	conspicuous	conspicuous	ADJ
dti-3019	66	11	absence	absence	NOUN
dti-3019	66	12	of	of	ADP
dti-3019	66	13	any	any	DET
dti-3019	66	14	discernible	discernible	ADJ
dti-3019	66	15	benefit	benefit	NOUN
dti-3019	66	16	(	(	PUNCT
dti-3019	66	17	32	32	NUM
dti-3019	66	18	)	)	PUNCT
dti-3019	66	19	.	.	PUNCT
dti-3019	67	1	in	in	ADP
dti-3019	67	2	the	the	DET
dti-3019	67	3	same	same	ADJ
dti-3019	67	4	domain	domain	NOUN
dti-3019	67	5	,	,	PUNCT
dti-3019	67	6	another	another	DET
dti-3019	67	7	agent	agent	NOUN
dti-3019	67	8	,	,	PUNCT
dti-3019	67	9	colchicine	colchicine	PROPN
dti-3019	67	10	,	,	PUNCT
dti-3019	67	11	which	which	PRON
dti-3019	67	12	had	have	AUX
dti-3019	67	13	been	be	AUX
dti-3019	67	14	repurposed	repurpose	VERB
dti-3019	67	15	,	,	PUNCT
dti-3019	67	16	was	be	AUX
dti-3019	67	17	subjected	subject	VERB
dti-3019	67	18	to	to	ADP
dti-3019	67	19	different	different	ADJ
dti-3019	67	20	clinical	clinical	ADJ
dti-3019	67	21	trials	trial	NOUN
dti-3019	67	22	as	as	SCONJ
dti-3019	67	23	illustrated	illustrate	VERB
dti-3019	67	24	in	in	ADP
dti-3019	67	25	figure	figure	NOUN
dti-3019	67	26	2	2	NUM
dti-3019	67	27	.	.	PUNCT
dti-3019	68	1	these	these	DET
dti-3019	68	2	trials	trial	NOUN
dti-3019	68	3	brought	bring	VERB
dti-3019	68	4	to	to	PART
dti-3019	68	5	light	light	VERB
dti-3019	68	6	a	a	DET
dti-3019	68	7	noteworthy	noteworthy	ADJ
dti-3019	68	8	escalation	escalation	NOUN
dti-3019	68	9	in	in	ADP
dti-3019	68	10	adverse	adverse	ADJ
dti-3019	68	11	gastrointestinal	gastrointestinal	ADJ
dti-3019	68	12	symptoms	symptom	NOUN
dti-3019	68	13	and	and	CCONJ
dti-3019	68	14	an	an	DET
dti-3019	68	15	increased	increase	VERB
dti-3019	68	16	vulnerability	vulnerability	NOUN
dti-3019	68	17	to	to	ADP
dti-3019	68	18	pneumonia	pneumonia	NOUN
dti-3019	68	19	(	(	PUNCT
dti-3019	68	20	33,34	33,34	NOUN
dti-3019	68	21	)	)	PUNCT
dti-3019	68	22	.	.	PUNCT
dti-3019	69	1	moreover	moreover	ADV
dti-3019	69	2	,	,	PUNCT
dti-3019	69	3	it	it	PRON
dti-3019	69	4	is	be	AUX
dti-3019	69	5	important	important	ADJ
dti-3019	69	6	to	to	PART
dti-3019	69	7	note	note	VERB
dti-3019	69	8	that	that	SCONJ
dti-3019	69	9	there	there	PRON
dti-3019	69	10	was	be	VERB
dti-3019	69	11	no	no	DET
dti-3019	69	12	significant	significant	ADJ
dti-3019	69	13	discrepancy	discrepancy	NOUN
dti-3019	69	14	observed	observe	VERB
dti-3019	69	15	in	in	ADP
dti-3019	69	16	major	major	ADJ
dti-3019	69	17	adverse	adverse	ADJ
dti-3019	69	18	cardiovascular	cardiovascular	ADJ
dti-3019	69	19	events	event	NOUN
dti-3019	69	20	(	(	PUNCT
dti-3019	69	21	maces	mace	NOUN
dti-3019	69	22	)	)	PUNCT
dti-3019	69	23	between	between	ADP
dti-3019	69	24	the	the	DET
dti-3019	69	25	group	group	NOUN
dti-3019	69	26	administered	administer	VERB
dti-3019	69	27	with	with	ADP
dti-3019	69	28	colchicine	colchicine	PROPN
dti-3019	69	29	and	and	CCONJ
dti-3019	69	30	the	the	DET
dti-3019	69	31	group	group	NOUN
dti-3019	69	32	administered	administer	VERB
dti-3019	69	33	with	with	ADP
dti-3019	69	34	a	a	DET
dti-3019	69	35	placebo	placebo	NOUN
dti-3019	69	36	(	(	PUNCT
dti-3019	69	37	35	35	NUM
dti-3019	69	38	)	)	PUNCT
dti-3019	69	39	.	.	PUNCT
dti-3019	70	1	however	however	ADV
dti-3019	70	2	,	,	PUNCT
dti-3019	70	3	it	it	PRON
dti-3019	70	4	is	be	AUX
dti-3019	70	5	worth	worth	ADJ
dti-3019	70	6	mentioning	mention	VERB
dti-3019	70	7	that	that	SCONJ
dti-3019	70	8	the	the	DET
dti-3019	70	9	incidence	incidence	NOUN
dti-3019	70	10	of	of	ADP
dti-3019	70	11	total	total	ADJ
dti-3019	70	12	mortality	mortality	NOUN
dti-3019	70	13	exhibited	exhibit	VERB
dti-3019	70	14	an	an	DET
dti-3019	70	15	augmentation	augmentation	NOUN
dti-3019	70	16	in	in	ADP
dti-3019	70	17	the	the	DET
dti-3019	70	18	colchicine	colchicine	PROPN
dti-3019	70	19	group	group	NOUN
dti-3019	70	20	,	,	PUNCT
dti-3019	70	21	primarily	primarily	ADV
dti-3019	70	22	due	due	ADP
dti-3019	70	23	to	to	ADP
dti-3019	70	24	sepsis	sepsis	NOUN
dti-3019	70	25	(	(	PUNCT
dti-3019	70	26	35	35	NUM
dti-3019	70	27	)	)	PUNCT
dti-3019	70	28	.	.	PUNCT
dti-3019	71	1	additionally	additionally	ADV
dti-3019	71	2	,	,	PUNCT
dti-3019	71	3	in	in	ADP
dti-3019	71	4	a	a	DET
dti-3019	71	5	study	study	NOUN
dti-3019	71	6	conducted	conduct	VERB
dti-3019	71	7	by	by	ADP
dti-3019	71	8	mewton	mewton	PROPN
dti-3019	71	9	et	et	PROPN
dti-3019	71	10	al	al	PROPN
dti-3019	71	11	(	(	PUNCT
dti-3019	71	12	36	36	NUM
dti-3019	71	13	)	)	PUNCT
dti-3019	71	14	,	,	PUNCT
dti-3019	71	15	it	it	PRON
dti-3019	71	16	was	be	AUX
dti-3019	71	17	observed	observe	VERB
dti-3019	71	18	that	that	SCONJ
dti-3019	71	19	there	there	PRON
dti-3019	71	20	was	be	VERB
dti-3019	71	21	no	no	DET
dti-3019	71	22	substantial	substantial	ADJ
dti-3019	71	23	reduction	reduction	NOUN
dti-3019	71	24	in	in	ADP
dti-3019	71	25	the	the	DET
dti-3019	71	26	size	size	NOUN
dti-3019	71	27	of	of	ADP
dti-3019	71	28	the	the	DET
dti-3019	71	29	infarct	infarct	NOUN
dti-3019	71	30	at	at	ADP
dti-3019	71	31	the	the	DET
dti-3019	71	32	conclusion	conclusion	NOUN
dti-3019	71	33	of	of	ADP
dti-3019	71	34	a	a	DET
dti-3019	71	35	5	5	NUM
dti-3019	71	36	-	-	PUNCT
dti-3019	71	37	day	day	NOUN
dti-3019	71	38	period	period	NOUN
dti-3019	71	39	(	(	PUNCT
dti-3019	71	40	36	36	NUM
dti-3019	71	41	)	)	PUNCT
dti-3019	71	42	.	.	PUNCT
dti-3019	72	1	within	within	ADP
dti-3019	72	2	the	the	DET
dti-3019	72	3	same	same	ADJ
dti-3019	72	4	clinical	clinical	ADJ
dti-3019	72	5	trial	trial	NOUN
dti-3019	72	6	,	,	PUNCT
dti-3019	72	7	there	there	PRON
dti-3019	72	8	was	be	VERB
dti-3019	72	9	no	no	DET
dti-3019	72	10	significant	significant	ADJ
dti-3019	72	11	decrease	decrease	NOUN
dti-3019	72	12	in	in	ADP
dti-3019	72	13	mace	mace	NOUN
dti-3019	72	14	during	during	ADP
dti-3019	72	15	the	the	DET
dti-3019	72	16	3	3	NUM
dti-3019	72	17	-	-	PUNCT
dti-3019	72	18	month	month	NOUN
dti-3019	72	19	follow	follow	NOUN
dti-3019	72	20	-	-	PUNCT
dti-3019	72	21	up	up	NOUN
dti-3019	72	22	period	period	NOUN
dti-3019	72	23	.	.	PUNCT
dti-3019	73	1	furthermore	furthermore	ADV
dti-3019	73	2	,	,	PUNCT
dti-3019	73	3	no	no	DET
dti-3019	73	4	disparity	disparity	NOUN
dti-3019	73	5	was	be	AUX
dti-3019	73	6	discovered	discover	VERB
dti-3019	73	7	in	in	ADP
dti-3019	73	8	the	the	DET
dti-3019	73	9	levels	level	NOUN
dti-3019	73	10	of	of	ADP
dti-3019	73	11	inflammatory	inflammatory	ADJ
dti-3019	73	12	markers	marker	NOUN
dti-3019	73	13	,	,	PUNCT
dti-3019	73	14	including	include	VERB
dti-3019	73	15	white	white	ADJ
dti-3019	73	16	blood	blood	NOUN
dti-3019	73	17	cell	cell	NOUN
dti-3019	73	18	count	count	NOUN
dti-3019	73	19	and	and	CCONJ
dti-3019	73	20	c	c	NOUN
dti-3019	73	21	-	-	PUNCT
dti-3019	73	22	reactive	reactive	ADJ
dti-3019	73	23	protein	protein	NOUN
dti-3019	73	24	(	(	PUNCT
dti-3019	73	25	crp	crp	PROPN
dti-3019	73	26	)	)	PUNCT
dti-3019	73	27	,	,	PUNCT
dti-3019	73	28	within	within	ADP
dti-3019	73	29	the	the	DET
dti-3019	73	30	initial	initial	ADJ
dti-3019	73	31	48	48	NUM
dti-3019	73	32	hours	hour	NOUN
dti-3019	73	33	.	.	PUNCT
dti-3019	74	1	on	on	ADP
dti-3019	74	2	the	the	DET
dti-3019	74	3	other	other	ADJ
dti-3019	74	4	hand	hand	NOUN
dti-3019	74	5	,	,	PUNCT
dti-3019	74	6	etanercept	etanercept	VERB
dti-3019	74	7	is	be	AUX
dti-3019	74	8	a	a	DET
dti-3019	74	9	pharmaceutical	pharmaceutical	ADJ
dti-3019	74	10	agent	agent	NOUN
dti-3019	74	11	employed	employ	VERB
dti-3019	74	12	for	for	ADP
dti-3019	74	13	the	the	DET
dti-3019	74	14	purpose	purpose	NOUN
dti-3019	74	15	of	of	ADP
dti-3019	74	16	managing	manage	VERB
dti-3019	74	17	and	and	CCONJ
dti-3019	74	18	addressing	address	VERB
dti-3019	74	19	autoimmune	autoimmune	ADJ
dti-3019	74	20	disorders	disorder	NOUN
dti-3019	74	21	,	,	PUNCT
dti-3019	74	22	such	such	ADJ
dti-3019	74	23	as	as	ADP
dti-3019	74	24	plaque	plaque	NOUN
dti-3019	74	25	psoriasis	psoriasis	NOUN
dti-3019	74	26	,	,	PUNCT
dti-3019	74	27	rheumatoid	rheumatoid	NOUN
dti-3019	74	28	figure	figure	NOUN
dti-3019	74	29	1	1	NUM
dti-3019	74	30	examples	example	NOUN
dti-3019	74	31	on	on	ADP
dti-3019	74	32	drug	drug	NOUN
dti-3019	74	33	repurposed	repurpose	VERB
dti-3019	74	34	in	in	ADP
dti-3019	74	35	cardiovascular	cardiovascular	ADJ
dti-3019	74	36	endeavor	endeavor	NOUN
dti-3019	74	37	.	.	PUNCT
dti-3019	75	1	canakinumab	canakinumab	NOUN
dti-3019	75	2	(	(	PUNCT
dti-3019	75	3	acz885	acz885	PROPN
dti-3019	75	4	,	,	PUNCT
dti-3019	75	5	ilaris	ilaris	NOUN
dti-3019	75	6	)	)	PUNCT
dti-3019	75	7	,	,	PUNCT
dti-3019	75	8	a	a	DET
dti-3019	75	9	monoclonal	monoclonal	NOUN
dti-3019	75	10	antibody	antibody	NOUN
dti-3019	75	11	targeting	target	VERB
dti-3019	75	12	human	human	ADJ
dti-3019	75	13	anti	anti	NOUN
dti-3019	75	14	-	-	NOUN
dti-3019	75	15	interleukin-1β	interleukin-1β	ADJ
dti-3019	75	16	,	,	PUNCT
dti-3019	75	17	has	have	AUX
dti-3019	75	18	been	be	AUX
dti-3019	75	19	developed	develop	VERB
dti-3019	75	20	by	by	ADP
dti-3019	75	21	novartis	novartis	PROPN
dti-3019	75	22	(	(	PUNCT
dti-3019	75	23	37	37	NUM
dti-3019	75	24	)	)	PUNCT
dti-3019	75	25	.	.	PUNCT
dti-3019	76	1	in	in	ADP
dti-3019	76	2	june	june	PROPN
dti-3019	76	3	2009	2009	NUM
dti-3019	76	4	,	,	PUNCT
dti-3019	76	5	the	the	DET
dti-3019	76	6	us	us	PROPN
dti-3019	76	7	food	food	NOUN
dti-3019	76	8	and	and	CCONJ
dti-3019	76	9	drug	drug	NOUN
dti-3019	76	10	administration	administration	NOUN
dti-3019	76	11	granted	grant	VERB
dti-3019	76	12	approval	approval	NOUN
dti-3019	76	13	for	for	ADP
dti-3019	76	14	its	its	PRON
dti-3019	76	15	use	use	NOUN
dti-3019	76	16	in	in	ADP
dti-3019	76	17	the	the	DET
dti-3019	76	18	treatment	treatment	NOUN
dti-3019	76	19	of	of	ADP
dti-3019	76	20	familial	familial	ADJ
dti-3019	76	21	cold	cold	ADJ
dti-3019	76	22	autoinflammatory	autoinflammatory	NOUN
dti-3019	76	23	syndrome	syndrome	NOUN
dti-3019	76	24	and	and	CCONJ
dti-3019	76	25	muckle	muckle	ADJ
dti-3019	76	26	-	-	PUNCT
dti-3019	76	27	wells	wells	NOUN
dti-3019	76	28	syndrome	syndrome	NOUN
dti-3019	76	29	,	,	PUNCT
dti-3019	76	30	both	both	PRON
dti-3019	76	31	of	of	ADP
dti-3019	76	32	which	which	PRON
dti-3019	76	33	pertain	pertain	VERB
dti-3019	76	34	to	to	ADP
dti-3019	76	35	cryopyrin	cryopyrin	NOUN
dti-3019	76	36	-	-	PUNCT
dti-3019	76	37	associated	associate	VERB
dti-3019	76	38	periodic	periodic	ADJ
dti-3019	76	39	syndromes	syndrome	NOUN
dti-3019	76	40	,	,	PUNCT
dti-3019	76	41	a	a	DET
dti-3019	76	42	group	group	NOUN
dti-3019	76	43	of	of	ADP
dti-3019	76	44	inflammatory	inflammatory	ADJ
dti-3019	76	45	diseases	disease	NOUN
dti-3019	76	46	.	.	PUNCT
dti-3019	77	1	however	however	ADV
dti-3019	77	2	,	,	PUNCT
dti-3019	77	3	the	the	DET
dti-3019	77	4	attempt	attempt	NOUN
dti-3019	77	5	by	by	ADP
dti-3019	77	6	novartis	novartis	PROPN
dti-3019	77	7	to	to	PART
dti-3019	77	8	repurpose	repurpose	VERB
dti-3019	77	9	this	this	DET
dti-3019	77	10	drug	drug	NOUN
dti-3019	77	11	,	,	PUNCT
dti-3019	77	12	which	which	PRON
dti-3019	77	13	has	have	AUX
dti-3019	77	14	been	be	AUX
dti-3019	77	15	approved	approve	VERB
dti-3019	77	16	for	for	ADP
dti-3019	77	17	rare	rare	ADJ
dti-3019	77	18	inflammatory	inflammatory	ADJ
dti-3019	77	19	diseases	disease	NOUN
dti-3019	77	20	,	,	PUNCT
dti-3019	77	21	for	for	ADP
dti-3019	77	22	a	a	DET
dti-3019	77	23	cohort	cohort	NOUN
dti-3019	77	24	of	of	ADP
dti-3019	77	25	heart	heart	NOUN
dti-3019	77	26	attack	attack	NOUN
dti-3019	77	27	survivors	survivor	NOUN
dti-3019	77	28	has	have	AUX
dti-3019	77	29	been	be	AUX
dti-3019	77	30	rejected	reject	VERB
dti-3019	77	31	by	by	ADP
dti-3019	77	32	the	the	DET
dti-3019	77	33	us	us	PROPN
dti-3019	77	34	food	food	NOUN
dti-3019	77	35	and	and	CCONJ
dti-3019	77	36	drug	drug	NOUN
dti-3019	77	37	administration	administration	NOUN
dti-3019	77	38	,	,	PUNCT
dti-3019	77	39	as	as	SCONJ
dti-3019	77	40	announced	announce	VERB
dti-3019	77	41	by	by	ADP
dti-3019	77	42	the	the	DET
dti-3019	77	43	swiss	swiss	ADJ
dti-3019	77	44	pharmaceutical	pharmaceutical	NOUN
dti-3019	77	45	company	company	NOUN
dti-3019	77	46	(	(	PUNCT
dti-3019	77	47	38	38	NUM
dti-3019	77	48	)	)	PUNCT
dti-3019	77	49	.	.	PUNCT
dti-3019	78	1	it	it	PRON
dti-3019	78	2	is	be	AUX
dti-3019	78	3	worth	worth	ADJ
dti-3019	78	4	noting	note	VERB
dti-3019	78	5	that	that	SCONJ
dti-3019	78	6	although	although	SCONJ
dti-3019	78	7	the	the	DET
dti-3019	78	8	scientific	scientific	ADJ
dti-3019	78	9	community	community	NOUN
dti-3019	78	10	highly	highly	ADV
dti-3019	78	11	praised	praise	VERB
dti-3019	78	12	the	the	DET
dti-3019	78	13	results	result	NOUN
dti-3019	78	14	obtained	obtain	VERB
dti-3019	78	15	from	from	ADP
dti-3019	78	16	novartis	novartis	PROPN
dti-3019	78	17	’	'	PUNCT
dti-3019	78	18	cantos	canto	NOUN
dti-3019	78	19	study	study	NOUN
dti-3019	78	20	,	,	PUNCT
dti-3019	78	21	some	some	DET
dti-3019	78	22	cardiovascular	cardiovascular	ADJ
dti-3019	78	23	experts	expert	NOUN
dti-3019	78	24	were	be	AUX
dti-3019	78	25	less	less	ADV
dti-3019	78	26	enthusiastic	enthusiastic	ADJ
dti-3019	78	27	.	.	PUNCT
dti-3019	79	1	these	these	DET
dti-3019	79	2	experts	expert	NOUN
dti-3019	79	3	concluded	conclude	VERB
dti-3019	79	4	that	that	SCONJ
dti-3019	79	5	the	the	DET
dti-3019	79	6	benefits	benefit	NOUN
dti-3019	79	7	of	of	ADP
dti-3019	79	8	this	this	DET
dti-3019	79	9	medication	medication	NOUN
dti-3019	79	10	were	be	AUX
dti-3019	79	11	not	not	PART
dti-3019	79	12	significant	significant	ADJ
dti-3019	79	13	enough	enough	ADV
dti-3019	79	14	to	to	PART
dti-3019	79	15	warrant	warrant	VERB
dti-3019	79	16	expanding	expand	VERB
dti-3019	79	17	its	its	PRON
dti-3019	79	18	approved	approve	VERB
dti-3019	79	19	use	use	NOUN
dti-3019	79	20	to	to	PART
dti-3019	79	21	include	include	VERB
dti-3019	79	22	routine	routine	ADJ
dti-3019	79	23	treatment	treatment	NOUN
dti-3019	79	24	of	of	ADP
dti-3019	79	25	cardiac	cardiac	ADJ
dti-3019	79	26	patients	patient	NOUN
dti-3019	79	27	.	.	PUNCT
dti-3019	80	1	a	a	DET
dti-3019	80	2	noteworthy	noteworthy	ADJ
dti-3019	80	3	example	example	NOUN
dti-3019	80	4	supporting	support	VERB
dti-3019	80	5	the	the	DET
dti-3019	80	6	viewpoint	viewpoint	NOUN
dti-3019	80	7	of	of	ADP
dti-3019	80	8	these	these	DET
dti-3019	80	9	cardiovascular	cardiovascular	ADJ
dti-3019	80	10	experts	expert	NOUN
dti-3019	80	11	is	be	AUX
dti-3019	80	12	the	the	DET
dti-3019	80	13	study	study	NOUN
dti-3019	80	14	conducted	conduct	VERB
dti-3019	80	15	by	by	ADP
dti-3019	80	16	ridker	ridker	NOUN
dti-3019	80	17	et	et	PROPN
dti-3019	80	18	al	al	PROPN
dti-3019	80	19	(	(	PUNCT
dti-3019	80	20	31	31	NUM
dti-3019	80	21	)	)	PUNCT
dti-3019	80	22	,	,	PUNCT
dti-3019	80	23	which	which	PRON
dti-3019	80	24	demonstrated	demonstrate	VERB
dti-3019	80	25	that	that	SCONJ
dti-3019	80	26	the	the	DET
dti-3019	80	27	repurposing	repurposing	NOUN
dti-3019	80	28	of	of	ADP
dti-3019	80	29	this	this	DET
dti-3019	80	30	therapeutic	therapeutic	ADJ
dti-3019	80	31	agent	agent	NOUN
dti-3019	80	32	yielded	yield	VERB
dti-3019	80	33	various	various	ADJ
dti-3019	80	34	adverse	adverse	ADJ
dti-3019	80	35	effects	effect	NOUN
dti-3019	80	36	,	,	PUNCT
dti-3019	80	37	as	as	SCONJ
dti-3019	80	38	depicted	depict	VERB
dti-3019	80	39	in	in	ADP
dti-3019	80	40	this	this	DET
dti-3019	80	41	figure	figure	NOUN
dti-3019	80	42	.	.	PUNCT
dti-3019	81	1	figure	figure	VERB
dti-3019	81	2	2	2	NUM
dti-3019	81	3	challenges	challenge	NOUN
dti-3019	81	4	in	in	ADP
dti-3019	81	5	clinical	clinical	ADJ
dti-3019	81	6	trials	trial	NOUN
dti-3019	81	7	using	use	VERB
dti-3019	81	8	colchicine	colchicine	NOUN
dti-3019	81	9	.	.	PUNCT
dti-3019	82	1	in	in	ADP
dti-3019	82	2	the	the	DET
dti-3019	82	3	year	year	NOUN
dti-3019	82	4	2009	2009	NUM
dti-3019	82	5	,	,	PUNCT
dti-3019	82	6	the	the	DET
dti-3019	82	7	us	us	PROPN
dti-3019	82	8	fda	fda	PROPN
dti-3019	82	9	granted	grant	VERB
dti-3019	82	10	approval	approval	NOUN
dti-3019	82	11	for	for	ADP
dti-3019	82	12	the	the	DET
dti-3019	82	13	use	use	NOUN
dti-3019	82	14	of	of	ADP
dti-3019	82	15	colchicine	colchicine	NOUN
dti-3019	82	16	in	in	ADP
dti-3019	82	17	the	the	DET
dti-3019	82	18	treatment	treatment	NOUN
dti-3019	82	19	of	of	ADP
dti-3019	82	20	familial	familial	ADJ
dti-3019	82	21	mediterranean	mediterranean	ADJ
dti-3019	82	22	fever	fever	NOUN
dti-3019	82	23	(	(	PUNCT
dti-3019	82	24	fmf	fmf	NOUN
dti-3019	82	25	)	)	PUNCT
dti-3019	82	26	and	and	CCONJ
dti-3019	82	27	the	the	DET
dti-3019	82	28	prevention	prevention	NOUN
dti-3019	82	29	and	and	CCONJ
dti-3019	82	30	management	management	NOUN
dti-3019	82	31	of	of	ADP
dti-3019	82	32	gout	gout	NOUN
dti-3019	82	33	attacks	attack	NOUN
dti-3019	82	34	(	(	PUNCT
dti-3019	82	35	41	41	NUM
dti-3019	82	36	)	)	PUNCT
dti-3019	82	37	.	.	PUNCT
dti-3019	83	1	detailed	detailed	ADJ
dti-3019	83	2	investigations	investigation	NOUN
dti-3019	83	3	into	into	ADP
dti-3019	83	4	the	the	DET
dti-3019	83	5	mechanisms	mechanism	NOUN
dti-3019	83	6	of	of	ADP
dti-3019	83	7	action	action	NOUN
dti-3019	83	8	have	have	AUX
dti-3019	83	9	revealed	reveal	VERB
dti-3019	83	10	that	that	SCONJ
dti-3019	83	11	colchicine	colchicine	PROPN
dti-3019	83	12	exhibits	exhibit	VERB
dti-3019	83	13	its	its	PRON
dti-3019	83	14	effects	effect	NOUN
dti-3019	83	15	by	by	ADP
dti-3019	83	16	binding	bind	VERB
dti-3019	83	17	to	to	ADP
dti-3019	83	18	microtubules	microtubule	NOUN
dti-3019	83	19	,	,	PUNCT
dti-3019	83	20	thereby	thereby	ADV
dti-3019	83	21	exerting	exert	VERB
dti-3019	83	22	an	an	DET
dti-3019	83	23	influence	influence	NOUN
dti-3019	83	24	on	on	ADP
dti-3019	83	25	numerous	numerous	ADJ
dti-3019	83	26	cellular	cellular	ADJ
dti-3019	83	27	processes	process	NOUN
dti-3019	83	28	(	(	PUNCT
dti-3019	83	29	42	42	NUM
dti-3019	83	30	)	)	PUNCT
dti-3019	83	31	.	.	PUNCT
dti-3019	84	1	additionally	additionally	ADV
dti-3019	84	2	,	,	PUNCT
dti-3019	84	3	colchicine	colchicine	PROPN
dti-3019	84	4	has	have	AUX
dti-3019	84	5	been	be	AUX
dti-3019	84	6	found	find	VERB
dti-3019	84	7	to	to	PART
dti-3019	84	8	impede	impede	VERB
dti-3019	84	9	the	the	DET
dti-3019	84	10	expression	expression	NOUN
dti-3019	84	11	of	of	ADP
dti-3019	84	12	various	various	ADJ
dti-3019	84	13	inflammatory	inflammatory	ADJ
dti-3019	84	14	cytokines	cytokine	NOUN
dti-3019	84	15	(	(	PUNCT
dti-3019	84	16	43	43	NUM
dti-3019	84	17	)	)	PUNCT
dti-3019	84	18	.	.	PUNCT
dti-3019	85	1	the	the	DET
dti-3019	85	2	concept	concept	NOUN
dti-3019	85	3	that	that	SCONJ
dti-3019	85	4	chronic	chronic	ADJ
dti-3019	85	5	inflammation	inflammation	NOUN
dti-3019	85	6	contributes	contribute	VERB
dti-3019	85	7	to	to	ADP
dti-3019	85	8	the	the	DET
dti-3019	85	9	development	development	NOUN
dti-3019	85	10	of	of	ADP
dti-3019	85	11	cardiovascular	cardiovascular	ADJ
dti-3019	85	12	diseases	disease	NOUN
dti-3019	85	13	,	,	PUNCT
dti-3019	85	14	such	such	ADJ
dti-3019	85	15	as	as	ADP
dti-3019	85	16	coronary	coronary	ADJ
dti-3019	85	17	artery	artery	NOUN
dti-3019	85	18	disease	disease	NOUN
dti-3019	85	19	(	(	PUNCT
dti-3019	85	20	cad	cad	NOUN
dti-3019	85	21	)	)	PUNCT
dti-3019	85	22	,	,	PUNCT
dti-3019	85	23	is	be	AUX
dti-3019	85	24	currently	currently	ADV
dti-3019	85	25	gaining	gain	VERB
dti-3019	85	26	considerable	considerable	ADJ
dti-3019	85	27	scientific	scientific	ADJ
dti-3019	85	28	attention	attention	NOUN
dti-3019	85	29	(	(	PUNCT
dti-3019	85	30	44	44	NUM
dti-3019	85	31	)	)	PUNCT
dti-3019	85	32	.	.	PUNCT
dti-3019	86	1	the	the	DET
dti-3019	86	2	distinctive	distinctive	ADJ
dti-3019	86	3	anti	anti	ADJ
dti-3019	86	4	-	-	ADJ
dti-3019	86	5	inflammatory	inflammatory	ADJ
dti-3019	86	6	mechanism	mechanism	NOUN
dti-3019	86	7	of	of	ADP
dti-3019	86	8	colchicine	colchicine	PROPN
dti-3019	86	9	has	have	AUX
dti-3019	86	10	consequently	consequently	ADV
dti-3019	86	11	prompted	prompt	VERB
dti-3019	86	12	further	further	ADJ
dti-3019	86	13	investigations	investigation	NOUN
dti-3019	86	14	in	in	ADP
dti-3019	86	15	the	the	DET
dti-3019	86	16	domain	domain	NOUN
dti-3019	86	17	of	of	ADP
dti-3019	86	18	cardiovascular	cardiovascular	ADJ
dti-3019	86	19	medicine	medicine	NOUN
dti-3019	86	20	(	(	PUNCT
dti-3019	86	21	45	45	NUM
dti-3019	86	22	)	)	PUNCT
dti-3019	86	23	.	.	PUNCT
dti-3019	87	1	at	at	ADP
dti-3019	87	2	present	present	ADJ
dti-3019	87	3	,	,	PUNCT
dti-3019	87	4	the	the	DET
dti-3019	87	5	utilization	utilization	NOUN
dti-3019	87	6	of	of	ADP
dti-3019	87	7	colchicine	colchicine	NOUN
dti-3019	87	8	in	in	ADP
dti-3019	87	9	cardiovascular	cardiovascular	ADJ
dti-3019	87	10	therapy	therapy	NOUN
dti-3019	87	11	remains	remain	VERB
dti-3019	87	12	quite	quite	ADV
dti-3019	87	13	limited	limited	ADJ
dti-3019	87	14	(	(	PUNCT
dti-3019	87	15	46,47	46,47	NUM
dti-3019	87	16	)	)	PUNCT
dti-3019	87	17	.	.	PUNCT
dti-3019	88	1	this	this	DET
dti-3019	88	2	constraint	constraint	NOUN
dti-3019	88	3	may	may	AUX
dti-3019	88	4	be	be	AUX
dti-3019	88	5	attributed	attribute	VERB
dti-3019	88	6	to	to	ADP
dti-3019	88	7	the	the	DET
dti-3019	88	8	adverse	adverse	ADJ
dti-3019	88	9	effects	effect	NOUN
dti-3019	88	10	observed	observe	VERB
dti-3019	88	11	in	in	ADP
dti-3019	88	12	clinical	clinical	ADJ
dti-3019	88	13	trials	trial	NOUN
dti-3019	88	14	focused	focus	VERB
dti-3019	88	15	on	on	ADP
dti-3019	88	16	cardiovascular	cardiovascular	ADJ
dti-3019	88	17	conditions	condition	NOUN
dti-3019	88	18	.	.	PUNCT
dti-3019	89	1	these	these	DET
dti-3019	89	2	adverse	adverse	ADJ
dti-3019	89	3	effects	effect	NOUN
dti-3019	89	4	,	,	PUNCT
dti-3019	89	5	as	as	SCONJ
dti-3019	89	6	depicted	depict	VERB
dti-3019	89	7	in	in	ADP
dti-3019	89	8	the	the	DET
dti-3019	89	9	figure	figure	NOUN
dti-3019	89	10	,	,	PUNCT
dti-3019	89	11	encompass	encompass	VERB
dti-3019	89	12	gastrointestinal	gastrointestinal	ADJ
dti-3019	89	13	disorders	disorder	NOUN
dti-3019	89	14	(	(	PUNCT
dti-3019	89	15	33	33	NUM
dti-3019	89	16	)	)	PUNCT
dti-3019	89	17	,	,	PUNCT
dti-3019	89	18	pneumonia	pneumonia	NOUN
dti-3019	89	19	(	(	PUNCT
dti-3019	89	20	34	34	NUM
dti-3019	89	21	)	)	PUNCT
dti-3019	89	22	,	,	PUNCT
dti-3019	89	23	and	and	CCONJ
dti-3019	89	24	sepsis	sepsis	NOUN
dti-3019	89	25	,	,	PUNCT
dti-3019	89	26	which	which	PRON
dti-3019	89	27	may	may	AUX
dti-3019	89	28	ultimately	ultimately	ADV
dti-3019	89	29	lead	lead	VERB
dti-3019	89	30	to	to	ADP
dti-3019	89	31	an	an	DET
dti-3019	89	32	increased	increase	VERB
dti-3019	89	33	incidence	incidence	NOUN
dti-3019	89	34	of	of	ADP
dti-3019	89	35	overall	overall	ADJ
dti-3019	89	36	mortality	mortality	NOUN
dti-3019	89	37	(	(	PUNCT
dti-3019	89	38	35	35	NUM
dti-3019	89	39	)	)	PUNCT
dti-3019	89	40	.	.	PUNCT
dti-3019	90	1	furthermore	furthermore	ADV
dti-3019	90	2	,	,	PUNCT
dti-3019	90	3	individuals	individual	NOUN
dti-3019	90	4	treated	treat	VERB
dti-3019	90	5	with	with	ADP
dti-3019	90	6	this	this	DET
dti-3019	90	7	medication	medication	NOUN
dti-3019	90	8	did	do	AUX
dti-3019	90	9	not	not	PART
dti-3019	90	10	exhibit	exhibit	VERB
dti-3019	90	11	any	any	DET
dti-3019	90	12	notable	notable	ADJ
dti-3019	90	13	differences	difference	NOUN
dti-3019	90	14	in	in	ADP
dti-3019	90	15	terms	term	NOUN
dti-3019	90	16	of	of	ADP
dti-3019	90	17	infarct	infarct	ADJ
dti-3019	90	18	size	size	NOUN
dti-3019	90	19	or	or	CCONJ
dti-3019	90	20	levels	level	NOUN
dti-3019	90	21	of	of	ADP
dti-3019	90	22	inflammatory	inflammatory	ADJ
dti-3019	90	23	markers	marker	NOUN
dti-3019	90	24	,	,	PUNCT
dti-3019	90	25	including	include	VERB
dti-3019	90	26	white	white	ADJ
dti-3019	90	27	blood	blood	NOUN
dti-3019	90	28	cell	cell	NOUN
dti-3019	90	29	count	count	NOUN
dti-3019	90	30	and	and	CCONJ
dti-3019	90	31	c	c	NOUN
dti-3019	90	32	-	-	PUNCT
dti-3019	90	33	reactive	reactive	ADJ
dti-3019	90	34	protein	protein	NOUN
dti-3019	90	35	,	,	PUNCT
dti-3019	90	36	within	within	ADP
dti-3019	90	37	the	the	DET
dti-3019	90	38	initial	initial	ADJ
dti-3019	90	39	48	48	NUM
dti-3019	90	40	-	-	PUNCT
dti-3019	90	41	hour	hour	NOUN
dti-3019	90	42	period	period	NOUN
dti-3019	90	43	.	.	PUNCT
dti-3019	91	1	moreover	moreover	ADV
dti-3019	91	2	,	,	PUNCT
dti-3019	91	3	a	a	DET
dti-3019	91	4	significant	significant	ADJ
dti-3019	91	5	decrease	decrease	NOUN
dti-3019	91	6	in	in	ADP
dti-3019	91	7	the	the	DET
dti-3019	91	8	occurrence	occurrence	NOUN
dti-3019	91	9	of	of	ADP
dti-3019	91	10	mace	mace	NOUN
dti-3019	91	11	was	be	AUX
dti-3019	91	12	not	not	PART
dti-3019	91	13	observed	observe	VERB
dti-3019	91	14	during	during	ADP
dti-3019	91	15	the	the	DET
dti-3019	91	16	3	3	NUM
dti-3019	91	17	-	-	PUNCT
dti-3019	91	18	month	month	NOUN
dti-3019	91	19	follow	follow	NOUN
dti-3019	91	20	-	-	PUNCT
dti-3019	91	21	up	up	NOUN
dti-3019	91	22	period	period	NOUN
dti-3019	91	23	(	(	PUNCT
dti-3019	91	24	36	36	NUM
dti-3019	91	25	)	)	PUNCT
dti-3019	91	26	.	.	PUNCT
dti-3019	92	1	natsheh	natsheh	PROPN
dti-3019	92	2	et	et	PROPN
dti-3019	92	3	al	al	PROPN
dti-3019	92	4	drug	drug	PROPN
dti-3019	92	5	target	target	NOUN
dti-3019	92	6	insights	insight	NOUN
dti-3019	92	7	2024	2024	NUM
dti-3019	92	8	;	;	PUNCT
dti-3019	92	9	18	18	NUM
dti-3019	92	10	:	:	SYM
dti-3019	92	11	11	11	NUM
dti-3019	92	12	©	©	ADP
dti-3019	92	13	2024	2024	NUM
dti-3019	92	14	the	the	DET
dti-3019	92	15	authors	author	NOUN
dti-3019	92	16	.	.	PUNCT
dti-3019	93	1	published	publish	VERB
dti-3019	93	2	by	by	ADP
dti-3019	93	3	aboutscience	aboutscience	NOUN
dti-3019	93	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3019	93	5	arthritis	arthritis	NOUN
dti-3019	93	6	,	,	PUNCT
dti-3019	93	7	psoriatic	psoriatic	ADJ
dti-3019	93	8	arthritis	arthritis	NOUN
dti-3019	93	9	,	,	PUNCT
dti-3019	93	10	juvenile	juvenile	ADJ
dti-3019	93	11	idiopathic	idiopathic	ADJ
dti-3019	93	12	arthritis	arthritis	NOUN
dti-3019	93	13	,	,	PUNCT
dti-3019	93	14	and	and	CCONJ
dti-3019	93	15	ankylosing	ankylose	VERB
dti-3019	93	16	spondylitis	spondylitis	NOUN
dti-3019	93	17	.	.	PUNCT
dti-3019	94	1	it	it	PRON
dti-3019	94	2	belongs	belong	VERB
dti-3019	94	3	to	to	ADP
dti-3019	94	4	the	the	DET
dti-3019	94	5	class	class	NOUN
dti-3019	94	6	of	of	ADP
dti-3019	94	7	biologic	biologic	ADJ
dti-3019	94	8	fusion	fusion	NOUN
dti-3019	94	9	proteins	protein	NOUN
dti-3019	94	10	categorized	categorize	VERB
dti-3019	94	11	as	as	ADP
dti-3019	94	12	tumor	tumor	NOUN
dti-3019	94	13	necrosis	necrosis	NOUN
dti-3019	94	14	factor	factor	NOUN
dti-3019	94	15	(	(	PUNCT
dti-3019	94	16	tnf	tnf	PROPN
dti-3019	94	17	)	)	PUNCT
dti-3019	94	18	blockers	blocker	NOUN
dti-3019	94	19	(	(	PUNCT
dti-3019	94	20	39	39	NUM
dti-3019	94	21	)	)	PUNCT
dti-3019	94	22	.	.	PUNCT
dti-3019	95	1	although	although	SCONJ
dti-3019	95	2	the	the	DET
dti-3019	95	3	approval	approval	NOUN
dti-3019	95	4	of	of	ADP
dti-3019	95	5	systemic	systemic	ADJ
dti-3019	95	6	etanercept	etanercept	NOUN
dti-3019	95	7	for	for	ADP
dti-3019	95	8	adults	adult	NOUN
dti-3019	95	9	occurred	occur	VERB
dti-3019	95	10	in	in	ADP
dti-3019	95	11	2004	2004	NUM
dti-3019	95	12	,	,	PUNCT
dti-3019	95	13	the	the	DET
dti-3019	95	14	fda	fda	PROPN
dti-3019	95	15	declined	decline	VERB
dti-3019	95	16	to	to	PART
dti-3019	95	17	approve	approve	VERB
dti-3019	95	18	its	its	PRON
dti-3019	95	19	use	use	NOUN
dti-3019	95	20	in	in	ADP
dti-3019	95	21	children	child	NOUN
dti-3019	95	22	with	with	ADP
dti-3019	95	23	psoriasis	psoriasis	NOUN
dti-3019	95	24	in	in	ADP
dti-3019	95	25	2018	2018	NUM
dti-3019	95	26	(	(	PUNCT
dti-3019	95	27	40	40	NUM
dti-3019	95	28	)	)	PUNCT
dti-3019	95	29	.	.	PUNCT
dti-3019	96	1	however	however	ADV
dti-3019	96	2	,	,	PUNCT
dti-3019	96	3	the	the	DET
dti-3019	96	4	fda	fda	PROPN
dti-3019	96	5	later	later	ADV
dti-3019	96	6	revised	revise	VERB
dti-3019	96	7	their	their	PRON
dti-3019	96	8	risk	risk	NOUN
dti-3019	96	9	-	-	PUNCT
dti-3019	96	10	benefit	benefit	NOUN
dti-3019	96	11	assessment	assessment	NOUN
dti-3019	96	12	in	in	ADP
dti-3019	96	13	light	light	NOUN
dti-3019	96	14	of	of	ADP
dti-3019	96	15	a	a	DET
dti-3019	96	16	better	well	ADJ
dti-3019	96	17	understanding	understanding	NOUN
dti-3019	96	18	of	of	ADP
dti-3019	96	19	the	the	DET
dti-3019	96	20	disease	disease	NOUN
dti-3019	96	21	burden	burden	NOUN
dti-3019	96	22	,	,	PUNCT
dti-3019	96	23	the	the	DET
dti-3019	96	24	unmet	unmet	NOUN
dti-3019	96	25	medical	medical	ADJ
dti-3019	96	26	needs	need	NOUN
dti-3019	96	27	,	,	PUNCT
dti-3019	96	28	and	and	CCONJ
dti-3019	96	29	the	the	DET
dti-3019	96	30	impact	impact	NOUN
dti-3019	96	31	of	of	ADP
dti-3019	96	32	off	off	ADP
dti-3019	96	33	-	-	PUNCT
dti-3019	96	34	label	label	NOUN
dti-3019	96	35	use	use	NOUN
dti-3019	96	36	in	in	ADP
dti-3019	96	37	children	child	NOUN
dti-3019	96	38	with	with	ADP
dti-3019	96	39	psoriasis	psoriasis	NOUN
dti-3019	96	40	.	.	PUNCT
dti-3019	97	1	consequently	consequently	ADV
dti-3019	97	2	,	,	PUNCT
dti-3019	97	3	in	in	ADP
dti-3019	97	4	2016	2016	NUM
dti-3019	97	5	,	,	PUNCT
dti-3019	97	6	this	this	PRON
dti-3019	97	7	led	lead	VERB
dti-3019	97	8	to	to	ADP
dti-3019	97	9	the	the	DET
dti-3019	97	10	approval	approval	NOUN
dti-3019	97	11	of	of	ADP
dti-3019	97	12	etanercept	etanercept	NOUN
dti-3019	97	13	as	as	ADP
dti-3019	97	14	the	the	DET
dti-3019	97	15	first	first	ADJ
dti-3019	97	16	systemic	systemic	ADJ
dti-3019	97	17	biologic	biologic	NOUN
dti-3019	97	18	product	product	NOUN
dti-3019	97	19	for	for	ADP
dti-3019	97	20	the	the	DET
dti-3019	97	21	treatment	treatment	NOUN
dti-3019	97	22	of	of	ADP
dti-3019	97	23	moderate	moderate	ADJ
dti-3019	97	24	to	to	ADP
dti-3019	97	25	severe	severe	ADJ
dti-3019	97	26	psoriasis	psoriasis	NOUN
dti-3019	97	27	in	in	ADP
dti-3019	97	28	children	child	NOUN
dti-3019	97	29	aged	age	VERB
dti-3019	97	30	4	4	NUM
dti-3019	97	31	-	-	SYM
dti-3019	97	32	17	17	NUM
dti-3019	97	33	.	.	PUNCT
dti-3019	98	1	despite	despite	SCONJ
dti-3019	98	2	these	these	DET
dti-3019	98	3	findings	finding	NOUN
dti-3019	98	4	,	,	PUNCT
dti-3019	98	5	some	some	DET
dti-3019	98	6	researchers	researcher	NOUN
dti-3019	98	7	have	have	AUX
dti-3019	98	8	attempted	attempt	VERB
dti-3019	98	9	to	to	PART
dti-3019	98	10	repurpose	repurpose	VERB
dti-3019	98	11	this	this	DET
dti-3019	98	12	drug	drug	NOUN
dti-3019	98	13	for	for	ADP
dti-3019	98	14	the	the	DET
dti-3019	98	15	treatment	treatment	NOUN
dti-3019	98	16	of	of	ADP
dti-3019	98	17	cardiovascular	cardiovascular	ADJ
dti-3019	98	18	diseases	disease	NOUN
dti-3019	98	19	.	.	PUNCT
dti-3019	99	1	an	an	DET
dti-3019	99	2	example	example	NOUN
dti-3019	99	3	of	of	ADP
dti-3019	99	4	such	such	DET
dti-3019	99	5	an	an	DET
dti-3019	99	6	attempt	attempt	NOUN
dti-3019	99	7	is	be	AUX
dti-3019	99	8	seen	see	VERB
dti-3019	99	9	in	in	ADP
dti-3019	99	10	a	a	DET
dti-3019	99	11	clinical	clinical	ADJ
dti-3019	99	12	trial	trial	NOUN
dti-3019	99	13	,	,	PUNCT
dti-3019	99	14	depicted	depict	VERB
dti-3019	99	15	in	in	ADP
dti-3019	99	16	the	the	DET
dti-3019	99	17	accompanying	accompanying	ADJ
dti-3019	99	18	figure	figure	NOUN
dti-3019	99	19	,	,	PUNCT
dti-3019	99	20	which	which	PRON
dti-3019	99	21	was	be	AUX
dti-3019	99	22	terminated	terminate	VERB
dti-3019	99	23	due	due	ADP
dti-3019	99	24	to	to	ADP
dti-3019	99	25	the	the	DET
dti-3019	99	26	absence	absence	NOUN
dti-3019	99	27	of	of	ADP
dti-3019	99	28	any	any	DET
dti-3019	99	29	significant	significant	ADJ
dti-3019	99	30	advantages	advantage	NOUN
dti-3019	99	31	(	(	PUNCT
dti-3019	99	32	32	32	NUM
dti-3019	99	33	)	)	PUNCT
dti-3019	99	34	.	.	PUNCT
dti-3019	100	1	another	another	DET
dti-3019	100	2	drug	drug	NOUN
dti-3019	100	3	repurposed	repurpose	VERB
dti-3019	100	4	for	for	ADP
dti-3019	100	5	cardiovascular	cardiovascular	ADJ
dti-3019	100	6	diseases	disease	NOUN
dti-3019	100	7	that	that	PRON
dti-3019	100	8	faces	face	VERB
dti-3019	100	9	challenges	challenge	NOUN
dti-3019	100	10	during	during	ADP
dti-3019	100	11	clinical	clinical	ADJ
dti-3019	100	12	trials	trial	NOUN
dti-3019	100	13	is	be	AUX
dti-3019	100	14	methotrexate	methotrexate	ADJ
dti-3019	100	15	.	.	PUNCT
dti-3019	101	1	as	as	SCONJ
dti-3019	101	2	indicated	indicate	VERB
dti-3019	101	3	by	by	ADP
dti-3019	101	4	the	the	DET
dti-3019	101	5	study	study	NOUN
dti-3019	101	6	conducted	conduct	VERB
dti-3019	101	7	by	by	ADP
dti-3019	101	8	moreira	moreira	PROPN
dti-3019	101	9	et	et	PROPN
dti-3019	101	10	al	al	PROPN
dti-3019	101	11	(	(	PUNCT
dti-3019	101	12	48	48	NUM
dti-3019	101	13	)	)	PUNCT
dti-3019	101	14	,	,	PUNCT
dti-3019	101	15	methotrexate	methotrexate	NOUN
dti-3019	101	16	demonstrates	demonstrate	VERB
dti-3019	101	17	no	no	DET
dti-3019	101	18	disparity	disparity	NOUN
dti-3019	101	19	in	in	ADP
dti-3019	101	20	the	the	DET
dti-3019	101	21	duration	duration	NOUN
dti-3019	101	22	of	of	ADP
dti-3019	101	23	a	a	DET
dti-3019	101	24	6	6	NUM
dti-3019	101	25	-	-	PUNCT
dti-3019	101	26	minute	minute	NOUN
dti-3019	101	27	walk	walk	NOUN
dti-3019	101	28	before	before	ADV
dti-3019	101	29	and	and	CCONJ
dti-3019	101	30	after	after	ADP
dti-3019	101	31	treatment	treatment	NOUN
dti-3019	101	32	.	.	PUNCT
dti-3019	102	1	it	it	PRON
dti-3019	102	2	also	also	ADV
dti-3019	102	3	exhibits	exhibit	VERB
dti-3019	102	4	no	no	DET
dti-3019	102	5	impact	impact	NOUN
dti-3019	102	6	on	on	ADP
dti-3019	102	7	the	the	DET
dti-3019	102	8	levels	level	NOUN
dti-3019	102	9	of	of	ADP
dti-3019	102	10	crp	crp	PROPN
dti-3019	102	11	,	,	PUNCT
dti-3019	102	12	nor	nor	CCONJ
dti-3019	102	13	does	do	AUX
dti-3019	102	14	it	it	PRON
dti-3019	102	15	affect	affect	VERB
dti-3019	102	16	the	the	DET
dti-3019	102	17	incidence	incidence	NOUN
dti-3019	102	18	of	of	ADP
dti-3019	102	19	mace	mace	NOUN
dti-3019	102	20	when	when	SCONJ
dti-3019	102	21	compared	compare	VERB
dti-3019	102	22	to	to	ADP
dti-3019	102	23	a	a	DET
dti-3019	102	24	placebo	placebo	NOUN
dti-3019	102	25	.	.	PUNCT
dti-3019	103	1	moreover	moreover	ADV
dti-3019	103	2	,	,	PUNCT
dti-3019	103	3	the	the	DET
dti-3019	103	4	same	same	ADJ
dti-3019	103	5	author	author	NOUN
dti-3019	103	6	’s	’s	PART
dti-3019	103	7	additional	additional	ADJ
dti-3019	103	8	study	study	NOUN
dti-3019	103	9	(	(	PUNCT
dti-3019	103	10	49	49	NUM
dti-3019	103	11	)	)	PUNCT
dti-3019	103	12	reveals	reveal	VERB
dti-3019	103	13	that	that	SCONJ
dti-3019	103	14	methotrexate	methotrexate	NOUN
dti-3019	103	15	has	have	VERB
dti-3019	103	16	no	no	DET
dti-3019	103	17	effect	effect	NOUN
dti-3019	103	18	on	on	ADP
dti-3019	103	19	the	the	DET
dti-3019	103	20	release	release	NOUN
dti-3019	103	21	of	of	ADP
dti-3019	103	22	creatine	creatine	PROPN
dti-3019	103	23	kinase	kinase	NOUN
dti-3019	103	24	during	during	ADP
dti-3019	103	25	the	the	DET
dti-3019	103	26	initial	initial	ADJ
dti-3019	103	27	72	72	NUM
dti-3019	103	28	hours	hour	NOUN
dti-3019	103	29	,	,	PUNCT
dti-3019	103	30	no	no	DET
dti-3019	103	31	discrepancy	discrepancy	NOUN
dti-3019	103	32	in	in	ADP
dti-3019	103	33	crp	crp	PROPN
dti-3019	103	34	levels	level	NOUN
dti-3019	103	35	,	,	PUNCT
dti-3019	103	36	a	a	DET
dti-3019	103	37	significantly	significantly	ADV
dti-3019	103	38	poorer	poor	ADJ
dti-3019	103	39	left	left	ADJ
dti-3019	103	40	ventricular	ventricular	ADJ
dti-3019	103	41	ejection	ejection	NOUN
dti-3019	103	42	fraction	fraction	NOUN
dti-3019	103	43	(	(	PUNCT
dti-3019	103	44	lvef	lvef	NOUN
dti-3019	103	45	)	)	PUNCT
dti-3019	103	46	in	in	ADP
dti-3019	103	47	the	the	DET
dti-3019	103	48	methotrexate	methotrexate	NOUN
dti-3019	103	49	group	group	NOUN
dti-3019	103	50	at	at	ADP
dti-3019	103	51	3	3	NUM
dti-3019	103	52	months	month	NOUN
dti-3019	103	53	,	,	PUNCT
dti-3019	103	54	and	and	CCONJ
dti-3019	103	55	no	no	DET
dti-3019	103	56	impact	impact	NOUN
dti-3019	103	57	on	on	ADP
dti-3019	103	58	the	the	DET
dti-3019	103	59	incidence	incidence	NOUN
dti-3019	103	60	of	of	ADP
dti-3019	103	61	mace	mace	NOUN
dti-3019	103	62	.	.	PUNCT
dti-3019	104	1	conversely	conversely	ADV
dti-3019	104	2	,	,	PUNCT
dti-3019	104	3	in	in	ADP
dti-3019	104	4	ridker	ridker	NOUN
dti-3019	104	5	et	et	PROPN
dti-3019	104	6	al	al	PROPN
dti-3019	104	7	’s	’s	PART
dti-3019	104	8	(	(	PUNCT
dti-3019	104	9	50	50	NUM
dti-3019	104	10	)	)	PUNCT
dti-3019	104	11	study	study	NOUN
dti-3019	104	12	,	,	PUNCT
dti-3019	104	13	the	the	DET
dti-3019	104	14	trial	trial	NOUN
dti-3019	104	15	was	be	AUX
dti-3019	104	16	terminated	terminate	VERB
dti-3019	104	17	prematurely	prematurely	ADV
dti-3019	104	18	due	due	ADP
dti-3019	104	19	to	to	ADP
dti-3019	104	20	the	the	DET
dti-3019	104	21	absence	absence	NOUN
dti-3019	104	22	of	of	ADP
dti-3019	104	23	any	any	DET
dti-3019	104	24	benefits	benefit	NOUN
dti-3019	104	25	.	.	PUNCT
dti-3019	105	1	no	no	DET
dti-3019	105	2	difference	difference	NOUN
dti-3019	105	3	was	be	AUX
dti-3019	105	4	observed	observe	VERB
dti-3019	105	5	in	in	ADP
dti-3019	105	6	the	the	DET
dti-3019	105	7	incidence	incidence	NOUN
dti-3019	105	8	of	of	ADP
dti-3019	105	9	mace	mace	NOUN
dti-3019	105	10	or	or	CCONJ
dti-3019	105	11	in	in	ADP
dti-3019	105	12	the	the	DET
dti-3019	105	13	levels	level	NOUN
dti-3019	105	14	of	of	ADP
dti-3019	105	15	inflammatory	inflammatory	ADJ
dti-3019	105	16	markers	marker	NOUN
dti-3019	105	17	(	(	PUNCT
dti-3019	105	18	white	white	ADJ
dti-3019	105	19	blood	blood	NOUN
dti-3019	105	20	cell	cell	NOUN
dti-3019	105	21	count	count	NOUN
dti-3019	105	22	,	,	PUNCT
dti-3019	105	23	crp	crp	PROPN
dti-3019	105	24	,	,	PUNCT
dti-3019	105	25	interleukin-1β	interleukin-1β	PROPN
dti-3019	105	26	,	,	PUNCT
dti-3019	105	27	interleukin-6	interleukin-6	NUM
dti-3019	105	28	)	)	PUNCT
dti-3019	105	29	at	at	ADP
dti-3019	105	30	8	8	NUM
dti-3019	105	31	months	month	NOUN
dti-3019	105	32	.	.	PUNCT
dti-3019	106	1	however	however	ADV
dti-3019	106	2	,	,	PUNCT
dti-3019	106	3	an	an	DET
dti-3019	106	4	increased	increase	VERB
dti-3019	106	5	occurrence	occurrence	NOUN
dti-3019	106	6	of	of	ADP
dti-3019	106	7	leukopenia	leukopenia	PROPN
dti-3019	106	8	and	and	CCONJ
dti-3019	106	9	non	non	ADJ
dti-3019	106	10	-	-	ADJ
dti-3019	106	11	basal	basal	ADJ
dti-3019	106	12	cell	cell	NOUN
dti-3019	106	13	skin	skin	NOUN
dti-3019	106	14	cancer	cancer	NOUN
dti-3019	106	15	was	be	AUX
dti-3019	106	16	noted	note	VERB
dti-3019	106	17	.	.	PUNCT
dti-3019	107	1	the	the	DET
dti-3019	107	2	final	final	ADJ
dti-3019	107	3	example	example	NOUN
dti-3019	107	4	in	in	ADP
dti-3019	107	5	the	the	DET
dti-3019	107	6	realm	realm	NOUN
dti-3019	107	7	of	of	ADP
dti-3019	107	8	cardiovascular	cardiovascular	ADJ
dti-3019	107	9	medicine	medicine	NOUN
dti-3019	107	10	is	be	AUX
dti-3019	107	11	the	the	DET
dti-3019	107	12	drug	drug	NOUN
dti-3019	107	13	known	know	VERB
dti-3019	107	14	as	as	ADP
dti-3019	107	15	cyclosporine	cyclosporine	NOUN
dti-3019	107	16	.	.	PUNCT
dti-3019	108	1	since	since	SCONJ
dti-3019	108	2	its	its	PRON
dti-3019	108	3	introduction	introduction	NOUN
dti-3019	108	4	into	into	ADP
dti-3019	108	5	clinical	clinical	ADJ
dti-3019	108	6	practice	practice	NOUN
dti-3019	108	7	in	in	ADP
dti-3019	108	8	the	the	DET
dti-3019	108	9	late	late	ADJ
dti-3019	108	10	1970s	1970	NOUN
dti-3019	108	11	(	(	PUNCT
dti-3019	108	12	51	51	NUM
dti-3019	108	13	)	)	PUNCT
dti-3019	108	14	,	,	PUNCT
dti-3019	108	15	the	the	DET
dti-3019	108	16	discovery	discovery	NOUN
dti-3019	108	17	and	and	CCONJ
dti-3019	108	18	utilization	utilization	NOUN
dti-3019	108	19	of	of	ADP
dti-3019	108	20	cyclosporine	cyclosporine	PROPN
dti-3019	108	21	has	have	AUX
dti-3019	108	22	had	have	VERB
dti-3019	108	23	a	a	DET
dti-3019	108	24	significant	significant	ADJ
dti-3019	108	25	impact	impact	NOUN
dti-3019	108	26	on	on	ADP
dti-3019	108	27	the	the	DET
dti-3019	108	28	advancement	advancement	NOUN
dti-3019	108	29	of	of	ADP
dti-3019	108	30	transplant	transplant	NOUN
dti-3019	108	31	medicine	medicine	NOUN
dti-3019	108	32	(	(	PUNCT
dti-3019	108	33	52,53	52,53	NOUN
dti-3019	108	34	)	)	PUNCT
dti-3019	108	35	.	.	PUNCT
dti-3019	109	1	while	while	SCONJ
dti-3019	109	2	it	it	PRON
dti-3019	109	3	has	have	AUX
dti-3019	109	4	shown	show	VERB
dti-3019	109	5	improvements	improvement	NOUN
dti-3019	109	6	in	in	ADP
dti-3019	109	7	the	the	DET
dti-3019	109	8	rates	rate	NOUN
dti-3019	109	9	of	of	ADP
dti-3019	109	10	acute	acute	ADJ
dti-3019	109	11	rejection	rejection	NOUN
dti-3019	109	12	and	and	CCONJ
dti-3019	109	13	early	early	ADJ
dti-3019	109	14	graft	graft	NOUN
dti-3019	109	15	survival	survival	NOUN
dti-3019	109	16	,	,	PUNCT
dti-3019	109	17	the	the	DET
dti-3019	109	18	evidence	evidence	NOUN
dti-3019	109	19	regarding	regard	VERB
dti-3019	109	20	long	long	ADJ
dti-3019	109	21	-	-	PUNCT
dti-3019	109	22	term	term	NOUN
dti-3019	109	23	survival	survival	NOUN
dti-3019	109	24	of	of	ADP
dti-3019	109	25	renal	renal	ADJ
dti-3019	109	26	allografts	allograft	NOUN
dti-3019	109	27	is	be	AUX
dti-3019	109	28	less	less	ADV
dti-3019	109	29	convincing	convincing	ADJ
dti-3019	109	30	(	(	PUNCT
dti-3019	109	31	54	54	NUM
dti-3019	109	32	)	)	PUNCT
dti-3019	109	33	.	.	PUNCT
dti-3019	110	1	the	the	DET
dti-3019	110	2	identification	identification	NOUN
dti-3019	110	3	of	of	ADP
dti-3019	110	4	acute	acute	ADJ
dti-3019	110	5	reversible	reversible	ADJ
dti-3019	110	6	nephrotoxicity	nephrotoxicity	NOUN
dti-3019	110	7	and	and	CCONJ
dti-3019	110	8	nephrotoxicity	nephrotoxicity	NOUN
dti-3019	110	9	in	in	ADP
dti-3019	110	10	nonrenal	nonrenal	ADJ
dti-3019	110	11	transplants	transplant	NOUN
dti-3019	110	12	has	have	AUX
dti-3019	110	13	subsequently	subsequently	ADV
dti-3019	110	14	led	lead	VERB
dti-3019	110	15	to	to	ADP
dti-3019	110	16	the	the	DET
dti-3019	110	17	widely	widely	ADV
dti-3019	110	18	accepted	accept	VERB
dti-3019	110	19	notion	notion	NOUN
dti-3019	110	20	that	that	SCONJ
dti-3019	110	21	there	there	PRON
dti-3019	110	22	is	be	VERB
dti-3019	110	23	also	also	ADV
dti-3019	110	24	a	a	DET
dti-3019	110	25	chronic	chronic	ADJ
dti-3019	110	26	and	and	CCONJ
dti-3019	110	27	more	more	ADV
dti-3019	110	28	irreversible	irreversible	ADJ
dti-3019	110	29	component	component	NOUN
dti-3019	110	30	to	to	ADP
dti-3019	110	31	this	this	DET
dti-3019	110	32	drug	drug	NOUN
dti-3019	110	33	(	(	PUNCT
dti-3019	110	34	55	55	NUM
dti-3019	110	35	)	)	PUNCT
dti-3019	110	36	.	.	PUNCT
dti-3019	111	1	consequently	consequently	ADV
dti-3019	111	2	,	,	PUNCT
dti-3019	111	3	there	there	PRON
dti-3019	111	4	has	have	AUX
dti-3019	111	5	been	be	AUX
dti-3019	111	6	a	a	DET
dti-3019	111	7	strong	strong	ADJ
dti-3019	111	8	interest	interest	NOUN
dti-3019	111	9	in	in	ADP
dti-3019	111	10	developing	develop	VERB
dti-3019	111	11	protocols	protocol	NOUN
dti-3019	111	12	that	that	PRON
dti-3019	111	13	aim	aim	VERB
dti-3019	111	14	to	to	PART
dti-3019	111	15	minimize	minimize	VERB
dti-3019	111	16	or	or	CCONJ
dti-3019	111	17	even	even	ADV
dti-3019	111	18	eliminate	eliminate	VERB
dti-3019	111	19	the	the	DET
dti-3019	111	20	use	use	NOUN
dti-3019	111	21	of	of	ADP
dti-3019	111	22	calcineurin	calcineurin	ADJ
dti-3019	111	23	inhibitors	inhibitor	NOUN
dti-3019	111	24	altogether	altogether	ADV
dti-3019	111	25	(	(	PUNCT
dti-3019	111	26	56	56	NUM
dti-3019	111	27	)	)	PUNCT
dti-3019	111	28	.	.	PUNCT
dti-3019	112	1	despite	despite	SCONJ
dti-3019	112	2	these	these	DET
dti-3019	112	3	considerations	consideration	NOUN
dti-3019	112	4	,	,	PUNCT
dti-3019	112	5	cyclosporine	cyclosporine	NOUN
dti-3019	112	6	has	have	AUX
dti-3019	112	7	been	be	AUX
dti-3019	112	8	repurposed	repurpose	VERB
dti-3019	112	9	for	for	ADP
dti-3019	112	10	various	various	ADJ
dti-3019	112	11	other	other	ADJ
dti-3019	112	12	diseases	disease	NOUN
dti-3019	112	13	,	,	PUNCT
dti-3019	112	14	including	include	VERB
dti-3019	112	15	cardiovascular	cardiovascular	ADJ
dti-3019	112	16	diseases	disease	NOUN
dti-3019	112	17	(	(	PUNCT
dti-3019	112	18	57,58	57,58	NUM
dti-3019	112	19	)	)	PUNCT
dti-3019	112	20	.	.	PUNCT
dti-3019	113	1	in	in	ADP
dti-3019	113	2	two	two	NUM
dti-3019	113	3	separate	separate	ADJ
dti-3019	113	4	trials	trial	NOUN
dti-3019	113	5	involving	involve	VERB
dti-3019	113	6	patients	patient	NOUN
dti-3019	113	7	with	with	ADP
dti-3019	113	8	st	st	PROPN
dti-3019	113	9	-	-	PUNCT
dti-3019	113	10	segment	segment	NOUN
dti-3019	113	11	elevation	elevation	NOUN
dti-3019	113	12	myocardial	myocardial	ADJ
dti-3019	113	13	infarction	infarction	NOUN
dti-3019	113	14	(	(	PUNCT
dti-3019	113	15	stemi	stemi	PROPN
dti-3019	113	16	)	)	PUNCT
dti-3019	113	17	,	,	PUNCT
dti-3019	113	18	cyclosporine	cyclosporine	PROPN
dti-3019	113	19	failed	fail	VERB
dti-3019	113	20	to	to	PART
dti-3019	113	21	demonstrate	demonstrate	VERB
dti-3019	113	22	any	any	DET
dti-3019	113	23	beneficial	beneficial	ADJ
dti-3019	113	24	effects	effect	NOUN
dti-3019	113	25	on	on	ADP
dti-3019	113	26	st	st	ADJ
dti-3019	113	27	-	-	PUNCT
dti-3019	113	28	segment	segment	NOUN
dti-3019	113	29	resolution	resolution	NOUN
dti-3019	113	30	,	,	PUNCT
dti-3019	113	31	left	leave	VERB
dti-3019	113	32	ventricular	ventricular	ADJ
dti-3019	113	33	remodeling	remodeling	NOUN
dti-3019	113	34	,	,	PUNCT
dti-3019	113	35	or	or	CCONJ
dti-3019	113	36	the	the	DET
dti-3019	113	37	incidence	incidence	NOUN
dti-3019	113	38	of	of	ADP
dti-3019	113	39	cardiovascular	cardiovascular	ADJ
dti-3019	113	40	events	event	NOUN
dti-3019	113	41	during	during	ADP
dti-3019	113	42	the	the	DET
dti-3019	113	43	respective	respective	ADJ
dti-3019	113	44	trial	trial	NOUN
dti-3019	113	45	periods	period	NOUN
dti-3019	113	46	of	of	ADP
dti-3019	113	47	6	6	NUM
dti-3019	113	48	months	month	NOUN
dti-3019	113	49	and	and	CCONJ
dti-3019	113	50	1	1	NUM
dti-3019	113	51	year	year	NOUN
dti-3019	113	52	(	(	PUNCT
dti-3019	113	53	57,58	57,58	NUM
dti-3019	113	54	)	)	PUNCT
dti-3019	113	55	.	.	PUNCT
dti-3019	114	1	moreover	moreover	ADV
dti-3019	114	2	,	,	PUNCT
dti-3019	114	3	the	the	DET
dti-3019	114	4	use	use	NOUN
dti-3019	114	5	of	of	ADP
dti-3019	114	6	cyclosporine	cyclosporine	NOUN
dti-3019	114	7	in	in	ADP
dti-3019	114	8	cardiovascular	cardiovascular	ADJ
dti-3019	114	9	medicine	medicine	NOUN
dti-3019	114	10	has	have	AUX
dti-3019	114	11	been	be	AUX
dti-3019	114	12	associated	associate	VERB
dti-3019	114	13	with	with	ADP
dti-3019	114	14	certain	certain	ADJ
dti-3019	114	15	side	side	NOUN
dti-3019	114	16	effects	effect	NOUN
dti-3019	114	17	such	such	ADJ
dti-3019	114	18	as	as	ADP
dti-3019	114	19	hypertension	hypertension	NOUN
dti-3019	114	20	,	,	PUNCT
dti-3019	114	21	hyperlipidemia	hyperlipidemia	NOUN
dti-3019	114	22	,	,	PUNCT
dti-3019	114	23	and	and	CCONJ
dti-3019	114	24	diabetes	diabetes	NOUN
dti-3019	114	25	mellitus	mellitus	NOUN
dti-3019	114	26	(	(	PUNCT
dti-3019	114	27	59	59	NUM
dti-3019	114	28	)	)	PUNCT
dti-3019	114	29	.	.	PUNCT
dti-3019	115	1	these	these	DET
dti-3019	115	2	side	side	NOUN
dti-3019	115	3	effects	effect	NOUN
dti-3019	115	4	may	may	AUX
dti-3019	115	5	contribute	contribute	VERB
dti-3019	115	6	to	to	ADP
dti-3019	115	7	the	the	DET
dti-3019	115	8	high	high	ADJ
dti-3019	115	9	cardiovascular	cardiovascular	ADJ
dti-3019	115	10	morbidity	morbidity	NOUN
dti-3019	115	11	in	in	ADP
dti-3019	115	12	renal	renal	ADJ
dti-3019	115	13	transplant	transplant	NOUN
dti-3019	115	14	patients	patient	NOUN
dti-3019	115	15	and	and	CCONJ
dti-3019	115	16	the	the	DET
dti-3019	115	17	development	development	NOUN
dti-3019	115	18	of	of	ADP
dti-3019	115	19	chronic	chronic	ADJ
dti-3019	115	20	transplant	transplant	NOUN
dti-3019	115	21	nephropathy	nephropathy	NOUN
dti-3019	115	22	(	(	PUNCT
dti-3019	115	23	60	60	NUM
dti-3019	115	24	)	)	PUNCT
dti-3019	115	25	.	.	PUNCT
dti-3019	116	1	in	in	ADP
dti-3019	116	2	conclusion	conclusion	NOUN
dti-3019	116	3	,	,	PUNCT
dti-3019	116	4	while	while	SCONJ
dti-3019	116	5	cyclosporine	cyclosporine	NOUN
dti-3019	116	6	has	have	AUX
dti-3019	116	7	revolutionized	revolutionize	VERB
dti-3019	116	8	transplant	transplant	NOUN
dti-3019	116	9	medicine	medicine	NOUN
dti-3019	116	10	,	,	PUNCT
dti-3019	116	11	its	its	PRON
dti-3019	116	12	use	use	NOUN
dti-3019	116	13	in	in	ADP
dti-3019	116	14	cardiovascular	cardiovascular	ADJ
dti-3019	116	15	medicine	medicine	NOUN
dti-3019	116	16	comes	come	VERB
dti-3019	116	17	with	with	ADP
dti-3019	116	18	potential	potential	ADJ
dti-3019	116	19	side	side	NOUN
dti-3019	116	20	effects	effect	NOUN
dti-3019	116	21	that	that	PRON
dti-3019	116	22	must	must	AUX
dti-3019	116	23	be	be	AUX
dti-3019	116	24	carefully	carefully	ADV
dti-3019	116	25	monitored	monitor	VERB
dti-3019	116	26	and	and	CCONJ
dti-3019	116	27	managed	manage	VERB
dti-3019	116	28	to	to	PART
dti-3019	116	29	ensure	ensure	VERB
dti-3019	116	30	patient	patient	ADJ
dti-3019	116	31	safety	safety	NOUN
dti-3019	116	32	and	and	CCONJ
dti-3019	116	33	optimal	optimal	ADJ
dti-3019	116	34	outcomes	outcome	NOUN
dti-3019	116	35	(	(	PUNCT
dti-3019	116	36	61	61	NUM
dti-3019	116	37	)	)	PUNCT
dti-3019	116	38	.	.	PUNCT
dti-3019	117	1	challenges	challenge	NOUN
dti-3019	117	2	in	in	ADP
dti-3019	117	3	cancer	cancer	NOUN
dti-3019	117	4	endeavor	endeavor	NOUN
dti-3019	117	5	in	in	ADP
dti-3019	117	6	the	the	DET
dti-3019	117	7	field	field	NOUN
dti-3019	117	8	of	of	ADP
dti-3019	117	9	hematological	hematological	ADJ
dti-3019	117	10	malignancies	malignancy	NOUN
dti-3019	117	11	,	,	PUNCT
dti-3019	117	12	despite	despite	SCONJ
dti-3019	117	13	the	the	DET
dti-3019	117	14	introduction	introduction	NOUN
dti-3019	117	15	of	of	ADP
dti-3019	117	16	drug	drug	NOUN
dti-3019	117	17	repurposing	repurposing	NOUN
dti-3019	117	18	,	,	PUNCT
dti-3019	117	19	which	which	PRON
dti-3019	117	20	presents	present	VERB
dti-3019	117	21	new	new	ADJ
dti-3019	117	22	possibilities	possibility	NOUN
dti-3019	117	23	for	for	ADP
dti-3019	117	24	innovative	innovative	ADJ
dti-3019	117	25	treatments	treatment	NOUN
dti-3019	117	26	,	,	PUNCT
dti-3019	117	27	achieving	achieve	VERB
dti-3019	117	28	complete	complete	ADJ
dti-3019	117	29	remission	remission	NOUN
dti-3019	117	30	remains	remain	VERB
dti-3019	117	31	an	an	DET
dti-3019	117	32	arduous	arduous	ADJ
dti-3019	117	33	task	task	NOUN
dti-3019	117	34	(	(	PUNCT
dti-3019	117	35	62	62	NUM
dti-3019	117	36	)	)	PUNCT
dti-3019	117	37	.	.	PUNCT
dti-3019	118	1	clinical	clinical	ADJ
dti-3019	118	2	trials	trial	NOUN
dti-3019	118	3	that	that	PRON
dti-3019	118	4	explore	explore	VERB
dti-3019	118	5	the	the	DET
dti-3019	118	6	repurposing	repurposing	NOUN
dti-3019	118	7	of	of	ADP
dti-3019	118	8	drugs	drug	NOUN
dti-3019	118	9	in	in	ADP
dti-3019	118	10	oncology	oncology	NOUN
dti-3019	118	11	have	have	AUX
dti-3019	118	12	exhibited	exhibit	VERB
dti-3019	118	13	varying	vary	VERB
dti-3019	118	14	levels	level	NOUN
dti-3019	118	15	of	of	ADP
dti-3019	118	16	success	success	NOUN
dti-3019	118	17	,	,	PUNCT
dti-3019	118	18	with	with	ADP
dti-3019	118	19	certain	certain	ADJ
dti-3019	118	20	limitations	limitation	NOUN
dti-3019	118	21	such	such	ADJ
dti-3019	118	22	as	as	ADP
dti-3019	118	23	limited	limited	ADJ
dti-3019	118	24	sample	sample	NOUN
dti-3019	118	25	sizes	size	NOUN
dti-3019	118	26	and	and	CCONJ
dti-3019	118	27	participant	participant	ADJ
dti-3019	118	28	heterogeneity	heterogeneity	NOUN
dti-3019	118	29	(	(	PUNCT
dti-3019	118	30	63	63	NUM
dti-3019	118	31	)	)	PUNCT
dti-3019	118	32	.	.	PUNCT
dti-3019	119	1	an	an	DET
dti-3019	119	2	illustration	illustration	NOUN
dti-3019	119	3	of	of	ADP
dti-3019	119	4	repurposing	repurpose	VERB
dti-3019	119	5	challenges	challenge	NOUN
dti-3019	119	6	in	in	ADP
dti-3019	119	7	multiple	multiple	ADJ
dti-3019	119	8	clinical	clinical	ADJ
dti-3019	119	9	trials	trial	NOUN
dti-3019	119	10	has	have	AUX
dti-3019	119	11	come	come	VERB
dti-3019	119	12	to	to	ADP
dti-3019	119	13	light	light	NOUN
dti-3019	119	14	.	.	PUNCT
dti-3019	120	1	one	one	NUM
dti-3019	120	2	such	such	ADJ
dti-3019	120	3	instance	instance	NOUN
dti-3019	120	4	involves	involve	VERB
dti-3019	120	5	the	the	DET
dti-3019	120	6	repurposing	repurposing	NOUN
dti-3019	120	7	of	of	ADP
dti-3019	120	8	bortezomib	bortezomib	NOUN
dti-3019	120	9	to	to	PART
dti-3019	120	10	target	target	VERB
dti-3019	120	11	hematological	hematological	ADJ
dti-3019	120	12	malignancies	malignancy	NOUN
dti-3019	120	13	.	.	PUNCT
dti-3019	121	1	however	however	ADV
dti-3019	121	2	,	,	PUNCT
dti-3019	121	3	this	this	DET
dti-3019	121	4	drug	drug	NOUN
dti-3019	121	5	proved	prove	VERB
dti-3019	121	6	to	to	PART
dti-3019	121	7	be	be	AUX
dti-3019	121	8	ineffective	ineffective	ADJ
dti-3019	121	9	as	as	ADP
dti-3019	121	10	a	a	DET
dti-3019	121	11	stand	stand	VERB
dti-3019	121	12	-	-	PUNCT
dti-3019	121	13	alone	alone	ADJ
dti-3019	121	14	treatment	treatment	NOUN
dti-3019	121	15	for	for	ADP
dti-3019	121	16	other	other	ADJ
dti-3019	121	17	malignancies	malignancy	NOUN
dti-3019	121	18	,	,	PUNCT
dti-3019	121	19	including	include	VERB
dti-3019	121	20	acute	acute	ADJ
dti-3019	121	21	myelogenous	myelogenous	ADJ
dti-3019	121	22	leukemia	leukemia	NOUN
dti-3019	121	23	(	(	PUNCT
dti-3019	121	24	aml	aml	PROPN
dti-3019	121	25	)	)	PUNCT
dti-3019	121	26	(	(	PUNCT
dti-3019	121	27	62	62	NUM
dti-3019	121	28	)	)	PUNCT
dti-3019	121	29	.	.	PUNCT
dti-3019	122	1	another	another	DET
dti-3019	122	2	example	example	NOUN
dti-3019	122	3	that	that	PRON
dti-3019	122	4	showcases	showcase	VERB
dti-3019	122	5	the	the	DET
dti-3019	122	6	act	act	NOUN
dti-3019	122	7	of	of	ADP
dti-3019	122	8	appropriating	appropriate	VERB
dti-3019	122	9	preexisting	preexist	VERB
dti-3019	122	10	resources	resource	NOUN
dti-3019	122	11	for	for	ADP
dti-3019	122	12	alternative	alternative	ADJ
dti-3019	122	13	purposes	purpose	NOUN
dti-3019	122	14	pertains	pertain	NOUN
dti-3019	122	15	to	to	ADP
dti-3019	122	16	the	the	DET
dti-3019	122	17	potential	potential	ADJ
dti-3019	122	18	drawbacks	drawback	NOUN
dti-3019	122	19	that	that	PRON
dti-3019	122	20	arise	arise	VERB
dti-3019	122	21	when	when	SCONJ
dti-3019	122	22	repurposing	repurpose	VERB
dti-3019	122	23	the	the	DET
dti-3019	122	24	chemical	chemical	NOUN
dti-3019	122	25	compound	compound	NOUN
dti-3019	122	26	valproic	valproic	ADJ
dti-3019	122	27	acid	acid	NOUN
dti-3019	122	28	(	(	PUNCT
dti-3019	122	29	vpa	vpa	PROPN
dti-3019	122	30	)	)	PUNCT
dti-3019	122	31	for	for	ADP
dti-3019	122	32	various	various	ADJ
dti-3019	122	33	medical	medical	ADJ
dti-3019	122	34	applications	application	NOUN
dti-3019	122	35	.	.	PUNCT
dti-3019	123	1	these	these	DET
dti-3019	123	2	disadvantages	disadvantage	NOUN
dti-3019	123	3	,	,	PUNCT
dti-3019	123	4	such	such	ADJ
dti-3019	123	5	as	as	ADP
dti-3019	123	6	its	its	PRON
dti-3019	123	7	lack	lack	NOUN
dti-3019	123	8	of	of	ADP
dti-3019	123	9	improvement	improvement	NOUN
dti-3019	123	10	in	in	ADP
dti-3019	123	11	clinical	clinical	ADJ
dti-3019	123	12	outcomes	outcome	NOUN
dti-3019	123	13	for	for	ADP
dti-3019	123	14	patients	patient	NOUN
dti-3019	123	15	with	with	ADP
dti-3019	123	16	myelodysplastic	myelodysplastic	ADJ
dti-3019	123	17	syndrome	syndrome	NOUN
dti-3019	123	18	(	(	PUNCT
dti-3019	123	19	mds	mds	PROPN
dti-3019	123	20	)	)	PUNCT
dti-3019	123	21	or	or	CCONJ
dti-3019	123	22	elderly	elderly	ADJ
dti-3019	123	23	patients	patient	NOUN
dti-3019	123	24	with	with	ADP
dti-3019	123	25	aml	aml	PROPN
dti-3019	123	26	in	in	ADP
dti-3019	123	27	a	a	DET
dti-3019	123	28	randomized	randomized	ADJ
dti-3019	123	29	phase	phase	NOUN
dti-3019	123	30	ii	ii	NOUN
dti-3019	123	31	study	study	NOUN
dti-3019	123	32	of	of	ADP
dti-3019	123	33	low	low	ADJ
dti-3019	123	34	-	-	PUNCT
dti-3019	123	35	dose	dose	NOUN
dti-3019	123	36	decitabine	decitabine	NOUN
dti-3019	123	37	with	with	ADP
dti-3019	123	38	vpa	vpa	PROPN
dti-3019	123	39	,	,	PUNCT
dti-3019	123	40	have	have	AUX
dti-3019	123	41	been	be	AUX
dti-3019	123	42	observed	observe	VERB
dti-3019	123	43	(	(	PUNCT
dti-3019	123	44	64	64	NUM
dti-3019	123	45	)	)	PUNCT
dti-3019	123	46	.	.	PUNCT
dti-3019	124	1	additionally	additionally	ADV
dti-3019	124	2	,	,	PUNCT
dti-3019	124	3	another	another	DET
dti-3019	124	4	study	study	NOUN
dti-3019	124	5	found	find	VERB
dti-3019	124	6	that	that	SCONJ
dti-3019	124	7	vpa	vpa	PROPN
dti-3019	124	8	did	do	AUX
dti-3019	124	9	not	not	PART
dti-3019	124	10	have	have	VERB
dti-3019	124	11	an	an	DET
dti-3019	124	12	impact	impact	NOUN
dti-3019	124	13	on	on	ADP
dti-3019	124	14	the	the	DET
dti-3019	124	15	objective	objective	ADJ
dti-3019	124	16	response	response	NOUN
dti-3019	124	17	rate	rate	NOUN
dti-3019	124	18	or	or	CCONJ
dti-3019	124	19	overall	overall	ADJ
dti-3019	124	20	survival	survival	NOUN
dti-3019	124	21	(	(	PUNCT
dti-3019	124	22	65	65	NUM
dti-3019	124	23	)	)	PUNCT
dti-3019	124	24	.	.	PUNCT
dti-3019	125	1	furthermore	furthermore	ADV
dti-3019	125	2	,	,	PUNCT
dti-3019	125	3	a	a	DET
dti-3019	125	4	randomized	randomized	ADJ
dti-3019	125	5	phase	phase	NOUN
dti-3019	125	6	iii	iii	NUM
dti-3019	125	7	study	study	NOUN
dti-3019	125	8	examining	examine	VERB
dti-3019	125	9	the	the	DET
dti-3019	125	10	safety	safety	NOUN
dti-3019	125	11	and	and	CCONJ
dti-3019	125	12	efficacy	efficacy	NOUN
dti-3019	125	13	of	of	ADP
dti-3019	125	14	combining	combine	VERB
dti-3019	125	15	vpa	vpa	PROPN
dti-3019	125	16	and	and	CCONJ
dti-3019	125	17	all	all	PROPN
dti-3019	125	18	-	-	PUNCT
dti-3019	125	19	trans	trans	PROPN
dti-3019	125	20	retinoic	retinoic	PROPN
dti-3019	125	21	acid	acid	PROPN
dti-3019	125	22	(	(	PUNCT
dti-3019	125	23	atra	atra	PROPN
dti-3019	125	24	)	)	PUNCT
dti-3019	125	25	with	with	ADP
dti-3019	125	26	induction	induction	NOUN
dti-3019	125	27	therapy	therapy	NOUN
dti-3019	125	28	(	(	PUNCT
dti-3019	125	29	idarubicin	idarubicin	NOUN
dti-3019	125	30	and	and	CCONJ
dti-3019	125	31	cytarabine	cytarabine	NOUN
dti-3019	125	32	)	)	PUNCT
dti-3019	125	33	for	for	ADP
dti-3019	125	34	the	the	DET
dti-3019	125	35	treatment	treatment	NOUN
dti-3019	125	36	of	of	ADP
dti-3019	125	37	elderly	elderly	ADJ
dti-3019	125	38	aml	aml	NOUN
dti-3019	125	39	patients	patient	NOUN
dti-3019	125	40	was	be	AUX
dti-3019	125	41	terminated	terminate	VERB
dti-3019	125	42	prematurely	prematurely	ADV
dti-3019	125	43	due	due	ADP
dti-3019	125	44	to	to	ADP
dti-3019	125	45	the	the	DET
dti-3019	125	46	absence	absence	NOUN
dti-3019	125	47	of	of	ADP
dti-3019	125	48	clinical	clinical	ADJ
dti-3019	125	49	improvement	improvement	NOUN
dti-3019	125	50	in	in	ADP
dti-3019	125	51	the	the	DET
dti-3019	125	52	vpa	vpa	PROPN
dti-3019	125	53	group	group	NOUN
dti-3019	125	54	compared	compare	VERB
dti-3019	125	55	to	to	ADP
dti-3019	125	56	standard	standard	ADJ
dti-3019	125	57	treatment	treatment	NOUN
dti-3019	125	58	(	(	PUNCT
dti-3019	125	59	66	66	NUM
dti-3019	125	60	)	)	PUNCT
dti-3019	125	61	.	.	PUNCT
dti-3019	126	1	this	this	DET
dti-3019	126	2	lack	lack	NOUN
dti-3019	126	3	of	of	ADP
dti-3019	126	4	improvement	improvement	NOUN
dti-3019	126	5	was	be	AUX
dti-3019	126	6	further	far	ADV
dti-3019	126	7	compounded	compound	VERB
dti-3019	126	8	by	by	ADP
dti-3019	126	9	hematologic	hematologic	NOUN
dti-3019	126	10	toxicity	toxicity	NOUN
dti-3019	126	11	and	and	CCONJ
dti-3019	126	12	higher	high	ADJ
dti-3019	126	13	mortality	mortality	NOUN
dti-3019	126	14	rates	rate	NOUN
dti-3019	126	15	associated	associate	VERB
dti-3019	126	16	with	with	ADP
dti-3019	126	17	vpa	vpa	PROPN
dti-3019	126	18	(	(	PUNCT
dti-3019	126	19	67	67	NUM
dti-3019	126	20	)	)	PUNCT
dti-3019	126	21	.	.	PUNCT
dti-3019	127	1	all	all	PRON
dti-3019	127	2	of	of	ADP
dti-3019	127	3	these	these	DET
dti-3019	127	4	clinical	clinical	ADJ
dti-3019	127	5	studies	study	NOUN
dti-3019	127	6	shed	shed	VERB
dti-3019	127	7	light	light	NOUN
dti-3019	127	8	on	on	ADP
dti-3019	127	9	the	the	DET
dti-3019	127	10	limitations	limitation	NOUN
dti-3019	127	11	and	and	CCONJ
dti-3019	127	12	challenges	challenge	VERB
dti-3019	127	13	inherent	inherent	ADJ
dti-3019	127	14	in	in	ADP
dti-3019	127	15	using	use	VERB
dti-3019	127	16	vpa	vpa	PROPN
dti-3019	127	17	in	in	ADP
dti-3019	127	18	contexts	context	NOUN
dti-3019	127	19	other	other	ADJ
dti-3019	127	20	than	than	ADP
dti-3019	127	21	its	its	PRON
dti-3019	127	22	original	original	ADJ
dti-3019	127	23	intention	intention	NOUN
dti-3019	127	24	.	.	PUNCT
dti-3019	128	1	however	however	ADV
dti-3019	128	2	,	,	PUNCT
dti-3019	128	3	there	there	PRON
dti-3019	128	4	is	be	VERB
dti-3019	128	5	promising	promise	VERB
dti-3019	128	6	potential	potential	NOUN
dti-3019	128	7	for	for	ADP
dti-3019	128	8	computational	computational	ADJ
dti-3019	128	9	drug	drug	NOUN
dti-3019	128	10	repurposing	repurpose	VERB
dti-3019	128	11	to	to	PART
dti-3019	128	12	forecast	forecast	VERB
dti-3019	128	13	the	the	DET
dti-3019	128	14	effectiveness	effectiveness	NOUN
dti-3019	128	15	of	of	ADP
dti-3019	128	16	repurposed	repurpose	VERB
dti-3019	128	17	medications	medication	NOUN
dti-3019	128	18	in	in	ADP
dti-3019	128	19	phase	phase	NOUN
dti-3019	128	20	iii	iii	NUM
dti-3019	128	21	clinical	clinical	ADJ
dti-3019	128	22	trials	trial	NOUN
dti-3019	128	23	,	,	PUNCT
dti-3019	128	24	thereby	thereby	ADV
dti-3019	128	25	streamlining	streamline	VERB
dti-3019	128	26	the	the	DET
dti-3019	128	27	process	process	NOUN
dti-3019	128	28	(	(	PUNCT
dti-3019	128	29	68	68	NUM
dti-3019	128	30	)	)	PUNCT
dti-3019	128	31	.	.	PUNCT
dti-3019	129	1	challenges	challenge	NOUN
dti-3019	129	2	in	in	ADP
dti-3019	129	3	diabetes	diabetes	NOUN
dti-3019	129	4	endeavor	endeavor	VERB
dti-3019	129	5	drug	drug	NOUN
dti-3019	129	6	repurposing	repurpose	VERB
dti-3019	129	7	trials	trial	NOUN
dti-3019	129	8	in	in	ADP
dti-3019	129	9	the	the	DET
dti-3019	129	10	field	field	NOUN
dti-3019	129	11	of	of	ADP
dti-3019	129	12	diabetes	diabetes	NOUN
dti-3019	129	13	have	have	AUX
dti-3019	129	14	encountered	encounter	VERB
dti-3019	129	15	numerous	numerous	ADJ
dti-3019	129	16	hurdles	hurdle	NOUN
dti-3019	129	17	and	and	CCONJ
dti-3019	129	18	instances	instance	NOUN
dti-3019	129	19	of	of	ADP
dti-3019	129	20	failure	failure	NOUN
dti-3019	129	21	.	.	PUNCT
dti-3019	130	1	a	a	DET
dti-3019	130	2	particular	particular	ADJ
dti-3019	130	3	study	study	NOUN
dti-3019	130	4	examined	examine	VERB
dti-3019	130	5	the	the	DET
dti-3019	130	6	inability	inability	NOUN
dti-3019	130	7	of	of	ADP
dti-3019	130	8	prominent	prominent	ADJ
dti-3019	130	9	pharmaceutical	pharmaceutical	ADJ
dti-3019	130	10	companies	company	NOUN
dti-3019	130	11	to	to	PART
dti-3019	130	12	develop	develop	VERB
dti-3019	130	13	novel	novel	ADJ
dti-3019	130	14	treatments	treatment	NOUN
dti-3019	130	15	for	for	ADP
dti-3019	130	16	type	type	NOUN
dti-3019	130	17	2	2	NUM
dti-3019	130	18	diabetes	diabetes	NOUN
dti-3019	130	19	(	(	PUNCT
dti-3019	130	20	t2d	t2d	NOUN
dti-3019	130	21	)	)	PUNCT
dti-3019	130	22	despite	despite	SCONJ
dti-3019	130	23	significant	significant	ADJ
dti-3019	130	24	investments	investment	NOUN
dti-3019	130	25	in	in	ADP
dti-3019	130	26	traditional	traditional	ADJ
dti-3019	130	27	drug	drug	NOUN
dti-3019	130	28	development	development	NOUN
dti-3019	130	29	pipelines	pipeline	NOUN
dti-3019	130	30	(	(	PUNCT
dti-3019	130	31	69	69	NUM
dti-3019	130	32	)	)	PUNCT
dti-3019	130	33	.	.	PUNCT
dti-3019	131	1	another	another	DET
dti-3019	131	2	scholarly	scholarly	ADJ
dti-3019	131	3	article	article	NOUN
dti-3019	131	4	highlighted	highlight	VERB
dti-3019	131	5	the	the	DET
dti-3019	131	6	challenges	challenge	NOUN
dti-3019	131	7	faced	face	VERB
dti-3019	131	8	by	by	ADP
dti-3019	131	9	potentially	potentially	ADV
dti-3019	131	10	effective	effective	ADJ
dti-3019	131	11	the	the	DET
dti-3019	131	12	dark	dark	ADJ
dti-3019	131	13	side	side	NOUN
dti-3019	131	14	of	of	ADP
dti-3019	131	15	drug	drug	NOUN
dti-3019	131	16	repurposing12	repurposing12	NOUN
dti-3019	132	1	©	©	ADP
dti-3019	132	2	2024	2024	NUM
dti-3019	133	1	the	the	DET
dti-3019	133	2	authors	author	NOUN
dti-3019	133	3	.	.	PUNCT
dti-3019	134	1	drug	drug	NOUN
dti-3019	134	2	target	target	NOUN
dti-3019	134	3	insights	insight	NOUN
dti-3019	134	4	issn	issn	VERB
dti-3019	134	5	1177	1177	NUM
dti-3019	134	6	-	-	SYM
dti-3019	134	7	3928	3928	NUM
dti-3019	134	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3019	134	9	medications	medication	NOUN
dti-3019	134	10	during	during	ADP
dti-3019	134	11	the	the	DET
dti-3019	134	12	advanced	advanced	ADJ
dti-3019	134	13	stages	stage	NOUN
dti-3019	134	14	of	of	ADP
dti-3019	134	15	clinical	clinical	ADJ
dti-3019	134	16	trials	trial	NOUN
dti-3019	134	17	for	for	ADP
dti-3019	134	18	diabetes	diabetes	NOUN
dti-3019	134	19	management	management	NOUN
dti-3019	134	20	(	(	PUNCT
dti-3019	134	21	70	70	NUM
dti-3019	134	22	)	)	PUNCT
dti-3019	134	23	.	.	PUNCT
dti-3019	135	1	researchers	researcher	NOUN
dti-3019	135	2	in	in	ADP
dti-3019	135	3	the	the	DET
dti-3019	135	4	same	same	ADJ
dti-3019	135	5	field	field	NOUN
dti-3019	135	6	are	be	AUX
dti-3019	135	7	presently	presently	ADV
dti-3019	135	8	attempting	attempt	VERB
dti-3019	135	9	to	to	PART
dti-3019	135	10	repurpose	repurpose	VERB
dti-3019	135	11	antidiabetic	antidiabetic	ADJ
dti-3019	135	12	medications	medication	NOUN
dti-3019	135	13	with	with	ADP
dti-3019	135	14	the	the	DET
dti-3019	135	15	aim	aim	NOUN
dti-3019	135	16	of	of	ADP
dti-3019	135	17	addressing	address	VERB
dti-3019	135	18	dementia	dementia	NOUN
dti-3019	135	19	,	,	PUNCT
dti-3019	135	20	characterized	characterize	VERB
dti-3019	135	21	by	by	ADP
dti-3019	135	22	the	the	DET
dti-3019	135	23	prevalence	prevalence	NOUN
dti-3019	135	24	of	of	ADP
dti-3019	135	25	insulin	insulin	NOUN
dti-3019	135	26	sensitizers	sensitizer	NOUN
dti-3019	135	27	and	and	CCONJ
dti-3019	135	28	insulin	insulin	NOUN
dti-3019	135	29	substrates	substrate	NOUN
dti-3019	135	30	.	.	PUNCT
dti-3019	136	1	despite	despite	SCONJ
dti-3019	136	2	the	the	DET
dti-3019	136	3	initial	initial	ADJ
dti-3019	136	4	appearance	appearance	NOUN
dti-3019	136	5	of	of	ADP
dti-3019	136	6	promise	promise	NOUN
dti-3019	136	7	and	and	CCONJ
dti-3019	136	8	the	the	DET
dti-3019	136	9	potential	potential	NOUN
dti-3019	136	10	for	for	ADP
dti-3019	136	11	success	success	NOUN
dti-3019	136	12	,	,	PUNCT
dti-3019	136	13	none	none	NOUN
dti-3019	136	14	of	of	ADP
dti-3019	136	15	the	the	DET
dti-3019	136	16	clinical	clinical	ADJ
dti-3019	136	17	trials	trial	NOUN
dti-3019	136	18	conducted	conduct	VERB
dti-3019	136	19	thus	thus	ADV
dti-3019	136	20	far	far	ADV
dti-3019	136	21	have	have	AUX
dti-3019	136	22	achieved	achieve	VERB
dti-3019	136	23	the	the	DET
dti-3019	136	24	desired	desire	VERB
dti-3019	136	25	outcome	outcome	NOUN
dti-3019	136	26	of	of	ADP
dti-3019	136	27	mitigating	mitigate	VERB
dti-3019	136	28	the	the	DET
dti-3019	136	29	cognitive	cognitive	ADJ
dti-3019	136	30	deterioration	deterioration	NOUN
dti-3019	136	31	associated	associate	VERB
dti-3019	136	32	with	with	ADP
dti-3019	136	33	late	late	ADJ
dti-3019	136	34	-	-	PUNCT
dti-3019	136	35	onset	onset	NOUN
dti-3019	136	36	dementia	dementia	NOUN
dti-3019	136	37	(	(	PUNCT
dti-3019	136	38	71	71	NUM
dti-3019	136	39	)	)	PUNCT
dti-3019	136	40	.	.	PUNCT
dti-3019	137	1	in	in	ADP
dti-3019	137	2	recent	recent	ADJ
dti-3019	137	3	years	year	NOUN
dti-3019	137	4	,	,	PUNCT
dti-3019	137	5	there	there	PRON
dti-3019	137	6	has	have	AUX
dti-3019	137	7	been	be	AUX
dti-3019	137	8	a	a	DET
dti-3019	137	9	significant	significant	ADJ
dti-3019	137	10	focus	focus	NOUN
dti-3019	137	11	on	on	ADP
dti-3019	137	12	the	the	DET
dti-3019	137	13	repurposing	repurposing	NOUN
dti-3019	137	14	of	of	ADP
dti-3019	137	15	antidiabetic	antidiabetic	ADJ
dti-3019	137	16	drugs	drug	NOUN
dti-3019	137	17	for	for	ADP
dti-3019	137	18	the	the	DET
dti-3019	137	19	purpose	purpose	NOUN
dti-3019	137	20	of	of	ADP
dti-3019	137	21	weight	weight	NOUN
dti-3019	137	22	control	control	NOUN
dti-3019	137	23	,	,	PUNCT
dti-3019	137	24	alongside	alongside	ADP
dti-3019	137	25	the	the	DET
dti-3019	137	26	use	use	NOUN
dti-3019	137	27	of	of	ADP
dti-3019	137	28	other	other	ADJ
dti-3019	137	29	medications	medication	NOUN
dti-3019	137	30	.	.	PUNCT
dti-3019	138	1	the	the	DET
dti-3019	138	2	use	use	NOUN
dti-3019	138	3	of	of	ADP
dti-3019	138	4	antidiabetic	antidiabetic	ADJ
dti-3019	138	5	drugs	drug	NOUN
dti-3019	138	6	,	,	PUNCT
dti-3019	138	7	such	such	ADJ
dti-3019	138	8	as	as	ADP
dti-3019	138	9	metformin	metformin	NOUN
dti-3019	138	10	,	,	PUNCT
dti-3019	138	11	glyburide	glyburide	NOUN
dti-3019	138	12	,	,	PUNCT
dti-3019	138	13	and	and	CCONJ
dti-3019	138	14	sglt-2	sglt-2	NUM
dti-3019	138	15	inhibitors	inhibitor	NOUN
dti-3019	138	16	,	,	PUNCT
dti-3019	138	17	has	have	AUX
dti-3019	138	18	shown	show	VERB
dti-3019	138	19	promising	promising	ADJ
dti-3019	138	20	results	result	NOUN
dti-3019	138	21	in	in	ADP
dti-3019	138	22	terms	term	NOUN
dti-3019	138	23	of	of	ADP
dti-3019	138	24	promoting	promote	VERB
dti-3019	138	25	weight	weight	NOUN
dti-3019	138	26	loss	loss	NOUN
dti-3019	138	27	,	,	PUNCT
dti-3019	138	28	which	which	PRON
dti-3019	138	29	has	have	AUX
dti-3019	138	30	garnered	garner	VERB
dti-3019	138	31	considerable	considerable	ADJ
dti-3019	138	32	attention	attention	NOUN
dti-3019	138	33	(	(	PUNCT
dti-3019	138	34	72	72	NUM
dti-3019	138	35	)	)	PUNCT
dti-3019	138	36	.	.	PUNCT
dti-3019	139	1	additionally	additionally	ADV
dti-3019	139	2	,	,	PUNCT
dti-3019	139	3	disulfiram	disulfiram	PROPN
dti-3019	139	4	,	,	PUNCT
dti-3019	139	5	a	a	DET
dti-3019	139	6	medication	medication	NOUN
dti-3019	139	7	commonly	commonly	ADV
dti-3019	139	8	prescribed	prescribe	VERB
dti-3019	139	9	for	for	ADP
dti-3019	139	10	chronic	chronic	ADJ
dti-3019	139	11	alcoholism	alcoholism	NOUN
dti-3019	139	12	,	,	PUNCT
dti-3019	139	13	has	have	AUX
dti-3019	139	14	demonstrated	demonstrate	VERB
dti-3019	139	15	a	a	DET
dti-3019	139	16	significant	significant	ADJ
dti-3019	139	17	capability	capability	NOUN
dti-3019	139	18	to	to	PART
dti-3019	139	19	counteract	counteract	VERB
dti-3019	139	20	obesity	obesity	NOUN
dti-3019	139	21	in	in	ADP
dti-3019	139	22	rats	rat	NOUN
dti-3019	139	23	(	(	PUNCT
dti-3019	139	24	73	73	NUM
dti-3019	139	25	)	)	PUNCT
dti-3019	139	26	.	.	PUNCT
dti-3019	140	1	although	although	SCONJ
dti-3019	140	2	the	the	DET
dti-3019	140	3	specific	specific	ADJ
dti-3019	140	4	mechanisms	mechanism	NOUN
dti-3019	140	5	by	by	ADP
dti-3019	140	6	which	which	PRON
dti-3019	140	7	these	these	DET
dti-3019	140	8	drugs	drug	NOUN
dti-3019	140	9	facilitate	facilitate	VERB
dti-3019	140	10	weight	weight	NOUN
dti-3019	140	11	loss	loss	NOUN
dti-3019	140	12	are	be	AUX
dti-3019	140	13	still	still	ADV
dti-3019	140	14	being	be	AUX
dti-3019	140	15	investigated	investigate	VERB
dti-3019	140	16	,	,	PUNCT
dti-3019	140	17	their	their	PRON
dti-3019	140	18	potential	potential	NOUN
dti-3019	140	19	as	as	ADP
dti-3019	140	20	treatments	treatment	NOUN
dti-3019	140	21	for	for	ADP
dti-3019	140	22	obesity	obesity	NOUN
dti-3019	140	23	should	should	AUX
dti-3019	140	24	not	not	PART
dti-3019	140	25	be	be	AUX
dti-3019	140	26	underestimated	underestimate	VERB
dti-3019	140	27	.	.	PUNCT
dti-3019	141	1	it	it	PRON
dti-3019	141	2	is	be	AUX
dti-3019	141	3	important	important	ADJ
dti-3019	141	4	to	to	PART
dti-3019	141	5	note	note	VERB
dti-3019	141	6	that	that	SCONJ
dti-3019	141	7	despite	despite	SCONJ
dti-3019	141	8	the	the	DET
dti-3019	141	9	positive	positive	ADJ
dti-3019	141	10	effects	effect	NOUN
dti-3019	141	11	of	of	ADP
dti-3019	141	12	these	these	DET
dti-3019	141	13	repurposed	repurpose	VERB
dti-3019	141	14	drugs	drug	NOUN
dti-3019	141	15	for	for	ADP
dti-3019	141	16	obesity	obesity	NOUN
dti-3019	141	17	,	,	PUNCT
dti-3019	141	18	there	there	PRON
dti-3019	141	19	is	be	VERB
dti-3019	141	20	also	also	ADV
dti-3019	141	21	a	a	DET
dti-3019	141	22	focus	focus	NOUN
dti-3019	141	23	on	on	ADP
dti-3019	141	24	the	the	DET
dti-3019	141	25	repurposing	repurposing	NOUN
dti-3019	141	26	of	of	ADP
dti-3019	141	27	antidiabetic	antidiabetic	ADJ
dti-3019	141	28	drugs	drug	NOUN
dti-3019	141	29	such	such	ADJ
dti-3019	141	30	as	as	ADP
dti-3019	141	31	semaglutide	semaglutide	ADJ
dti-3019	141	32	and	and	CCONJ
dti-3019	141	33	tirzepatide	tirzepatide	ADJ
dti-3019	141	34	,	,	PUNCT
dti-3019	141	35	which	which	PRON
dti-3019	141	36	were	be	AUX
dti-3019	141	37	initially	initially	ADV
dti-3019	141	38	developed	develop	VERB
dti-3019	141	39	to	to	PART
dti-3019	141	40	address	address	VERB
dti-3019	141	41	the	the	DET
dti-3019	141	42	challenges	challenge	NOUN
dti-3019	141	43	associated	associate	VERB
dti-3019	141	44	with	with	ADP
dti-3019	141	45	t2d	t2d	PROPN
dti-3019	141	46	(	(	PUNCT
dti-3019	141	47	74	74	NUM
dti-3019	141	48	)	)	PUNCT
dti-3019	141	49	.	.	PUNCT
dti-3019	142	1	these	these	DET
dti-3019	142	2	drugs	drug	NOUN
dti-3019	142	3	can	can	AUX
dti-3019	142	4	be	be	AUX
dti-3019	142	5	traced	trace	VERB
dti-3019	142	6	back	back	ADV
dti-3019	142	7	to	to	ADP
dti-3019	142	8	a	a	DET
dti-3019	142	9	peptide	peptide	NOUN
dti-3019	142	10	that	that	PRON
dti-3019	142	11	was	be	AUX
dti-3019	142	12	discovered	discover	VERB
dti-3019	142	13	in	in	ADP
dti-3019	142	14	the	the	DET
dti-3019	142	15	venom	venom	NOUN
dti-3019	142	16	of	of	ADP
dti-3019	142	17	the	the	DET
dti-3019	142	18	gila	gila	PROPN
dti-3019	142	19	monster	monster	NOUN
dti-3019	142	20	and	and	CCONJ
dti-3019	142	21	have	have	VERB
dti-3019	142	22	the	the	DET
dti-3019	142	23	ability	ability	NOUN
dti-3019	142	24	to	to	PART
dti-3019	142	25	mimic	mimic	VERB
dti-3019	142	26	the	the	DET
dti-3019	142	27	actions	action	NOUN
dti-3019	142	28	of	of	ADP
dti-3019	142	29	a	a	DET
dti-3019	142	30	naturally	naturally	ADV
dti-3019	142	31	occurring	occur	VERB
dti-3019	142	32	hormone	hormone	NOUN
dti-3019	142	33	that	that	PRON
dti-3019	142	34	is	be	AUX
dti-3019	142	35	released	release	VERB
dti-3019	142	36	after	after	ADP
dti-3019	142	37	food	food	NOUN
dti-3019	142	38	consumption	consumption	NOUN
dti-3019	142	39	.	.	PUNCT
dti-3019	143	1	as	as	ADP
dti-3019	143	2	a	a	DET
dti-3019	143	3	result	result	NOUN
dti-3019	143	4	,	,	PUNCT
dti-3019	143	5	they	they	PRON
dti-3019	143	6	have	have	AUX
dti-3019	143	7	shown	show	VERB
dti-3019	143	8	promising	promising	ADJ
dti-3019	143	9	results	result	NOUN
dti-3019	143	10	in	in	ADP
dti-3019	143	11	terms	term	NOUN
dti-3019	143	12	of	of	ADP
dti-3019	143	13	inducing	induce	VERB
dti-3019	143	14	weight	weight	NOUN
dti-3019	143	15	loss	loss	NOUN
dti-3019	143	16	.	.	PUNCT
dti-3019	144	1	however	however	ADV
dti-3019	144	2	,	,	PUNCT
dti-3019	144	3	it	it	PRON
dti-3019	144	4	is	be	AUX
dti-3019	144	5	essential	essential	ADJ
dti-3019	144	6	to	to	PART
dti-3019	144	7	acknowledge	acknowledge	VERB
dti-3019	144	8	that	that	SCONJ
dti-3019	144	9	these	these	DET
dti-3019	144	10	drugs	drug	NOUN
dti-3019	144	11	do	do	AUX
dti-3019	144	12	come	come	VERB
dti-3019	144	13	with	with	ADP
dti-3019	144	14	their	their	PRON
dti-3019	144	15	fair	fair	ADJ
dti-3019	144	16	share	share	NOUN
dti-3019	144	17	of	of	ADP
dti-3019	144	18	adverse	adverse	ADJ
dti-3019	144	19	effects	effect	NOUN
dti-3019	144	20	,	,	PUNCT
dti-3019	144	21	particularly	particularly	ADV
dti-3019	144	22	in	in	ADP
dti-3019	144	23	the	the	DET
dti-3019	144	24	gastrointestinal	gastrointestinal	ADJ
dti-3019	144	25	realm	realm	NOUN
dti-3019	144	26	.	.	PUNCT
dti-3019	145	1	potential	potential	ADJ
dti-3019	145	2	side	side	NOUN
dti-3019	145	3	effects	effect	NOUN
dti-3019	145	4	such	such	ADJ
dti-3019	145	5	as	as	ADP
dti-3019	145	6	nausea	nausea	NOUN
dti-3019	145	7	,	,	PUNCT
dti-3019	145	8	vomiting	vomiting	NOUN
dti-3019	145	9	,	,	PUNCT
dti-3019	145	10	diarrhea	diarrhea	PROPN
dti-3019	145	11	,	,	PUNCT
dti-3019	145	12	and	and	CCONJ
dti-3019	145	13	constipation	constipation	NOUN
dti-3019	145	14	have	have	AUX
dti-3019	145	15	been	be	AUX
dti-3019	145	16	reported	report	VERB
dti-3019	145	17	with	with	ADP
dti-3019	145	18	their	their	PRON
dti-3019	145	19	use	use	NOUN
dti-3019	145	20	.	.	PUNCT
dti-3019	146	1	therefore	therefore	ADV
dti-3019	146	2	,	,	PUNCT
dti-3019	146	3	it	it	PRON
dti-3019	146	4	is	be	AUX
dti-3019	146	5	crucial	crucial	ADJ
dti-3019	146	6	to	to	PART
dti-3019	146	7	strike	strike	VERB
dti-3019	146	8	a	a	DET
dti-3019	146	9	careful	careful	ADJ
dti-3019	146	10	balance	balance	NOUN
dti-3019	146	11	between	between	ADP
dti-3019	146	12	the	the	DET
dti-3019	146	13	beneficial	beneficial	ADJ
dti-3019	146	14	effects	effect	NOUN
dti-3019	146	15	and	and	CCONJ
dti-3019	146	16	the	the	DET
dti-3019	146	17	potential	potential	ADJ
dti-3019	146	18	adverse	adverse	ADJ
dti-3019	146	19	effects	effect	NOUN
dti-3019	146	20	when	when	SCONJ
dti-3019	146	21	considering	consider	VERB
dti-3019	146	22	the	the	DET
dti-3019	146	23	use	use	NOUN
dti-3019	146	24	of	of	ADP
dti-3019	146	25	these	these	DET
dti-3019	146	26	drugs	drug	NOUN
dti-3019	146	27	for	for	ADP
dti-3019	146	28	the	the	DET
dti-3019	146	29	treatment	treatment	NOUN
dti-3019	146	30	of	of	ADP
dti-3019	146	31	obesity	obesity	NOUN
dti-3019	146	32	.	.	PUNCT
dti-3019	147	1	potential	potential	ADJ
dti-3019	147	2	risk	risk	NOUN
dti-3019	147	3	of	of	ADP
dti-3019	147	4	repurposed	repurpose	VERB
dti-3019	147	5	antibiotics	antibiotic	NOUN
dti-3019	147	6	one	one	NUM
dti-3019	147	7	of	of	ADP
dti-3019	147	8	the	the	DET
dti-3019	147	9	foremost	foremost	ADJ
dti-3019	147	10	concerns	concern	NOUN
dti-3019	147	11	that	that	PRON
dti-3019	147	12	need	need	VERB
dti-3019	147	13	careful	careful	ADJ
dti-3019	147	14	study	study	NOUN
dti-3019	147	15	is	be	AUX
dti-3019	147	16	the	the	DET
dti-3019	147	17	repurposing	repurposing	NOUN
dti-3019	147	18	of	of	ADP
dti-3019	147	19	antibiotics	antibiotic	NOUN
dti-3019	147	20	for	for	ADP
dti-3019	147	21	noninfectious	noninfectious	ADJ
dti-3019	147	22	disorders	disorder	NOUN
dti-3019	147	23	,	,	PUNCT
dti-3019	147	24	some	some	DET
dti-3019	147	25	antibiotics	antibiotic	NOUN
dti-3019	147	26	of	of	ADP
dti-3019	147	27	which	which	PRON
dti-3019	147	28	are	be	AUX
dti-3019	147	29	listed	list	VERB
dti-3019	147	30	in	in	ADP
dti-3019	147	31	table	table	NOUN
dti-3019	147	32	1	1	NUM
dti-3019	147	33	.	.	PUNCT
dti-3019	148	1	in	in	ADP
dti-3019	148	2	this	this	DET
dti-3019	148	3	context	context	NOUN
dti-3019	148	4	,	,	PUNCT
dti-3019	148	5	it	it	PRON
dti-3019	148	6	is	be	AUX
dti-3019	148	7	crucial	crucial	ADJ
dti-3019	148	8	to	to	PART
dti-3019	148	9	assess	assess	VERB
dti-3019	148	10	both	both	DET
dti-3019	148	11	the	the	DET
dti-3019	148	12	efficacy	efficacy	NOUN
dti-3019	148	13	of	of	ADP
dti-3019	148	14	these	these	DET
dti-3019	148	15	repurposed	repurpose	VERB
dti-3019	148	16	drugs	drug	NOUN
dti-3019	148	17	and	and	CCONJ
dti-3019	148	18	their	their	PRON
dti-3019	148	19	potential	potential	NOUN
dti-3019	148	20	to	to	PART
dti-3019	148	21	exacerbate	exacerbate	VERB
dti-3019	148	22	the	the	DET
dti-3019	148	23	problem	problem	NOUN
dti-3019	148	24	of	of	ADP
dti-3019	148	25	multidrug	multidrug	NOUN
dti-3019	148	26	resistance	resistance	NOUN
dti-3019	148	27	(	(	PUNCT
dti-3019	148	28	75	75	NUM
dti-3019	148	29	)	)	PUNCT
dti-3019	148	30	.	.	PUNCT
dti-3019	149	1	in	in	ADP
dti-3019	149	2	a	a	DET
dti-3019	149	3	study	study	NOUN
dti-3019	149	4	conducted	conduct	VERB
dti-3019	149	5	by	by	ADP
dti-3019	149	6	wang	wang	PROPN
dti-3019	149	7	et	et	PROPN
dti-3019	149	8	al	al	PROPN
dti-3019	149	9	(	(	PUNCT
dti-3019	149	10	76	76	NUM
dti-3019	149	11	)	)	PUNCT
dti-3019	149	12	,	,	PUNCT
dti-3019	149	13	it	it	PRON
dti-3019	149	14	was	be	AUX
dti-3019	149	15	shown	show	VERB
dti-3019	149	16	that	that	SCONJ
dti-3019	149	17	some	some	DET
dti-3019	149	18	non	non	ADJ
dti-3019	149	19	-	-	ADJ
dti-3019	149	20	antibiotic	antibiotic	ADJ
dti-3019	149	21	medications	medication	NOUN
dti-3019	149	22	,	,	PUNCT
dti-3019	149	23	when	when	SCONJ
dti-3019	149	24	present	present	ADJ
dti-3019	149	25	at	at	ADP
dti-3019	149	26	levels	level	NOUN
dti-3019	149	27	that	that	PRON
dti-3019	149	28	are	be	AUX
dti-3019	149	29	both	both	ADV
dti-3019	149	30	clinically	clinically	ADV
dti-3019	149	31	and	and	CCONJ
dti-3019	149	32	ecologically	ecologically	ADV
dti-3019	149	33	relevant	relevant	ADJ
dti-3019	149	34	,	,	PUNCT
dti-3019	149	35	had	have	VERB
dti-3019	149	36	a	a	DET
dti-3019	149	37	notable	notable	ADJ
dti-3019	149	38	impact	impact	NOUN
dti-3019	149	39	on	on	ADP
dti-3019	149	40	the	the	DET
dti-3019	149	41	dissemination	dissemination	NOUN
dti-3019	149	42	of	of	ADP
dti-3019	149	43	antibiotic	antibiotic	ADJ
dti-3019	149	44	resistance	resistance	NOUN
dti-3019	149	45	.	.	PUNCT
dti-3019	150	1	this	this	DET
dti-3019	150	2	effect	effect	NOUN
dti-3019	150	3	was	be	AUX
dti-3019	150	4	shown	show	VERB
dti-3019	150	5	through	through	ADP
dti-3019	150	6	the	the	DET
dti-3019	150	7	absorption	absorption	NOUN
dti-3019	150	8	of	of	ADP
dti-3019	150	9	exogenous	exogenous	ADJ
dti-3019	150	10	antibiotic	antibiotic	ADJ
dti-3019	150	11	resistance	resistance	NOUN
dti-3019	150	12	genes	gene	NOUN
dti-3019	150	13	(	(	PUNCT
dti-3019	150	14	args	args	PROPN
dti-3019	150	15	)	)	PUNCT
dti-3019	150	16	(	(	PUNCT
dti-3019	150	17	77,78	77,78	PROPN
dti-3019	150	18	)	)	PUNCT
dti-3019	150	19	,	,	PUNCT
dti-3019	150	20	due	due	ADP
dti-3019	150	21	to	to	ADP
dti-3019	150	22	the	the	DET
dti-3019	150	23	fact	fact	NOUN
dti-3019	150	24	that	that	SCONJ
dti-3019	150	25	the	the	DET
dti-3019	150	26	administration	administration	NOUN
dti-3019	150	27	of	of	ADP
dti-3019	150	28	non	non	ADJ
dti-3019	150	29	-	-	ADJ
dti-3019	150	30	antibiotic	antibiotic	ADJ
dti-3019	150	31	substances	substance	NOUN
dti-3019	150	32	has	have	AUX
dti-3019	150	33	the	the	DET
dti-3019	150	34	potential	potential	NOUN
dti-3019	150	35	to	to	PART
dti-3019	150	36	increase	increase	VERB
dti-3019	150	37	the	the	DET
dti-3019	150	38	likelihood	likelihood	NOUN
dti-3019	150	39	of	of	ADP
dti-3019	150	40	the	the	DET
dti-3019	150	41	development	development	NOUN
dti-3019	150	42	of	of	ADP
dti-3019	150	43	multidrug	multidrug	NOUN
dti-3019	150	44	resistance	resistance	NOUN
dti-3019	150	45	at	at	ADP
dti-3019	150	46	the	the	DET
dti-3019	150	47	clinical	clinical	ADJ
dti-3019	150	48	level	level	NOUN
dti-3019	150	49	(	(	PUNCT
dti-3019	150	50	79	79	NUM
dti-3019	150	51	)	)	PUNCT
dti-3019	150	52	.	.	PUNCT
dti-3019	151	1	it	it	PRON
dti-3019	151	2	is	be	AUX
dti-3019	151	3	plausible	plausible	ADJ
dti-3019	151	4	to	to	PART
dti-3019	151	5	suggest	suggest	VERB
dti-3019	151	6	that	that	SCONJ
dti-3019	151	7	the	the	DET
dti-3019	151	8	utilization	utilization	NOUN
dti-3019	151	9	of	of	ADP
dti-3019	151	10	repurposed	repurposed	ADJ
dti-3019	151	11	drugs	drug	NOUN
dti-3019	151	12	could	could	AUX
dti-3019	151	13	exacerbate	exacerbate	VERB
dti-3019	151	14	this	this	DET
dti-3019	151	15	issue	issue	NOUN
dti-3019	151	16	even	even	ADV
dti-3019	151	17	further	far	ADV
dti-3019	151	18	.	.	PUNCT
dti-3019	152	1	therefore	therefore	ADV
dti-3019	152	2	,	,	PUNCT
dti-3019	152	3	the	the	DET
dti-3019	152	4	present	present	ADJ
dti-3019	152	5	work	work	NOUN
dti-3019	152	6	strives	strive	VERB
dti-3019	152	7	to	to	PART
dti-3019	152	8	clarify	clarify	VERB
dti-3019	152	9	this	this	DET
dti-3019	152	10	threat	threat	NOUN
dti-3019	152	11	in	in	ADP
dti-3019	152	12	the	the	DET
dti-3019	152	13	subsequent	subsequent	ADJ
dti-3019	152	14	section	section	NOUN
dti-3019	152	15	.	.	PUNCT
dti-3019	153	1	the	the	DET
dti-3019	153	2	phenomenon	phenomenon	NOUN
dti-3019	153	3	of	of	ADP
dti-3019	153	4	antibiotic	antibiotic	ADJ
dti-3019	153	5	resistance	resistance	NOUN
dti-3019	153	6	has	have	AUX
dti-3019	153	7	been	be	AUX
dti-3019	153	8	steadily	steadily	ADV
dti-3019	153	9	increasing	increase	VERB
dti-3019	153	10	over	over	ADP
dti-3019	153	11	the	the	DET
dti-3019	153	12	past	past	ADJ
dti-3019	153	13	few	few	ADJ
dti-3019	153	14	decades	decade	NOUN
dti-3019	153	15	,	,	PUNCT
dti-3019	153	16	with	with	ADP
dti-3019	153	17	no	no	DET
dti-3019	153	18	new	new	ADJ
dti-3019	153	19	categories	category	NOUN
dti-3019	153	20	of	of	ADP
dti-3019	153	21	antibiotics	antibiotic	NOUN
dti-3019	153	22	or	or	CCONJ
dti-3019	153	23	viable	viable	ADJ
dti-3019	153	24	alternatives	alternative	NOUN
dti-3019	153	25	receiving	receive	VERB
dti-3019	153	26	clinical	clinical	ADJ
dti-3019	153	27	approval	approval	NOUN
dti-3019	153	28	within	within	ADP
dti-3019	153	29	the	the	DET
dti-3019	153	30	last	last	ADJ
dti-3019	153	31	three	three	NUM
dti-3019	153	32	decades	decade	NOUN
dti-3019	153	33	(	(	PUNCT
dti-3019	153	34	75,80	75,80	NOUN
dti-3019	153	35	)	)	PUNCT
dti-3019	153	36	.	.	PUNCT
dti-3019	154	1	table	table	NOUN
dti-3019	154	2	1	1	NUM
dti-3019	154	3	some	some	DET
dti-3019	154	4	repurposed	repurpose	VERB
dti-3019	154	5	antibiotics	antibiotic	NOUN
dti-3019	154	6	and	and	CCONJ
dti-3019	154	7	microbes	microbe	NOUN
dti-3019	154	8	that	that	PRON
dti-3019	154	9	developed	develop	VERB
dti-3019	154	10	resistance	resistance	NOUN
dti-3019	154	11	to	to	ADP
dti-3019	154	12	these	these	DET
dti-3019	154	13	antibiotics	antibiotic	NOUN
dti-3019	154	14	antibiotic	antibiotic	ADJ
dti-3019	154	15	repurposed	repurpose	VERB
dti-3019	154	16	for	for	ADP
dti-3019	154	17	microbes	microbe	NOUN
dti-3019	154	18	resistant	resistant	ADJ
dti-3019	154	19	to	to	ADP
dti-3019	154	20	this	this	DET
dti-3019	154	21	antibiotic	antibiotic	ADJ
dti-3019	154	22	1	1	NUM
dti-3019	154	23	levofloxacin	levofloxacin	NOUN
dti-3019	154	24	lung	lung	NOUN
dti-3019	154	25	cancer	cancer	PROPN
dti-3019	154	26	alzheimer	alzheimer	PROPN
dti-3019	154	27	’s	’s	PART
dti-3019	154	28	disease	disease	NOUN
dti-3019	154	29	anti	anti	ADJ
dti-3019	154	30	-	-	ADJ
dti-3019	154	31	amyloidogenic	amyloidogenic	ADJ
dti-3019	154	32	cutibacterium	cutibacterium	NOUN
dti-3019	154	33	avidum	avidum	PROPN
dti-3019	154	34	(	(	PUNCT
dti-3019	154	35	82	82	NUM
dti-3019	154	36	)	)	PUNCT
dti-3019	154	37	stenotrophomonas	stenotrophomona	NOUN
dti-3019	154	38	maltophilia	maltophilia	PROPN
dti-3019	154	39	(	(	PUNCT
dti-3019	154	40	83,84	83,84	ADJ
dti-3019	154	41	)	)	PUNCT
dti-3019	154	42	haemophillus	haemophillus	NOUN
dti-3019	154	43	,	,	PUNCT
dti-3019	154	44	streptococcus	streptococcus	NOUN
dti-3019	154	45	,	,	PUNCT
dti-3019	154	46	corynebacterium	corynebacterium	NOUN
dti-3019	154	47	,	,	PUNCT
dti-3019	154	48	staphylococcus	staphylococcus	NOUN
dti-3019	154	49	,	,	PUNCT
dti-3019	154	50	and	and	CCONJ
dti-3019	154	51	bordetella	bordetella	NOUN
dti-3019	154	52	(	(	PUNCT
dti-3019	154	53	85	85	NUM
dti-3019	154	54	)	)	PUNCT
dti-3019	154	55	helicobacter	helicobacter	NOUN
dti-3019	154	56	pylori	pylori	NOUN
dti-3019	154	57	(	(	PUNCT
dti-3019	154	58	86	86	NUM
dti-3019	154	59	)	)	PUNCT
dti-3019	154	60	acinetobacter	acinetobacter	ADV
dti-3019	154	61	baumannii	baumannii	ADJ
dti-3019	154	62	(	(	PUNCT
dti-3019	154	63	87	87	NUM
dti-3019	154	64	)	)	PUNCT
dti-3019	154	65	acinetobacter	acinetobacter	ADJ
dti-3019	154	66	spp	spp	NOUN
dti-3019	154	67	.	.	PUNCT
dti-3019	155	1	and	and	CCONJ
dti-3019	155	2	escherichia	escherichia	NOUN
dti-3019	155	3	coli	coli	NOUN
dti-3019	155	4	(	(	PUNCT
dti-3019	155	5	88	88	NUM
dti-3019	155	6	)	)	SYM
dti-3019	155	7	2	2	NUM
dti-3019	155	8	benzylpenicillin	benzylpenicillin	NOUN
dti-3019	155	9	alzheimer	alzheimer	PROPN
dti-3019	155	10	’s	’s	PART
dti-3019	155	11	disease	disease	NOUN
dti-3019	155	12	all	all	PRON
dti-3019	155	13	of	of	ADP
dti-3019	155	14	the	the	DET
dti-3019	155	15	strains	strain	NOUN
dti-3019	155	16	of	of	ADP
dti-3019	155	17	nonfermenting	nonfermente	VERB
dti-3019	155	18	gram	gram	NOUN
dti-3019	155	19	-	-	PUNCT
dti-3019	155	20	negative	negative	ADJ
dti-3019	155	21	bacteria	bacteria	NOUN
dti-3019	155	22	(	(	PUNCT
dti-3019	155	23	ngnb	ngnb	NOUN
dti-3019	155	24	)	)	PUNCT
dti-3019	155	25	exhibited	exhibit	VERB
dti-3019	155	26	resistance	resistance	NOUN
dti-3019	155	27	to	to	ADP
dti-3019	155	28	benzylpenicillin	benzylpenicillin	NOUN
dti-3019	155	29	.	.	PUNCT
dti-3019	156	1	pseudomonas	pseudomona	VERB
dti-3019	156	2	cepacia	cepacia	NOUN
dti-3019	156	3	and	and	CCONJ
dti-3019	156	4	p.	p.	PROPN
dti-3019	156	5	stutzeri	stutzeri	PROPN
dti-3019	156	6	were	be	AUX
dti-3019	156	7	identified	identify	VERB
dti-3019	156	8	as	as	ADP
dti-3019	156	9	the	the	DET
dti-3019	156	10	species	specie	NOUN
dti-3019	156	11	displaying	display	VERB
dti-3019	156	12	the	the	DET
dti-3019	156	13	highest	high	ADJ
dti-3019	156	14	levels	level	NOUN
dti-3019	156	15	of	of	ADP
dti-3019	156	16	resistance	resistance	NOUN
dti-3019	156	17	(	(	PUNCT
dti-3019	156	18	89	89	NUM
dti-3019	156	19	)	)	PUNCT
dti-3019	156	20	.	.	PUNCT
dti-3019	156	21	.	.	PUNCT
dti-3019	157	1	pseudomonas	pseudomona	NOUN
dti-3019	157	2	aeruginosa	aeruginosa	NOUN
dti-3019	157	3	(	(	PUNCT
dti-3019	157	4	90	90	NUM
dti-3019	157	5	)	)	PUNCT
dti-3019	157	6	indole	indole	NOUN
dti-3019	157	7	-	-	PUNCT
dti-3019	157	8	positive	positive	ADJ
dti-3019	157	9	proteus	proteus	NOUN
dti-3019	157	10	strains	strain	NOUN
dti-3019	157	11	are	be	AUX
dti-3019	157	12	uniformly	uniformly	ADV
dti-3019	157	13	resistant	resistant	ADJ
dti-3019	157	14	to	to	ADP
dti-3019	157	15	benzylpenicillin	benzylpenicillin	NOUN
dti-3019	157	16	(	(	PUNCT
dti-3019	157	17	91	91	NUM
dti-3019	157	18	)	)	PUNCT
dti-3019	157	19	.	.	PUNCT
dti-3019	158	1	3	3	NUM
dti-3019	158	2	doxycycline	doxycycline	NOUN
dti-3019	158	3	treatment	treatment	NOUN
dti-3019	158	4	of	of	ADP
dti-3019	158	5	malaria	malaria	NOUN
dti-3019	158	6	a	a	DET
dti-3019	158	7	range	range	NOUN
dti-3019	158	8	of	of	ADP
dti-3019	158	9	anaerobic	anaerobic	ADJ
dti-3019	158	10	bacteria	bacteria	NOUN
dti-3019	158	11	,	,	PUNCT
dti-3019	158	12	such	such	ADJ
dti-3019	158	13	as	as	ADP
dti-3019	158	14	bac	bac	PROPN
dti-3019	158	15	teroides	teroide	NOUN
dti-3019	158	16	fragilis	fragilis	PROPN
dti-3019	158	17	,	,	PUNCT
dti-3019	158	18	exhibit	exhibit	VERB
dti-3019	158	19	resistance	resistance	NOUN
dti-3019	158	20	to	to	ADP
dti-3019	158	21	attainable	attainable	ADJ
dti-3019	158	22	blood	blood	NOUN
dti-3019	158	23	levels	level	NOUN
dti-3019	158	24	of	of	ADP
dti-3019	158	25	doxycycline	doxycycline	NOUN
dti-3019	158	26	(	(	PUNCT
dti-3019	158	27	92	92	NUM
dti-3019	158	28	)	)	PUNCT
dti-3019	158	29	.	.	PUNCT
dti-3019	159	1	in	in	ADP
dti-3019	159	2	the	the	DET
dti-3019	159	3	oral	oral	ADJ
dti-3019	159	4	cavity	cavity	NOUN
dti-3019	159	5	,	,	PUNCT
dti-3019	159	6	the	the	DET
dti-3019	159	7	prevailing	prevail	VERB
dti-3019	159	8	type	type	NOUN
dti-3019	159	9	of	of	ADP
dti-3019	159	10	antibiotic	antibiotic	ADJ
dti-3019	159	11	-	-	PUNCT
dti-3019	159	12	resistant	resistant	ADJ
dti-3019	159	13	bacteria	bacteria	NOUN
dti-3019	159	14	discovered	discover	VERB
dti-3019	159	15	were	be	AUX
dti-3019	159	16	gram	gram	NOUN
dti-3019	159	17	-	-	PUNCT
dti-3019	159	18	positive	positive	ADJ
dti-3019	159	19	cocci	cocci	NOUN
dti-3019	159	20	(	(	PUNCT
dti-3019	159	21	93	93	NUM
dti-3019	159	22	)	)	PUNCT
dti-3019	159	23	.	.	PUNCT
dti-3019	160	1	all	all	DET
dti-3019	160	2	isolated	isolated	ADJ
dti-3019	160	3	gram	gram	NOUN
dti-3019	160	4	-	-	PUNCT
dti-3019	160	5	negative	negative	ADJ
dti-3019	160	6	strains	strain	NOUN
dti-3019	160	7	,	,	PUNCT
dti-3019	160	8	such	such	ADJ
dti-3019	160	9	as	as	ADP
dti-3019	160	10	e.	e.	PROPN
dti-3019	160	11	coli	coli	PROPN
dti-3019	160	12	,	,	PUNCT
dti-3019	160	13	e.	e.	PROPN
dti-3019	160	14	fergusonii	fergusonii	PROPN
dti-3019	160	15	,	,	PUNCT
dti-3019	160	16	and	and	CCONJ
dti-3019	160	17	proteus	proteus	PROPN
dti-3019	160	18	mirabilis	mirabilis	PROPN
dti-3019	160	19	,	,	PUNCT
dti-3019	160	20	exhibited	exhibit	VERB
dti-3019	160	21	resistance	resistance	NOUN
dti-3019	160	22	to	to	AUX
dti-3019	160	23	doxycycline	doxycycline	NOUN
dti-3019	160	24	(	(	PUNCT
dti-3019	160	25	94	94	NUM
dti-3019	160	26	)	)	PUNCT
dti-3019	160	27	.	.	PUNCT
dti-3019	161	1	4	4	NUM
dti-3019	161	2	azithromycin	azithromycin	NOUN
dti-3019	161	3	covid-19	covid-19	PROPN
dti-3019	161	4	pandemic	pandemic	ADJ
dti-3019	161	5	treatment	treatment	NOUN
dti-3019	161	6	of	of	ADP
dti-3019	161	7	malaria	malaria	NOUN
dti-3019	161	8	25	25	NUM
dti-3019	161	9	different	different	ADJ
dti-3019	161	10	strains	strain	NOUN
dti-3019	161	11	of	of	ADP
dti-3019	161	12	legionella	legionella	NOUN
dti-3019	161	13	pneumophila	pneumophila	NOUN
dti-3019	161	14	exhibited	exhibit	VERB
dti-3019	161	15	resistance	resistance	NOUN
dti-3019	161	16	to	to	ADP
dti-3019	161	17	the	the	DET
dti-3019	161	18	antimicrobial	antimicrobial	ADJ
dti-3019	161	19	drug	drug	NOUN
dti-3019	161	20	azithromycin	azithromycin	PROPN
dti-3019	161	21	.	.	PUNCT
dti-3019	162	1	natsheh	natsheh	PROPN
dti-3019	162	2	et	et	PROPN
dti-3019	162	3	al	al	PROPN
dti-3019	162	4	drug	drug	PROPN
dti-3019	162	5	target	target	NOUN
dti-3019	162	6	insights	insight	NOUN
dti-3019	162	7	2024	2024	NUM
dti-3019	162	8	;	;	PUNCT
dti-3019	162	9	18	18	NUM
dti-3019	162	10	:	:	SYM
dti-3019	162	11	13	13	NUM
dti-3019	162	12	©	©	PROPN
dti-3019	162	13	2024	2024	NUM
dti-3019	162	14	the	the	DET
dti-3019	162	15	authors	author	NOUN
dti-3019	162	16	.	.	PUNCT
dti-3019	163	1	published	publish	VERB
dti-3019	163	2	by	by	ADP
dti-3019	163	3	aboutscience	aboutscience	NOUN
dti-3019	163	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3019	163	5	doxycycline	doxycycline	NOUN
dti-3019	163	6	is	be	AUX
dti-3019	163	7	an	an	DET
dti-3019	163	8	antibiotic	antibiotic	NOUN
dti-3019	163	9	that	that	PRON
dti-3019	163	10	has	have	AUX
dti-3019	163	11	been	be	AUX
dti-3019	163	12	repurposed	repurpose	VERB
dti-3019	163	13	for	for	ADP
dti-3019	163	14	the	the	DET
dti-3019	163	15	treatment	treatment	NOUN
dti-3019	163	16	of	of	ADP
dti-3019	163	17	malaria	malaria	NOUN
dti-3019	163	18	(	(	PUNCT
dti-3019	163	19	tab	tab	NOUN
dti-3019	163	20	.	.	NOUN
dti-3019	163	21	1	1	NUM
dti-3019	163	22	)	)	PUNCT
dti-3019	163	23	.	.	PUNCT
dti-3019	164	1	while	while	SCONJ
dti-3019	164	2	there	there	PRON
dti-3019	164	3	is	be	VERB
dti-3019	164	4	no	no	DET
dti-3019	164	5	documented	document	VERB
dti-3019	164	6	evidence	evidence	NOUN
dti-3019	164	7	of	of	ADP
dti-3019	164	8	increased	increase	VERB
dti-3019	164	9	amr	amr	NOUN
dti-3019	164	10	due	due	ADP
dti-3019	164	11	to	to	ADP
dti-3019	164	12	the	the	DET
dti-3019	164	13	use	use	NOUN
dti-3019	164	14	of	of	ADP
dti-3019	164	15	doxycycline	doxycycline	NOUN
dti-3019	164	16	for	for	ADP
dti-3019	164	17	malaria	malaria	NOUN
dti-3019	164	18	prophylaxis	prophylaxis	NOUN
dti-3019	164	19	,	,	PUNCT
dti-3019	164	20	reports	report	NOUN
dti-3019	164	21	have	have	AUX
dti-3019	164	22	indicated	indicate	VERB
dti-3019	164	23	the	the	DET
dti-3019	164	24	development	development	NOUN
dti-3019	164	25	of	of	ADP
dti-3019	164	26	doxycycline	doxycycline	NOUN
dti-3019	164	27	resistance	resistance	NOUN
dti-3019	164	28	and	and	CCONJ
dti-3019	164	29	coresistance	coresistance	NOUN
dti-3019	164	30	to	to	ADP
dti-3019	164	31	other	other	ADJ
dti-3019	164	32	antibiotics	antibiotic	NOUN
dti-3019	164	33	when	when	SCONJ
dti-3019	164	34	used	use	VERB
dti-3019	164	35	to	to	PART
dti-3019	164	36	treat	treat	VERB
dti-3019	164	37	other	other	ADJ
dti-3019	164	38	diseases	disease	NOUN
dti-3019	164	39	.	.	PUNCT
dti-3019	165	1	a	a	DET
dti-3019	165	2	study	study	NOUN
dti-3019	165	3	revealed	reveal	VERB
dti-3019	165	4	that	that	SCONJ
dti-3019	165	5	doxycycline	doxycycline	NOUN
dti-3019	165	6	-	-	PUNCT
dti-3019	165	7	induced	induce	VERB
dti-3019	165	8	stress	stress	NOUN
dti-3019	165	9	led	lead	VERB
dti-3019	165	10	to	to	ADP
dti-3019	165	11	the	the	DET
dti-3019	165	12	emergence	emergence	NOUN
dti-3019	165	13	of	of	ADP
dti-3019	165	14	coresistance	coresistance	NOUN
dti-3019	165	15	to	to	PART
dti-3019	165	16	colistin	colistin	VERB
dti-3019	165	17	,	,	PUNCT
dti-3019	165	18	which	which	PRON
dti-3019	165	19	is	be	AUX
dti-3019	165	20	considered	consider	VERB
dti-3019	165	21	a	a	DET
dti-3019	165	22	last	last	ADJ
dti-3019	165	23	-	-	PUNCT
dti-3019	165	24	resort	resort	NOUN
dti-3019	165	25	antibiotic	antibiotic	NOUN
dti-3019	165	26	for	for	ADP
dti-3019	165	27	extensively	extensively	ADV
dti-3019	165	28	drug	drug	NOUN
dti-3019	165	29	-	-	PUNCT
dti-3019	165	30	resistant	resistant	ADJ
dti-3019	165	31	bacteria	bacteria	NOUN
dti-3019	165	32	(	(	PUNCT
dti-3019	165	33	108	108	NUM
dti-3019	165	34	)	)	PUNCT
dti-3019	165	35	.	.	PUNCT
dti-3019	166	1	this	this	DET
dti-3019	166	2	study	study	NOUN
dti-3019	166	3	shed	shed	VERB
dti-3019	166	4	light	light	NOUN
dti-3019	166	5	on	on	ADP
dti-3019	166	6	a	a	DET
dti-3019	166	7	potential	potential	ADJ
dti-3019	166	8	mechanism	mechanism	NOUN
dti-3019	166	9	of	of	ADP
dti-3019	166	10	doxycycline	doxycycline	NOUN
dti-3019	166	11	-	-	PUNCT
dti-3019	166	12	selected	select	VERB
dti-3019	166	13	resistance	resistance	NOUN
dti-3019	166	14	and	and	CCONJ
dti-3019	166	15	coresistance	coresistance	NOUN
dti-3019	166	16	in	in	ADP
dti-3019	166	17	vibrio	vibrio	ADJ
dti-3019	166	18	cholerae	cholerae	NOUN
dti-3019	166	19	,	,	PUNCT
dti-3019	166	20	emphasizing	emphasize	VERB
dti-3019	166	21	the	the	DET
dti-3019	166	22	need	need	NOUN
dti-3019	166	23	for	for	ADP
dti-3019	166	24	stringent	stringent	ADJ
dti-3019	166	25	regulations	regulation	NOUN
dti-3019	166	26	regarding	regard	VERB
dti-3019	166	27	the	the	DET
dti-3019	166	28	indiscriminate	indiscriminate	ADJ
dti-3019	166	29	use	use	NOUN
dti-3019	166	30	of	of	ADP
dti-3019	166	31	antibiotics	antibiotic	NOUN
dti-3019	166	32	.	.	PUNCT
dti-3019	167	1	another	another	DET
dti-3019	167	2	aspect	aspect	NOUN
dti-3019	167	3	to	to	PART
dti-3019	167	4	consider	consider	VERB
dti-3019	167	5	is	be	AUX
dti-3019	167	6	the	the	DET
dti-3019	167	7	unrestricted	unrestricted	ADJ
dti-3019	167	8	sale	sale	NOUN
dti-3019	167	9	of	of	ADP
dti-3019	167	10	these	these	DET
dti-3019	167	11	antibiotics	antibiotic	NOUN
dti-3019	167	12	without	without	ADP
dti-3019	167	13	prescription	prescription	NOUN
dti-3019	167	14	,	,	PUNCT
dti-3019	167	15	particularly	particularly	ADV
dti-3019	167	16	in	in	ADP
dti-3019	167	17	developing	develop	VERB
dti-3019	167	18	countries	country	NOUN
dti-3019	167	19	such	such	ADJ
dti-3019	167	20	as	as	ADP
dti-3019	167	21	india	india	PROPN
dti-3019	167	22	,	,	PUNCT
dti-3019	167	23	which	which	PRON
dti-3019	167	24	is	be	AUX
dti-3019	167	25	one	one	NUM
dti-3019	167	26	of	of	ADP
dti-3019	167	27	the	the	DET
dti-3019	167	28	largest	large	ADJ
dti-3019	167	29	consumers	consumer	NOUN
dti-3019	167	30	of	of	ADP
dti-3019	167	31	antibiotics	antibiotic	NOUN
dti-3019	167	32	(	(	PUNCT
dti-3019	167	33	109	109	NUM
dti-3019	167	34	)	)	PUNCT
dti-3019	167	35	.	.	PUNCT
dti-3019	168	1	consequently	consequently	ADV
dti-3019	168	2	,	,	PUNCT
dti-3019	168	3	the	the	DET
dti-3019	168	4	controlled	control	VERB
dti-3019	168	5	usage	usage	NOUN
dti-3019	168	6	of	of	ADP
dti-3019	168	7	these	these	DET
dti-3019	168	8	repurposed	repurpose	VERB
dti-3019	168	9	antibiotics	antibiotic	NOUN
dti-3019	168	10	may	may	AUX
dti-3019	168	11	be	be	AUX
dti-3019	168	12	compromised	compromise	VERB
dti-3019	168	13	.	.	PUNCT
dti-3019	169	1	prolonged	prolong	VERB
dti-3019	169	2	use	use	NOUN
dti-3019	169	3	of	of	ADP
dti-3019	169	4	repurposed	repurpose	VERB
dti-3019	169	5	antibiotics	antibiotic	NOUN
dti-3019	169	6	could	could	AUX
dti-3019	169	7	exert	exert	VERB
dti-3019	169	8	selective	selective	ADJ
dti-3019	169	9	pressure	pressure	NOUN
dti-3019	169	10	,	,	PUNCT
dti-3019	169	11	resulting	result	VERB
dti-3019	169	12	in	in	ADP
dti-3019	169	13	the	the	DET
dti-3019	169	14	survival	survival	NOUN
dti-3019	169	15	of	of	ADP
dti-3019	169	16	multidrug	multidrug	NOUN
dti-3019	169	17	-	-	PUNCT
dti-3019	169	18	resistant	resistant	ADJ
dti-3019	169	19	and	and	CCONJ
dti-3019	169	20	extremely	extremely	ADV
dti-3019	169	21	drug	drug	NOUN
dti-3019	169	22	-	-	PUNCT
dti-3019	169	23	resistant	resistant	ADJ
dti-3019	169	24	bacteria	bacteria	NOUN
dti-3019	169	25	.	.	PUNCT
dti-3019	170	1	in	in	ADP
dti-3019	170	2	the	the	DET
dti-3019	170	3	absence	absence	NOUN
dti-3019	170	4	of	of	ADP
dti-3019	170	5	a	a	DET
dti-3019	170	6	competitive	competitive	ADJ
dti-3019	170	7	environment	environment	NOUN
dti-3019	170	8	,	,	PUNCT
dti-3019	170	9	these	these	DET
dti-3019	170	10	drug	drug	NOUN
dti-3019	170	11	-	-	PUNCT
dti-3019	170	12	resistant	resistant	ADJ
dti-3019	170	13	strains	strain	NOUN
dti-3019	170	14	may	may	AUX
dti-3019	170	15	thrive	thrive	VERB
dti-3019	170	16	more	more	ADV
dti-3019	170	17	successfully	successfully	ADV
dti-3019	170	18	,	,	PUNCT
dti-3019	170	19	leading	lead	VERB
dti-3019	170	20	to	to	ADP
dti-3019	170	21	the	the	DET
dti-3019	170	22	elimination	elimination	NOUN
dti-3019	170	23	of	of	ADP
dti-3019	170	24	phenotypically	phenotypically	ADV
dti-3019	170	25	sensitive	sensitive	ADJ
dti-3019	170	26	strains	strain	NOUN
dti-3019	170	27	,	,	PUNCT
dti-3019	170	28	as	as	SCONJ
dti-3019	170	29	illustrated	illustrate	VERB
dti-3019	170	30	in	in	ADP
dti-3019	170	31	figure	figure	NOUN
dti-3019	170	32	3	3	NUM
dti-3019	170	33	(	(	PUNCT
dti-3019	170	34	110	110	NUM
dti-3019	170	35	)	)	PUNCT
dti-3019	170	36	.	.	PUNCT
dti-3019	171	1	during	during	ADP
dti-3019	171	2	the	the	DET
dti-3019	171	3	covid-19	covid-19	PROPN
dti-3019	171	4	pandemic	pandemic	NOUN
dti-3019	171	5	,	,	PUNCT
dti-3019	171	6	health	health	NOUN
dti-3019	171	7	professionals	professional	NOUN
dti-3019	171	8	turned	turn	VERB
dti-3019	171	9	to	to	ADP
dti-3019	171	10	the	the	DET
dti-3019	171	11	administration	administration	NOUN
dti-3019	171	12	of	of	ADP
dti-3019	171	13	azithromycin	azithromycin	PROPN
dti-3019	171	14	alone	alone	ADJ
dti-3019	171	15	or	or	CCONJ
dti-3019	171	16	in	in	ADP
dti-3019	171	17	combination	combination	NOUN
dti-3019	171	18	with	with	ADP
dti-3019	171	19	drugs	drug	NOUN
dti-3019	171	20	like	like	ADP
dti-3019	171	21	hydroxychloroquine	hydroxychloroquine	PROPN
dti-3019	171	22	.	.	PUNCT
dti-3019	172	1	this	this	DET
dti-3019	172	2	repurposing	repurposing	NOUN
dti-3019	172	3	of	of	ADP
dti-3019	172	4	an	an	DET
dti-3019	172	5	antibiotic	antibiotic	NOUN
dti-3019	172	6	without	without	ADP
dti-3019	172	7	any	any	DET
dti-3019	172	8	evidence	evidence	NOUN
dti-3019	172	9	of	of	ADP
dti-3019	172	10	its	its	PRON
dti-3019	172	11	antiviral	antiviral	NOUN
dti-3019	172	12	there	there	PRON
dti-3019	172	13	is	be	VERB
dti-3019	172	14	an	an	DET
dti-3019	172	15	ongoing	ongoing	ADJ
dti-3019	172	16	endeavor	endeavor	NOUN
dti-3019	172	17	to	to	PART
dti-3019	172	18	discover	discover	VERB
dti-3019	172	19	novel	novel	ADJ
dti-3019	172	20	drugs	drug	NOUN
dti-3019	172	21	or	or	CCONJ
dti-3019	172	22	alternative	alternative	ADJ
dti-3019	172	23	approaches	approach	NOUN
dti-3019	172	24	to	to	PART
dti-3019	172	25	combat	combat	VERB
dti-3019	172	26	bacterial	bacterial	ADJ
dti-3019	172	27	infections	infection	NOUN
dti-3019	172	28	,	,	PUNCT
dti-3019	172	29	but	but	CCONJ
dti-3019	172	30	unfortunately	unfortunately	ADV
dti-3019	172	31	,	,	PUNCT
dti-3019	172	32	the	the	DET
dti-3019	172	33	rate	rate	NOUN
dti-3019	172	34	at	at	ADP
dti-3019	172	35	which	which	PRON
dti-3019	172	36	bacterial	bacterial	ADJ
dti-3019	172	37	resistance	resistance	NOUN
dti-3019	172	38	develops	develop	VERB
dti-3019	172	39	surpasses	surpass	VERB
dti-3019	172	40	the	the	DET
dti-3019	172	41	pace	pace	NOUN
dti-3019	172	42	of	of	ADP
dti-3019	172	43	these	these	DET
dti-3019	172	44	endeavors	endeavor	NOUN
dti-3019	172	45	(	(	PUNCT
dti-3019	172	46	81	81	NUM
dti-3019	172	47	)	)	PUNCT
dti-3019	172	48	.	.	PUNCT
dti-3019	173	1	while	while	SCONJ
dti-3019	173	2	the	the	DET
dti-3019	173	3	notion	notion	NOUN
dti-3019	173	4	of	of	ADP
dti-3019	173	5	repurposing	repurpose	VERB
dti-3019	173	6	drugs	drug	NOUN
dti-3019	173	7	may	may	AUX
dti-3019	173	8	appear	appear	VERB
dti-3019	173	9	rational	rational	ADJ
dti-3019	173	10	and	and	CCONJ
dti-3019	173	11	a	a	DET
dti-3019	173	12	scientific	scientific	ADJ
dti-3019	173	13	approach	approach	NOUN
dti-3019	173	14	to	to	ADP
dti-3019	173	15	addressing	address	VERB
dti-3019	173	16	previously	previously	ADV
dti-3019	173	17	incurable	incurable	ADJ
dti-3019	173	18	ailments	ailment	NOUN
dti-3019	173	19	such	such	ADJ
dti-3019	173	20	as	as	ADP
dti-3019	173	21	alzheimer	alzheimer	PROPN
dti-3019	173	22	’s	’s	PART
dti-3019	173	23	,	,	PUNCT
dti-3019	173	24	cancer	cancer	NOUN
dti-3019	173	25	,	,	PUNCT
dti-3019	173	26	and	and	CCONJ
dti-3019	173	27	parkinson	parkinson	NOUN
dti-3019	173	28	’s	’s	PART
dti-3019	173	29	,	,	PUNCT
dti-3019	173	30	the	the	DET
dti-3019	173	31	repurposing	repurposing	NOUN
dti-3019	173	32	of	of	ADP
dti-3019	173	33	antibiotic	antibiotic	ADJ
dti-3019	173	34	medications	medication	NOUN
dti-3019	173	35	has	have	AUX
dti-3019	173	36	generated	generate	VERB
dti-3019	173	37	concerns	concern	NOUN
dti-3019	173	38	regarding	regard	VERB
dti-3019	173	39	their	their	PRON
dti-3019	173	40	use	use	NOUN
dti-3019	173	41	in	in	ADP
dti-3019	173	42	treating	treat	VERB
dti-3019	173	43	such	such	ADJ
dti-3019	173	44	diseases	disease	NOUN
dti-3019	173	45	,	,	PUNCT
dti-3019	173	46	particularly	particularly	ADV
dti-3019	173	47	in	in	ADP
dti-3019	173	48	light	light	NOUN
dti-3019	173	49	of	of	ADP
dti-3019	173	50	the	the	DET
dti-3019	173	51	widespread	widespread	ADJ
dti-3019	173	52	prevalence	prevalence	NOUN
dti-3019	173	53	of	of	ADP
dti-3019	173	54	amr	amr	NOUN
dti-3019	173	55	that	that	PRON
dti-3019	173	56	has	have	AUX
dti-3019	173	57	wreaked	wreak	VERB
dti-3019	173	58	havoc	havoc	NOUN
dti-3019	173	59	in	in	ADP
dti-3019	173	60	our	our	PRON
dti-3019	173	61	contemporary	contemporary	ADJ
dti-3019	173	62	era	era	NOUN
dti-3019	173	63	.	.	PUNCT
dti-3019	174	1	amr	amr	PROPN
dti-3019	174	2	is	be	AUX
dti-3019	174	3	well	well	ADV
dti-3019	174	4	-	-	PUNCT
dti-3019	174	5	known	know	VERB
dti-3019	174	6	for	for	ADP
dti-3019	174	7	its	its	PRON
dti-3019	174	8	devastating	devastating	ADJ
dti-3019	174	9	impact	impact	NOUN
dti-3019	174	10	,	,	PUNCT
dti-3019	174	11	with	with	ADP
dti-3019	174	12	over	over	ADP
dti-3019	174	13	700,000	700,000	NUM
dti-3019	174	14	deaths	death	NOUN
dti-3019	174	15	occurring	occur	VERB
dti-3019	174	16	globally	globally	ADV
dti-3019	174	17	as	as	ADP
dti-3019	174	18	a	a	DET
dti-3019	174	19	result	result	NOUN
dti-3019	174	20	,	,	PUNCT
dti-3019	174	21	and	and	CCONJ
dti-3019	174	22	projections	projection	NOUN
dti-3019	174	23	indicating	indicate	VERB
dti-3019	174	24	that	that	SCONJ
dti-3019	174	25	this	this	DET
dti-3019	174	26	number	number	NOUN
dti-3019	174	27	could	could	AUX
dti-3019	174	28	escalate	escalate	VERB
dti-3019	174	29	to	to	ADP
dti-3019	174	30	approximately	approximately	ADV
dti-3019	174	31	10	10	NUM
dti-3019	174	32	million	million	NUM
dti-3019	174	33	people	people	NOUN
dti-3019	174	34	worldwide	worldwide	ADV
dti-3019	174	35	by	by	ADP
dti-3019	174	36	the	the	DET
dti-3019	174	37	year	year	NOUN
dti-3019	174	38	2050	2050	NUM
dti-3019	174	39	(	(	PUNCT
dti-3019	174	40	95	95	NUM
dti-3019	174	41	)	)	PUNCT
dti-3019	174	42	.	.	PUNCT
dti-3019	175	1	a	a	DET
dti-3019	175	2	number	number	NOUN
dti-3019	175	3	of	of	ADP
dti-3019	175	4	research	research	NOUN
dti-3019	175	5	studies	study	NOUN
dti-3019	175	6	have	have	AUX
dti-3019	175	7	delved	delve	VERB
dti-3019	175	8	into	into	ADP
dti-3019	175	9	the	the	DET
dti-3019	175	10	utilization	utilization	NOUN
dti-3019	175	11	of	of	ADP
dti-3019	175	12	antibiotics	antibiotic	NOUN
dti-3019	175	13	for	for	ADP
dti-3019	175	14	the	the	DET
dti-3019	175	15	treatment	treatment	NOUN
dti-3019	175	16	of	of	ADP
dti-3019	175	17	conditions	condition	NOUN
dti-3019	175	18	other	other	ADJ
dti-3019	175	19	than	than	ADP
dti-3019	175	20	bacterial	bacterial	ADJ
dti-3019	175	21	infections	infection	NOUN
dti-3019	175	22	,	,	PUNCT
dti-3019	175	23	attempting	attempt	VERB
dti-3019	175	24	to	to	PART
dti-3019	175	25	repurpose	repurpose	VERB
dti-3019	175	26	these	these	DET
dti-3019	175	27	medications	medication	NOUN
dti-3019	175	28	(	(	PUNCT
dti-3019	175	29	96	96	NUM
dti-3019	175	30	-	-	SYM
dti-3019	175	31	98	98	NUM
dti-3019	175	32	)	)	PUNCT
dti-3019	175	33	.	.	PUNCT
dti-3019	176	1	however	however	ADV
dti-3019	176	2	,	,	PUNCT
dti-3019	176	3	these	these	DET
dti-3019	176	4	studies	study	NOUN
dti-3019	176	5	have	have	AUX
dti-3019	176	6	failed	fail	VERB
dti-3019	176	7	to	to	PART
dti-3019	176	8	adequately	adequately	ADV
dti-3019	176	9	acknowledge	acknowledge	VERB
dti-3019	176	10	the	the	DET
dti-3019	176	11	grave	grave	ADJ
dti-3019	176	12	peril	peril	NOUN
dti-3019	176	13	associated	associate	VERB
dti-3019	176	14	with	with	ADP
dti-3019	176	15	employing	employ	VERB
dti-3019	176	16	antibiotics	antibiotic	NOUN
dti-3019	176	17	for	for	ADP
dti-3019	176	18	repurposing	repurpose	VERB
dti-3019	176	19	,	,	PUNCT
dti-3019	176	20	namely	namely	ADV
dti-3019	176	21	the	the	DET
dti-3019	176	22	progression	progression	NOUN
dti-3019	176	23	of	of	ADP
dti-3019	176	24	amr	amr	PROPN
dti-3019	176	25	(	(	PUNCT
dti-3019	176	26	as	as	SCONJ
dti-3019	176	27	depicted	depict	VERB
dti-3019	176	28	in	in	ADP
dti-3019	176	29	fig	fig	NOUN
dti-3019	176	30	.	.	PUNCT
dti-3019	177	1	1	1	NUM
dti-3019	177	2	)	)	PUNCT
dti-3019	177	3	.	.	PUNCT
dti-3019	178	1	the	the	DET
dti-3019	178	2	antibiotic	antibiotic	ADJ
dti-3019	178	3	levofloxacin	levofloxacin	NOUN
dti-3019	178	4	has	have	AUX
dti-3019	178	5	recently	recently	ADV
dti-3019	178	6	been	be	AUX
dti-3019	178	7	proposed	propose	VERB
dti-3019	178	8	as	as	ADP
dti-3019	178	9	a	a	DET
dti-3019	178	10	potential	potential	ADJ
dti-3019	178	11	repurposed	repurpose	VERB
dti-3019	178	12	medication	medication	NOUN
dti-3019	178	13	for	for	ADP
dti-3019	178	14	alzheimer	alzheimer	PROPN
dti-3019	178	15	’s	’s	PART
dti-3019	178	16	disease	disease	NOUN
dti-3019	178	17	(	(	PUNCT
dti-3019	178	18	ad	ad	NOUN
dti-3019	178	19	)	)	PUNCT
dti-3019	178	20	(	(	PUNCT
dti-3019	178	21	98	98	NUM
dti-3019	178	22	)	)	PUNCT
dti-3019	178	23	.	.	PUNCT
dti-3019	179	1	however	however	ADV
dti-3019	179	2	,	,	PUNCT
dti-3019	179	3	several	several	ADJ
dti-3019	179	4	other	other	ADJ
dti-3019	179	5	studies	study	NOUN
dti-3019	179	6	examining	examine	VERB
dti-3019	179	7	the	the	DET
dti-3019	179	8	effects	effect	NOUN
dti-3019	179	9	of	of	ADP
dti-3019	179	10	this	this	DET
dti-3019	179	11	antibiotic	antibiotic	NOUN
dti-3019	179	12	on	on	ADP
dti-3019	179	13	alzheimer	alzheimer	PROPN
dti-3019	179	14	’s	’s	PART
dti-3019	179	15	patients	patient	NOUN
dti-3019	179	16	have	have	AUX
dti-3019	179	17	been	be	AUX
dti-3019	179	18	disregarded	disregard	VERB
dti-3019	179	19	.	.	PUNCT
dti-3019	180	1	one	one	NUM
dti-3019	180	2	of	of	ADP
dti-3019	180	3	these	these	DET
dti-3019	180	4	studies	study	NOUN
dti-3019	180	5	involves	involve	VERB
dti-3019	180	6	a	a	DET
dti-3019	180	7	case	case	NOUN
dti-3019	180	8	report	report	NOUN
dti-3019	180	9	that	that	PRON
dti-3019	180	10	observed	observe	VERB
dti-3019	180	11	an	an	DET
dti-3019	180	12	increase	increase	NOUN
dti-3019	180	13	in	in	ADP
dti-3019	180	14	seizures	seizure	NOUN
dti-3019	180	15	in	in	ADP
dti-3019	180	16	an	an	DET
dti-3019	180	17	ad	ad	NOUN
dti-3019	180	18	patient	patient	NOUN
dti-3019	180	19	who	who	PRON
dti-3019	180	20	was	be	AUX
dti-3019	180	21	administered	administer	VERB
dti-3019	180	22	a	a	DET
dti-3019	180	23	dose	dose	NOUN
dti-3019	180	24	of	of	ADP
dti-3019	180	25	500	500	NUM
dti-3019	180	26	mg	mg	NUM
dti-3019	180	27	/	/	SYM
dti-3019	180	28	day	day	NOUN
dti-3019	180	29	of	of	ADP
dti-3019	180	30	levofloxacin	levofloxacin	PROPN
dti-3019	180	31	(	(	PUNCT
dti-3019	180	32	99	99	NUM
dti-3019	180	33	)	)	PUNCT
dti-3019	180	34	.	.	PUNCT
dti-3019	181	1	additionally	additionally	ADV
dti-3019	181	2	,	,	PUNCT
dti-3019	181	3	research	research	NOUN
dti-3019	181	4	on	on	ADP
dti-3019	181	5	the	the	DET
dti-3019	181	6	gut	gut	NOUN
dti-3019	181	7	microbiome	microbiome	NOUN
dti-3019	181	8	of	of	ADP
dti-3019	181	9	alzheimer	alzheimer	PROPN
dti-3019	181	10	’s	’s	PART
dti-3019	181	11	patients	patient	NOUN
dti-3019	181	12	has	have	AUX
dti-3019	181	13	indicated	indicate	VERB
dti-3019	181	14	that	that	SCONJ
dti-3019	181	15	helicobacter	helicobacter	NOUN
dti-3019	181	16	pylori	pylori	NOUN
dti-3019	181	17	infection	infection	NOUN
dti-3019	181	18	may	may	AUX
dti-3019	181	19	serve	serve	VERB
dti-3019	181	20	as	as	ADP
dti-3019	181	21	a	a	DET
dti-3019	181	22	trigger	trigger	NOUN
dti-3019	181	23	for	for	ADP
dti-3019	181	24	the	the	DET
dti-3019	181	25	release	release	NOUN
dti-3019	181	26	of	of	ADP
dti-3019	181	27	inflammatory	inflammatory	ADJ
dti-3019	181	28	mediators	mediator	NOUN
dti-3019	181	29	in	in	ADP
dti-3019	181	30	ad	ad	NOUN
dti-3019	181	31	patients	patient	NOUN
dti-3019	181	32	(	(	PUNCT
dti-3019	181	33	104	104	NUM
dti-3019	181	34	)	)	PUNCT
dti-3019	181	35	.	.	PUNCT
dti-3019	182	1	it	it	PRON
dti-3019	182	2	is	be	AUX
dti-3019	182	3	worth	worth	ADJ
dti-3019	182	4	noting	note	VERB
dti-3019	182	5	that	that	SCONJ
dti-3019	182	6	h.	h.	PROPN
dti-3019	182	7	pylori	pylori	NOUN
dti-3019	182	8	is	be	AUX
dti-3019	182	9	known	know	VERB
dti-3019	182	10	for	for	ADP
dti-3019	182	11	its	its	PRON
dti-3019	182	12	resistance	resistance	NOUN
dti-3019	182	13	to	to	ADP
dti-3019	182	14	levofloxacin	levofloxacin	PROPN
dti-3019	182	15	(	(	PUNCT
dti-3019	182	16	tab	tab	NOUN
dti-3019	182	17	.	.	NOUN
dti-3019	182	18	1	1	NUM
dti-3019	182	19	)	)	PUNCT
dti-3019	182	20	(	(	PUNCT
dti-3019	182	21	105	105	NUM
dti-3019	182	22	)	)	PUNCT
dti-3019	182	23	.	.	PUNCT
dti-3019	183	1	the	the	DET
dti-3019	183	2	primary	primary	ADJ
dti-3019	183	3	concern	concern	NOUN
dti-3019	183	4	with	with	ADP
dti-3019	183	5	repurposed	repurpose	VERB
dti-3019	183	6	antibiotics	antibiotic	NOUN
dti-3019	183	7	lies	lie	VERB
dti-3019	183	8	in	in	ADP
dti-3019	183	9	their	their	PRON
dti-3019	183	10	dosage	dosage	NOUN
dti-3019	183	11	,	,	PUNCT
dti-3019	183	12	duration	duration	NOUN
dti-3019	183	13	of	of	ADP
dti-3019	183	14	use	use	NOUN
dti-3019	183	15	,	,	PUNCT
dti-3019	183	16	and	and	CCONJ
dti-3019	183	17	their	their	PRON
dti-3019	183	18	impact	impact	NOUN
dti-3019	183	19	on	on	ADP
dti-3019	183	20	amr	amr	PROPN
dti-3019	183	21	.	.	PROPN
dti-3019	183	22	antibiotics	antibiotic	NOUN
dti-3019	183	23	are	be	AUX
dti-3019	183	24	typically	typically	ADV
dti-3019	183	25	administered	administer	VERB
dti-3019	183	26	at	at	ADP
dti-3019	183	27	doses	dose	NOUN
dti-3019	183	28	significantly	significantly	ADV
dti-3019	183	29	higher	high	ADJ
dti-3019	183	30	than	than	ADP
dti-3019	183	31	non	non	ADJ
dti-3019	183	32	-	-	ADJ
dti-3019	183	33	antibiotic	antibiotic	ADJ
dti-3019	183	34	drugs	drug	NOUN
dti-3019	183	35	(	(	PUNCT
dti-3019	183	36	27	27	NUM
dti-3019	183	37	)	)	PUNCT
dti-3019	183	38	.	.	PUNCT
dti-3019	184	1	in	in	ADP
dti-3019	184	2	fact	fact	NOUN
dti-3019	184	3	,	,	PUNCT
dti-3019	184	4	a	a	DET
dti-3019	184	5	concentration	concentration	NOUN
dti-3019	184	6	of	of	ADP
dti-3019	184	7	400	400	NUM
dti-3019	184	8	mg	mg	NOUN
dti-3019	184	9	of	of	ADP
dti-3019	184	10	minocycline	minocycline	NOUN
dti-3019	184	11	was	be	AUX
dti-3019	184	12	found	find	VERB
dti-3019	184	13	to	to	PART
dti-3019	184	14	be	be	AUX
dti-3019	184	15	ineffective	ineffective	ADJ
dti-3019	184	16	in	in	ADP
dti-3019	184	17	delaying	delay	VERB
dti-3019	184	18	the	the	DET
dti-3019	184	19	progression	progression	NOUN
dti-3019	184	20	of	of	ADP
dti-3019	184	21	cognitive	cognitive	ADJ
dti-3019	184	22	or	or	CCONJ
dti-3019	184	23	functional	functional	ADJ
dti-3019	184	24	impairment	impairment	NOUN
dti-3019	184	25	in	in	ADP
dti-3019	184	26	patients	patient	NOUN
dti-3019	184	27	with	with	ADP
dti-3019	184	28	mild	mild	ADJ
dti-3019	184	29	ad	ad	NOUN
dti-3019	184	30	over	over	ADP
dti-3019	184	31	a	a	DET
dti-3019	184	32	2	2	NUM
dti-3019	184	33	-	-	PUNCT
dti-3019	184	34	year	year	NOUN
dti-3019	184	35	period	period	NOUN
dti-3019	184	36	(	(	PUNCT
dti-3019	184	37	106	106	NUM
dti-3019	184	38	)	)	PUNCT
dti-3019	184	39	.	.	PUNCT
dti-3019	185	1	despite	despite	SCONJ
dti-3019	185	2	their	their	PRON
dti-3019	185	3	potential	potential	NOUN
dti-3019	185	4	as	as	ADP
dti-3019	185	5	candidates	candidate	NOUN
dti-3019	185	6	in	in	ADP
dti-3019	185	7	laboratory	laboratory	NOUN
dti-3019	185	8	settings	setting	NOUN
dti-3019	185	9	,	,	PUNCT
dti-3019	185	10	the	the	DET
dti-3019	185	11	efficacy	efficacy	NOUN
dti-3019	185	12	of	of	ADP
dti-3019	185	13	these	these	DET
dti-3019	185	14	antibiotics	antibiotic	NOUN
dti-3019	185	15	in	in	ADP
dti-3019	185	16	vivo	vivo	NOUN
dti-3019	185	17	is	be	AUX
dti-3019	185	18	not	not	PART
dti-3019	185	19	guaranteed	guarantee	VERB
dti-3019	185	20	.	.	PUNCT
dti-3019	186	1	moreover	moreover	ADV
dti-3019	186	2	,	,	PUNCT
dti-3019	186	3	long	long	ADJ
dti-3019	186	4	-	-	PUNCT
dti-3019	186	5	term	term	NOUN
dti-3019	186	6	exposure	exposure	NOUN
dti-3019	186	7	to	to	ADP
dti-3019	186	8	antibiotics	antibiotic	NOUN
dti-3019	186	9	,	,	PUNCT
dti-3019	186	10	whether	whether	SCONJ
dti-3019	186	11	at	at	ADP
dti-3019	186	12	clinical	clinical	ADJ
dti-3019	186	13	or	or	CCONJ
dti-3019	186	14	sub	sub	ADJ
dti-3019	186	15	-	-	ADJ
dti-3019	186	16	stoichiometric	stoichiometric	ADJ
dti-3019	186	17	doses	dose	NOUN
dti-3019	186	18	,	,	PUNCT
dti-3019	186	19	can	can	AUX
dti-3019	186	20	lead	lead	VERB
dti-3019	186	21	to	to	ADP
dti-3019	186	22	the	the	DET
dti-3019	186	23	development	development	NOUN
dti-3019	186	24	of	of	ADP
dti-3019	186	25	drug	drug	NOUN
dti-3019	186	26	resistance	resistance	NOUN
dti-3019	186	27	among	among	ADP
dti-3019	186	28	gut	gut	NOUN
dti-3019	186	29	microbes	microbe	NOUN
dti-3019	186	30	.	.	PUNCT
dti-3019	187	1	chronic	chronic	ADJ
dti-3019	187	2	administration	administration	NOUN
dti-3019	187	3	of	of	ADP
dti-3019	187	4	these	these	DET
dti-3019	187	5	antibiotics	antibiotic	NOUN
dti-3019	187	6	is	be	AUX
dti-3019	187	7	necessary	necessary	ADJ
dti-3019	187	8	for	for	ADP
dti-3019	187	9	the	the	DET
dti-3019	187	10	treatment	treatment	NOUN
dti-3019	187	11	or	or	CCONJ
dti-3019	187	12	management	management	NOUN
dti-3019	187	13	of	of	ADP
dti-3019	187	14	ad	ad	NOUN
dti-3019	187	15	.	.	PUNCT
dti-3019	188	1	consequently	consequently	ADV
dti-3019	188	2	,	,	PUNCT
dti-3019	188	3	the	the	DET
dti-3019	188	4	chronic	chronic	ADJ
dti-3019	188	5	use	use	NOUN
dti-3019	188	6	of	of	ADP
dti-3019	188	7	antibiotics	antibiotic	NOUN
dti-3019	188	8	at	at	ADP
dti-3019	188	9	clinical	clinical	ADJ
dti-3019	188	10	doses	dose	NOUN
dti-3019	188	11	may	may	AUX
dti-3019	188	12	result	result	VERB
dti-3019	188	13	in	in	ADP
dti-3019	188	14	antibiotic	antibiotic	ADJ
dti-3019	188	15	resistance	resistance	NOUN
dti-3019	188	16	,	,	PUNCT
dti-3019	188	17	making	make	VERB
dti-3019	188	18	it	it	PRON
dti-3019	188	19	challenging	challenging	ADJ
dti-3019	188	20	to	to	PART
dti-3019	188	21	treat	treat	VERB
dti-3019	188	22	common	common	ADJ
dti-3019	188	23	infections	infection	NOUN
dti-3019	188	24	.	.	PUNCT
dti-3019	189	1	furthermore	furthermore	ADV
dti-3019	189	2	,	,	PUNCT
dti-3019	189	3	prolonged	prolonged	ADJ
dti-3019	189	4	antibiotic	antibiotic	ADJ
dti-3019	189	5	use	use	NOUN
dti-3019	189	6	may	may	AUX
dti-3019	189	7	increase	increase	VERB
dti-3019	189	8	a	a	DET
dti-3019	189	9	patient	patient	NOUN
dti-3019	189	10	’s	’s	PART
dti-3019	189	11	susceptibility	susceptibility	NOUN
dti-3019	189	12	to	to	ADP
dti-3019	189	13	infections	infection	NOUN
dti-3019	189	14	.	.	PUNCT
dti-3019	190	1	if	if	SCONJ
dti-3019	190	2	any	any	DET
dti-3019	190	3	antibiotics	antibiotic	NOUN
dti-3019	190	4	demonstrate	demonstrate	VERB
dti-3019	190	5	potential	potential	ADJ
dti-3019	190	6	as	as	ADP
dti-3019	190	7	antialzheimer	antialzheimer	NOUN
dti-3019	190	8	’s	’s	PART
dti-3019	190	9	agents	agent	NOUN
dti-3019	190	10	in	in	ADP
dti-3019	190	11	either	either	CCONJ
dti-3019	190	12	laboratory	laboratory	NOUN
dti-3019	190	13	or	or	CCONJ
dti-3019	190	14	clinical	clinical	ADJ
dti-3019	190	15	studies	study	NOUN
dti-3019	190	16	,	,	PUNCT
dti-3019	190	17	it	it	PRON
dti-3019	190	18	is	be	AUX
dti-3019	190	19	imperative	imperative	ADJ
dti-3019	190	20	to	to	PART
dti-3019	190	21	assess	assess	VERB
dti-3019	190	22	their	their	PRON
dti-3019	190	23	long	long	ADJ
dti-3019	190	24	-	-	PUNCT
dti-3019	190	25	term	term	NOUN
dti-3019	190	26	consequences	consequence	NOUN
dti-3019	190	27	.	.	PUNCT
dti-3019	191	1	there	there	PRON
dti-3019	191	2	has	have	AUX
dti-3019	191	3	been	be	AUX
dti-3019	191	4	a	a	DET
dti-3019	191	5	lack	lack	NOUN
dti-3019	191	6	of	of	ADP
dti-3019	191	7	comprehensive	comprehensive	ADJ
dti-3019	191	8	research	research	NOUN
dti-3019	191	9	aimed	aim	VERB
dti-3019	191	10	at	at	ADP
dti-3019	191	11	comprehending	comprehend	VERB
dti-3019	191	12	the	the	DET
dti-3019	191	13	prolonged	prolonged	ADJ
dti-3019	191	14	implications	implication	NOUN
dti-3019	191	15	of	of	ADP
dti-3019	191	16	utilizing	utilize	VERB
dti-3019	191	17	repurposed	repurpose	VERB
dti-3019	191	18	antibiotics	antibiotic	NOUN
dti-3019	191	19	to	to	PART
dti-3019	191	20	enhance	enhance	VERB
dti-3019	191	21	amr	amr	PROPN
dti-3019	191	22	.	.	PUNCT
dti-3019	192	1	however	however	ADV
dti-3019	192	2	,	,	PUNCT
dti-3019	192	3	existing	exist	VERB
dti-3019	192	4	data	datum	NOUN
dti-3019	192	5	have	have	AUX
dti-3019	192	6	demonstrated	demonstrate	VERB
dti-3019	192	7	a	a	DET
dti-3019	192	8	direct	direct	ADJ
dti-3019	192	9	correlation	correlation	NOUN
dti-3019	192	10	between	between	ADP
dti-3019	192	11	the	the	DET
dti-3019	192	12	consumption	consumption	NOUN
dti-3019	192	13	of	of	ADP
dti-3019	192	14	antibiotics	antibiotic	NOUN
dti-3019	192	15	and	and	CCONJ
dti-3019	192	16	the	the	DET
dti-3019	192	17	emergence	emergence	NOUN
dti-3019	192	18	of	of	ADP
dti-3019	192	19	amr	amr	PROPN
dti-3019	192	20	(	(	PUNCT
dti-3019	192	21	107	107	NUM
dti-3019	192	22	)	)	PUNCT
dti-3019	192	23	.	.	PUNCT
dti-3019	193	1	consequently	consequently	ADV
dti-3019	193	2	,	,	PUNCT
dti-3019	193	3	an	an	DET
dti-3019	193	4	escalation	escalation	NOUN
dti-3019	193	5	of	of	ADP
dti-3019	193	6	multidrug	multidrug	NOUN
dti-3019	193	7	resistance	resistance	NOUN
dti-3019	193	8	may	may	AUX
dti-3019	193	9	occur	occur	VERB
dti-3019	193	10	as	as	ADP
dti-3019	193	11	the	the	DET
dti-3019	193	12	consumption	consumption	NOUN
dti-3019	193	13	of	of	ADP
dti-3019	193	14	these	these	DET
dti-3019	193	15	repurposed	repurpose	VERB
dti-3019	193	16	antibiotics	antibiotic	NOUN
dti-3019	193	17	increases	increase	NOUN
dti-3019	193	18	.	.	PUNCT
dti-3019	194	1	for	for	ADP
dti-3019	194	2	example	example	NOUN
dti-3019	194	3	,	,	PUNCT
dti-3019	194	4	figure	figure	VERB
dti-3019	194	5	3	3	NUM
dti-3019	194	6	progression	progression	NOUN
dti-3019	194	7	of	of	ADP
dti-3019	194	8	antimicrobial	antimicrobial	ADJ
dti-3019	194	9	resistance	resistance	NOUN
dti-3019	194	10	.	.	PUNCT
dti-3019	195	1	antimicrobial	antimicrobial	ADJ
dti-3019	195	2	resistance	resistance	NOUN
dti-3019	195	3	may	may	AUX
dti-3019	195	4	arise	arise	VERB
dti-3019	195	5	as	as	ADP
dti-3019	195	6	a	a	DET
dti-3019	195	7	consequence	consequence	NOUN
dti-3019	195	8	of	of	ADP
dti-3019	195	9	the	the	DET
dti-3019	195	10	improper	improper	ADJ
dti-3019	195	11	utilization	utilization	NOUN
dti-3019	195	12	of	of	ADP
dti-3019	195	13	antibiotics	antibiotic	NOUN
dti-3019	195	14	or	or	CCONJ
dti-3019	195	15	their	their	PRON
dti-3019	195	16	employment	employment	NOUN
dti-3019	195	17	for	for	ADP
dti-3019	195	18	indications	indication	NOUN
dti-3019	195	19	other	other	ADJ
dti-3019	195	20	than	than	ADP
dti-3019	195	21	the	the	DET
dti-3019	195	22	treatment	treatment	NOUN
dti-3019	195	23	of	of	ADP
dti-3019	195	24	bacterial	bacterial	ADJ
dti-3019	195	25	infections	infection	NOUN
dti-3019	195	26	(	(	PUNCT
dti-3019	195	27	100	100	NUM
dti-3019	195	28	)	)	PUNCT
dti-3019	195	29	.	.	PUNCT
dti-3019	196	1	this	this	DET
dti-3019	196	2	resistance	resistance	NOUN
dti-3019	196	3	can	can	AUX
dti-3019	196	4	manifest	manifest	VERB
dti-3019	196	5	through	through	ADP
dti-3019	196	6	the	the	DET
dti-3019	196	7	transmission	transmission	NOUN
dti-3019	196	8	of	of	ADP
dti-3019	196	9	genes	gene	NOUN
dti-3019	196	10	associated	associate	VERB
dti-3019	196	11	with	with	ADP
dti-3019	196	12	antimicrobial	antimicrobial	ADJ
dti-3019	196	13	resistance	resistance	NOUN
dti-3019	196	14	when	when	SCONJ
dti-3019	196	15	bacteria	bacteria	NOUN
dti-3019	196	16	are	be	AUX
dti-3019	196	17	subjected	subject	VERB
dti-3019	196	18	to	to	ADP
dti-3019	196	19	prolonged	prolonged	ADJ
dti-3019	196	20	exposure	exposure	NOUN
dti-3019	196	21	to	to	ADP
dti-3019	196	22	low	low	ADJ
dti-3019	196	23	levels	level	NOUN
dti-3019	196	24	of	of	ADP
dti-3019	196	25	antibiotics	antibiotic	NOUN
dti-3019	196	26	(	(	PUNCT
dti-3019	196	27	101	101	NUM
dti-3019	196	28	)	)	PUNCT
dti-3019	196	29	.	.	PUNCT
dti-3019	197	1	such	such	DET
dti-3019	197	2	a	a	DET
dti-3019	197	3	situation	situation	NOUN
dti-3019	197	4	can	can	AUX
dti-3019	197	5	result	result	VERB
dti-3019	197	6	in	in	ADP
dti-3019	197	7	the	the	DET
dti-3019	197	8	emergence	emergence	NOUN
dti-3019	197	9	of	of	ADP
dti-3019	197	10	bacteria	bacteria	NOUN
dti-3019	197	11	that	that	PRON
dti-3019	197	12	are	be	AUX
dti-3019	197	13	resistant	resistant	ADJ
dti-3019	197	14	to	to	ADP
dti-3019	197	15	multiple	multiple	ADJ
dti-3019	197	16	drugs	drug	NOUN
dti-3019	197	17	,	,	PUNCT
dti-3019	197	18	thereby	thereby	ADV
dti-3019	197	19	impeding	impede	VERB
dti-3019	197	20	the	the	DET
dti-3019	197	21	effective	effective	ADJ
dti-3019	197	22	management	management	NOUN
dti-3019	197	23	of	of	ADP
dti-3019	197	24	bacterial	bacterial	ADJ
dti-3019	197	25	infections	infection	NOUN
dti-3019	197	26	and	and	CCONJ
dti-3019	197	27	presenting	present	VERB
dti-3019	197	28	a	a	DET
dti-3019	197	29	significant	significant	ADJ
dti-3019	197	30	public	public	ADJ
dti-3019	197	31	health	health	NOUN
dti-3019	197	32	challenge	challenge	NOUN
dti-3019	197	33	(	(	PUNCT
dti-3019	197	34	102	102	NUM
dti-3019	197	35	)	)	PUNCT
dti-3019	197	36	.	.	PUNCT
dti-3019	198	1	to	to	PART
dti-3019	198	2	effectively	effectively	ADV
dti-3019	198	3	address	address	VERB
dti-3019	198	4	antimicrobial	antimicrobial	ADJ
dti-3019	198	5	resistance	resistance	NOUN
dti-3019	198	6	,	,	PUNCT
dti-3019	198	7	it	it	PRON
dti-3019	198	8	is	be	AUX
dti-3019	198	9	imperative	imperative	ADJ
dti-3019	198	10	to	to	PART
dti-3019	198	11	advocate	advocate	VERB
dti-3019	198	12	for	for	ADP
dti-3019	198	13	the	the	DET
dti-3019	198	14	responsible	responsible	ADJ
dti-3019	198	15	and	and	CCONJ
dti-3019	198	16	prudent	prudent	ADJ
dti-3019	198	17	utilization	utilization	NOUN
dti-3019	198	18	of	of	ADP
dti-3019	198	19	antibiotics	antibiotic	NOUN
dti-3019	198	20	,	,	PUNCT
dti-3019	198	21	ensuring	ensure	VERB
dti-3019	198	22	their	their	PRON
dti-3019	198	23	administration	administration	NOUN
dti-3019	198	24	solely	solely	ADV
dti-3019	198	25	when	when	SCONJ
dti-3019	198	26	warranted	warrant	VERB
dti-3019	198	27	and	and	CCONJ
dti-3019	198	28	in	in	ADP
dti-3019	198	29	accordance	accordance	NOUN
dti-3019	198	30	with	with	ADP
dti-3019	198	31	appropriate	appropriate	ADJ
dti-3019	198	32	dosages	dosage	NOUN
dti-3019	198	33	and	and	CCONJ
dti-3019	198	34	durations	duration	NOUN
dti-3019	198	35	(	(	PUNCT
dti-3019	198	36	103	103	NUM
dti-3019	198	37	)	)	PUNCT
dti-3019	198	38	.	.	PUNCT
dti-3019	199	1	this	this	DET
dti-3019	199	2	diagram	diagram	NOUN
dti-3019	199	3	elucidates	elucidate	VERB
dti-3019	199	4	the	the	DET
dti-3019	199	5	manner	manner	NOUN
dti-3019	199	6	in	in	ADP
dti-3019	199	7	which	which	PRON
dti-3019	199	8	the	the	DET
dti-3019	199	9	inappropriate	inappropriate	ADJ
dti-3019	199	10	employment	employment	NOUN
dti-3019	199	11	of	of	ADP
dti-3019	199	12	antibiotics	antibiotic	NOUN
dti-3019	199	13	,	,	PUNCT
dti-3019	199	14	whether	whether	SCONJ
dti-3019	199	15	in	in	ADP
dti-3019	199	16	terms	term	NOUN
dti-3019	199	17	of	of	ADP
dti-3019	199	18	sublethal	sublethal	NOUN
dti-3019	199	19	dosages	dosage	NOUN
dti-3019	199	20	or	or	CCONJ
dti-3019	199	21	durations	duration	NOUN
dti-3019	199	22	,	,	PUNCT
dti-3019	199	23	leads	lead	VERB
dti-3019	199	24	to	to	ADP
dti-3019	199	25	the	the	DET
dti-3019	199	26	dissemination	dissemination	NOUN
dti-3019	199	27	of	of	ADP
dti-3019	199	28	resistance	resistance	NOUN
dti-3019	199	29	genes	gene	NOUN
dti-3019	199	30	within	within	ADP
dti-3019	199	31	bacterial	bacterial	ADJ
dti-3019	199	32	populations	population	NOUN
dti-3019	199	33	,	,	PUNCT
dti-3019	199	34	consequently	consequently	ADV
dti-3019	199	35	giving	give	VERB
dti-3019	199	36	rise	rise	NOUN
dti-3019	199	37	to	to	ADP
dti-3019	199	38	an	an	DET
dti-3019	199	39	entirely	entirely	ADV
dti-3019	199	40	resistant	resistant	ADJ
dti-3019	199	41	population	population	NOUN
dti-3019	199	42	.	.	PUNCT
dti-3019	200	1	the	the	DET
dti-3019	200	2	dark	dark	ADJ
dti-3019	200	3	side	side	NOUN
dti-3019	200	4	of	of	ADP
dti-3019	200	5	drug	drug	NOUN
dti-3019	200	6	repurposing14	repurposing14	NOUN
dti-3019	200	7	©	©	ADP
dti-3019	200	8	2024	2024	NUM
dti-3019	200	9	the	the	DET
dti-3019	200	10	authors	author	NOUN
dti-3019	200	11	.	.	PUNCT
dti-3019	201	1	drug	drug	NOUN
dti-3019	201	2	target	target	NOUN
dti-3019	201	3	insights	insight	NOUN
dti-3019	201	4	issn	issn	VERB
dti-3019	201	5	1177	1177	NUM
dti-3019	201	6	-	-	SYM
dti-3019	201	7	3928	3928	NUM
dti-3019	201	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3019	201	9	properties	property	NOUN
dti-3019	201	10	became	become	VERB
dti-3019	201	11	a	a	DET
dti-3019	201	12	highly	highly	ADV
dti-3019	201	13	controversial	controversial	ADJ
dti-3019	201	14	practice	practice	NOUN
dti-3019	201	15	.	.	PUNCT
dti-3019	202	1	however	however	ADV
dti-3019	202	2	,	,	PUNCT
dti-3019	202	3	its	its	PRON
dti-3019	202	4	utilization	utilization	NOUN
dti-3019	202	5	continued	continue	VERB
dti-3019	202	6	to	to	PART
dti-3019	202	7	increase	increase	VERB
dti-3019	202	8	with	with	ADP
dti-3019	202	9	the	the	DET
dti-3019	202	10	successive	successive	ADJ
dti-3019	202	11	waves	wave	NOUN
dti-3019	202	12	of	of	ADP
dti-3019	202	13	covid-19	covid-19	PROPN
dti-3019	202	14	.	.	PUNCT
dti-3019	203	1	the	the	DET
dti-3019	203	2	future	future	ADJ
dti-3019	203	3	implications	implication	NOUN
dti-3019	203	4	of	of	ADP
dti-3019	203	5	such	such	ADJ
dti-3019	203	6	unregulated	unregulated	ADJ
dti-3019	203	7	and	and	CCONJ
dti-3019	203	8	unscientific	unscientific	ADJ
dti-3019	203	9	use	use	NOUN
dti-3019	203	10	of	of	ADP
dti-3019	203	11	antibiotics	antibiotic	NOUN
dti-3019	203	12	remain	remain	VERB
dti-3019	203	13	uncertain	uncertain	ADJ
dti-3019	203	14	.	.	PUNCT
dti-3019	204	1	the	the	DET
dti-3019	204	2	consequences	consequence	NOUN
dti-3019	204	3	of	of	ADP
dti-3019	204	4	this	this	DET
dti-3019	204	5	practice	practice	NOUN
dti-3019	204	6	on	on	ADP
dti-3019	204	7	amr	amr	NOUN
dti-3019	204	8	will	will	AUX
dti-3019	204	9	further	far	ADV
dti-3019	204	10	exacerbate	exacerbate	VERB
dti-3019	204	11	the	the	DET
dti-3019	204	12	situation	situation	NOUN
dti-3019	204	13	(	(	PUNCT
dti-3019	204	14	111	111	NUM
dti-3019	204	15	)	)	PUNCT
dti-3019	204	16	.	.	PUNCT
dti-3019	205	1	in	in	ADP
dti-3019	205	2	addition	addition	NOUN
dti-3019	205	3	to	to	ADP
dti-3019	205	4	the	the	DET
dti-3019	205	5	repurposing	repurposing	NOUN
dti-3019	205	6	of	of	ADP
dti-3019	205	7	azithromycin	azithromycin	NOUN
dti-3019	205	8	in	in	ADP
dti-3019	205	9	the	the	DET
dti-3019	205	10	context	context	NOUN
dti-3019	205	11	of	of	ADP
dti-3019	205	12	the	the	DET
dti-3019	205	13	covid-19	covid-19	PROPN
dti-3019	205	14	pandemic	pandemic	ADJ
dti-3019	205	15	,	,	PUNCT
dti-3019	205	16	numerous	numerous	ADJ
dti-3019	205	17	studies	study	NOUN
dti-3019	205	18	have	have	AUX
dti-3019	205	19	revealed	reveal	VERB
dti-3019	205	20	its	its	PRON
dti-3019	205	21	antimalarial	antimalarial	ADJ
dti-3019	205	22	properties	property	NOUN
dti-3019	205	23	.	.	PUNCT
dti-3019	206	1	the	the	DET
dti-3019	206	2	eradication	eradication	NOUN
dti-3019	206	3	of	of	ADP
dti-3019	206	4	plasmodium	plasmodium	NOUN
dti-3019	206	5	falciparum	falciparum	ADJ
dti-3019	206	6	parasites	parasite	NOUN
dti-3019	206	7	is	be	AUX
dti-3019	206	8	accomplished	accomplish	VERB
dti-3019	206	9	through	through	ADP
dti-3019	206	10	two	two	NUM
dti-3019	206	11	distinct	distinct	ADJ
dti-3019	206	12	mechanisms	mechanism	NOUN
dti-3019	206	13	:	:	PUNCT
dti-3019	206	14	delayed	delay	VERB
dti-3019	206	15	death	death	NOUN
dti-3019	206	16	by	by	ADP
dti-3019	206	17	means	mean	NOUN
dti-3019	206	18	of	of	ADP
dti-3019	206	19	inhibiting	inhibit	VERB
dti-3019	206	20	the	the	DET
dti-3019	206	21	apicoplast	apicoplast	ADJ
dti-3019	206	22	ribosomes	ribosome	NOUN
dti-3019	206	23	and	and	CCONJ
dti-3019	206	24	rapid	rapid	ADJ
dti-3019	206	25	elimination	elimination	NOUN
dti-3019	206	26	throughout	throughout	ADP
dti-3019	206	27	the	the	DET
dti-3019	206	28	blood	blood	NOUN
dti-3019	206	29	stage	stage	NOUN
dti-3019	206	30	development	development	NOUN
dti-3019	206	31	(	(	PUNCT
dti-3019	206	32	112	112	NUM
dti-3019	206	33	)	)	PUNCT
dti-3019	206	34	.	.	PUNCT
dti-3019	207	1	a	a	DET
dti-3019	207	2	trial	trial	NOUN
dti-3019	207	3	carried	carry	VERB
dti-3019	207	4	out	out	ADP
dti-3019	207	5	in	in	ADP
dti-3019	207	6	burkina	burkina	PROPN
dti-3019	207	7	faso	faso	PROPN
dti-3019	207	8	discovered	discover	VERB
dti-3019	207	9	that	that	SCONJ
dti-3019	207	10	a	a	DET
dti-3019	207	11	solitary	solitary	ADJ
dti-3019	207	12	oral	oral	ADJ
dti-3019	207	13	dose	dose	NOUN
dti-3019	207	14	of	of	ADP
dti-3019	207	15	azithromycin	azithromycin	PROPN
dti-3019	207	16	did	do	AUX
dti-3019	207	17	not	not	PART
dti-3019	207	18	result	result	VERB
dti-3019	207	19	in	in	ADP
dti-3019	207	20	a	a	DET
dti-3019	207	21	reduction	reduction	NOUN
dti-3019	207	22	in	in	ADP
dti-3019	207	23	malaria	malaria	NOUN
dti-3019	207	24	positivity	positivity	NOUN
dti-3019	207	25	;	;	PUNCT
dti-3019	207	26	however	however	ADV
dti-3019	207	27	,	,	PUNCT
dti-3019	207	28	it	it	PRON
dti-3019	207	29	did	do	AUX
dti-3019	207	30	alleviate	alleviate	VERB
dti-3019	207	31	caregiverreported	caregiverreporte	VERB
dti-3019	207	32	fever	fever	NOUN
dti-3019	207	33	as	as	ADP
dti-3019	207	34	an	an	DET
dti-3019	207	35	adverse	adverse	ADJ
dti-3019	207	36	event	event	NOUN
dti-3019	207	37	(	(	PUNCT
dti-3019	207	38	113	113	NUM
dti-3019	207	39	)	)	PUNCT
dti-3019	207	40	.	.	PUNCT
dti-3019	208	1	furthermore	furthermore	ADV
dti-3019	208	2	,	,	PUNCT
dti-3019	208	3	an	an	DET
dti-3019	208	4	additional	additional	ADJ
dti-3019	208	5	study	study	NOUN
dti-3019	208	6	determined	determine	VERB
dti-3019	208	7	that	that	SCONJ
dti-3019	208	8	the	the	DET
dti-3019	208	9	supplementation	supplementation	NOUN
dti-3019	208	10	of	of	ADP
dti-3019	208	11	azithromycin	azithromycin	PROPN
dti-3019	208	12	to	to	ADP
dti-3019	208	13	seasonal	seasonal	ADJ
dti-3019	208	14	malaria	malaria	NOUN
dti-3019	208	15	chemoprevention	chemoprevention	NOUN
dti-3019	208	16	did	do	AUX
dti-3019	208	17	not	not	PART
dti-3019	208	18	yield	yield	VERB
dti-3019	208	19	improved	improved	ADJ
dti-3019	208	20	nutritional	nutritional	ADJ
dti-3019	208	21	outcomes	outcome	NOUN
dti-3019	208	22	among	among	ADP
dti-3019	208	23	children	child	NOUN
dti-3019	208	24	(	(	PUNCT
dti-3019	208	25	114	114	NUM
dti-3019	208	26	)	)	PUNCT
dti-3019	208	27	.	.	PUNCT
dti-3019	209	1	furthermore	furthermore	ADV
dti-3019	209	2	,	,	PUNCT
dti-3019	209	3	novel	novel	ADJ
dti-3019	209	4	derivatives	derivative	NOUN
dti-3019	209	5	of	of	ADP
dti-3019	209	6	azithromycin	azithromycin	NOUN
dti-3019	209	7	that	that	PRON
dti-3019	209	8	exhibit	exhibit	VERB
dti-3019	209	9	swift	swift	ADJ
dti-3019	209	10	action	action	NOUN
dti-3019	209	11	have	have	AUX
dti-3019	209	12	been	be	AUX
dti-3019	209	13	developed	develop	VERB
dti-3019	209	14	,	,	PUNCT
dti-3019	209	15	manifesting	manifest	VERB
dti-3019	209	16	exceptional	exceptional	ADJ
dti-3019	209	17	antimalarial	antimalarial	ADJ
dti-3019	209	18	activity	activity	NOUN
dti-3019	209	19	in	in	ADP
dti-3019	209	20	both	both	CCONJ
dti-3019	209	21	in	in	ADP
dti-3019	209	22	vitro	vitro	X
dti-3019	209	23	and	and	CCONJ
dti-3019	209	24	in	in	ADP
dti-3019	209	25	vivo	vivo	ADJ
dti-3019	209	26	settings	setting	NOUN
dti-3019	209	27	,	,	PUNCT
dti-3019	209	28	while	while	SCONJ
dti-3019	209	29	employing	employ	VERB
dti-3019	209	30	a	a	DET
dti-3019	209	31	distinct	distinct	ADJ
dti-3019	209	32	mode	mode	NOUN
dti-3019	209	33	of	of	ADP
dti-3019	209	34	action	action	NOUN
dti-3019	209	35	compared	compare	VERB
dti-3019	209	36	to	to	ADP
dti-3019	209	37	the	the	DET
dti-3019	209	38	more	more	ADV
dti-3019	209	39	gradual	gradual	ADJ
dti-3019	209	40	acting	act	VERB
dti-3019	209	41	azithromycin	azithromycin	NOUN
dti-3019	209	42	(	(	PUNCT
dti-3019	209	43	115	115	NUM
dti-3019	209	44	)	)	PUNCT
dti-3019	209	45	.	.	PUNCT
dti-3019	210	1	although	although	SCONJ
dti-3019	210	2	azithromycin	azithromycin	PROPN
dti-3019	210	3	has	have	AUX
dti-3019	210	4	indeed	indeed	ADV
dti-3019	210	5	exhibited	exhibit	VERB
dti-3019	210	6	potential	potential	NOUN
dti-3019	210	7	as	as	ADP
dti-3019	210	8	an	an	DET
dti-3019	210	9	antimalarial	antimalarial	ADJ
dti-3019	210	10	agent	agent	NOUN
dti-3019	210	11	,	,	PUNCT
dti-3019	210	12	further	further	ADJ
dti-3019	210	13	investigation	investigation	NOUN
dti-3019	210	14	is	be	AUX
dti-3019	210	15	necessary	necessary	ADJ
dti-3019	210	16	to	to	PART
dti-3019	210	17	optimize	optimize	VERB
dti-3019	210	18	its	its	PRON
dti-3019	210	19	efficacy	efficacy	NOUN
dti-3019	210	20	and	and	CCONJ
dti-3019	210	21	comprehend	comprehend	VERB
dti-3019	210	22	its	its	PRON
dti-3019	210	23	mechanisms	mechanism	NOUN
dti-3019	210	24	of	of	ADP
dti-3019	210	25	action	action	NOUN
dti-3019	210	26	.	.	PUNCT
dti-3019	211	1	considering	consider	VERB
dti-3019	211	2	the	the	DET
dti-3019	211	3	positive	positive	ADJ
dti-3019	211	4	correlation	correlation	NOUN
dti-3019	211	5	between	between	ADP
dti-3019	211	6	extensive	extensive	ADJ
dti-3019	211	7	antibiotic	antibiotic	ADJ
dti-3019	211	8	usage	usage	NOUN
dti-3019	211	9	and	and	CCONJ
dti-3019	211	10	the	the	DET
dti-3019	211	11	worsening	worsening	NOUN
dti-3019	211	12	of	of	ADP
dti-3019	211	13	the	the	DET
dti-3019	211	14	antibiotic	antibiotic	ADJ
dti-3019	211	15	resistance	resistance	NOUN
dti-3019	211	16	crisis	crisis	NOUN
dti-3019	211	17	in	in	ADP
dti-3019	211	18	the	the	DET
dti-3019	211	19	present	present	ADJ
dti-3019	211	20	era	era	NOUN
dti-3019	211	21	,	,	PUNCT
dti-3019	211	22	it	it	PRON
dti-3019	211	23	is	be	AUX
dti-3019	211	24	imperative	imperative	ADJ
dti-3019	211	25	to	to	PART
dti-3019	211	26	enhance	enhance	VERB
dti-3019	211	27	amr	amr	ADJ
dti-3019	211	28	stewardship	stewardship	NOUN
dti-3019	211	29	at	at	ADP
dti-3019	211	30	an	an	DET
dti-3019	211	31	international	international	ADJ
dti-3019	211	32	level	level	NOUN
dti-3019	211	33	in	in	ADP
dti-3019	211	34	order	order	NOUN
dti-3019	211	35	to	to	PART
dti-3019	211	36	mitigate	mitigate	VERB
dti-3019	211	37	the	the	DET
dti-3019	211	38	impact	impact	NOUN
dti-3019	211	39	of	of	ADP
dti-3019	211	40	antibiotic	antibiotic	ADJ
dti-3019	211	41	use	use	NOUN
dti-3019	211	42	on	on	ADP
dti-3019	211	43	the	the	DET
dti-3019	211	44	menace	menace	NOUN
dti-3019	211	45	of	of	ADP
dti-3019	211	46	antibiotic	antibiotic	ADJ
dti-3019	211	47	resistance	resistance	NOUN
dti-3019	211	48	.	.	PUNCT
dti-3019	212	1	particular	particular	ADJ
dti-3019	212	2	emphasis	emphasis	NOUN
dti-3019	212	3	should	should	AUX
dti-3019	212	4	be	be	AUX
dti-3019	212	5	placed	place	VERB
dti-3019	212	6	on	on	ADP
dti-3019	212	7	comprehending	comprehend	VERB
dti-3019	212	8	the	the	DET
dti-3019	212	9	ramifications	ramification	NOUN
dti-3019	212	10	of	of	ADP
dti-3019	212	11	antibiotic	antibiotic	ADJ
dti-3019	212	12	repurposing	repurposing	NOUN
dti-3019	212	13	.	.	PUNCT
dti-3019	213	1	there	there	PRON
dti-3019	213	2	is	be	VERB
dti-3019	213	3	a	a	DET
dti-3019	213	4	profound	profound	ADJ
dti-3019	213	5	necessity	necessity	NOUN
dti-3019	213	6	to	to	PART
dti-3019	213	7	explore	explore	VERB
dti-3019	213	8	alternatives	alternative	NOUN
dti-3019	213	9	to	to	ADP
dti-3019	213	10	antibiotics	antibiotic	NOUN
dti-3019	213	11	in	in	ADP
dti-3019	213	12	the	the	DET
dti-3019	213	13	context	context	NOUN
dti-3019	213	14	of	of	ADP
dti-3019	213	15	repurposing	repurpose	VERB
dti-3019	213	16	,	,	PUNCT
dti-3019	213	17	especially	especially	ADV
dti-3019	213	18	those	those	PRON
dti-3019	213	19	that	that	PRON
dti-3019	213	20	have	have	AUX
dti-3019	213	21	already	already	ADV
dti-3019	213	22	demonstrated	demonstrate	VERB
dti-3019	213	23	resistance	resistance	NOUN
dti-3019	213	24	.	.	PUNCT
dti-3019	214	1	the	the	DET
dti-3019	214	2	successful	successful	ADJ
dti-3019	214	3	repurposing	repurposing	NOUN
dti-3019	214	4	of	of	ADP
dti-3019	214	5	non	non	ADJ
dti-3019	214	6	-	-	ADJ
dti-3019	214	7	antibiotic	antibiotic	ADJ
dti-3019	214	8	drugs	drug	NOUN
dti-3019	214	9	for	for	ADP
dti-3019	214	10	cancer	cancer	NOUN
dti-3019	214	11	treatment	treatment	NOUN
dti-3019	214	12	has	have	AUX
dti-3019	214	13	been	be	AUX
dti-3019	214	14	documented	document	VERB
dti-3019	214	15	(	(	PUNCT
dti-3019	214	16	116,117	116,117	NUM
dti-3019	214	17	)	)	PUNCT
dti-3019	214	18	and	and	CCONJ
dti-3019	214	19	a	a	DET
dti-3019	214	20	similar	similar	ADJ
dti-3019	214	21	approach	approach	NOUN
dti-3019	214	22	can	can	AUX
dti-3019	214	23	be	be	AUX
dti-3019	214	24	adopted	adopt	VERB
dti-3019	214	25	for	for	ADP
dti-3019	214	26	other	other	ADJ
dti-3019	214	27	diseases	disease	NOUN
dti-3019	214	28	as	as	ADV
dti-3019	214	29	well	well	ADV
dti-3019	214	30	.	.	PUNCT
dti-3019	215	1	while	while	SCONJ
dti-3019	215	2	the	the	DET
dti-3019	215	3	repurposed	repurpose	VERB
dti-3019	215	4	antibiotics	antibiotic	NOUN
dti-3019	215	5	may	may	AUX
dti-3019	215	6	circumvent	circumvent	VERB
dti-3019	215	7	clinical	clinical	ADJ
dti-3019	215	8	trials	trial	NOUN
dti-3019	215	9	,	,	PUNCT
dti-3019	215	10	the	the	DET
dti-3019	215	11	absence	absence	NOUN
dti-3019	215	12	of	of	ADP
dti-3019	215	13	substantial	substantial	ADJ
dti-3019	215	14	studies	study	NOUN
dti-3019	215	15	addressing	address	VERB
dti-3019	215	16	the	the	DET
dti-3019	215	17	grave	grave	ADJ
dti-3019	215	18	issue	issue	NOUN
dti-3019	215	19	of	of	ADP
dti-3019	215	20	amr	amr	NOUN
dti-3019	215	21	may	may	AUX
dti-3019	215	22	prove	prove	VERB
dti-3019	215	23	to	to	PART
dti-3019	215	24	be	be	AUX
dti-3019	215	25	catastrophic	catastrophic	ADJ
dti-3019	215	26	for	for	SCONJ
dti-3019	215	27	the	the	PRON
dti-3019	215	28	already	already	ADV
dti-3019	215	29	advancing	advance	VERB
dti-3019	215	30	amr	amr	NOUN
dti-3019	215	31	against	against	ADP
dti-3019	215	32	most	most	ADJ
dti-3019	215	33	antibiotics	antibiotic	NOUN
dti-3019	215	34	.	.	PUNCT
dti-3019	216	1	the	the	DET
dti-3019	216	2	role	role	NOUN
dti-3019	216	3	of	of	ADP
dti-3019	216	4	amr	amr	NOUN
dti-3019	216	5	in	in	ADP
dti-3019	216	6	exacerbating	exacerbate	VERB
dti-3019	216	7	challenges	challenge	NOUN
dti-3019	216	8	in	in	ADP
dti-3019	216	9	the	the	DET
dti-3019	216	10	management	management	NOUN
dti-3019	216	11	of	of	ADP
dti-3019	216	12	nosocomial	nosocomial	ADJ
dti-3019	216	13	infections	infection	NOUN
dti-3019	216	14	and	and	CCONJ
dti-3019	216	15	the	the	DET
dti-3019	216	16	resulting	result	VERB
dti-3019	216	17	mortality	mortality	NOUN
dti-3019	216	18	due	due	ADP
dti-3019	216	19	to	to	PART
dti-3019	216	20	multidrug	multidrug	VERB
dti-3019	216	21	resistance	resistance	NOUN
dti-3019	216	22	should	should	AUX
dti-3019	216	23	not	not	PART
dti-3019	216	24	be	be	AUX
dti-3019	216	25	underestimated	underestimate	VERB
dti-3019	216	26	,	,	PUNCT
dti-3019	216	27	particularly	particularly	ADV
dti-3019	216	28	in	in	ADP
dti-3019	216	29	an	an	DET
dti-3019	216	30	era	era	NOUN
dti-3019	216	31	where	where	SCONJ
dti-3019	216	32	the	the	DET
dti-3019	216	33	efficacy	efficacy	NOUN
dti-3019	216	34	of	of	ADP
dti-3019	216	35	most	most	ADJ
dti-3019	216	36	antibiotics	antibiotic	NOUN
dti-3019	216	37	is	be	AUX
dti-3019	216	38	waning	wane	VERB
dti-3019	216	39	and	and	CCONJ
dti-3019	216	40	treatment	treatment	NOUN
dti-3019	216	41	regimens	regimen	NOUN
dti-3019	216	42	rely	rely	VERB
dti-3019	216	43	on	on	ADP
dti-3019	216	44	last	last	ADJ
dti-3019	216	45	-	-	PUNCT
dti-3019	216	46	resort	resort	NOUN
dti-3019	216	47	antibiotics	antibiotic	NOUN
dti-3019	216	48	(	(	PUNCT
dti-3019	216	49	118	118	NUM
dti-3019	216	50	)	)	PUNCT
dti-3019	216	51	.	.	PUNCT
dti-3019	217	1	it	it	PRON
dti-3019	217	2	is	be	AUX
dti-3019	217	3	imperative	imperative	ADJ
dti-3019	217	4	to	to	PART
dti-3019	217	5	find	find	VERB
dti-3019	217	6	a	a	DET
dti-3019	217	7	solution	solution	NOUN
dti-3019	217	8	that	that	PRON
dti-3019	217	9	does	do	AUX
dti-3019	217	10	not	not	PART
dti-3019	217	11	further	far	ADV
dti-3019	217	12	burden	burden	VERB
dti-3019	217	13	the	the	DET
dti-3019	217	14	existing	exist	VERB
dti-3019	217	15	load	load	NOUN
dti-3019	217	16	of	of	ADP
dti-3019	217	17	amr	amr	NOUN
dti-3019	217	18	.	.	PROPN
dti-3019	218	1	therefore	therefore	ADV
dti-3019	218	2	,	,	PUNCT
dti-3019	218	3	we	we	PRON
dti-3019	218	4	propose	propose	VERB
dti-3019	218	5	that	that	SCONJ
dti-3019	218	6	clinicians	clinician	NOUN
dti-3019	218	7	and	and	CCONJ
dti-3019	218	8	researchers	researcher	NOUN
dti-3019	218	9	raise	raise	VERB
dti-3019	218	10	awareness	awareness	NOUN
dti-3019	218	11	about	about	ADP
dti-3019	218	12	the	the	DET
dti-3019	218	13	rampant	rampant	ADJ
dti-3019	218	14	problem	problem	NOUN
dti-3019	218	15	of	of	ADP
dti-3019	218	16	amr	amr	PROPN
dti-3019	218	17	and	and	CCONJ
dti-3019	218	18	its	its	PRON
dti-3019	218	19	consequences	consequence	NOUN
dti-3019	218	20	,	,	PUNCT
dti-3019	218	21	while	while	SCONJ
dti-3019	218	22	discouraging	discourage	VERB
dti-3019	218	23	the	the	DET
dti-3019	218	24	use	use	NOUN
dti-3019	218	25	of	of	ADP
dti-3019	218	26	antibiotics	antibiotic	NOUN
dti-3019	218	27	in	in	ADP
dti-3019	218	28	drug	drug	NOUN
dti-3019	218	29	repurposing	repurposing	NOUN
dti-3019	218	30	.	.	PUNCT
dti-3019	219	1	after	after	ADP
dti-3019	219	2	considering	consider	VERB
dti-3019	219	3	the	the	DET
dti-3019	219	4	knowledge	knowledge	NOUN
dti-3019	219	5	mentioned	mention	VERB
dti-3019	219	6	above	above	ADV
dti-3019	219	7	,	,	PUNCT
dti-3019	219	8	one	one	PRON
dti-3019	219	9	could	could	AUX
dti-3019	219	10	potentially	potentially	ADV
dti-3019	219	11	inquire	inquire	VERB
dti-3019	219	12	whether	whether	SCONJ
dti-3019	219	13	the	the	DET
dti-3019	219	14	practice	practice	NOUN
dti-3019	219	15	of	of	ADP
dti-3019	219	16	repurposing	repurpose	VERB
dti-3019	219	17	antibiotics	antibiotic	NOUN
dti-3019	219	18	to	to	PART
dti-3019	219	19	address	address	VERB
dti-3019	219	20	noninfectious	noninfectious	ADJ
dti-3019	219	21	ailments	ailment	NOUN
dti-3019	219	22	could	could	AUX
dti-3019	219	23	potentially	potentially	ADV
dti-3019	219	24	elevate	elevate	VERB
dti-3019	219	25	the	the	DET
dti-3019	219	26	likelihood	likelihood	NOUN
dti-3019	219	27	of	of	ADP
dti-3019	219	28	amr	amr	NOUN
dti-3019	219	29	.	.	PROPN
dti-3019	220	1	furthermore	furthermore	ADV
dti-3019	220	2	,	,	PUNCT
dti-3019	220	3	one	one	PRON
dti-3019	220	4	may	may	AUX
dti-3019	220	5	also	also	ADV
dti-3019	220	6	wonder	wonder	VERB
dti-3019	220	7	about	about	ADP
dti-3019	220	8	the	the	DET
dti-3019	220	9	implications	implication	NOUN
dti-3019	220	10	of	of	ADP
dti-3019	220	11	reusing	reuse	VERB
dti-3019	220	12	antibiotics	antibiotic	NOUN
dti-3019	220	13	that	that	PRON
dti-3019	220	14	were	be	AUX
dti-3019	220	15	originally	originally	ADV
dti-3019	220	16	approved	approve	VERB
dti-3019	220	17	for	for	ADP
dti-3019	220	18	the	the	DET
dti-3019	220	19	treatment	treatment	NOUN
dti-3019	220	20	of	of	ADP
dti-3019	220	21	one	one	NUM
dti-3019	220	22	specific	specific	ADJ
dti-3019	220	23	infection	infection	NOUN
dti-3019	220	24	in	in	ADP
dti-3019	220	25	the	the	DET
dti-3019	220	26	context	context	NOUN
dti-3019	220	27	of	of	ADP
dti-3019	220	28	treating	treat	VERB
dti-3019	220	29	a	a	DET
dti-3019	220	30	different	different	ADJ
dti-3019	220	31	infection	infection	NOUN
dti-3019	220	32	.	.	PUNCT
dti-3019	221	1	in	in	ADP
dti-3019	221	2	previous	previous	ADJ
dti-3019	221	3	times	time	NOUN
dti-3019	221	4	,	,	PUNCT
dti-3019	221	5	newer	new	ADJ
dti-3019	221	6	antibiotics	antibiotic	NOUN
dti-3019	221	7	were	be	AUX
dti-3019	221	8	consistently	consistently	ADV
dti-3019	221	9	being	be	AUX
dti-3019	221	10	surpassed	surpass	VERB
dti-3019	221	11	by	by	ADP
dti-3019	221	12	more	more	ADJ
dti-3019	221	13	recent	recent	ADJ
dti-3019	221	14	ones	one	NOUN
dti-3019	221	15	,	,	PUNCT
dti-3019	221	16	which	which	PRON
dti-3019	221	17	were	be	AUX
dti-3019	221	18	devised	devise	VERB
dti-3019	221	19	to	to	PART
dti-3019	221	20	circumvent	circumvent	VERB
dti-3019	221	21	the	the	DET
dti-3019	221	22	most	most	ADV
dti-3019	221	23	recent	recent	ADJ
dti-3019	221	24	resistance	resistance	NOUN
dti-3019	221	25	mechanism	mechanism	NOUN
dti-3019	221	26	discovered	discover	VERB
dti-3019	221	27	in	in	ADP
dti-3019	221	28	clinical	clinical	ADJ
dti-3019	221	29	isolates	isolate	NOUN
dti-3019	221	30	.	.	PUNCT
dti-3019	222	1	nevertheless	nevertheless	ADV
dti-3019	222	2	,	,	PUNCT
dti-3019	222	3	numerous	numerous	ADJ
dti-3019	222	4	companies	company	NOUN
dti-3019	222	5	have	have	AUX
dti-3019	222	6	abandoned	abandon	VERB
dti-3019	222	7	initiatives	initiative	NOUN
dti-3019	222	8	aimed	aim	VERB
dti-3019	222	9	at	at	ADP
dti-3019	222	10	developing	develop	VERB
dti-3019	222	11	novel	novel	ADJ
dti-3019	222	12	anti	anti	ADJ
dti-3019	222	13	-	-	ADJ
dti-3019	222	14	infectives	infective	NOUN
dti-3019	222	15	due	due	ADP
dti-3019	222	16	to	to	ADP
dti-3019	222	17	the	the	DET
dti-3019	222	18	time	time	NOUN
dti-3019	222	19	and	and	CCONJ
dti-3019	222	20	expense	expense	NOUN
dti-3019	222	21	associated	associate	VERB
dti-3019	222	22	with	with	ADP
dti-3019	222	23	clinical	clinical	ADJ
dti-3019	222	24	trials	trial	NOUN
dti-3019	222	25	.	.	PUNCT
dti-3019	223	1	the	the	DET
dti-3019	223	2	insufficient	insufficient	ADJ
dti-3019	223	3	availability	availability	NOUN
dti-3019	223	4	of	of	ADP
dti-3019	223	5	new	new	ADJ
dti-3019	223	6	drugs	drug	NOUN
dti-3019	223	7	has	have	AUX
dti-3019	223	8	provided	provide	VERB
dti-3019	223	9	a	a	DET
dti-3019	223	10	compelling	compelling	ADJ
dti-3019	223	11	impetus	impetus	NOUN
dti-3019	223	12	to	to	PART
dti-3019	223	13	repurpose	repurpose	VERB
dti-3019	223	14	older	old	ADJ
dti-3019	223	15	antibiotics	antibiotic	NOUN
dti-3019	223	16	for	for	ADP
dti-3019	223	17	treating	treat	VERB
dti-3019	223	18	multidrug	multidrug	NOUN
dti-3019	223	19	-	-	PUNCT
dti-3019	223	20	resistant	resistant	ADJ
dti-3019	223	21	strains	strain	NOUN
dti-3019	223	22	or	or	CCONJ
dti-3019	223	23	to	to	PART
dti-3019	223	24	combine	combine	VERB
dti-3019	223	25	them	they	PRON
dti-3019	223	26	with	with	ADP
dti-3019	223	27	agents	agent	NOUN
dti-3019	223	28	capable	capable	ADJ
dti-3019	223	29	of	of	ADP
dti-3019	223	30	targeting	target	VERB
dti-3019	223	31	multiple	multiple	ADJ
dti-3019	223	32	distinct	distinct	ADJ
dti-3019	223	33	pathways	pathway	NOUN
dti-3019	223	34	within	within	ADP
dti-3019	223	35	the	the	DET
dti-3019	223	36	pathogen	pathogen	NOUN
dti-3019	223	37	or	or	CCONJ
dti-3019	223	38	activating	activate	VERB
dti-3019	223	39	the	the	DET
dti-3019	223	40	resistance	resistance	NOUN
dti-3019	223	41	pathways	pathway	NOUN
dti-3019	223	42	of	of	ADP
dti-3019	223	43	host	host	NOUN
dti-3019	223	44	cells	cell	NOUN
dti-3019	223	45	.	.	PUNCT
dti-3019	224	1	this	this	DET
dti-3019	224	2	approach	approach	NOUN
dti-3019	224	3	is	be	AUX
dti-3019	224	4	anticipated	anticipate	VERB
dti-3019	224	5	to	to	PART
dti-3019	224	6	result	result	VERB
dti-3019	224	7	in	in	ADP
dti-3019	224	8	heightened	heightened	ADJ
dti-3019	224	9	effectiveness	effectiveness	NOUN
dti-3019	224	10	and	and	CCONJ
dti-3019	224	11	reduce	reduce	VERB
dti-3019	224	12	the	the	DET
dti-3019	224	13	likelihood	likelihood	NOUN
dti-3019	224	14	of	of	ADP
dti-3019	224	15	resistance	resistance	NOUN
dti-3019	224	16	emergence	emergence	NOUN
dti-3019	224	17	(	(	PUNCT
dti-3019	224	18	119	119	NUM
dti-3019	224	19	)	)	PUNCT
dti-3019	224	20	.	.	PUNCT
dti-3019	225	1	reverting	revert	VERB
dti-3019	225	2	to	to	ADP
dti-3019	225	3	previous	previous	ADJ
dti-3019	225	4	antibiotics	antibiotic	NOUN
dti-3019	225	5	can	can	AUX
dti-3019	225	6	,	,	PUNCT
dti-3019	225	7	under	under	ADP
dti-3019	225	8	certain	certain	ADJ
dti-3019	225	9	circumstances	circumstance	NOUN
dti-3019	225	10	,	,	PUNCT
dti-3019	225	11	overcome	overcome	VERB
dti-3019	225	12	antibiotic	antibiotic	ADJ
dti-3019	225	13	resistance	resistance	NOUN
dti-3019	225	14	.	.	PUNCT
dti-3019	226	1	for	for	ADP
dti-3019	226	2	instance	instance	NOUN
dti-3019	226	3	,	,	PUNCT
dti-3019	226	4	strains	strain	NOUN
dti-3019	226	5	of	of	ADP
dti-3019	226	6	tuberculosis	tuberculosis	NOUN
dti-3019	226	7	that	that	PRON
dti-3019	226	8	are	be	AUX
dti-3019	226	9	resistant	resistant	ADJ
dti-3019	226	10	to	to	ADP
dti-3019	226	11	the	the	DET
dti-3019	226	12	drug	drug	NOUN
dti-3019	226	13	combinations	combination	NOUN
dti-3019	226	14	currently	currently	ADV
dti-3019	226	15	in	in	ADP
dti-3019	226	16	use	use	NOUN
dti-3019	226	17	can	can	AUX
dti-3019	226	18	be	be	AUX
dti-3019	226	19	found	find	VERB
dti-3019	226	20	in	in	ADP
dti-3019	226	21	all	all	DET
dti-3019	226	22	regions	region	NOUN
dti-3019	226	23	of	of	ADP
dti-3019	226	24	the	the	DET
dti-3019	226	25	world	world	NOUN
dti-3019	226	26	.	.	PUNCT
dti-3019	227	1	one	one	NUM
dti-3019	227	2	effective	effective	ADJ
dti-3019	227	3	tuberculosis	tuberculosis	NOUN
dti-3019	227	4	medication	medication	NOUN
dti-3019	227	5	,	,	PUNCT
dti-3019	227	6	known	know	VERB
dti-3019	227	7	as	as	ADP
dti-3019	227	8	isoniazid	isoniazid	NOUN
dti-3019	227	9	,	,	PUNCT
dti-3019	227	10	hinders	hinder	VERB
dti-3019	227	11	the	the	DET
dti-3019	227	12	enzyme	enzyme	NOUN
dti-3019	227	13	inha	inha	NOUN
dti-3019	227	14	,	,	PUNCT
dti-3019	227	15	thereby	thereby	ADV
dti-3019	227	16	obstructing	obstruct	VERB
dti-3019	227	17	the	the	DET
dti-3019	227	18	synthesis	synthesis	NOUN
dti-3019	227	19	of	of	ADP
dti-3019	227	20	the	the	DET
dti-3019	227	21	mycolic	mycolic	ADJ
dti-3019	227	22	acids	acid	NOUN
dti-3019	227	23	that	that	PRON
dti-3019	227	24	constitute	constitute	VERB
dti-3019	227	25	the	the	DET
dti-3019	227	26	cell	cell	NOUN
dti-3019	227	27	wall	wall	NOUN
dti-3019	227	28	of	of	ADP
dti-3019	227	29	the	the	DET
dti-3019	227	30	mycobacterium	mycobacterium	NOUN
dti-3019	227	31	.	.	PUNCT
dti-3019	228	1	the	the	DET
dti-3019	228	2	resistance	resistance	NOUN
dti-3019	228	3	to	to	ADP
dti-3019	228	4	isoniazid	isoniazid	NOUN
dti-3019	228	5	,	,	PUNCT
dti-3019	228	6	which	which	PRON
dti-3019	228	7	is	be	AUX
dti-3019	228	8	a	a	DET
dti-3019	228	9	prodrug	prodrug	NOUN
dti-3019	228	10	,	,	PUNCT
dti-3019	228	11	largely	largely	ADV
dti-3019	228	12	arises	arise	VERB
dti-3019	228	13	from	from	ADP
dti-3019	228	14	mutations	mutation	NOUN
dti-3019	228	15	in	in	ADP
dti-3019	228	16	the	the	DET
dti-3019	228	17	bacterial	bacterial	ADJ
dti-3019	228	18	enzymes	enzyme	NOUN
dti-3019	228	19	that	that	PRON
dti-3019	228	20	are	be	AUX
dti-3019	228	21	necessary	necessary	ADJ
dti-3019	228	22	for	for	ADP
dti-3019	228	23	its	its	PRON
dti-3019	228	24	activation	activation	NOUN
dti-3019	228	25	.	.	PUNCT
dti-3019	229	1	recently	recently	ADV
dti-3019	229	2	,	,	PUNCT
dti-3019	229	3	it	it	PRON
dti-3019	229	4	has	have	AUX
dti-3019	229	5	been	be	AUX
dti-3019	229	6	discovered	discover	VERB
dti-3019	229	7	that	that	SCONJ
dti-3019	229	8	an	an	DET
dti-3019	229	9	older	old	ADJ
dti-3019	229	10	antibiotic	antibiotic	ADJ
dti-3019	229	11	derived	derive	VERB
dti-3019	229	12	from	from	ADP
dti-3019	229	13	natural	natural	ADJ
dti-3019	229	14	sources	source	NOUN
dti-3019	229	15	,	,	PUNCT
dti-3019	229	16	called	call	VERB
dti-3019	229	17	pyridomycin	pyridomycin	NOUN
dti-3019	229	18	and	and	CCONJ
dti-3019	229	19	first	first	ADV
dti-3019	229	20	identified	identify	VERB
dti-3019	229	21	in	in	ADP
dti-3019	229	22	the	the	DET
dti-3019	229	23	1950s	1950	NOUN
dti-3019	229	24	,	,	PUNCT
dti-3019	229	25	directly	directly	ADV
dti-3019	229	26	inhibits	inhibit	VERB
dti-3019	229	27	inha	inha	NOUN
dti-3019	229	28	.	.	PUNCT
dti-3019	230	1	consequently	consequently	ADV
dti-3019	230	2	,	,	PUNCT
dti-3019	230	3	it	it	PRON
dti-3019	230	4	can	can	AUX
dti-3019	230	5	be	be	AUX
dti-3019	230	6	employed	employ	VERB
dti-3019	230	7	to	to	PART
dti-3019	230	8	treat	treat	VERB
dti-3019	230	9	infections	infection	NOUN
dti-3019	230	10	caused	cause	VERB
dti-3019	230	11	by	by	ADP
dti-3019	230	12	drug	drug	NOUN
dti-3019	230	13	-	-	PUNCT
dti-3019	230	14	resistant	resistant	ADJ
dti-3019	230	15	strains	strain	NOUN
dti-3019	230	16	of	of	ADP
dti-3019	230	17	tuberculosis	tuberculosis	NOUN
dti-3019	230	18	that	that	PRON
dti-3019	230	19	survive	survive	VERB
dti-3019	230	20	due	due	ADP
dti-3019	230	21	to	to	ADP
dti-3019	230	22	their	their	PRON
dti-3019	230	23	inability	inability	NOUN
dti-3019	230	24	to	to	PART
dti-3019	230	25	activate	activate	VERB
dti-3019	230	26	isoniazid	isoniazid	NOUN
dti-3019	230	27	(	(	PUNCT
dti-3019	230	28	120	120	NUM
dti-3019	230	29	)	)	PUNCT
dti-3019	230	30	.	.	PUNCT
dti-3019	231	1	the	the	DET
dti-3019	231	2	comprehension	comprehension	NOUN
dti-3019	231	3	of	of	ADP
dti-3019	231	4	this	this	DET
dti-3019	231	5	mechanism	mechanism	NOUN
dti-3019	231	6	of	of	ADP
dti-3019	231	7	action	action	NOUN
dti-3019	231	8	may	may	AUX
dti-3019	231	9	also	also	ADV
dti-3019	231	10	promote	promote	VERB
dti-3019	231	11	the	the	DET
dti-3019	231	12	utilization	utilization	NOUN
dti-3019	231	13	of	of	ADP
dti-3019	231	14	pyridomycin	pyridomycin	NOUN
dti-3019	231	15	in	in	ADP
dti-3019	231	16	conjunction	conjunction	NOUN
dti-3019	231	17	with	with	ADP
dti-3019	231	18	other	other	ADJ
dti-3019	231	19	medications	medication	NOUN
dti-3019	231	20	(	(	PUNCT
dti-3019	231	21	121	121	NUM
dti-3019	231	22	)	)	PUNCT
dti-3019	231	23	.	.	PUNCT
dti-3019	232	1	however	however	ADV
dti-3019	232	2	,	,	PUNCT
dti-3019	232	3	there	there	PRON
dti-3019	232	4	are	be	VERB
dti-3019	232	5	several	several	ADJ
dti-3019	232	6	difficulties	difficulty	NOUN
dti-3019	232	7	in	in	ADP
dti-3019	232	8	repurposing	repurpose	VERB
dti-3019	232	9	drugs	drug	NOUN
dti-3019	232	10	for	for	ADP
dti-3019	232	11	infectious	infectious	ADJ
dti-3019	232	12	diseases	disease	NOUN
dti-3019	232	13	,	,	PUNCT
dti-3019	232	14	and	and	CCONJ
dti-3019	232	15	the	the	DET
dti-3019	232	16	subsequent	subsequent	ADJ
dti-3019	232	17	sections	section	NOUN
dti-3019	232	18	will	will	AUX
dti-3019	232	19	outline	outline	VERB
dti-3019	232	20	some	some	PRON
dti-3019	232	21	of	of	ADP
dti-3019	232	22	the	the	DET
dti-3019	232	23	primary	primary	ADJ
dti-3019	232	24	challenges	challenge	NOUN
dti-3019	232	25	that	that	PRON
dti-3019	232	26	arise	arise	VERB
dti-3019	232	27	in	in	ADP
dti-3019	232	28	this	this	DET
dti-3019	232	29	domain	domain	NOUN
dti-3019	232	30	.	.	PUNCT
dti-3019	233	1	the	the	DET
dti-3019	233	2	complexity	complexity	NOUN
dti-3019	233	3	of	of	ADP
dti-3019	233	4	microorganisms	microorganism	NOUN
dti-3019	233	5	and	and	CCONJ
dti-3019	233	6	the	the	DET
dti-3019	233	7	limited	limited	ADJ
dti-3019	233	8	understanding	understanding	NOUN
dti-3019	233	9	of	of	ADP
dti-3019	233	10	the	the	DET
dti-3019	233	11	complicated	complicated	ADJ
dti-3019	233	12	interactions	interaction	NOUN
dti-3019	233	13	between	between	ADP
dti-3019	233	14	pathogens	pathogen	NOUN
dti-3019	233	15	and	and	CCONJ
dti-3019	233	16	their	their	PRON
dti-3019	233	17	hosts	host	NOUN
dti-3019	233	18	identifying	identify	VERB
dti-3019	233	19	appropriate	appropriate	ADJ
dti-3019	233	20	therapeutic	therapeutic	ADJ
dti-3019	233	21	targets	target	NOUN
dti-3019	233	22	for	for	ADP
dti-3019	233	23	anti	anti	ADJ
dti-3019	233	24	-	-	ADJ
dti-3019	233	25	infective	infective	ADJ
dti-3019	233	26	medications	medication	NOUN
dti-3019	233	27	is	be	AUX
dti-3019	233	28	a	a	DET
dti-3019	233	29	challenging	challenging	ADJ
dti-3019	233	30	endeavor	endeavor	NOUN
dti-3019	233	31	due	due	ADJ
dti-3019	233	32	to	to	ADP
dti-3019	233	33	the	the	DET
dti-3019	233	34	complex	complex	ADJ
dti-3019	233	35	nature	nature	NOUN
dti-3019	233	36	of	of	ADP
dti-3019	233	37	infection	infection	NOUN
dti-3019	233	38	processes	process	NOUN
dti-3019	233	39	and	and	CCONJ
dti-3019	233	40	the	the	DET
dti-3019	233	41	intricate	intricate	ADJ
dti-3019	233	42	interplay	interplay	NOUN
dti-3019	233	43	between	between	ADP
dti-3019	233	44	hosts	host	NOUN
dti-3019	233	45	and	and	CCONJ
dti-3019	233	46	pathogens	pathogen	NOUN
dti-3019	233	47	(	(	PUNCT
dti-3019	233	48	122	122	NUM
dti-3019	233	49	)	)	PUNCT
dti-3019	233	50	.	.	PUNCT
dti-3019	234	1	pathogens	pathogen	NOUN
dti-3019	234	2	,	,	PUNCT
dti-3019	234	3	encompassing	encompass	VERB
dti-3019	234	4	viruses	virus	NOUN
dti-3019	234	5	,	,	PUNCT
dti-3019	234	6	bacteria	bacteria	NOUN
dti-3019	234	7	,	,	PUNCT
dti-3019	234	8	protozoa	protozoan	NOUN
dti-3019	234	9	,	,	PUNCT
dti-3019	234	10	and	and	CCONJ
dti-3019	234	11	nematodes	nematode	NOUN
dti-3019	234	12	,	,	PUNCT
dti-3019	234	13	acquire	acquire	VERB
dti-3019	234	14	significant	significant	ADJ
dti-3019	234	15	genetic	genetic	ADJ
dti-3019	234	16	diversity	diversity	NOUN
dti-3019	234	17	through	through	ADP
dti-3019	234	18	mutation	mutation	NOUN
dti-3019	234	19	and	and	CCONJ
dti-3019	234	20	recombination	recombination	NOUN
dti-3019	234	21	,	,	PUNCT
dti-3019	234	22	resulting	result	VERB
dti-3019	234	23	in	in	ADP
dti-3019	234	24	the	the	DET
dti-3019	234	25	emergence	emergence	NOUN
dti-3019	234	26	of	of	ADP
dti-3019	234	27	drug	drug	NOUN
dti-3019	234	28	-	-	PUNCT
dti-3019	234	29	resistant	resistant	ADJ
dti-3019	234	30	mutants	mutant	NOUN
dti-3019	234	31	(	(	PUNCT
dti-3019	234	32	123	123	NUM
dti-3019	234	33	)	)	PUNCT
dti-3019	234	34	.	.	PUNCT
dti-3019	235	1	consequently	consequently	ADV
dti-3019	235	2	,	,	PUNCT
dti-3019	235	3	the	the	DET
dti-3019	235	4	development	development	NOUN
dti-3019	235	5	of	of	ADP
dti-3019	235	6	drugs	drug	NOUN
dti-3019	235	7	that	that	PRON
dti-3019	235	8	can	can	AUX
dti-3019	235	9	effectively	effectively	ADV
dti-3019	235	10	target	target	VERB
dti-3019	235	11	all	all	DET
dti-3019	235	12	viral	viral	ADJ
dti-3019	235	13	variations	variation	NOUN
dti-3019	235	14	becomes	become	VERB
dti-3019	235	15	arduous	arduous	ADJ
dti-3019	235	16	.	.	PUNCT
dti-3019	236	1	hence	hence	ADV
dti-3019	236	2	,	,	PUNCT
dti-3019	236	3	it	it	PRON
dti-3019	236	4	is	be	AUX
dti-3019	236	5	imperative	imperative	ADJ
dti-3019	236	6	to	to	PART
dti-3019	236	7	consistently	consistently	ADV
dti-3019	236	8	exert	exert	VERB
dti-3019	236	9	efforts	effort	NOUN
dti-3019	236	10	to	to	PART
dti-3019	236	11	stay	stay	VERB
dti-3019	236	12	ahead	ahead	ADV
dti-3019	236	13	of	of	ADP
dti-3019	236	14	evolving	evolve	VERB
dti-3019	236	15	resistance	resistance	NOUN
dti-3019	236	16	mechanisms	mechanism	NOUN
dti-3019	236	17	(	(	PUNCT
dti-3019	236	18	124	124	NUM
dti-3019	236	19	)	)	PUNCT
dti-3019	236	20	.	.	PUNCT
dti-3019	237	1	furthermore	furthermore	ADV
dti-3019	237	2	,	,	PUNCT
dti-3019	237	3	certain	certain	ADJ
dti-3019	237	4	infections	infection	NOUN
dti-3019	237	5	,	,	PUNCT
dti-3019	237	6	including	include	VERB
dti-3019	237	7	neisseria	neisseria	PROPN
dti-3019	237	8	spp	spp	PROPN
dti-3019	237	9	.	.	PROPN
dti-3019	237	10	or	or	CCONJ
dti-3019	237	11	plasmodium	plasmodium	NOUN
dti-3019	237	12	spp	spp	NOUN
dti-3019	237	13	.	.	PROPN
dti-3019	237	14	,	,	PUNCT
dti-3019	237	15	possess	possess	VERB
dti-3019	237	16	the	the	DET
dti-3019	237	17	capability	capability	NOUN
dti-3019	237	18	to	to	PART
dti-3019	237	19	undergo	undergo	VERB
dti-3019	237	20	antigenic	antigenic	ADJ
dti-3019	237	21	variation	variation	NOUN
dti-3019	237	22	,	,	PUNCT
dti-3019	237	23	wherein	wherein	SCONJ
dti-3019	237	24	they	they	PRON
dti-3019	237	25	modify	modify	VERB
dti-3019	237	26	the	the	DET
dti-3019	237	27	surface	surface	NOUN
dti-3019	237	28	proteins	protein	NOUN
dti-3019	237	29	on	on	ADP
dti-3019	237	30	their	their	PRON
dti-3019	237	31	cells	cell	NOUN
dti-3019	237	32	to	to	PART
dti-3019	237	33	evade	evade	VERB
dti-3019	237	34	detection	detection	NOUN
dti-3019	237	35	and	and	CCONJ
dti-3019	237	36	attack	attack	NOUN
dti-3019	237	37	by	by	ADP
dti-3019	237	38	the	the	DET
dti-3019	237	39	host	host	NOUN
dti-3019	237	40	organism	organism	NOUN
dti-3019	237	41	’s	’s	PART
dti-3019	237	42	immune	immune	ADJ
dti-3019	237	43	system	system	NOUN
dti-3019	237	44	.	.	PUNCT
dti-3019	238	1	this	this	DET
dti-3019	238	2	ongoing	ongoing	ADJ
dti-3019	238	3	process	process	NOUN
dti-3019	238	4	of	of	ADP
dti-3019	238	5	adaptation	adaptation	NOUN
dti-3019	238	6	poses	pose	VERB
dti-3019	238	7	challenges	challenge	NOUN
dti-3019	238	8	in	in	ADP
dti-3019	238	9	identifying	identify	VERB
dti-3019	238	10	consistent	consistent	ADJ
dti-3019	238	11	therapeutic	therapeutic	ADJ
dti-3019	238	12	targets	target	NOUN
dti-3019	238	13	and	and	CCONJ
dti-3019	238	14	potential	potential	ADJ
dti-3019	238	15	natsheh	natsheh	PROPN
dti-3019	238	16	et	et	PROPN
dti-3019	238	17	al	al	PROPN
dti-3019	238	18	drug	drug	PROPN
dti-3019	238	19	target	target	NOUN
dti-3019	238	20	insights	insight	NOUN
dti-3019	238	21	2024	2024	NUM
dti-3019	238	22	;	;	PUNCT
dti-3019	238	23	18	18	NUM
dti-3019	238	24	:	:	SYM
dti-3019	238	25	15	15	NUM
dti-3019	238	26	©	©	PROPN
dti-3019	238	27	2024	2024	NUM
dti-3019	238	28	the	the	DET
dti-3019	238	29	authors	author	NOUN
dti-3019	238	30	.	.	PUNCT
dti-3019	239	1	published	publish	VERB
dti-3019	239	2	by	by	ADP
dti-3019	239	3	aboutscience	aboutscience	NOUN
dti-3019	239	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3019	239	5	candidates	candidate	NOUN
dti-3019	239	6	for	for	ADP
dti-3019	239	7	vaccination	vaccination	NOUN
dti-3019	239	8	(	(	PUNCT
dti-3019	239	9	125	125	NUM
dti-3019	239	10	)	)	PUNCT
dti-3019	239	11	.	.	PUNCT
dti-3019	240	1	additionally	additionally	ADV
dti-3019	240	2	,	,	PUNCT
dti-3019	240	3	several	several	ADJ
dti-3019	240	4	pathogens	pathogen	NOUN
dti-3019	240	5	like	like	ADP
dti-3019	240	6	trypanosoma	trypanosoma	PROPN
dti-3019	240	7	cruzi	cruzi	PROPN
dti-3019	240	8	,	,	PUNCT
dti-3019	240	9	mycobacterium	mycobacterium	NOUN
dti-3019	240	10	tuberculosis	tuberculosis	NOUN
dti-3019	240	11	,	,	PUNCT
dti-3019	240	12	and	and	CCONJ
dti-3019	240	13	herpes	herpe	NOUN
dti-3019	240	14	viruses	virus	NOUN
dti-3019	240	15	can	can	AUX
dti-3019	240	16	establish	establish	VERB
dti-3019	240	17	latent	latent	NOUN
dti-3019	240	18	or	or	CCONJ
dti-3019	240	19	chronic	chronic	ADJ
dti-3019	240	20	infections	infection	NOUN
dti-3019	240	21	,	,	PUNCT
dti-3019	240	22	wherein	wherein	SCONJ
dti-3019	240	23	they	they	PRON
dti-3019	240	24	remain	remain	VERB
dti-3019	240	25	inactive	inactive	ADJ
dti-3019	240	26	within	within	ADP
dti-3019	240	27	host	host	NOUN
dti-3019	240	28	cells	cell	NOUN
dti-3019	240	29	and	and	CCONJ
dti-3019	240	30	successfully	successfully	ADV
dti-3019	240	31	evade	evade	VERB
dti-3019	240	32	immune	immune	ADJ
dti-3019	240	33	detection	detection	NOUN
dti-3019	240	34	(	(	PUNCT
dti-3019	240	35	126,127	126,127	NUM
dti-3019	240	36	)	)	PUNCT
dti-3019	240	37	.	.	PUNCT
dti-3019	241	1	effectively	effectively	ADV
dti-3019	241	2	managing	manage	VERB
dti-3019	241	3	such	such	ADJ
dti-3019	241	4	infections	infection	NOUN
dti-3019	241	5	requires	require	VERB
dti-3019	241	6	medications	medication	NOUN
dti-3019	241	7	that	that	PRON
dti-3019	241	8	can	can	AUX
dti-3019	241	9	specifically	specifically	ADV
dti-3019	241	10	target	target	VERB
dti-3019	241	11	the	the	DET
dti-3019	241	12	pathogen	pathogen	NOUN
dti-3019	241	13	during	during	ADP
dti-3019	241	14	both	both	CCONJ
dti-3019	241	15	its	its	PRON
dti-3019	241	16	active	active	ADJ
dti-3019	241	17	and	and	CCONJ
dti-3019	241	18	latent	latent	ADJ
dti-3019	241	19	stages	stage	NOUN
dti-3019	241	20	.	.	PUNCT
dti-3019	242	1	moreover	moreover	ADV
dti-3019	242	2	,	,	PUNCT
dti-3019	242	3	certain	certain	ADJ
dti-3019	242	4	bacteria	bacteria	NOUN
dti-3019	242	5	such	such	ADJ
dti-3019	242	6	as	as	ADP
dti-3019	242	7	pseudomonas	pseudomona	NOUN
dti-3019	242	8	aeruginosa	aeruginosa	NOUN
dti-3019	242	9	,	,	PUNCT
dti-3019	242	10	acinetobacter	acinetobacter	ADV
dti-3019	242	11	baumannii	baumannii	PROPN
dti-3019	242	12	,	,	PUNCT
dti-3019	242	13	and	and	CCONJ
dti-3019	242	14	staphylococcus	staphylococcus	NOUN
dti-3019	242	15	aureus	aureus	NOUN
dti-3019	242	16	can	can	AUX
dti-3019	242	17	form	form	VERB
dti-3019	242	18	biofilms	biofilm	NOUN
dti-3019	242	19	,	,	PUNCT
dti-3019	242	20	which	which	PRON
dti-3019	242	21	augment	augment	VERB
dti-3019	242	22	their	their	PRON
dti-3019	242	23	resistance	resistance	NOUN
dti-3019	242	24	to	to	ADP
dti-3019	242	25	drugs	drug	NOUN
dti-3019	242	26	and	and	CCONJ
dti-3019	242	27	impede	impede	VERB
dti-3019	242	28	drug	drug	NOUN
dti-3019	242	29	accessibility	accessibility	NOUN
dti-3019	242	30	,	,	PUNCT
dti-3019	242	31	thereby	thereby	ADV
dti-3019	242	32	making	make	VERB
dti-3019	242	33	the	the	DET
dti-3019	242	34	eradication	eradication	NOUN
dti-3019	242	35	of	of	ADP
dti-3019	242	36	infections	infection	NOUN
dti-3019	242	37	more	more	ADV
dti-3019	242	38	formidable	formidable	ADJ
dti-3019	242	39	(	(	PUNCT
dti-3019	242	40	75,128	75,128	NUM
dti-3019	242	41	)	)	PUNCT
dti-3019	242	42	.	.	PUNCT
dti-3019	243	1	lack	lack	NOUN
dti-3019	243	2	of	of	ADP
dti-3019	243	3	efficient	efficient	ADJ
dti-3019	243	4	animal	animal	NOUN
dti-3019	243	5	models	model	NOUN
dti-3019	243	6	developing	develop	VERB
dti-3019	243	7	animal	animal	NOUN
dti-3019	243	8	models	model	NOUN
dti-3019	243	9	that	that	PRON
dti-3019	243	10	accurately	accurately	ADV
dti-3019	243	11	replicate	replicate	VERB
dti-3019	243	12	human	human	ADJ
dti-3019	243	13	infections	infection	NOUN
dti-3019	243	14	is	be	AUX
dti-3019	243	15	essential	essential	ADJ
dti-3019	243	16	for	for	ADP
dti-3019	243	17	preclinical	preclinical	ADJ
dti-3019	243	18	testing	testing	NOUN
dti-3019	243	19	.	.	PUNCT
dti-3019	244	1	however	however	ADV
dti-3019	244	2	,	,	PUNCT
dti-3019	244	3	creating	create	VERB
dti-3019	244	4	suitable	suitable	ADJ
dti-3019	244	5	models	model	NOUN
dti-3019	244	6	for	for	ADP
dti-3019	244	7	specific	specific	ADJ
dti-3019	244	8	infectious	infectious	ADJ
dti-3019	244	9	diseases	disease	NOUN
dti-3019	244	10	can	can	AUX
dti-3019	244	11	pose	pose	VERB
dti-3019	244	12	challenges	challenge	NOUN
dti-3019	244	13	due	due	ADP
dti-3019	244	14	to	to	ADP
dti-3019	244	15	the	the	DET
dti-3019	244	16	intricate	intricate	ADJ
dti-3019	244	17	interactions	interaction	NOUN
dti-3019	244	18	between	between	ADP
dti-3019	244	19	hosts	host	NOUN
dti-3019	244	20	and	and	CCONJ
dti-3019	244	21	pathogens	pathogen	NOUN
dti-3019	244	22	that	that	PRON
dti-3019	244	23	are	be	AUX
dti-3019	244	24	difficult	difficult	ADJ
dti-3019	244	25	to	to	PART
dti-3019	244	26	accurately	accurately	ADV
dti-3019	244	27	simulate	simulate	VERB
dti-3019	244	28	(	(	PUNCT
dti-3019	244	29	129	129	NUM
dti-3019	244	30	)	)	PUNCT
dti-3019	244	31	.	.	PUNCT
dti-3019	245	1	the	the	DET
dti-3019	245	2	absence	absence	NOUN
dti-3019	245	3	of	of	ADP
dti-3019	245	4	appropriate	appropriate	ADJ
dti-3019	245	5	predictive	predictive	ADJ
dti-3019	245	6	models	model	NOUN
dti-3019	245	7	can	can	AUX
dti-3019	245	8	hinder	hinder	VERB
dti-3019	245	9	the	the	DET
dti-3019	245	10	progress	progress	NOUN
dti-3019	245	11	of	of	ADP
dti-3019	245	12	drug	drug	NOUN
dti-3019	245	13	development	development	NOUN
dti-3019	245	14	,	,	PUNCT
dti-3019	245	15	as	as	SCONJ
dti-3019	245	16	it	it	PRON
dti-3019	245	17	becomes	become	VERB
dti-3019	245	18	arduous	arduous	ADJ
dti-3019	245	19	to	to	PART
dti-3019	245	20	comprehend	comprehend	VERB
dti-3019	245	21	the	the	DET
dti-3019	245	22	disease	disease	NOUN
dti-3019	245	23	mechanisms	mechanism	NOUN
dti-3019	245	24	and	and	CCONJ
dti-3019	245	25	evaluate	evaluate	VERB
dti-3019	245	26	the	the	DET
dti-3019	245	27	effectiveness	effectiveness	NOUN
dti-3019	245	28	of	of	ADP
dti-3019	245	29	potential	potential	ADJ
dti-3019	245	30	medications	medication	NOUN
dti-3019	245	31	(	(	PUNCT
dti-3019	245	32	130	130	NUM
dti-3019	245	33	)	)	PUNCT
dti-3019	245	34	.	.	PUNCT
dti-3019	246	1	an	an	DET
dti-3019	246	2	example	example	NOUN
dti-3019	246	3	is	be	AUX
dti-3019	246	4	the	the	DET
dti-3019	246	5	complexity	complexity	NOUN
dti-3019	246	6	involved	involve	VERB
dti-3019	246	7	in	in	ADP
dti-3019	246	8	modeling	model	VERB
dti-3019	246	9	diseases	disease	NOUN
dti-3019	246	10	like	like	ADP
dti-3019	246	11	covid19	covid19	NOUN
dti-3019	246	12	that	that	PRON
dti-3019	246	13	necessitates	necessitate	VERB
dti-3019	246	14	the	the	DET
dti-3019	246	15	consideration	consideration	NOUN
dti-3019	246	16	of	of	ADP
dti-3019	246	17	various	various	ADJ
dti-3019	246	18	factors	factor	NOUN
dti-3019	246	19	such	such	ADJ
dti-3019	246	20	as	as	ADP
dti-3019	246	21	stochasticity	stochasticity	NOUN
dti-3019	246	22	,	,	PUNCT
dti-3019	246	23	evolving	evolve	VERB
dti-3019	246	24	transmission	transmission	NOUN
dti-3019	246	25	dynamics	dynamic	NOUN
dti-3019	246	26	,	,	PUNCT
dti-3019	246	27	and	and	CCONJ
dti-3019	246	28	spatial	spatial	ADJ
dti-3019	246	29	configurations	configuration	NOUN
dti-3019	246	30	(	(	PUNCT
dti-3019	246	31	131	131	NUM
dti-3019	246	32	)	)	PUNCT
dti-3019	246	33	.	.	PUNCT
dti-3019	247	1	a	a	DET
dti-3019	247	2	significant	significant	ADJ
dti-3019	247	3	advancement	advancement	NOUN
dti-3019	247	4	in	in	ADP
dti-3019	247	5	the	the	DET
dti-3019	247	6	field	field	NOUN
dti-3019	247	7	of	of	ADP
dti-3019	247	8	antimalarial	antimalarial	ADJ
dti-3019	247	9	drug	drug	NOUN
dti-3019	247	10	research	research	NOUN
dti-3019	247	11	and	and	CCONJ
dti-3019	247	12	development	development	NOUN
dti-3019	247	13	was	be	AUX
dti-3019	247	14	the	the	DET
dti-3019	247	15	establishment	establishment	NOUN
dti-3019	247	16	of	of	ADP
dti-3019	247	17	a	a	DET
dti-3019	247	18	nodscid	nodscid	ADJ
dti-3019	247	19	mouse	mouse	NOUN
dti-3019	247	20	model	model	NOUN
dti-3019	247	21	for	for	ADP
dti-3019	247	22	p.	p.	PROPN
dti-3019	247	23	falciparum	falciparum	ADJ
dti-3019	247	24	infection	infection	NOUN
dti-3019	247	25	,	,	PUNCT
dti-3019	247	26	which	which	PRON
dti-3019	247	27	proved	prove	VERB
dti-3019	247	28	valuable	valuable	ADJ
dti-3019	247	29	for	for	ADP
dti-3019	247	30	testing	test	VERB
dti-3019	247	31	drug	drug	NOUN
dti-3019	247	32	efficacy	efficacy	NOUN
dti-3019	247	33	(	(	PUNCT
dti-3019	247	34	132	132	NUM
dti-3019	247	35	)	)	PUNCT
dti-3019	247	36	.	.	PUNCT
dti-3019	248	1	moreover	moreover	ADV
dti-3019	248	2	,	,	PUNCT
dti-3019	248	3	the	the	DET
dti-3019	248	4	utilization	utilization	NOUN
dti-3019	248	5	of	of	ADP
dti-3019	248	6	organoid	organoid	NOUN
dti-3019	248	7	cultures	culture	NOUN
dti-3019	248	8	derived	derive	VERB
dti-3019	248	9	from	from	ADP
dti-3019	248	10	stem	stem	NOUN
dti-3019	248	11	cells	cell	NOUN
dti-3019	248	12	holds	hold	VERB
dti-3019	248	13	significant	significant	ADJ
dti-3019	248	14	promise	promise	NOUN
dti-3019	248	15	in	in	ADP
dti-3019	248	16	providing	provide	VERB
dti-3019	248	17	valuable	valuable	ADJ
dti-3019	248	18	insights	insight	NOUN
dti-3019	248	19	into	into	ADP
dti-3019	248	20	infectious	infectious	ADJ
dti-3019	248	21	diseases	disease	NOUN
dti-3019	248	22	by	by	ADP
dti-3019	248	23	effectively	effectively	ADV
dti-3019	248	24	mimicking	mimic	VERB
dti-3019	248	25	in	in	ADP
dti-3019	248	26	vivo	vivo	ADJ
dti-3019	248	27	disease	disease	NOUN
dti-3019	248	28	characteristics	characteristic	NOUN
dti-3019	248	29	and	and	CCONJ
dti-3019	248	30	enhancing	enhance	VERB
dti-3019	248	31	the	the	DET
dti-3019	248	32	comprehension	comprehension	NOUN
dti-3019	248	33	of	of	ADP
dti-3019	248	34	host	host	NOUN
dti-3019	248	35	-	-	PUNCT
dti-3019	248	36	microbe	microbe	NOUN
dti-3019	248	37	interactions	interaction	NOUN
dti-3019	248	38	(	(	PUNCT
dti-3019	248	39	133,134	133,134	NUM
dti-3019	248	40	)	)	PUNCT
dti-3019	248	41	.	.	PUNCT
dti-3019	249	1	in	in	ADP
dti-3019	249	2	addition	addition	NOUN
dti-3019	249	3	,	,	PUNCT
dti-3019	249	4	the	the	DET
dti-3019	249	5	integration	integration	NOUN
dti-3019	249	6	of	of	ADP
dti-3019	249	7	sophisticated	sophisticated	ADJ
dti-3019	249	8	mathematical	mathematical	ADJ
dti-3019	249	9	models	model	NOUN
dti-3019	249	10	such	such	ADJ
dti-3019	249	11	as	as	ADP
dti-3019	249	12	the	the	DET
dti-3019	249	13	seir	seir	ADJ
dti-3019	249	14	model	model	NOUN
dti-3019	249	15	,	,	PUNCT
dti-3019	249	16	incorporating	incorporate	VERB
dti-3019	249	17	multiple	multiple	ADJ
dti-3019	249	18	variables	variable	NOUN
dti-3019	249	19	,	,	PUNCT
dti-3019	249	20	can	can	AUX
dti-3019	249	21	greatly	greatly	ADV
dti-3019	249	22	assist	assist	VERB
dti-3019	249	23	in	in	ADP
dti-3019	249	24	forecasting	forecasting	NOUN
dti-3019	249	25	disease	disease	NOUN
dti-3019	249	26	dissemination	dissemination	NOUN
dti-3019	249	27	,	,	PUNCT
dti-3019	249	28	particularly	particularly	ADV
dti-3019	249	29	for	for	ADP
dti-3019	249	30	infections	infection	NOUN
dti-3019	249	31	characterized	characterize	VERB
dti-3019	249	32	by	by	ADP
dti-3019	249	33	prolonged	prolonged	ADJ
dti-3019	249	34	incubation	incubation	NOUN
dti-3019	249	35	periods	period	NOUN
dti-3019	249	36	and	and	CCONJ
dti-3019	249	37	asymptomatic	asymptomatic	ADJ
dti-3019	249	38	carriers	carrier	NOUN
dti-3019	249	39	(	(	PUNCT
dti-3019	249	40	135	135	NUM
dti-3019	249	41	)	)	PUNCT
dti-3019	249	42	.	.	PUNCT
dti-3019	250	1	the	the	DET
dti-3019	250	2	optimization	optimization	NOUN
dti-3019	250	3	of	of	ADP
dti-3019	250	4	the	the	DET
dti-3019	250	5	modeling	modeling	NOUN
dti-3019	250	6	process	process	NOUN
dti-3019	250	7	through	through	ADP
dti-3019	250	8	the	the	DET
dti-3019	250	9	formulation	formulation	NOUN
dti-3019	250	10	of	of	ADP
dti-3019	250	11	well	well	ADV
dti-3019	250	12	-	-	PUNCT
dti-3019	250	13	defined	define	VERB
dti-3019	250	14	research	research	NOUN
dti-3019	250	15	questions	question	NOUN
dti-3019	250	16	,	,	PUNCT
dti-3019	250	17	implementation	implementation	NOUN
dti-3019	250	18	of	of	ADP
dti-3019	250	19	quality	quality	NOUN
dti-3019	250	20	assurance	assurance	NOUN
dti-3019	250	21	measures	measure	NOUN
dti-3019	250	22	,	,	PUNCT
dti-3019	250	23	and	and	CCONJ
dti-3019	250	24	meticulous	meticulous	ADJ
dti-3019	250	25	reporting	reporting	NOUN
dti-3019	250	26	practices	practice	NOUN
dti-3019	250	27	can	can	AUX
dti-3019	250	28	substantially	substantially	ADV
dti-3019	250	29	elevate	elevate	VERB
dti-3019	250	30	the	the	DET
dti-3019	250	31	relevance	relevance	NOUN
dti-3019	250	32	and	and	CCONJ
dti-3019	250	33	comprehensibility	comprehensibility	NOUN
dti-3019	250	34	of	of	ADP
dti-3019	250	35	findings	finding	NOUN
dti-3019	250	36	,	,	PUNCT
dti-3019	250	37	thereby	thereby	ADV
dti-3019	250	38	playing	play	VERB
dti-3019	250	39	a	a	DET
dti-3019	250	40	pivotal	pivotal	ADJ
dti-3019	250	41	role	role	NOUN
dti-3019	250	42	in	in	ADP
dti-3019	250	43	improving	improve	VERB
dti-3019	250	44	decision	decision	NOUN
dti-3019	250	45	-	-	PUNCT
dti-3019	250	46	making	make	VERB
dti-3019	250	47	processes	process	NOUN
dti-3019	250	48	related	relate	VERB
dti-3019	250	49	to	to	ADP
dti-3019	250	50	disease	disease	NOUN
dti-3019	250	51	management	management	NOUN
dti-3019	250	52	(	(	PUNCT
dti-3019	250	53	136	136	NUM
dti-3019	250	54	)	)	PUNCT
dti-3019	250	55	.	.	PUNCT
dti-3019	251	1	on	on	ADP
dti-3019	251	2	the	the	DET
dti-3019	251	3	other	other	ADJ
dti-3019	251	4	hand	hand	NOUN
dti-3019	251	5	,	,	PUNCT
dti-3019	251	6	epidemiological	epidemiological	ADJ
dti-3019	251	7	models	model	NOUN
dti-3019	251	8	,	,	PUNCT
dti-3019	251	9	such	such	ADJ
dti-3019	251	10	as	as	ADP
dti-3019	251	11	agent	agent	NOUN
dti-3019	251	12	-	-	PUNCT
dti-3019	251	13	based	base	VERB
dti-3019	251	14	simulation	simulation	NOUN
dti-3019	251	15	models	model	NOUN
dti-3019	251	16	and	and	CCONJ
dti-3019	251	17	compartmental	compartmental	ADJ
dti-3019	251	18	models	model	NOUN
dti-3019	251	19	,	,	PUNCT
dti-3019	251	20	play	play	VERB
dti-3019	251	21	a	a	DET
dti-3019	251	22	crucial	crucial	ADJ
dti-3019	251	23	role	role	NOUN
dti-3019	251	24	in	in	ADP
dti-3019	251	25	understanding	understand	VERB
dti-3019	251	26	disease	disease	NOUN
dti-3019	251	27	spread	spread	VERB
dti-3019	251	28	dynamics	dynamic	NOUN
dti-3019	251	29	and	and	CCONJ
dti-3019	251	30	evaluating	evaluate	VERB
dti-3019	251	31	intervention	intervention	NOUN
dti-3019	251	32	strategies	strategy	NOUN
dti-3019	251	33	(	(	PUNCT
dti-3019	251	34	137	137	NUM
dti-3019	251	35	-	-	SYM
dti-3019	251	36	139	139	NUM
dti-3019	251	37	)	)	PUNCT
dti-3019	251	38	.	.	PUNCT
dti-3019	252	1	these	these	DET
dti-3019	252	2	models	model	NOUN
dti-3019	252	3	often	often	ADV
dti-3019	252	4	involve	involve	VERB
dti-3019	252	5	making	make	VERB
dti-3019	252	6	assumptions	assumption	NOUN
dti-3019	252	7	that	that	PRON
dti-3019	252	8	may	may	AUX
dti-3019	252	9	limit	limit	VERB
dti-3019	252	10	their	their	PRON
dti-3019	252	11	scope	scope	NOUN
dti-3019	252	12	,	,	PUNCT
dti-3019	252	13	such	such	ADJ
dti-3019	252	14	as	as	ADP
dti-3019	252	15	focusing	focus	VERB
dti-3019	252	16	on	on	ADP
dti-3019	252	17	single	single	ADJ
dti-3019	252	18	-	-	PUNCT
dti-3019	252	19	strain	strain	NOUN
dti-3019	252	20	and	and	CCONJ
dti-3019	252	21	single	single	ADJ
dti-3019	252	22	-	-	PUNCT
dti-3019	252	23	vector	vector	NOUN
dti-3019	252	24	scenarios	scenario	NOUN
dti-3019	252	25	,	,	PUNCT
dti-3019	252	26	simplistic	simplistic	ADJ
dti-3019	252	27	human	human	ADJ
dti-3019	252	28	behavior	behavior	NOUN
dti-3019	252	29	modeling	modeling	NOUN
dti-3019	252	30	,	,	PUNCT
dti-3019	252	31	and	and	CCONJ
dti-3019	252	32	ignoring	ignore	VERB
dti-3019	252	33	data	data	NOUN
dti-3019	252	34	quality	quality	NOUN
dti-3019	252	35	evaluation	evaluation	NOUN
dti-3019	252	36	(	(	PUNCT
dti-3019	252	37	140	140	NUM
dti-3019	252	38	)	)	PUNCT
dti-3019	252	39	.	.	PUNCT
dti-3019	253	1	to	to	PART
dti-3019	253	2	improve	improve	VERB
dti-3019	253	3	the	the	DET
dti-3019	253	4	reliability	reliability	NOUN
dti-3019	253	5	of	of	ADP
dti-3019	253	6	these	these	DET
dti-3019	253	7	models	model	NOUN
dti-3019	253	8	,	,	PUNCT
dti-3019	253	9	it	it	PRON
dti-3019	253	10	is	be	AUX
dti-3019	253	11	essential	essential	ADJ
dti-3019	253	12	to	to	PART
dti-3019	253	13	consider	consider	VERB
dti-3019	253	14	factors	factor	NOUN
dti-3019	253	15	like	like	ADP
dti-3019	253	16	information	information	NOUN
dti-3019	253	17	quality	quality	NOUN
dti-3019	253	18	,	,	PUNCT
dti-3019	253	19	human	human	ADJ
dti-3019	253	20	behavior	behavior	NOUN
dti-3019	253	21	,	,	PUNCT
dti-3019	253	22	multi	multi	NOUN
dti-3019	253	23	-	-	NOUN
dti-3019	253	24	vector	vector	ADJ
dti-3019	253	25	,	,	PUNCT
dti-3019	253	26	and	and	CCONJ
dti-3019	253	27	multi	multi	ADJ
dti-3019	253	28	-	-	ADJ
dti-3019	253	29	strain	strain	ADJ
dti-3019	253	30	scenarios	scenario	NOUN
dti-3019	253	31	,	,	PUNCT
dti-3019	253	32	as	as	SCONJ
dti-3019	253	33	they	they	PRON
dti-3019	253	34	significantly	significantly	ADV
dti-3019	253	35	impact	impact	VERB
dti-3019	253	36	the	the	DET
dti-3019	253	37	model	model	NOUN
dti-3019	253	38	outcomes	outcome	NOUN
dti-3019	253	39	without	without	ADP
dti-3019	253	40	significantly	significantly	ADV
dti-3019	253	41	increasing	increase	VERB
dti-3019	253	42	computational	computational	ADJ
dti-3019	253	43	costs	cost	NOUN
dti-3019	253	44	(	(	PUNCT
dti-3019	253	45	141	141	NUM
dti-3019	253	46	)	)	PUNCT
dti-3019	253	47	.	.	PUNCT
dti-3019	254	1	collaborative	collaborative	ADJ
dti-3019	254	2	efforts	effort	NOUN
dti-3019	254	3	between	between	ADP
dti-3019	254	4	researchers	researcher	NOUN
dti-3019	254	5	and	and	CCONJ
dti-3019	254	6	modelers	modeler	NOUN
dti-3019	254	7	are	be	AUX
dti-3019	254	8	crucial	crucial	ADJ
dti-3019	254	9	to	to	ADP
dti-3019	254	10	enhancing	enhance	VERB
dti-3019	254	11	the	the	DET
dti-3019	254	12	accuracy	accuracy	NOUN
dti-3019	254	13	of	of	ADP
dti-3019	254	14	predictions	prediction	NOUN
dti-3019	254	15	and	and	CCONJ
dti-3019	254	16	optimizing	optimizing	NOUN
dti-3019	254	17	models	model	NOUN
dti-3019	254	18	for	for	ADP
dti-3019	254	19	effective	effective	ADJ
dti-3019	254	20	public	public	ADJ
dti-3019	254	21	health	health	NOUN
dti-3019	254	22	decision	decision	NOUN
dti-3019	254	23	-	-	PUNCT
dti-3019	254	24	making	making	NOUN
dti-3019	254	25	and	and	CCONJ
dti-3019	254	26	for	for	ADP
dti-3019	254	27	repurposing	repurpose	VERB
dti-3019	254	28	antibiotics	antibiotic	NOUN
dti-3019	254	29	.	.	PUNCT
dti-3019	255	1	elevated	elevated	ADJ
dti-3019	255	2	likelihood	likelihood	NOUN
dti-3019	255	3	of	of	ADP
dti-3019	255	4	clinical	clinical	ADJ
dti-3019	255	5	failure	failure	NOUN
dti-3019	255	6	clinical	clinical	ADJ
dti-3019	255	7	trials	trial	NOUN
dti-3019	255	8	for	for	ADP
dti-3019	255	9	anti	anti	ADJ
dti-3019	255	10	-	-	ADJ
dti-3019	255	11	infective	infective	ADJ
dti-3019	255	12	medications	medication	NOUN
dti-3019	255	13	frequently	frequently	ADV
dti-3019	255	14	encounter	encounter	VERB
dti-3019	255	15	significant	significant	ADJ
dti-3019	255	16	attrition	attrition	NOUN
dti-3019	255	17	rates	rate	NOUN
dti-3019	255	18	as	as	ADP
dti-3019	255	19	a	a	DET
dti-3019	255	20	result	result	NOUN
dti-3019	255	21	of	of	ADP
dti-3019	255	22	inadequate	inadequate	ADJ
dti-3019	255	23	effectiveness	effectiveness	NOUN
dti-3019	255	24	,	,	PUNCT
dti-3019	255	25	apprehensions	apprehension	NOUN
dti-3019	255	26	regarding	regard	VERB
dti-3019	255	27	safety	safety	NOUN
dti-3019	255	28	,	,	PUNCT
dti-3019	255	29	or	or	CCONJ
dti-3019	255	30	difficulties	difficulty	NOUN
dti-3019	255	31	in	in	ADP
dti-3019	255	32	the	the	DET
dti-3019	255	33	recruitment	recruitment	NOUN
dti-3019	255	34	of	of	ADP
dti-3019	255	35	patients	patient	NOUN
dti-3019	255	36	(	(	PUNCT
dti-3019	255	37	142	142	NUM
dti-3019	255	38	)	)	PUNCT
dti-3019	255	39	.	.	PUNCT
dti-3019	256	1	additionally	additionally	ADV
dti-3019	256	2	,	,	PUNCT
dti-3019	256	3	the	the	DET
dti-3019	256	4	execution	execution	NOUN
dti-3019	256	5	of	of	ADP
dti-3019	256	6	clinical	clinical	ADJ
dti-3019	256	7	trials	trial	NOUN
dti-3019	256	8	and	and	CCONJ
dti-3019	256	9	the	the	DET
dti-3019	256	10	subsequent	subsequent	ADJ
dti-3019	256	11	monitoring	monitoring	NOUN
dti-3019	256	12	in	in	ADP
dti-3019	256	13	resource	resource	NOUN
dti-3019	256	14	-	-	PUNCT
dti-3019	256	15	constrained	constrain	VERB
dti-3019	256	16	environments	environment	NOUN
dti-3019	256	17	,	,	PUNCT
dti-3019	256	18	along	along	ADP
dti-3019	256	19	with	with	ADP
dti-3019	256	20	the	the	DET
dti-3019	256	21	absence	absence	NOUN
dti-3019	256	22	of	of	ADP
dti-3019	256	23	suitable	suitable	ADJ
dti-3019	256	24	surrogate	surrogate	ADJ
dti-3019	256	25	endpoints	endpoint	NOUN
dti-3019	256	26	for	for	ADP
dti-3019	256	27	infectious	infectious	ADJ
dti-3019	256	28	diseases	disease	NOUN
dti-3019	256	29	,	,	PUNCT
dti-3019	256	30	collectively	collectively	ADV
dti-3019	256	31	contribute	contribute	VERB
dti-3019	256	32	to	to	ADP
dti-3019	256	33	the	the	DET
dti-3019	256	34	elevated	elevated	ADJ
dti-3019	256	35	levels	level	NOUN
dti-3019	256	36	of	of	ADP
dti-3019	256	37	unsuccessful	unsuccessful	ADJ
dti-3019	256	38	outcomes	outcome	NOUN
dti-3019	256	39	(	(	PUNCT
dti-3019	256	40	143	143	NUM
dti-3019	256	41	)	)	PUNCT
dti-3019	256	42	.	.	PUNCT
dti-3019	257	1	in	in	ADP
dti-3019	257	2	conclusion	conclusion	NOUN
dti-3019	257	3	,	,	PUNCT
dti-3019	257	4	while	while	SCONJ
dti-3019	257	5	there	there	PRON
dti-3019	257	6	is	be	VERB
dti-3019	257	7	potential	potential	ADJ
dti-3019	257	8	in	in	ADP
dti-3019	257	9	repurposing	repurpose	VERB
dti-3019	257	10	drugs	drug	NOUN
dti-3019	257	11	to	to	PART
dti-3019	257	12	overcome	overcome	VERB
dti-3019	257	13	antibiotic	antibiotic	ADJ
dti-3019	257	14	resistance	resistance	NOUN
dti-3019	257	15	in	in	ADP
dti-3019	257	16	infectious	infectious	ADJ
dti-3019	257	17	diseases	disease	NOUN
dti-3019	257	18	,	,	PUNCT
dti-3019	257	19	several	several	ADJ
dti-3019	257	20	difficulties	difficulty	NOUN
dti-3019	257	21	arise	arise	VERB
dti-3019	257	22	in	in	ADP
dti-3019	257	23	this	this	DET
dti-3019	257	24	domain	domain	NOUN
dti-3019	257	25	.	.	PUNCT
dti-3019	258	1	the	the	DET
dti-3019	258	2	complexity	complexity	NOUN
dti-3019	258	3	of	of	ADP
dti-3019	258	4	microorganisms	microorganism	NOUN
dti-3019	258	5	and	and	CCONJ
dti-3019	258	6	the	the	DET
dti-3019	258	7	intricate	intricate	ADJ
dti-3019	258	8	interactions	interaction	NOUN
dti-3019	258	9	between	between	ADP
dti-3019	258	10	pathogens	pathogen	NOUN
dti-3019	258	11	and	and	CCONJ
dti-3019	258	12	their	their	PRON
dti-3019	258	13	hosts	host	NOUN
dti-3019	258	14	pose	pose	VERB
dti-3019	258	15	challenges	challenge	NOUN
dti-3019	258	16	in	in	ADP
dti-3019	258	17	identifying	identify	VERB
dti-3019	258	18	suitable	suitable	ADJ
dti-3019	258	19	therapeutic	therapeutic	ADJ
dti-3019	258	20	targets	target	NOUN
dti-3019	258	21	.	.	PUNCT
dti-3019	259	1	pathogens	pathogen	NOUN
dti-3019	259	2	’	'	PUNCT
dti-3019	259	3	ability	ability	NOUN
dti-3019	259	4	to	to	PART
dti-3019	259	5	evolve	evolve	VERB
dti-3019	259	6	,	,	PUNCT
dti-3019	259	7	undergo	undergo	VERB
dti-3019	259	8	antigenic	antigenic	ADJ
dti-3019	259	9	variation	variation	NOUN
dti-3019	259	10	,	,	PUNCT
dti-3019	259	11	establish	establish	VERB
dti-3019	259	12	latent	latent	NOUN
dti-3019	259	13	or	or	CCONJ
dti-3019	259	14	chronic	chronic	ADJ
dti-3019	259	15	infections	infection	NOUN
dti-3019	259	16	,	,	PUNCT
dti-3019	259	17	and	and	CCONJ
dti-3019	259	18	form	form	VERB
dti-3019	259	19	biofilms	biofilm	NOUN
dti-3019	259	20	further	far	ADV
dti-3019	259	21	complicate	complicate	VERB
dti-3019	259	22	the	the	DET
dti-3019	259	23	development	development	NOUN
dti-3019	259	24	of	of	ADP
dti-3019	259	25	effective	effective	ADJ
dti-3019	259	26	medications	medication	NOUN
dti-3019	259	27	.	.	PUNCT
dti-3019	260	1	addressing	address	VERB
dti-3019	260	2	these	these	DET
dti-3019	260	3	challenges	challenge	NOUN
dti-3019	260	4	will	will	AUX
dti-3019	260	5	require	require	VERB
dti-3019	260	6	continued	continued	ADJ
dti-3019	260	7	research	research	NOUN
dti-3019	260	8	and	and	CCONJ
dti-3019	260	9	collaboration	collaboration	NOUN
dti-3019	260	10	to	to	PART
dti-3019	260	11	develop	develop	VERB
dti-3019	260	12	novel	novel	ADJ
dti-3019	260	13	strategies	strategy	NOUN
dti-3019	260	14	and	and	CCONJ
dti-3019	260	15	therapies	therapy	NOUN
dti-3019	260	16	to	to	AUX
dti-3019	260	17	combat	combat	VERB
dti-3019	260	18	drug	drug	NOUN
dti-3019	260	19	-	-	PUNCT
dti-3019	260	20	resistant	resistant	ADJ
dti-3019	260	21	infections	infection	NOUN
dti-3019	260	22	.	.	PUNCT
dti-3019	261	1	conclusion	conclusion	NOUN
dti-3019	261	2	drug	drug	NOUN
dti-3019	261	3	repurposing	repurposing	NOUN
dti-3019	261	4	is	be	AUX
dti-3019	261	5	a	a	DET
dti-3019	261	6	strategic	strategic	ADJ
dti-3019	261	7	initiative	initiative	NOUN
dti-3019	261	8	that	that	PRON
dti-3019	261	9	involves	involve	VERB
dti-3019	261	10	the	the	DET
dti-3019	261	11	exploration	exploration	NOUN
dti-3019	261	12	and	and	CCONJ
dti-3019	261	13	identification	identification	NOUN
dti-3019	261	14	of	of	ADP
dti-3019	261	15	fresh	fresh	ADJ
dti-3019	261	16	therapeutic	therapeutic	ADJ
dti-3019	261	17	applications	application	NOUN
dti-3019	261	18	for	for	ADP
dti-3019	261	19	pharmaceuticals	pharmaceutical	NOUN
dti-3019	261	20	that	that	PRON
dti-3019	261	21	already	already	ADV
dti-3019	261	22	exist	exist	VERB
dti-3019	261	23	in	in	ADP
dti-3019	261	24	the	the	DET
dti-3019	261	25	market	market	NOUN
dti-3019	261	26	.	.	PUNCT
dti-3019	262	1	this	this	DET
dti-3019	262	2	approach	approach	NOUN
dti-3019	262	3	has	have	AUX
dti-3019	262	4	proven	prove	VERB
dti-3019	262	5	to	to	PART
dti-3019	262	6	be	be	AUX
dti-3019	262	7	beneficial	beneficial	ADJ
dti-3019	262	8	due	due	ADP
dti-3019	262	9	to	to	ADP
dti-3019	262	10	its	its	PRON
dti-3019	262	11	costeffectiveness	costeffectiveness	NOUN
dti-3019	262	12	and	and	CCONJ
dti-3019	262	13	ability	ability	NOUN
dti-3019	262	14	to	to	PART
dti-3019	262	15	save	save	VERB
dti-3019	262	16	time	time	NOUN
dti-3019	262	17	in	in	ADP
dti-3019	262	18	the	the	DET
dti-3019	262	19	drug	drug	NOUN
dti-3019	262	20	discovery	discovery	NOUN
dti-3019	262	21	process	process	NOUN
dti-3019	262	22	.	.	PUNCT
dti-3019	263	1	however	however	ADV
dti-3019	263	2	,	,	PUNCT
dti-3019	263	3	it	it	PRON
dti-3019	263	4	is	be	AUX
dti-3019	263	5	important	important	ADJ
dti-3019	263	6	to	to	PART
dti-3019	263	7	consider	consider	VERB
dti-3019	263	8	various	various	ADJ
dti-3019	263	9	factors	factor	NOUN
dti-3019	263	10	before	before	ADP
dti-3019	263	11	fully	fully	ADV
dti-3019	263	12	embracing	embrace	VERB
dti-3019	263	13	this	this	DET
dti-3019	263	14	strategy	strategy	NOUN
dti-3019	263	15	.	.	PUNCT
dti-3019	264	1	one	one	NUM
dti-3019	264	2	such	such	ADJ
dti-3019	264	3	factor	factor	NOUN
dti-3019	264	4	is	be	AUX
dti-3019	264	5	the	the	DET
dti-3019	264	6	fact	fact	NOUN
dti-3019	264	7	that	that	SCONJ
dti-3019	264	8	numerous	numerous	ADJ
dti-3019	264	9	repurposed	repurposed	ADJ
dti-3019	264	10	drugs	drug	NOUN
dti-3019	264	11	have	have	AUX
dti-3019	264	12	failed	fail	VERB
dti-3019	264	13	to	to	PART
dti-3019	264	14	achieve	achieve	VERB
dti-3019	264	15	their	their	PRON
dti-3019	264	16	intended	intend	VERB
dti-3019	264	17	targets	target	NOUN
dti-3019	264	18	during	during	ADP
dti-3019	264	19	clinical	clinical	ADJ
dti-3019	264	20	trials	trial	NOUN
dti-3019	264	21	,	,	PUNCT
dti-3019	264	22	leading	lead	VERB
dti-3019	264	23	to	to	ADP
dti-3019	264	24	concerns	concern	NOUN
dti-3019	264	25	about	about	ADP
dti-3019	264	26	the	the	DET
dti-3019	264	27	effectiveness	effectiveness	NOUN
dti-3019	264	28	of	of	ADP
dti-3019	264	29	this	this	DET
dti-3019	264	30	approach	approach	NOUN
dti-3019	264	31	.	.	PUNCT
dti-3019	265	1	additionally	additionally	ADV
dti-3019	265	2	,	,	PUNCT
dti-3019	265	3	there	there	PRON
dti-3019	265	4	is	be	VERB
dti-3019	265	5	a	a	DET
dti-3019	265	6	growing	grow	VERB
dti-3019	265	7	apprehension	apprehension	NOUN
dti-3019	265	8	about	about	ADP
dti-3019	265	9	the	the	DET
dti-3019	265	10	potential	potential	ADJ
dti-3019	265	11	increase	increase	NOUN
dti-3019	265	12	in	in	ADP
dti-3019	265	13	the	the	DET
dti-3019	265	14	risk	risk	NOUN
dti-3019	265	15	of	of	ADP
dti-3019	265	16	multidrug	multidrug	NOUN
dti-3019	265	17	resistance	resistance	NOUN
dti-3019	265	18	,	,	PUNCT
dti-3019	265	19	which	which	PRON
dti-3019	265	20	further	far	ADV
dti-3019	265	21	emphasizes	emphasize	VERB
dti-3019	265	22	the	the	DET
dti-3019	265	23	need	need	NOUN
dti-3019	265	24	for	for	ADP
dti-3019	265	25	caution	caution	NOUN
dti-3019	265	26	when	when	SCONJ
dti-3019	265	27	repurposing	repurpose	VERB
dti-3019	265	28	drugs	drug	NOUN
dti-3019	265	29	.	.	PUNCT
dti-3019	266	1	the	the	DET
dti-3019	266	2	development	development	NOUN
dti-3019	266	3	of	of	ADP
dti-3019	266	4	repurposed	repurpose	VERB
dti-3019	266	5	medications	medication	NOUN
dti-3019	266	6	requires	require	VERB
dti-3019	266	7	a	a	DET
dti-3019	266	8	high	high	ADJ
dti-3019	266	9	level	level	NOUN
dti-3019	266	10	of	of	ADP
dti-3019	266	11	creativity	creativity	NOUN
dti-3019	266	12	and	and	CCONJ
dti-3019	266	13	innovation	innovation	NOUN
dti-3019	266	14	in	in	ADP
dti-3019	266	15	designing	design	VERB
dti-3019	266	16	the	the	DET
dti-3019	266	17	development	development	NOUN
dti-3019	266	18	program	program	NOUN
dti-3019	266	19	.	.	PUNCT
dti-3019	267	1	this	this	PRON
dti-3019	267	2	is	be	AUX
dti-3019	267	3	because	because	SCONJ
dti-3019	267	4	each	each	DET
dti-3019	267	5	case	case	NOUN
dti-3019	267	6	presents	present	VERB
dti-3019	267	7	a	a	DET
dti-3019	267	8	unique	unique	ADJ
dti-3019	267	9	set	set	NOUN
dti-3019	267	10	of	of	ADP
dti-3019	267	11	circumstances	circumstance	NOUN
dti-3019	267	12	and	and	CCONJ
dti-3019	267	13	evidence	evidence	NOUN
dti-3019	267	14	that	that	PRON
dti-3019	267	15	must	must	AUX
dti-3019	267	16	be	be	AUX
dti-3019	267	17	thoroughly	thoroughly	ADV
dti-3019	267	18	evaluated	evaluate	VERB
dti-3019	267	19	.	.	PUNCT
dti-3019	268	1	therefore	therefore	ADV
dti-3019	268	2	,	,	PUNCT
dti-3019	268	3	it	it	PRON
dti-3019	268	4	is	be	AUX
dti-3019	268	5	crucial	crucial	ADJ
dti-3019	268	6	to	to	PART
dti-3019	268	7	approach	approach	VERB
dti-3019	268	8	each	each	DET
dti-3019	268	9	drug	drug	NOUN
dti-3019	268	10	repurposing	repurpose	VERB
dti-3019	268	11	project	project	NOUN
dti-3019	268	12	with	with	ADP
dti-3019	268	13	a	a	DET
dti-3019	268	14	comprehensive	comprehensive	ADJ
dti-3019	268	15	understanding	understanding	NOUN
dti-3019	268	16	of	of	ADP
dti-3019	268	17	the	the	DET
dti-3019	268	18	ethical	ethical	ADJ
dti-3019	268	19	and	and	CCONJ
dti-3019	268	20	pharmaceutical	pharmaceutical	ADJ
dti-3019	268	21	considerations	consideration	NOUN
dti-3019	268	22	involved	involve	VERB
dti-3019	268	23	.	.	PUNCT
dti-3019	269	1	furthermore	furthermore	ADV
dti-3019	269	2	,	,	PUNCT
dti-3019	269	3	it	it	PRON
dti-3019	269	4	is	be	AUX
dti-3019	269	5	imperative	imperative	ADJ
dti-3019	269	6	that	that	SCONJ
dti-3019	269	7	repurposed	repurpose	VERB
dti-3019	269	8	drugs	drug	NOUN
dti-3019	269	9	undergo	undergo	VERB
dti-3019	269	10	rigorous	rigorous	ADJ
dti-3019	269	11	clinical	clinical	ADJ
dti-3019	269	12	trials	trial	NOUN
dti-3019	269	13	before	before	SCONJ
dti-3019	269	14	they	they	PRON
dti-3019	269	15	can	can	AUX
dti-3019	269	16	be	be	AUX
dti-3019	269	17	approved	approve	VERB
dti-3019	269	18	for	for	ADP
dti-3019	269	19	use	use	NOUN
dti-3019	269	20	.	.	PUNCT
dti-3019	270	1	this	this	PRON
dti-3019	270	2	ensures	ensure	VERB
dti-3019	270	3	that	that	SCONJ
dti-3019	270	4	the	the	DET
dti-3019	270	5	safety	safety	NOUN
dti-3019	270	6	and	and	CCONJ
dti-3019	270	7	efficacy	efficacy	NOUN
dti-3019	270	8	of	of	ADP
dti-3019	270	9	these	these	DET
dti-3019	270	10	drugs	drug	NOUN
dti-3019	270	11	are	be	AUX
dti-3019	270	12	thoroughly	thoroughly	ADV
dti-3019	270	13	evaluated	evaluate	VERB
dti-3019	270	14	,	,	PUNCT
dti-3019	270	15	and	and	CCONJ
dti-3019	270	16	any	any	DET
dti-3019	270	17	potential	potential	ADJ
dti-3019	270	18	risks	risk	NOUN
dti-3019	270	19	and	and	CCONJ
dti-3019	270	20	side	side	NOUN
dti-3019	270	21	effects	effect	NOUN
dti-3019	270	22	are	be	AUX
dti-3019	270	23	identified	identify	VERB
dti-3019	270	24	and	and	CCONJ
dti-3019	270	25	mitigated	mitigate	VERB
dti-3019	270	26	.	.	PUNCT
dti-3019	271	1	in	in	ADP
dti-3019	271	2	conclusion	conclusion	NOUN
dti-3019	271	3	,	,	PUNCT
dti-3019	271	4	the	the	DET
dti-3019	271	5	process	process	NOUN
dti-3019	271	6	of	of	ADP
dti-3019	271	7	selecting	select	VERB
dti-3019	271	8	a	a	DET
dti-3019	271	9	repurposed	repurpose	VERB
dti-3019	271	10	drug	drug	NOUN
dti-3019	271	11	should	should	AUX
dti-3019	271	12	be	be	AUX
dti-3019	271	13	guided	guide	VERB
dti-3019	271	14	by	by	ADP
dti-3019	271	15	a	a	DET
dti-3019	271	16	range	range	NOUN
dti-3019	271	17	of	of	ADP
dti-3019	271	18	ethical	ethical	ADJ
dti-3019	271	19	and	and	CCONJ
dti-3019	271	20	pharmaceutical	pharmaceutical	ADJ
dti-3019	271	21	considerations	consideration	NOUN
dti-3019	271	22	.	.	PUNCT
dti-3019	272	1	it	it	PRON
dti-3019	272	2	is	be	AUX
dti-3019	272	3	important	important	ADJ
dti-3019	272	4	to	to	PART
dti-3019	272	5	acknowledge	acknowledge	VERB
dti-3019	272	6	the	the	DET
dti-3019	272	7	limitations	limitation	NOUN
dti-3019	272	8	and	and	CCONJ
dti-3019	272	9	challenges	challenge	NOUN
dti-3019	272	10	associated	associate	VERB
dti-3019	272	11	the	the	DET
dti-3019	272	12	dark	dark	ADJ
dti-3019	272	13	side	side	NOUN
dti-3019	272	14	of	of	ADP
dti-3019	272	15	drug	drug	NOUN
dti-3019	272	16	repurposing16	repurposing16	NOUN
dti-3019	273	1	©	©	ADP
dti-3019	273	2	2024	2024	NUM
dti-3019	274	1	the	the	DET
dti-3019	274	2	authors	author	NOUN
dti-3019	274	3	.	.	PUNCT
dti-3019	275	1	drug	drug	NOUN
dti-3019	275	2	target	target	NOUN
dti-3019	275	3	insights	insight	NOUN
dti-3019	275	4	issn	issn	VERB
dti-3019	275	5	1177	1177	NUM
dti-3019	275	6	-	-	SYM
dti-3019	275	7	3928	3928	NUM
dti-3019	275	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3019	275	9	with	with	ADP
dti-3019	275	10	drug	drug	NOUN
dti-3019	275	11	repurposing	repurposing	NOUN
dti-3019	275	12	,	,	PUNCT
dti-3019	275	13	such	such	ADJ
dti-3019	275	14	as	as	ADP
dti-3019	275	15	the	the	DET
dti-3019	275	16	potential	potential	ADJ
dti-3019	275	17	failure	failure	NOUN
dti-3019	275	18	to	to	PART
dti-3019	275	19	reach	reach	VERB
dti-3019	275	20	therapeutic	therapeutic	ADJ
dti-3019	275	21	targets	target	NOUN
dti-3019	275	22	and	and	CCONJ
dti-3019	275	23	the	the	DET
dti-3019	275	24	risk	risk	NOUN
dti-3019	275	25	of	of	ADP
dti-3019	275	26	multidrug	multidrug	NOUN
dti-3019	275	27	resistance	resistance	NOUN
dti-3019	275	28	.	.	PUNCT
dti-3019	276	1	by	by	ADP
dti-3019	276	2	prioritizing	prioritize	VERB
dti-3019	276	3	the	the	DET
dti-3019	276	4	application	application	NOUN
dti-3019	276	5	of	of	ADP
dti-3019	276	6	creativity	creativity	NOUN
dti-3019	276	7	and	and	CCONJ
dti-3019	276	8	innovation	innovation	NOUN
dti-3019	276	9	in	in	ADP
dti-3019	276	10	the	the	DET
dti-3019	276	11	development	development	NOUN
dti-3019	276	12	program	program	NOUN
dti-3019	276	13	,	,	PUNCT
dti-3019	276	14	as	as	ADV
dti-3019	276	15	well	well	ADV
dti-3019	276	16	as	as	ADP
dti-3019	276	17	ensuring	ensure	VERB
dti-3019	276	18	the	the	DET
dti-3019	276	19	completion	completion	NOUN
dti-3019	276	20	of	of	ADP
dti-3019	276	21	rigorous	rigorous	ADJ
dti-3019	276	22	clinical	clinical	ADJ
dti-3019	276	23	trials	trial	NOUN
dti-3019	276	24	,	,	PUNCT
dti-3019	276	25	we	we	PRON
dti-3019	276	26	can	can	AUX
dti-3019	276	27	maximize	maximize	VERB
dti-3019	276	28	the	the	DET
dti-3019	276	29	potential	potential	ADJ
dti-3019	276	30	benefits	benefit	NOUN
dti-3019	276	31	of	of	ADP
dti-3019	276	32	repurposed	repurpose	VERB
dti-3019	276	33	drugs	drug	NOUN
dti-3019	276	34	while	while	SCONJ
dti-3019	276	35	minimizing	minimize	VERB
dti-3019	276	36	the	the	DET
dti-3019	276	37	associated	associated	ADJ
dti-3019	276	38	risks	risk	NOUN
dti-3019	276	39	.	.	PUNCT
dti-3019	277	1	disclosures	disclosure	NOUN
dti-3019	277	2	conflicts	conflict	NOUN
dti-3019	277	3	of	of	ADP
dti-3019	277	4	interest	interest	NOUN
dti-3019	277	5	:	:	PUNCT
dti-3019	277	6	the	the	DET
dti-3019	277	7	authors	author	NOUN
dti-3019	277	8	declare	declare	VERB
dti-3019	277	9	no	no	DET
dti-3019	277	10	conflict	conflict	NOUN
dti-3019	277	11	of	of	ADP
dti-3019	277	12	interest	interest	NOUN
dti-3019	277	13	.	.	PUNCT
dti-3019	278	1	funding	funding	NOUN
dti-3019	278	2	:	:	PUNCT
dti-3019	278	3	this	this	DET
dti-3019	278	4	research	research	NOUN
dti-3019	278	5	received	receive	VERB
dti-3019	278	6	no	no	DET
dti-3019	278	7	external	external	ADJ
dti-3019	278	8	funding	funding	NOUN
dti-3019	278	9	.	.	PUNCT
dti-3019	279	1	data	datum	NOUN
dti-3019	279	2	availability	availability	NOUN
dti-3019	279	3	statement	statement	NOUN
dti-3019	279	4	:	:	PUNCT
dti-3019	279	5	the	the	DET
dti-3019	279	6	data	datum	NOUN
dti-3019	279	7	presented	present	VERB
dti-3019	279	8	in	in	ADP
dti-3019	279	9	this	this	DET
dti-3019	279	10	study	study	NOUN
dti-3019	279	11	are	be	AUX
dti-3019	279	12	available	available	ADJ
dti-3019	279	13	on	on	ADP
dti-3019	279	14	request	request	NOUN
dti-3019	279	15	from	from	ADP
dti-3019	279	16	the	the	DET
dti-3019	279	17	corresponding	corresponding	ADJ
dti-3019	279	18	author	author	NOUN
dti-3019	279	19	.	.	PUNCT
dti-3019	280	1	author	author	NOUN
dti-3019	280	2	contributions	contribution	NOUN
dti-3019	280	3	:	:	PUNCT
dti-3019	280	4	conceptualization	conceptualization	NOUN
dti-3019	280	5	,	,	PUNCT
dti-3019	280	6	i.y.n	i.y.n	NOUN
dti-3019	280	7	.	.	PUNCT
dti-3019	281	1	and	and	CCONJ
dti-3019	281	2	m.m.a	m.m.a	NOUN
dti-3019	281	3	.	.	PUNCT
dti-3019	282	1	;	;	PUNCT
dti-3019	282	2	software	software	NOUN
dti-3019	282	3	,	,	PUNCT
dti-3019	282	4	d.k.a	d.k.a	PROPN
dti-3019	282	5	.	.	PUNCT
dti-3019	282	6	and	and	CCONJ
dti-3019	282	7	m.m.d	m.m.d	PROPN
dti-3019	282	8	.	.	PROPN
dti-3019	282	9	;	;	PUNCT
dti-3019	282	10	validation	validation	NOUN
dti-3019	282	11	,	,	PUNCT
dti-3019	282	12	i.y.n	i.y.n	NOUN
dti-3019	282	13	.	.	PUNCT
dti-3019	283	1	and	and	CCONJ
dti-3019	283	2	a.k.a	a.k.a	INTJ
dti-3019	283	3	.	.	PROPN
dti-3019	283	4	;	;	PUNCT
dti-3019	283	5	formal	formal	ADJ
dti-3019	283	6	analysis	analysis	NOUN
dti-3019	283	7	,	,	PUNCT
dti-3019	283	8	d.k.a	d.k.a	PROPN
dti-3019	283	9	.	.	PUNCT
dti-3019	283	10	and	and	CCONJ
dti-3019	283	11	m.m.a	m.m.a	NOUN
dti-3019	283	12	.	.	PUNCT
dti-3019	283	13	;	;	PUNCT
dti-3019	283	14	investigation	investigation	NOUN
dti-3019	283	15	,	,	PUNCT
dti-3019	283	16	a.k.a	a.k.a	INTJ
dti-3019	283	17	.	.	PROPN
dti-3019	283	18	and	and	CCONJ
dti-3019	283	19	m.m.d	m.m.d	PROPN
dti-3019	283	20	.	.	PROPN
dti-3019	283	21	;	;	PUNCT
dti-3019	283	22	resources	resource	NOUN
dti-3019	283	23	,	,	PUNCT
dti-3019	283	24	i.y.n	i.y.n	NOUN
dti-3019	283	25	.	.	PUNCT
dti-3019	283	26	,	,	PUNCT
dti-3019	283	27	m.m.d	m.m.d	PROPN
dti-3019	283	28	.	.	PROPN
dti-3019	283	29	,	,	PUNCT
dti-3019	283	30	mj.a.s	mj.a.s	PROPN
dti-3019	283	31	.	.	PROPN
dti-3019	283	32	,	,	PUNCT
dti-3019	283	33	and	and	CCONJ
dti-3019	283	34	a.k.a	a.k.a	INTJ
dti-3019	283	35	.	.	PROPN
dti-3019	283	36	;	;	PUNCT
dti-3019	283	37	data	datum	NOUN
dti-3019	283	38	curation	curation	NOUN
dti-3019	283	39	,	,	PUNCT
dti-3019	283	40	d.k.a	d.k.a	PROPN
dti-3019	283	41	.	.	PUNCT
dti-3019	283	42	and	and	CCONJ
dti-3019	283	43	m.m.a	m.m.a	NOUN
dti-3019	283	44	.	.	PUNCT
dti-3019	283	45	;	;	PUNCT
dti-3019	283	46	writing	writing	NOUN
dti-3019	283	47	—	—	PUNCT
dti-3019	283	48	original	original	ADJ
dti-3019	283	49	draft	draft	NOUN
dti-3019	283	50	preparation	preparation	NOUN
dti-3019	283	51	,	,	PUNCT
dti-3019	283	52	m.m.a	m.m.a	NOUN
dti-3019	283	53	.	.	PUNCT
dti-3019	283	54	and	and	CCONJ
dti-3019	283	55	i.y.n	i.y.n	PROPN
dti-3019	283	56	.	.	PUNCT
dti-3019	284	1	;	;	PUNCT
dti-3019	284	2	writing	writing	NOUN
dti-3019	284	3	—	—	PUNCT
dti-3019	284	4	review	review	NOUN
dti-3019	284	5	and	and	CCONJ
dti-3019	284	6	editing	editing	NOUN
dti-3019	284	7	,	,	PUNCT
dti-3019	284	8	m.m.a	m.m.a	NOUN
dti-3019	284	9	.	.	PUNCT
dti-3019	284	10	,	,	PUNCT
dti-3019	284	11	mj.a.s	mj.a.s	PROPN
dti-3019	284	12	.	.	PROPN
dti-3019	284	13	,	,	PUNCT
dti-3019	284	14	and	and	CCONJ
dti-3019	284	15	d.k.a	d.k.a	PROPN
dti-3019	284	16	.	.	PROPN
dti-3019	284	17	;	;	PUNCT
dti-3019	284	18	visualization	visualization	NOUN
dti-3019	284	19	,	,	PUNCT
dti-3019	284	20	i.y.n	i.y.n	NOUN
dti-3019	284	21	.	.	PUNCT
dti-3019	284	22	,	,	PUNCT
dti-3019	284	23	mj.a.s	mj.a.s	PROPN
dti-3019	284	24	.	.	PROPN
dti-3019	284	25	,	,	PUNCT
dti-3019	284	26	and	and	CCONJ
dti-3019	284	27	a.k.a	a.k.a	INTJ
dti-3019	284	28	.	.	PROPN
dti-3019	284	29	;	;	PUNCT
dti-3019	284	30	supervision	supervision	NOUN
dti-3019	284	31	,	,	PUNCT
dti-3019	284	32	m.m.a	m.m.a	NOUN
dti-3019	284	33	.	.	PUNCT
dti-3019	284	34	and	and	CCONJ
dti-3019	284	35	i.y.n	i.y.n	NOUN
dti-3019	284	36	.	.	PUNCT
dti-3019	284	37	;	;	PUNCT
dti-3019	284	38	project	project	NOUN
dti-3019	284	39	administration	administration	NOUN
dti-3019	284	40	,	,	PUNCT
dti-3019	284	41	i.y.n	i.y.n	NOUN
dti-3019	284	42	.	.	PUNCT
dti-3019	285	1	all	all	DET
dti-3019	285	2	authors	author	NOUN
dti-3019	285	3	have	have	AUX
dti-3019	285	4	read	read	VERB
dti-3019	285	5	and	and	CCONJ
dti-3019	285	6	agreed	agree	VERB
dti-3019	285	7	to	to	ADP
dti-3019	285	8	the	the	DET
dti-3019	285	9	published	publish	VERB
dti-3019	285	10	version	version	NOUN
dti-3019	285	11	of	of	ADP
dti-3019	285	12	the	the	DET
dti-3019	285	13	manuscript	manuscript	NOUN
dti-3019	285	14	.	.	PUNCT
dti-3019	286	1	references	reference	NOUN
dti-3019	286	2	1	1	NUM
dti-3019	286	3	.	.	PUNCT
dti-3019	286	4	agnihotri	agnihotri	PROPN
dti-3019	286	5	jaya	jaya	PROPN
dti-3019	286	6	,	,	PUNCT
dti-3019	286	7	r	r	NOUN
dti-3019	286	8	sunanda	sunanda	NOUN
dti-3019	286	9	,	,	PUNCT
dti-3019	286	10	patil	patil	PROPN
dti-3019	286	11	et	et	PROPN
dti-3019	286	12	al	al	PROPN
dti-3019	286	13	.	.	PUNCT
dti-3019	287	1	“	"	PUNCT
dti-3019	287	2	drug	drug	NOUN
dti-3019	287	3	repurposing	repurposing	NOUN
dti-3019	287	4	:	:	PUNCT
dti-3019	287	5	a	a	DET
dti-3019	287	6	futuristic	futuristic	ADJ
dti-3019	287	7	approach	approach	NOUN
dti-3019	287	8	in	in	ADP
dti-3019	287	9	drug	drug	NOUN
dti-3019	287	10	discovery	discovery	NOUN
dti-3019	287	11	”	"	PUNCT
dti-3019	287	12	.	.	PUNCT
dti-3019	288	1	journal	journal	PROPN
dti-3019	288	2	of	of	ADP
dti-3019	288	3	pharmaceutical	pharmaceutical	NOUN
dti-3019	288	4	and	and	CCONJ
dti-3019	288	5	biological	biological	ADJ
dti-3019	288	6	sciences	science	NOUN
dti-3019	288	7	,	,	PUNCT
dti-3019	288	8	vol	vol	NOUN
dti-3019	288	9	.	.	PROPN
dti-3019	288	10	11	11	NUM
dti-3019	288	11	,	,	PUNCT
dti-3019	288	12	no	no	INTJ
dti-3019	288	13	.	.	NOUN
dti-3019	288	14	1	1	NUM
dti-3019	288	15	,	,	PUNCT
dti-3019	288	16	66	66	NUM
dti-3019	288	17	-	-	SYM
dti-3019	288	18	69	69	NUM
dti-3019	288	19	,	,	PUNCT
dti-3019	288	20	2023	2023	NUM
dti-3019	288	21	.	.	X
dti-3019	289	1	2	2	NUM
dti-3019	289	2	.	.	X
dti-3019	289	3	hyeong	hyeong	PROPN
dti-3019	289	4	-	-	PUNCT
dti-3019	289	5	min	min	PROPN
dti-3019	289	6	l	l	PROPN
dti-3019	289	7	,	,	PUNCT
dti-3019	289	8	yuna	yuna	PROPN
dti-3019	289	9	k.	k.	PROPN
dti-3019	289	10	drug	drug	PROPN
dti-3019	289	11	repurposing	repurposing	NOUN
dti-3019	289	12	is	be	AUX
dti-3019	289	13	a	a	DET
dti-3019	289	14	new	new	ADJ
dti-3019	289	15	opportunity	opportunity	NOUN
dti-3019	289	16	for	for	ADP
dti-3019	289	17	developing	develop	VERB
dti-3019	289	18	drugs	drug	NOUN
dti-3019	289	19	against	against	ADP
dti-3019	289	20	neuropsychiatric	neuropsychiatric	ADJ
dti-3019	289	21	disorders	disorder	NOUN
dti-3019	289	22	.	.	PUNCT
dti-3019	290	1	schizophr	schizophr	PROPN
dti-3019	290	2	res	re	NOUN
dti-3019	290	3	treatment	treatment	NOUN
dti-3019	290	4	.	.	PUNCT
dti-3019	291	1	2016;2016:6378137	2016;2016:6378137	NUM
dti-3019	291	2	.	.	PUNCT
dti-3019	292	1	3	3	X
dti-3019	292	2	.	.	X
dti-3019	292	3	meera	meera	PROPN
dti-3019	292	4	m	m	PROPN
dti-3019	292	5	,	,	PUNCT
dti-3019	292	6	sekar	sekar	PROPN
dti-3019	292	7	s	s	PROPN
dti-3019	292	8	,	,	PUNCT
dti-3019	292	9	mahatao	mahatao	PROPN
dti-3019	292	10	r.	r.	PROPN
dti-3019	292	11	a	a	DET
dti-3019	292	12	novel	novel	ADJ
dti-3019	292	13	approach	approach	NOUN
dti-3019	292	14	for	for	ADP
dti-3019	292	15	drug	drug	NOUN
dti-3019	292	16	discovery	discovery	NOUN
dti-3019	292	17	-	-	PUNCT
dti-3019	292	18	drug	drug	NOUN
dti-3019	292	19	repurposing	repurposing	NOUN
dti-3019	292	20	.	.	PUNCT
dti-3019	293	1	natl	natl	PROPN
dti-3019	293	2	j	j	PROPN
dti-3019	293	3	physiol	physiol	PROPN
dti-3019	293	4	pharm	pharm	PROPN
dti-3019	293	5	pharmacol	pharmacol	PROPN
dti-3019	293	6	.	.	PUNCT
dti-3019	294	1	2022;12(5):546	2022;12(5):546	NUM
dti-3019	294	2	-	-	SYM
dti-3019	294	3	551	551	NUM
dti-3019	294	4	.	.	NOUN
dti-3019	295	1	4	4	X
dti-3019	295	2	.	.	X
dti-3019	295	3	iacopetta	iacopetta	PROPN
dti-3019	295	4	d.	d.	PROPN
dti-3019	295	5	special	special	PROPN
dti-3019	295	6	issue	issue	NOUN
dti-3019	295	7	on	on	ADP
dti-3019	295	8	“	"	PUNCT
dti-3019	295	9	anticancer	anticancer	NOUN
dti-3019	295	10	drugs	drug	NOUN
dti-3019	295	11	activity	activity	NOUN
dti-3019	295	12	and	and	CCONJ
dti-3019	295	13	underlying	underlying	ADJ
dti-3019	295	14	mechanisms	mechanism	NOUN
dti-3019	295	15	”	"	PUNCT
dti-3019	295	16	.	.	PUNCT
dti-3019	296	1	appl	appl	PROPN
dti-3019	296	2	sci	sci	PROPN
dti-3019	296	3	(	(	PUNCT
dti-3019	296	4	basel	basel	PROPN
dti-3019	296	5	)	)	PUNCT
dti-3019	296	6	.	.	PUNCT
dti-3019	297	1	2021;11(17):8169	2021;11(17):8169	X
dti-3019	297	2	.	.	PUNCT
dti-3019	297	3	crossref	crossref	PROPN
dti-3019	297	4	5	5	NUM
dti-3019	297	5	.	.	PUNCT
dti-3019	298	1	pardo	pardo	PROPN
dti-3019	298	2	-	-	PUNCT
dti-3019	298	3	yules	yules	PROPN
dti-3019	298	4	b	b	NOUN
dti-3019	298	5	,	,	PUNCT
dti-3019	298	6	gallego	gallego	NOUN
dti-3019	298	7	-	-	PUNCT
dti-3019	298	8	durán	durán	NOUN
dti-3019	298	9	r	r	NOUN
dti-3019	298	10	,	,	PUNCT
dti-3019	298	11	eslam	eslam	PROPN
dti-3019	298	12	m	m	PROPN
dti-3019	298	13	,	,	PUNCT
dti-3019	298	14	et	et	PROPN
dti-3019	298	15	al	al	PROPN
dti-3019	298	16	.	.	PUNCT
dti-3019	298	17	thalidomide	thalidomide	VERB
dti-3019	298	18	with	with	ADP
dti-3019	298	19	peginterferon	peginterferon	NOUN
dti-3019	298	20	alfa-2b	alfa-2b	PRON
dti-3019	298	21	and	and	CCONJ
dti-3019	298	22	ribavirin	ribavirin	NOUN
dti-3019	298	23	in	in	ADP
dti-3019	298	24	the	the	DET
dti-3019	298	25	treatment	treatment	NOUN
dti-3019	298	26	of	of	ADP
dti-3019	298	27	non	non	NOUN
dti-3019	298	28	-	-	NOUN
dti-3019	298	29	responders	responder	NOUN
dti-3019	298	30	genotype	genotype	NOUN
dti-3019	298	31	1	1	NUM
dti-3019	298	32	chronic	chronic	ADJ
dti-3019	298	33	hepatitis	hepatitis	NOUN
dti-3019	298	34	c	c	NOUN
dti-3019	298	35	patients	patient	NOUN
dti-3019	298	36	:	:	PUNCT
dti-3019	298	37	proof	proof	NOUN
dti-3019	298	38	of	of	ADP
dti-3019	298	39	concept	concept	NOUN
dti-3019	298	40	.	.	PUNCT
dti-3019	299	1	rev	rev	PROPN
dti-3019	299	2	esp	esp	ADJ
dti-3019	299	3	enferm	enferm	NOUN
dti-3019	299	4	dig	dig	NOUN
dti-3019	299	5	.	.	PUNCT
dti-3019	300	1	2011;103(12):619	2011;103(12):619	NUM
dti-3019	300	2	-	-	SYM
dti-3019	300	3	625	625	NUM
dti-3019	300	4	.	.	PUNCT
dti-3019	301	1	crossref	crossref	PROPN
dti-3019	301	2	pubmed	pubmed	PROPN
dti-3019	301	3	6	6	NUM
dti-3019	301	4	.	.	PUNCT
dti-3019	302	1	jesus	jesus	PROPN
dti-3019	302	2	sm	sm	PROPN
dti-3019	302	3	,	,	PUNCT
dti-3019	302	4	santana	santana	PROPN
dti-3019	302	5	rs	rs	PROPN
dti-3019	302	6	,	,	PUNCT
dti-3019	302	7	leite	leite	PROPN
dti-3019	302	8	sn	sn	PROPN
dti-3019	302	9	.	.	PUNCT
dti-3019	303	1	the	the	DET
dti-3019	303	2	organization	organization	NOUN
dti-3019	303	3	,	,	PUNCT
dti-3019	303	4	weaknesses	weakness	NOUN
dti-3019	303	5	,	,	PUNCT
dti-3019	303	6	and	and	CCONJ
dti-3019	303	7	challenges	challenge	NOUN
dti-3019	303	8	of	of	ADP
dti-3019	303	9	the	the	DET
dti-3019	303	10	control	control	NOUN
dti-3019	303	11	of	of	ADP
dti-3019	303	12	thalidomide	thalidomide	NOUN
dti-3019	303	13	in	in	ADP
dti-3019	303	14	brazil	brazil	PROPN
dti-3019	303	15	:	:	PUNCT
dti-3019	303	16	a	a	DET
dti-3019	303	17	review	review	NOUN
dti-3019	303	18	.	.	PUNCT
dti-3019	304	1	plos	plos	PROPN
dti-3019	304	2	negl	negl	PROPN
dti-3019	304	3	trop	trop	X
dti-3019	304	4	dis	dis	PROPN
dti-3019	304	5	.	.	PUNCT
dti-3019	305	1	2020;14(8):e0008329	2020;14(8):e0008329	NUM
dti-3019	305	2	.	.	PUNCT
dti-3019	306	1	crossref	crossref	PROPN
dti-3019	306	2	pubmed	pubmed	PROPN
dti-3019	306	3	7	7	PROPN
dti-3019	306	4	.	.	PUNCT
dti-3019	307	1	duarte	duarte	PROPN
dti-3019	307	2	d	d	PROPN
dti-3019	307	3	,	,	PUNCT
dti-3019	307	4	vale	vale	ADJ
dti-3019	307	5	n.	n.	PROPN
dti-3019	307	6	antidepressant	antidepressant	ADJ
dti-3019	307	7	drug	drug	NOUN
dti-3019	307	8	sertraline	sertraline	NOUN
dti-3019	307	9	against	against	ADP
dti-3019	307	10	human	human	ADJ
dti-3019	307	11	cancer	cancer	NOUN
dti-3019	307	12	cells	cell	NOUN
dti-3019	307	13	.	.	PUNCT
dti-3019	308	1	biomolecules	biomolecule	NOUN
dti-3019	308	2	.	.	PUNCT
dti-3019	309	1	2022;12(10):1513	2022;12(10):1513	X
dti-3019	309	2	.	.	PUNCT
dti-3019	310	1	crossref	crossref	PROPN
dti-3019	310	2	pubmed	pubmed	PROPN
dti-3019	310	3	8	8	PROPN
dti-3019	310	4	.	.	PUNCT
dti-3019	311	1	rehan	rehan	PROPN
dti-3019	311	2	m	m	PROPN
dti-3019	311	3	,	,	PUNCT
dti-3019	311	4	ahmed	ahmed	PROPN
dti-3019	311	5	f	f	PROPN
dti-3019	311	6	,	,	PUNCT
dti-3019	311	7	howladar	howladar	PROPN
dti-3019	311	8	sm	sm	PROPN
dti-3019	311	9	,	,	PUNCT
dti-3019	311	10	et	et	PROPN
dti-3019	311	11	al	al	PROPN
dti-3019	311	12	.	.	PUNCT
dti-3019	312	1	a	a	DET
dti-3019	312	2	computational	computational	ADJ
dti-3019	312	3	approach	approach	NOUN
dti-3019	312	4	identified	identify	VERB
dti-3019	312	5	andrographolide	andrographolide	ADV
dti-3019	312	6	as	as	ADP
dti-3019	312	7	a	a	DET
dti-3019	312	8	potential	potential	ADJ
dti-3019	312	9	drug	drug	NOUN
dti-3019	312	10	for	for	ADP
dti-3019	312	11	suppressing	suppress	VERB
dti-3019	312	12	covid-19	covid-19	PROPN
dti-3019	312	13	-	-	PUNCT
dti-3019	312	14	induced	induce	VERB
dti-3019	312	15	cytokine	cytokine	NOUN
dti-3019	312	16	storm	storm	NOUN
dti-3019	312	17	.	.	PUNCT
dti-3019	313	1	front	front	ADJ
dti-3019	313	2	immunol	immunol	NOUN
dti-3019	313	3	.	.	PUNCT
dti-3019	314	1	2021;12:648250	2021;12:648250	NUM
dti-3019	314	2	.	.	NOUN
dti-3019	314	3	9	9	NUM
dti-3019	314	4	.	.	X
dti-3019	315	1	talib	talib	PROPN
dti-3019	315	2	jawad	jawad	PROPN
dti-3019	315	3	kadhim	kadhim	PROPN
dti-3019	315	4	,	,	PUNCT
dti-3019	315	5	omer	omer	PROPN
dti-3019	315	6	abd	abd	PROPN
dti-3019	315	7	alkareem	alkareem	PROPN
dti-3019	315	8	khalf	khalf	PROPN
dti-3019	315	9	.	.	PUNCT
dti-3019	316	1	a	a	DET
dti-3019	316	2	review	review	NOUN
dti-3019	316	3	search	search	NOUN
dti-3019	316	4	of	of	ADP
dti-3019	316	5	sildenafil	sildenafil	NOUN
dti-3019	316	6	uses	use	NOUN
dti-3019	316	7	in	in	ADP
dti-3019	316	8	human	human	NOUN
dti-3019	316	9	and	and	CCONJ
dti-3019	316	10	in	in	ADP
dti-3019	316	11	the	the	DET
dti-3019	316	12	veterinary	veterinary	ADJ
dti-3019	316	13	medicine	medicine	NOUN
dti-3019	316	14	.	.	PUNCT
dti-3019	317	1	aip	aip	PROPN
dti-3019	317	2	conf	conf	PROPN
dti-3019	317	3	proc	proc	NOUN
dti-3019	317	4	.	.	PUNCT
dti-3019	318	1	2023;2475:100010	2023;2475:100010	NUM
dti-3019	318	2	.	.	PUNCT
dti-3019	319	1	10	10	NUM
dti-3019	319	2	.	.	PUNCT
dti-3019	320	1	al	al	PROPN
dti-3019	320	2	ibrahim	ibrahim	PROPN
dti-3019	320	3	ah	ah	INTJ
dti-3019	320	4	,	,	PUNCT
dti-3019	320	5	ghallab	ghallab	PROPN
dti-3019	320	6	kq	kq	PROPN
dti-3019	320	7	,	,	PUNCT
dti-3019	320	8	alhumaid	alhumaid	VERB
dti-3019	320	9	fi	fi	NOUN
dti-3019	320	10	,	,	PUNCT
dti-3019	320	11	et	et	PROPN
dti-3019	320	12	al	al	PROPN
dti-3019	320	13	.	.	PUNCT
dti-3019	321	1	a	a	DET
dti-3019	321	2	systematic	systematic	ADJ
dti-3019	321	3	review	review	NOUN
dti-3019	321	4	of	of	ADP
dti-3019	321	5	sildenafil	sildenafil	NOUN
dti-3019	321	6	mortality	mortality	NOUN
dti-3019	321	7	through	through	ADP
dti-3019	321	8	the	the	DET
dti-3019	321	9	years	year	NOUN
dti-3019	321	10	.	.	PUNCT
dti-3019	322	1	cureus	cureus	NOUN
dti-3019	322	2	.	.	PUNCT
dti-3019	323	1	2022;14(12):e32179	2022;14(12):e32179	NOUN
dti-3019	323	2	.	.	PUNCT
dti-3019	324	1	11	11	NUM
dti-3019	324	2	.	.	PUNCT
dti-3019	325	1	hussein	hussein	PROPN
dti-3019	325	2	ma	ma	PROPN
dti-3019	325	3	,	,	PUNCT
dti-3019	325	4	salah	salah	PROPN
dti-3019	325	5	el	el	PROPN
dti-3019	325	6	-	-	PROPN
dti-3019	325	7	din	din	PROPN
dti-3019	325	8	mm	mm	PROPN
dti-3019	325	9	,	,	PUNCT
dti-3019	325	10	saleh	saleh	VERB
dti-3019	325	11	em	em	PRON
dti-3019	325	12	,	,	PUNCT
dti-3019	325	13	et	et	PROPN
dti-3019	325	14	al	al	PROPN
dti-3019	325	15	.	.	PUNCT
dti-3019	325	16	sildenafil	sildenafil	PROPN
dti-3019	325	17	(	(	PUNCT
dti-3019	325	18	viagratm	viagratm	ADJ
dti-3019	325	19	):	):	PUNCT
dti-3019	325	20	a	a	DET
dti-3019	325	21	promising	promising	ADJ
dti-3019	325	22	anticancer	anticancer	NOUN
dti-3019	325	23	drug	drug	NOUN
dti-3019	325	24	against	against	ADP
dti-3019	325	25	certain	certain	ADJ
dti-3019	325	26	human	human	ADJ
dti-3019	325	27	cancer	cancer	NOUN
dti-3019	325	28	cell	cell	NOUN
dti-3019	325	29	lines	line	NOUN
dti-3019	325	30	.	.	PUNCT
dti-3019	326	1	asian	asian	PROPN
dti-3019	326	2	j	j	PROPN
dti-3019	326	3	chem	chem	NOUN
dti-3019	326	4	.	.	PUNCT
dti-3019	327	1	2021;33(6):1420	2021;33(6):1420	NUM
dti-3019	327	2	-	-	SYM
dti-3019	327	3	1424	1424	NUM
dti-3019	327	4	.	.	PUNCT
dti-3019	328	1	crossref	crossref	PROPN
dti-3019	328	2	12	12	NUM
dti-3019	328	3	.	.	PUNCT
dti-3019	329	1	goldstein	goldstein	PROPN
dti-3019	329	2	i	i	PROPN
dti-3019	329	3	,	,	PUNCT
dti-3019	329	4	burnett	burnett	PROPN
dti-3019	329	5	al	al	PROPN
dti-3019	329	6	,	,	PUNCT
dti-3019	329	7	rosen	rosen	PROPN
dti-3019	329	8	rc	rc	PROPN
dti-3019	329	9	,	,	PUNCT
dti-3019	329	10	et	et	PROPN
dti-3019	329	11	al	al	PROPN
dti-3019	329	12	.	.	PUNCT
dti-3019	330	1	the	the	DET
dti-3019	330	2	serendipitous	serendipitous	ADJ
dti-3019	330	3	story	story	NOUN
dti-3019	330	4	of	of	ADP
dti-3019	330	5	sildenafil	sildenafil	NOUN
dti-3019	330	6	:	:	PUNCT
dti-3019	330	7	an	an	DET
dti-3019	330	8	unexpected	unexpected	ADJ
dti-3019	330	9	oral	oral	ADJ
dti-3019	330	10	therapy	therapy	NOUN
dti-3019	330	11	for	for	ADP
dti-3019	330	12	erectile	erectile	ADJ
dti-3019	330	13	dysfunction	dysfunction	NOUN
dti-3019	330	14	.	.	PUNCT
dti-3019	331	1	sex	sex	NOUN
dti-3019	331	2	med	med	PROPN
dti-3019	331	3	rev	rev	PROPN
dti-3019	331	4	.	.	PROPN
dti-3019	331	5	2019;7(1):115	2019;7(1):115	PROPN
dti-3019	331	6	-	-	SYM
dti-3019	331	7	128	128	NUM
dti-3019	331	8	.	.	PUNCT
dti-3019	332	1	crossref	crossref	PROPN
dti-3019	332	2	pubmed	pubmed	PROPN
dti-3019	332	3	13	13	NUM
dti-3019	332	4	.	.	PUNCT
dti-3019	333	1	ala	ala	PROPN
dti-3019	333	2	m	m	PROPN
dti-3019	333	3	,	,	PUNCT
dti-3019	333	4	jafari	jafari	PROPN
dti-3019	333	5	rm	rm	PROPN
dti-3019	333	6	,	,	PUNCT
dti-3019	333	7	dehpour	dehpour	PROPN
dti-3019	333	8	ar	ar	PROPN
dti-3019	333	9	.	.	PROPN
dti-3019	333	10	sildenafil	sildenafil	PROPN
dti-3019	333	11	beyond	beyond	ADP
dti-3019	333	12	erectile	erectile	ADJ
dti-3019	333	13	dysfunction	dysfunction	NOUN
dti-3019	333	14	and	and	CCONJ
dti-3019	333	15	pulmonary	pulmonary	ADJ
dti-3019	333	16	arterial	arterial	ADJ
dti-3019	333	17	hypertension	hypertension	NOUN
dti-3019	333	18	:	:	PUNCT
dti-3019	333	19	thinking	think	VERB
dti-3019	333	20	about	about	ADP
dti-3019	333	21	new	new	ADJ
dti-3019	333	22	indications	indication	NOUN
dti-3019	333	23	.	.	PUNCT
dti-3019	334	1	fundam	fundam	PROPN
dti-3019	334	2	clin	clin	PROPN
dti-3019	334	3	pharmacol	pharmacol	PROPN
dti-3019	334	4	.	.	PUNCT
dti-3019	335	1	2021;35(2	2021;35(2	NUM
dti-3019	335	2	):	):	PUNCT
dti-3019	335	3	235	235	NUM
dti-3019	335	4	-	-	SYM
dti-3019	335	5	259	259	NUM
dti-3019	335	6	.	.	PUNCT
dti-3019	336	1	14	14	NUM
dti-3019	336	2	.	.	PUNCT
dti-3019	337	1	mpoeo	mpoeo	NOUN
dti-3019	337	2	,	,	PUNCT
dti-3019	337	3	a	a	DET
dti-3019	337	4	baa	baa	PROPN
dti-3019	337	5	,	,	PUNCT
dti-3019	337	6	ky	ky	PROPN
dti-3019	337	7	.	.	PROPN
dti-3019	338	1	hooe	hooe	PROPN
dti-3019	338	2	peaaee	peaaee	PROPN
dti-3019	338	3	capx	capx	PROPN
dti-3019	338	4	eapc	eapc	INTJ
dti-3019	338	5	(	(	PUNCT
dti-3019	338	6	oop	oop	NOUN
dti-3019	338	7	)	)	PUNCT
dti-3019	338	8	.	.	PUNCT
dti-3019	339	1	apaoa	apaoa	PROPN
dti-3019	339	2	pecpa	pecpa	VERB
dti-3019	339	3	eapcex	eapcex	ADJ
dti-3019	339	4	cpec	cpec	PROPN
dti-3019	339	5	,	,	PUNCT
dti-3019	339	6	2023;12(1):182	2023;12(1):182	PROPN
dti-3019	339	7	-	-	SYM
dti-3019	339	8	190	190	NUM
dti-3019	339	9	.	.	PUNCT
dti-3019	340	1	crossref	crossref	PROPN
dti-3019	340	2	15	15	NUM
dti-3019	340	3	.	.	PUNCT
dti-3019	341	1	krishnamurthy	krishnamurthy	PROPN
dti-3019	341	2	n	n	CCONJ
dti-3019	341	3	,	,	PUNCT
dti-3019	341	4	grimshaw	grimshaw	PROPN
dti-3019	341	5	aa	aa	PROPN
dti-3019	341	6	,	,	PUNCT
dti-3019	341	7	axson	axson	PROPN
dti-3019	341	8	sa	sa	PROPN
dti-3019	341	9	,	,	PUNCT
dti-3019	341	10	choe	choe	PROPN
dti-3019	341	11	sh	sh	PROPN
dti-3019	341	12	,	,	PUNCT
dti-3019	341	13	miller	miller	PROPN
dti-3019	341	14	je	je	PROPN
dti-3019	341	15	.	.	PROPN
dti-3019	341	16	drug	drug	NOUN
dti-3019	341	17	repurposing	repurposing	NOUN
dti-3019	341	18	:	:	PUNCT
dti-3019	341	19	a	a	DET
dti-3019	341	20	systematic	systematic	ADJ
dti-3019	341	21	review	review	NOUN
dti-3019	341	22	on	on	ADP
dti-3019	341	23	root	root	NOUN
dti-3019	341	24	causes	cause	NOUN
dti-3019	341	25	,	,	PUNCT
dti-3019	341	26	barriers	barrier	NOUN
dti-3019	341	27	and	and	CCONJ
dti-3019	341	28	facilitators	facilitator	NOUN
dti-3019	341	29	.	.	PUNCT
dti-3019	342	1	bmc	bmc	PROPN
dti-3019	342	2	health	health	PROPN
dti-3019	342	3	serv	serv	PROPN
dti-3019	342	4	res	res	PROPN
dti-3019	342	5	.	.	PUNCT
dti-3019	343	1	2022;22(1):1	2022;22(1):1	NUM
dti-3019	343	2	-	-	SYM
dti-3019	343	3	17	17	NUM
dti-3019	343	4	.	.	PUNCT
dti-3019	344	1	crossref	crossref	PROPN
dti-3019	344	2	pubmed	pubmed	PROPN
dti-3019	344	3	16	16	NUM
dti-3019	344	4	.	.	PUNCT
dti-3019	345	1	trivedi	trivedi	PROPN
dti-3019	345	2	j	j	PROPN
dti-3019	345	3	,	,	PUNCT
dti-3019	345	4	mohan	mohan	PROPN
dti-3019	345	5	m	m	PROPN
dti-3019	345	6	,	,	PUNCT
dti-3019	345	7	byrareddy	byrareddy	PROPN
dti-3019	345	8	sn	sn	PROPN
dti-3019	345	9	.	.	PUNCT
dti-3019	346	1	drug	drug	NOUN
dti-3019	346	2	repurposing	repurposing	NOUN
dti-3019	346	3	approaches	approach	NOUN
dti-3019	346	4	to	to	ADP
dti-3019	346	5	combating	combat	VERB
dti-3019	346	6	viral	viral	ADJ
dti-3019	346	7	infections	infection	NOUN
dti-3019	346	8	.	.	PUNCT
dti-3019	347	1	j	j	PROPN
dti-3019	347	2	clin	clin	PROPN
dti-3019	347	3	med	me	VERB
dti-3019	347	4	.	.	PUNCT
dti-3019	348	1	2020;9(11):3777	2020;9(11):3777	PROPN
dti-3019	348	2	.	.	PUNCT
dti-3019	349	1	crossref	crossref	PROPN
dti-3019	349	2	pubmed	pubmed	PROPN
dti-3019	349	3	17	17	NUM
dti-3019	349	4	.	.	PUNCT
dti-3019	350	1	ekeomodi	ekeomodi	PROPN
dti-3019	350	2	cc	cc	PROPN
dti-3019	350	3	,	,	PUNCT
dti-3019	350	4	obetta	obetta	PROPN
dti-3019	350	5	ki	ki	PROPN
dti-3019	350	6	,	,	PUNCT
dti-3019	350	7	okolocha	okolocha	ADJ
dti-3019	350	8	ml	ml	PROPN
dti-3019	350	9	,	,	PUNCT
dti-3019	350	10	et	et	PROPN
dti-3019	350	11	al	al	PROPN
dti-3019	350	12	.	.	PUNCT
dti-3019	351	1	computational	computational	ADJ
dti-3019	351	2	approaches	approach	NOUN
dti-3019	351	3	in	in	ADP
dti-3019	351	4	drug	drug	NOUN
dti-3019	351	5	repurposing	repurposing	NOUN
dti-3019	351	6	.	.	PUNCT
dti-3019	352	1	in	in	ADP
dti-3019	352	2	rudrapal	rudrapal	PROPN
dti-3019	352	3	m	m	PROPN
dti-3019	352	4	,	,	PUNCT
dti-3019	352	5	editor	editor	NOUN
dti-3019	352	6	,	,	PUNCT
dti-3019	352	7	drug	drug	NOUN
dti-3019	352	8	repurposing	repurposing	NOUN
dti-3019	352	9	–	–	PUNCT
dti-3019	352	10	advances	advance	NOUN
dti-3019	352	11	,	,	PUNCT
dti-3019	352	12	scopes	scope	NOUN
dti-3019	352	13	and	and	CCONJ
dti-3019	352	14	opportunities	opportunity	NOUN
dti-3019	352	15	in	in	ADP
dti-3019	352	16	drug	drug	NOUN
dti-3019	352	17	discovery	discovery	NOUN
dti-3019	352	18	.	.	PUNCT
dti-3019	353	1	intechopen	intechopen	ADJ
dti-3019	353	2	;	;	PUNCT
dti-3019	353	3	2023	2023	NUM
dti-3019	353	4	.	.	X
dti-3019	354	1	18	18	NUM
dti-3019	354	2	.	.	NUM
dti-3019	354	3	tuerkova	tuerkova	VERB
dti-3019	354	4	a	a	PRON
dti-3019	354	5	,	,	PUNCT
dti-3019	354	6	zdrazil	zdrazil	PROPN
dti-3019	354	7	b.	b.	PROPN
dti-3019	354	8	a	a	DET
dti-3019	354	9	ligand	ligand	NOUN
dti-3019	354	10	-	-	PUNCT
dti-3019	354	11	based	base	VERB
dti-3019	354	12	computational	computational	ADJ
dti-3019	354	13	drug	drug	NOUN
dti-3019	354	14	repurposing	repurpose	VERB
dti-3019	354	15	pipeline	pipeline	NOUN
dti-3019	354	16	using	use	VERB
dti-3019	354	17	knime	knime	ADJ
dti-3019	354	18	and	and	CCONJ
dti-3019	354	19	programmatic	programmatic	ADJ
dti-3019	354	20	data	datum	NOUN
dti-3019	354	21	access	access	NOUN
dti-3019	354	22	:	:	PUNCT
dti-3019	354	23	case	case	NOUN
dti-3019	354	24	studies	study	NOUN
dti-3019	354	25	for	for	ADP
dti-3019	354	26	rare	rare	ADJ
dti-3019	354	27	diseases	disease	NOUN
dti-3019	354	28	and	and	CCONJ
dti-3019	354	29	covid-19	covid-19	PROPN
dti-3019	354	30	.	.	PUNCT
dti-3019	355	1	j	j	PROPN
dti-3019	355	2	cheminform	cheminform	PROPN
dti-3019	355	3	.	.	PUNCT
dti-3019	356	1	2020;12(1):71	2020;12(1):71	X
dti-3019	356	2	.	.	PUNCT
dti-3019	357	1	crossref	crossref	PROPN
dti-3019	357	2	pubmed	pubmed	PROPN
dti-3019	357	3	19	19	NUM
dti-3019	357	4	.	.	PUNCT
dti-3019	358	1	jian	jian	PROPN
dti-3019	358	2	hong	hong	PROPN
dti-3019	358	3	gan	gan	PROPN
dti-3019	358	4	,	,	PUNCT
dti-3019	358	5	ji	ji	PROPN
dti-3019	358	6	xiang	xiang	PROPN
dti-3019	358	7	liu	liu	PROPN
dti-3019	358	8	,	,	PUNCT
dti-3019	358	9	yang	yang	PROPN
dti-3019	358	10	liu	liu	PROPN
dti-3019	358	11	,	,	PUNCT
dti-3019	358	12	et	et	PROPN
dti-3019	358	13	al	al	PROPN
dti-3019	358	14	.	.	PUNCT
dti-3019	359	1	drugrep	drugrep	PROPN
dti-3019	359	2	:	:	PUNCT
dti-3019	359	3	an	an	DET
dti-3019	359	4	automatic	automatic	ADJ
dti-3019	359	5	virtual	virtual	ADJ
dti-3019	359	6	screening	screening	NOUN
dti-3019	359	7	server	server	NOUN
dti-3019	359	8	for	for	ADP
dti-3019	359	9	drug	drug	NOUN
dti-3019	359	10	repurposing	repurposing	NOUN
dti-3019	359	11	.	.	PUNCT
dti-3019	360	1	acta	acta	PROPN
dti-3019	360	2	pharmacol	pharmacol	PROPN
dti-3019	360	3	sinica	sinica	PROPN
dti-3019	360	4	.	.	PUNCT
dti-3019	361	1	2023;44(4):888	2023;44(4):888	NUM
dti-3019	361	2	-	-	SYM
dti-3019	361	3	896	896	NUM
dti-3019	361	4	.	.	PUNCT
dti-3019	361	5	20	20	NUM
dti-3019	361	6	.	.	PUNCT
dti-3019	362	1	sadegh	sadegh	PROPN
dti-3019	362	2	s	s	PROPN
dti-3019	362	3	,	,	PUNCT
dti-3019	362	4	skelton	skelton	PROPN
dti-3019	362	5	j	j	PROPN
dti-3019	362	6	,	,	PUNCT
dti-3019	362	7	anastasi	anastasi	PROPN
dti-3019	362	8	e	e	PROPN
dti-3019	362	9	,	,	PUNCT
dti-3019	362	10	et	et	PROPN
dti-3019	362	11	al	al	PROPN
dti-3019	362	12	.	.	PROPN
dti-3019	362	13	nedrex	nedrex	PROPN
dti-3019	362	14	–	–	PUNCT
dti-3019	362	15	an	an	DET
dti-3019	362	16	integrative	integrative	ADJ
dti-3019	362	17	and	and	CCONJ
dti-3019	362	18	interactive	interactive	ADJ
dti-3019	362	19	network	network	NOUN
dti-3019	362	20	medicine	medicine	NOUN
dti-3019	362	21	platform	platform	NOUN
dti-3019	362	22	for	for	ADP
dti-3019	362	23	drug	drug	NOUN
dti-3019	362	24	repurposing	repurposing	NOUN
dti-3019	362	25	.	.	PUNCT
dti-3019	363	1	in	in	ADP
dti-3019	363	2	rexpo22	rexpo22	NOUN
dti-3019	363	3	,	,	PUNCT
dti-3019	363	4	the	the	DET
dti-3019	363	5	1st	1st	ADJ
dti-3019	363	6	international	international	ADJ
dti-3019	363	7	conference	conference	NOUN
dti-3019	363	8	on	on	ADP
dti-3019	363	9	drug	drug	NOUN
dti-3019	363	10	repurposing	repurposing	NOUN
dti-3019	363	11	,	,	PUNCT
dti-3019	363	12	maastricht	maastricht	PROPN
dti-3019	363	13	;	;	PUNCT
dti-3019	363	14	2022	2022	NUM
dti-3019	363	15	.	.	PUNCT
dti-3019	364	1	crossref	crossref	PROPN
dti-3019	364	2	21	21	NUM
dti-3019	364	3	.	.	PUNCT
dti-3019	365	1	parmar	parmar	PROPN
dti-3019	365	2	g	g	PROPN
dti-3019	365	3	,	,	PUNCT
dti-3019	365	4	chudasama	chudasama	PROPN
dti-3019	365	5	jm	jm	PROPN
dti-3019	365	6	,	,	PUNCT
dti-3019	365	7	shah	shah	PROPN
dti-3019	365	8	a	a	X
dti-3019	365	9	,	,	PUNCT
dti-3019	365	10	patel	patel	PROPN
dti-3019	365	11	a.	a.	NOUN
dti-3019	365	12	in	in	ADP
dti-3019	365	13	silico	silico	NOUN
dti-3019	365	14	pharmacology	pharmacology	NOUN
dti-3019	365	15	and	and	CCONJ
dti-3019	365	16	drug	drug	NOUN
dti-3019	365	17	repurposing	repurposing	NOUN
dti-3019	365	18	approaches	approach	NOUN
dti-3019	365	19	.	.	PUNCT
dti-3019	366	1	in	in	ADP
dti-3019	366	2	rudrapal	rudrapal	PROPN
dti-3019	366	3	m	m	PROPN
dti-3019	366	4	,	,	PUNCT
dti-3019	366	5	khan	khan	PROPN
dti-3019	366	6	j	j	PROPN
dti-3019	366	7	,	,	PUNCT
dti-3019	366	8	eds	ed	NOUN
dti-3019	366	9	,	,	PUNCT
dti-3019	366	10	cadd	cadd	NOUN
dti-3019	366	11	and	and	CCONJ
dti-3019	366	12	informatics	informatic	NOUN
dti-3019	366	13	in	in	ADP
dti-3019	366	14	drug	drug	NOUN
dti-3019	366	15	discovery	discovery	NOUN
dti-3019	366	16	.	.	PUNCT
dti-3019	366	17	springer	springer	NOUN
dti-3019	366	18	;	;	PUNCT
dti-3019	366	19	2023	2023	NUM
dti-3019	366	20	:	:	PUNCT
dti-3019	366	21	253	253	NUM
dti-3019	366	22	-	-	SYM
dti-3019	366	23	281	281	NUM
dti-3019	366	24	.	.	PUNCT
dti-3019	367	1	crossref	crossref	PROPN
dti-3019	367	2	22	22	NUM
dti-3019	367	3	.	.	PUNCT
dti-3019	368	1	khan	khan	PROPN
dti-3019	368	2	s	s	PROPN
dti-3019	368	3	,	,	PUNCT
dti-3019	368	4	agnihotri	agnihotri	PROPN
dti-3019	368	5	j	j	PROPN
dti-3019	368	6	,	,	PUNCT
dti-3019	368	7	patil	patil	PROPN
dti-3019	368	8	s	s	PROPN
dti-3019	368	9	,	,	PUNCT
dti-3019	368	10	khan	khan	PROPN
dti-3019	368	11	n.	n.	PROPN
dti-3019	368	12	drug	drug	NOUN
dti-3019	368	13	repurposing	repurposing	NOUN
dti-3019	368	14	:	:	PUNCT
dti-3019	368	15	a	a	DET
dti-3019	368	16	futuristic	futuristic	ADJ
dti-3019	368	17	approach	approach	NOUN
dti-3019	368	18	in	in	ADP
dti-3019	368	19	drug	drug	NOUN
dti-3019	368	20	discovery	discovery	NOUN
dti-3019	368	21	.	.	PUNCT
dti-3019	369	1	j	j	PROPN
dti-3019	369	2	pharm	pharm	PROPN
dti-3019	369	3	biol	biol	PROPN
dti-3019	369	4	sci	sci	PROPN
dti-3019	369	5	.	.	PUNCT
dti-3019	370	1	2023;11(1	2023;11(1	NUM
dti-3019	370	2	):	):	PUNCT
dti-3019	370	3	66	66	NUM
dti-3019	370	4	-	-	SYM
dti-3019	370	5	69	69	NUM
dti-3019	370	6	.	.	PUNCT
dti-3019	371	1	crossref	crossref	PROPN
dti-3019	371	2	23	23	NUM
dti-3019	371	3	.	.	PUNCT
dti-3019	372	1	geest	geest	PROPN
dti-3019	372	2	r	r	NOUN
dti-3019	372	3	,	,	PUNCT
dti-3019	372	4	nijholt	nijholt	PROPN
dti-3019	372	5	d.	d.	PROPN
dti-3019	372	6	hollander	hollander	PROPN
dti-3019	372	7	w.	w.	PROPN
dti-3019	372	8	clinical	clinical	PROPN
dti-3019	372	9	development	development	NOUN
dti-3019	372	10	in	in	ADP
dti-3019	372	11	drug	drug	NOUN
dti-3019	372	12	repurposing	repurposing	NOUN
dti-3019	372	13	.	.	PUNCT
dti-3019	373	1	in	in	ADP
dti-3019	373	2	rexpo22	rexpo22	NOUN
dti-3019	373	3	,	,	PUNCT
dti-3019	373	4	the	the	DET
dti-3019	373	5	1st	1st	ADJ
dti-3019	373	6	international	international	ADJ
dti-3019	373	7	conference	conference	NOUN
dti-3019	373	8	on	on	ADP
dti-3019	373	9	drug	drug	NOUN
dti-3019	373	10	repurposing	repurposing	NOUN
dti-3019	373	11	,	,	PUNCT
dti-3019	373	12	maastricht	maastricht	PROPN
dti-3019	373	13	;	;	PUNCT
dti-3019	373	14	scienceopen	scienceopen	NOUN
dti-3019	373	15	,	,	PUNCT
dti-3019	373	16	august	august	PROPN
dti-3019	373	17	2022	2022	NUM
dti-3019	373	18	.	.	PUNCT
dti-3019	374	1	24	24	NUM
dti-3019	374	2	.	.	PUNCT
dti-3019	375	1	tan	tan	PROPN
dti-3019	375	2	gsq	gsq	PROPN
dti-3019	375	3	,	,	PUNCT
dti-3019	375	4	sloan	sloan	PROPN
dti-3019	375	5	ek	ek	PROPN
dti-3019	375	6	,	,	PUNCT
dti-3019	375	7	lambert	lambert	PROPN
dti-3019	375	8	p	p	PROPN
dti-3019	375	9	,	,	PUNCT
dti-3019	375	10	kirkpatrick	kirkpatrick	PROPN
dti-3019	375	11	cmj	cmj	PROPN
dti-3019	375	12	,	,	PUNCT
dti-3019	375	13	ilomäki	ilomäki	PROPN
dti-3019	375	14	j.	j.	PROPN
dti-3019	375	15	drug	drug	PROPN
dti-3019	375	16	repurposing	repurpose	VERB
dti-3019	375	17	using	use	VERB
dti-3019	375	18	real	real	ADJ
dti-3019	375	19	-	-	PUNCT
dti-3019	375	20	world	world	NOUN
dti-3019	375	21	data	datum	NOUN
dti-3019	375	22	.	.	PUNCT
dti-3019	376	1	drug	drug	NOUN
dti-3019	376	2	discov	discov	PROPN
dti-3019	376	3	today	today	NOUN
dti-3019	376	4	.	.	PUNCT
dti-3019	377	1	2023;28(1):103422	2023;28(1):103422	NUM
dti-3019	377	2	.	.	PUNCT
dti-3019	378	1	crossref	crossref	PROPN
dti-3019	378	2	pubmed	pubmed	PROPN
dti-3019	378	3	25	25	NUM
dti-3019	378	4	.	.	PUNCT
dti-3019	379	1	juárez	juárez	NOUN
dti-3019	379	2	-	-	PUNCT
dti-3019	379	3	lópez	lópez	NOUN
dti-3019	379	4	d	d	NOUN
dti-3019	379	5	,	,	PUNCT
dti-3019	379	6	schcolnik	schcolnik	PROPN
dti-3019	379	7	-	-	PUNCT
dti-3019	379	8	cabrera	cabrera	PROPN
dti-3019	379	9	a.	a.	NOUN
dti-3019	379	10	drug	drug	NOUN
dti-3019	379	11	repurposing	repurposing	NOUN
dti-3019	379	12	:	:	PUNCT
dti-3019	379	13	considerations	consideration	NOUN
dti-3019	379	14	to	to	PART
dti-3019	379	15	surpass	surpass	VERB
dti-3019	379	16	while	while	SCONJ
dti-3019	379	17	re	re	VERB
dti-3019	379	18	-	-	VERB
dti-3019	379	19	directing	direct	VERB
dti-3019	379	20	old	old	ADJ
dti-3019	379	21	compounds	compound	NOUN
dti-3019	379	22	for	for	ADP
dti-3019	379	23	new	new	ADJ
dti-3019	379	24	treatments	treatment	NOUN
dti-3019	379	25	.	.	PUNCT
dti-3019	380	1	arch	arch	ADJ
dti-3019	380	2	med	med	ADJ
dti-3019	380	3	res	re	NOUN
dti-3019	380	4	.	.	PUNCT
dti-3019	381	1	2021;52(3):243	2021;52(3):243	NOUN
dti-3019	381	2	-	-	PUNCT
dti-3019	381	3	251	251	NUM
dti-3019	381	4	.	.	PUNCT
dti-3019	382	1	crossref	crossref	PROPN
dti-3019	382	2	pubmed	pubmed	PROPN
dti-3019	382	3	26	26	NUM
dti-3019	382	4	.	.	PUNCT
dti-3019	383	1	selvaraj	selvaraj	PROPN
dti-3019	383	2	n	n	CCONJ
dti-3019	383	3	,	,	PUNCT
dti-3019	383	4	swaroop	swaroop	PROPN
dti-3019	383	5	ak	ak	PROPN
dti-3019	383	6	,	,	PUNCT
dti-3019	383	7	nidamanuri	nidamanuri	PROPN
dti-3019	383	8	bss	bss	PROPN
dti-3019	383	9	,	,	PUNCT
dti-3019	383	10	kumar	kumar	PROPN
dti-3019	383	11	rr	rr	PROPN
dti-3019	383	12	,	,	PUNCT
dti-3019	383	13	natarajan	natarajan	PROPN
dti-3019	383	14	j	j	PROPN
dti-3019	383	15	,	,	PUNCT
dti-3019	383	16	selvaraj	selvaraj	ADJ
dti-3019	383	17	j.	j.	PROPN
dti-3019	383	18	network	network	PROPN
dti-3019	383	19	-	-	PUNCT
dti-3019	383	20	based	base	VERB
dti-3019	383	21	drug	drug	NOUN
dti-3019	383	22	repurposing	repurposing	NOUN
dti-3019	383	23	:	:	PUNCT
dti-3019	383	24	a	a	DET
dti-3019	383	25	critical	critical	ADJ
dti-3019	383	26	review	review	NOUN
dti-3019	383	27	.	.	PUNCT
dti-3019	384	1	curr	curr	PROPN
dti-3019	384	2	drug	drug	PROPN
dti-3019	384	3	res	re	NOUN
dti-3019	384	4	rev	rev	PROPN
dti-3019	384	5	.	.	PROPN
dti-3019	385	1	2022;14(2):116	2022;14(2):116	PROPN
dti-3019	385	2	-	-	PUNCT
dti-3019	385	3	131	131	NUM
dti-3019	385	4	.	.	PUNCT
dti-3019	386	1	crossref	crossref	PROPN
dti-3019	386	2	pubmed	pubmed	PROPN
dti-3019	386	3	27	27	NUM
dti-3019	386	4	.	.	PUNCT
dti-3019	387	1	farha	farha	PROPN
dti-3019	387	2	ma	ma	PROPN
dti-3019	387	3	,	,	PUNCT
dti-3019	387	4	brown	brown	ADJ
dti-3019	387	5	ed	ed	NOUN
dti-3019	387	6	.	.	PUNCT
dti-3019	388	1	drug	drug	NOUN
dti-3019	388	2	repurposing	repurpose	VERB
dti-3019	388	3	for	for	ADP
dti-3019	388	4	antimicrobial	antimicrobial	ADJ
dti-3019	388	5	discovery	discovery	NOUN
dti-3019	388	6	.	.	PUNCT
dti-3019	389	1	nat	nat	PROPN
dti-3019	389	2	microbiol	microbiol	PROPN
dti-3019	389	3	.	.	PUNCT
dti-3019	390	1	2019;4(4):565	2019;4(4):565	NUM
dti-3019	390	2	-	-	SYM
dti-3019	390	3	577	577	NUM
dti-3019	390	4	.	.	PUNCT
dti-3019	391	1	crossref	crossref	PROPN
dti-3019	391	2	pubmed	pubmed	PROPN
dti-3019	391	3	28	28	PROPN
dti-3019	391	4	.	.	PUNCT
dti-3019	392	1	fetro	fetro	VERB
dti-3019	392	2	c	c	NOUN
dti-3019	392	3	,	,	PUNCT
dti-3019	392	4	scherman	scherman	PROPN
dti-3019	392	5	d.	d.	PROPN
dti-3019	392	6	drug	drug	NOUN
dti-3019	392	7	repurposing	repurpose	VERB
dti-3019	392	8	in	in	ADP
dti-3019	392	9	rare	rare	ADJ
dti-3019	392	10	diseases	disease	NOUN
dti-3019	392	11	:	:	PUNCT
dti-3019	392	12	myths	myth	NOUN
dti-3019	392	13	and	and	CCONJ
dti-3019	392	14	reality	reality	NOUN
dti-3019	392	15	.	.	PUNCT
dti-3019	393	1	therapie	therapie	NOUN
dti-3019	393	2	.	.	PUNCT
dti-3019	394	1	2020;75(2):157	2020;75(2):157	NUM
dti-3019	394	2	-	-	SYM
dti-3019	394	3	160	160	NUM
dti-3019	394	4	.	.	PUNCT
dti-3019	395	1	crossref	crossref	PROPN
dti-3019	395	2	pubmed	pubmed	PROPN
dti-3019	395	3	29	29	NUM
dti-3019	395	4	.	.	PUNCT
dti-3019	396	1	aggarwal	aggarwal	PROPN
dti-3019	396	2	nn	nn	PROPN
dti-3019	396	3	,	,	PUNCT
dti-3019	396	4	sindhoor	sindhoor	PROPN
dti-3019	396	5	sm	sm	PROPN
dti-3019	396	6	,	,	PUNCT
dti-3019	396	7	naveen	naveen	PROPN
dti-3019	396	8	nr	nr	PROPN
dti-3019	396	9	,	,	PUNCT
dti-3019	396	10	gowthami	gowthami	NOUN
dti-3019	396	11	b	b	PROPN
dti-3019	396	12	,	,	PUNCT
dti-3019	397	1	biju	biju	PROPN
dti-3019	397	2	p.	p.	PROPN
dti-3019	397	3	drug	drug	NOUN
dti-3019	397	4	reprofiling	reprofiling	PROPN
dti-3019	397	5	:	:	PUNCT
dti-3019	397	6	a	a	DET
dti-3019	397	7	prospective	prospective	ADJ
dti-3019	397	8	approach	approach	NOUN
dti-3019	397	9	to	to	ADP
dti-3019	397	10	battle	battle	NOUN
dti-3019	397	11	chronic	chronic	ADJ
dti-3019	397	12	ailments	ailment	NOUN
dti-3019	397	13	.	.	PUNCT
dti-3019	398	1	j	j	PROPN
dti-3019	398	2	health	health	PROPN
dti-3019	398	3	allied	ally	VERB
dti-3019	398	4	sci	sci	PROPN
dti-3019	398	5	2023;14:38	2023;14:38	NUM
dti-3019	398	6	-	-	SYM
dti-3019	398	7	46	46	NUM
dti-3019	398	8	.	.	PUNCT
dti-3019	398	9	30	30	NUM
dti-3019	398	10	.	.	PUNCT
dti-3019	399	1	annabell	annabell	PROPN
dti-3019	399	2	c	c	PROPN
dti-3019	399	3	,	,	PUNCT
dti-3019	399	4	david	david	PROPN
dti-3019	399	5	r	r	PROPN
dti-3019	399	6	,	,	PUNCT
dti-3019	399	7	greaves	greave	VERB
dti-3019	399	8	r.	r.	PROPN
dti-3019	399	9	drug	drug	NOUN
dti-3019	399	10	repurposing	repurpose	VERB
dti-3019	399	11	in	in	ADP
dti-3019	399	12	cardiovascular	cardiovascular	ADJ
dti-3019	399	13	inflammation	inflammation	NOUN
dti-3019	399	14	:	:	PUNCT
dti-3019	399	15	successes	success	NOUN
dti-3019	399	16	,	,	PUNCT
dti-3019	399	17	failures	failure	NOUN
dti-3019	399	18	,	,	PUNCT
dti-3019	399	19	and	and	CCONJ
dti-3019	399	20	future	future	ADJ
dti-3019	399	21	opportunities	opportunity	NOUN
dti-3019	399	22	.	.	PUNCT
dti-3019	400	1	front	front	ADJ
dti-3019	400	2	pharmacol	pharmacol	PROPN
dti-3019	400	3	.	.	PUNCT
dti-3019	401	1	2022;13:1046406	2022;13:1046406	NUM
dti-3019	401	2	.	.	PUNCT
dti-3019	402	1	31	31	NUM
dti-3019	402	2	.	.	PUNCT
dti-3019	403	1	ridker	ridker	NOUN
dti-3019	403	2	pm	pm	PROPN
dti-3019	403	3	,	,	PUNCT
dti-3019	403	4	everett	everett	PROPN
dti-3019	403	5	bm	bm	PROPN
dti-3019	403	6	,	,	PUNCT
dti-3019	403	7	thuren	thuren	PROPN
dti-3019	403	8	t	t	PROPN
dti-3019	403	9	,	,	PUNCT
dti-3019	403	10	et	et	PROPN
dti-3019	403	11	al	al	PROPN
dti-3019	403	12	.	.	PROPN
dti-3019	403	13	antiinflammatory	antiinflammatory	NOUN
dti-3019	403	14	therapy	therapy	NOUN
dti-3019	403	15	with	with	ADP
dti-3019	403	16	canakinumab	canakinumab	NOUN
dti-3019	403	17	for	for	ADP
dti-3019	403	18	atherosclerotic	atherosclerotic	ADJ
dti-3019	403	19	disease	disease	NOUN
dti-3019	403	20	.	.	PUNCT
dti-3019	404	1	n	n	PROPN
dti-3019	404	2	engl	engl	PROPN
dti-3019	404	3	j	j	PROPN
dti-3019	404	4	med	med	PROPN
dti-3019	404	5	.	.	PUNCT
dti-3019	405	1	2017;377(12	2017;377(12	PROPN
dti-3019	405	2	):	):	PUNCT
dti-3019	405	3	1119	1119	NUM
dti-3019	405	4	-	-	SYM
dti-3019	405	5	1131	1131	NUM
dti-3019	405	6	.	.	PUNCT
dti-3019	406	1	32	32	NUM
dti-3019	406	2	.	.	PUNCT
dti-3019	407	1	dhimolea	dhimolea	PROPN
dti-3019	407	2	e.	e.	PROPN
dti-3019	407	3	canakinumab	canakinumab	PROPN
dti-3019	407	4	.	.	PUNCT
dti-3019	408	1	mabs	mab	NOUN
dti-3019	408	2	.	.	PUNCT
dti-3019	409	1	2010;2(1):3	2010;2(1):3	PROPN
dti-3019	409	2	-	-	PUNCT
dti-3019	409	3	13	13	NUM
dti-3019	409	4	.	.	PUNCT
dti-3019	410	1	crossref	crossref	PROPN
dti-3019	410	2	pubmed	pubmed	PROPN
dti-3019	410	3	33	33	NUM
dti-3019	410	4	.	.	PUNCT
dti-3019	411	1	miller	miller	PROPN
dti-3019	411	2	j.	j.	PROPN
dti-3019	411	3	fda	fda	PROPN
dti-3019	411	4	snubs	snub	VERB
dti-3019	411	5	novartis	novartis	PROPN
dti-3019	411	6	bid	bid	NOUN
dti-3019	411	7	to	to	PART
dti-3019	411	8	repurpose	repurpose	VERB
dti-3019	411	9	inflammation	inflammation	ADJ
dti-3019	411	10	drug	drug	NOUN
dti-3019	411	11	for	for	ADP
dti-3019	411	12	heart	heart	NOUN
dti-3019	411	13	attacks	attack	NOUN
dti-3019	411	14	,	,	PUNCT
dti-3019	411	15	october	october	PROPN
dti-3019	411	16	2018	2018	NUM
dti-3019	411	17	.	.	PUNCT
dti-3019	412	1	online	online	PROPN
dti-3019	412	2	.	.	PUNCT
dti-3019	413	1	https://doi.org/10.3390/app11178169	https://doi.org/10.3390/app11178169	PROPN
dti-3019	413	2	https://doi.org/10.4321/s1130-01082011001200003	https://doi.org/10.4321/s1130-01082011001200003	PROPN
dti-3019	413	3	https://www.ncbi.nlm.nih.gov/pubmed/22217345	https://www.ncbi.nlm.nih.gov/pubmed/22217345	PROPN
dti-3019	414	1	https://doi.org/10.1371/journal.pntd.0008329	https://doi.org/10.1371/journal.pntd.0008329	PROPN
dti-3019	414	2	https://www.ncbi.nlm.nih.gov/pubmed/32760161	https://www.ncbi.nlm.nih.gov/pubmed/32760161	ADJ
dti-3019	414	3	https://doi.org/10.3390/biom12101513	https://doi.org/10.3390/biom12101513	NOUN
dti-3019	414	4	https://www.ncbi.nlm.nih.gov/pubmed/36291722	https://www.ncbi.nlm.nih.gov/pubmed/36291722	NUM
dti-3019	414	5	https://doi.org/10.14233/ajchem.2021.23199	https://doi.org/10.14233/ajchem.2021.23199	PROPN
dti-3019	414	6	https://doi.org/10.1016/j.sxmr.2018.06.005	https://doi.org/10.1016/j.sxmr.2018.06.005	VERB
dti-3019	414	7	https://www.ncbi.nlm.nih.gov/pubmed/30301707	https://www.ncbi.nlm.nih.gov/pubmed/30301707	NUM
dti-3019	414	8	https://doi.org/10.33380/2305-2066-2023-12-1-182-190	https://doi.org/10.33380/2305-2066-2023-12-1-182-190	PROPN
dti-3019	414	9	https://doi.org/10.1186/s12913-022-08272-z	https://doi.org/10.1186/s12913-022-08272-z	PROPN
dti-3019	414	10	https://www.ncbi.nlm.nih.gov/pubmed/34974828	https://www.ncbi.nlm.nih.gov/pubmed/34974828	PRON
dti-3019	414	11	https://doi.org/10.3390/jcm9113777	https://doi.org/10.3390/jcm9113777	PROPN
dti-3019	414	12	https://www.ncbi.nlm.nih.gov/pubmed/33238464	https://www.ncbi.nlm.nih.gov/pubmed/33238464	ADP
dti-3019	414	13	https://doi.org/10.1186/s13321-020-00474-z	https://doi.org/10.1186/s13321-020-00474-z	PROPN
dti-3019	414	14	https://www.ncbi.nlm.nih.gov/pubmed/33250934	https://www.ncbi.nlm.nih.gov/pubmed/33250934	PART
dti-3019	414	15	https://doi.org/10.14293/s2199-1006.1.sor-.pppy90r8.v1	https://doi.org/10.14293/s2199-1006.1.sor-.pppy90r8.v1	PROPN
dti-3019	414	16	https://doi.org/10.1007/978-981-99-1316-9_11	https://doi.org/10.1007/978-981-99-1316-9_11	NUM
dti-3019	414	17	https://doi.org/10.18231/j.jpbs.2023.011	https://doi.org/10.18231/j.jpbs.2023.011	NOUN
dti-3019	415	1	https://doi.org/10.1016/j.drudis.2022.103422	https://doi.org/10.1016/j.drudis.2022.103422	ADJ
dti-3019	415	2	https://www.ncbi.nlm.nih.gov/pubmed/36341896	https://www.ncbi.nlm.nih.gov/pubmed/36341896	PRON
dti-3019	415	3	https://doi.org/10.1016/j.arcmed.2020.10.021	https://doi.org/10.1016/j.arcmed.2020.10.021	NOUN
dti-3019	415	4	https://www.ncbi.nlm.nih.gov/pubmed/33190955	https://www.ncbi.nlm.nih.gov/pubmed/33190955	NOUN
dti-3019	415	5	https://doi.org/10.2174/2589977514666220214120403	https://doi.org/10.2174/2589977514666220214120403	PRON
dti-3019	415	6	https://www.ncbi.nlm.nih.gov/pubmed/35156575	https://www.ncbi.nlm.nih.gov/pubmed/35156575	DET
dti-3019	415	7	https://doi.org/10.1038/s41564-019-0357-1	https://doi.org/10.1038/s41564-019-0357-1	NUM
dti-3019	415	8	https://www.ncbi.nlm.nih.gov/pubmed/30833727	https://www.ncbi.nlm.nih.gov/pubmed/30833727	NUM
dti-3019	415	9	https://doi.org/10.1016/j.therap.2020.02.006	https://doi.org/10.1016/j.therap.2020.02.006	ADJ
dti-3019	415	10	https://www.ncbi.nlm.nih.gov/pubmed/32241561	https://www.ncbi.nlm.nih.gov/pubmed/32241561	NOUN
dti-3019	415	11	https://doi.org/10.4161/mabs.2.1.10328	https://doi.org/10.4161/mabs.2.1.10328	PROPN
dti-3019	415	12	https://www.ncbi.nlm.nih.gov/pubmed/20065636	https://www.ncbi.nlm.nih.gov/pubmed/20065636	NUM
dti-3019	415	13	https://www.reuters.com/article/us-novartis-heart-disease/fda-snubs-novartis-bid-to-repurpose-inflammation-drug-for-heart-attacks-iduskcn1ms2qy/	https://www.reuters.com/article/us-novartis-heart-disease/fda-snubs-novartis-bid-to-repurpose-inflammation-drug-for-heart-attacks-iduskcn1ms2qy/	VERB
dti-3019	415	14	natsheh	natsheh	PROPN
dti-3019	415	15	et	et	PROPN
dti-3019	415	16	al	al	PROPN
dti-3019	415	17	drug	drug	PROPN
dti-3019	415	18	target	target	NOUN
dti-3019	415	19	insights	insight	NOUN
dti-3019	415	20	2024	2024	NUM
dti-3019	415	21	;	;	PUNCT
dti-3019	415	22	18	18	NUM
dti-3019	415	23	:	:	SYM
dti-3019	415	24	17	17	NUM
dti-3019	415	25	©	©	PROPN
dti-3019	415	26	2024	2024	NUM
dti-3019	415	27	the	the	DET
dti-3019	415	28	authors	author	NOUN
dti-3019	415	29	.	.	PUNCT
dti-3019	416	1	published	publish	VERB
dti-3019	416	2	by	by	ADP
dti-3019	416	3	aboutscience	aboutscience	NOUN
dti-3019	416	4	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-3019	416	5	34	34	NUM
dti-3019	416	6	.	.	PUNCT
dti-3019	417	1	davis	davis	PROPN
dti-3019	417	2	jc	jc	PROPN
dti-3019	417	3	jr	jr	PROPN
dti-3019	417	4	,	,	PUNCT
dti-3019	417	5	heijde	heijde	NOUN
dti-3019	417	6	d	d	NOUN
dti-3019	417	7	,	,	PUNCT
dti-3019	417	8	braun	braun	PROPN
dti-3019	417	9	j	j	PROPN
dti-3019	417	10	,	,	PUNCT
dti-3019	417	11	et	et	PROPN
dti-3019	417	12	al	al	PROPN
dti-3019	417	13	.	.	PROPN
dti-3019	417	14	recombinant	recombinant	ADJ
dti-3019	417	15	human	human	ADJ
dti-3019	417	16	tumor	tumor	NOUN
dti-3019	417	17	necrosis	necrosis	NOUN
dti-3019	417	18	factor	factor	NOUN
dti-3019	417	19	receptor	receptor	NOUN
dti-3019	417	20	(	(	PUNCT
dti-3019	417	21	etanercept	etanercept	NOUN
dti-3019	417	22	)	)	PUNCT
dti-3019	417	23	for	for	ADP
dti-3019	417	24	treating	treat	VERB
dti-3019	417	25	ankylosing	ankylose	VERB
dti-3019	417	26	spondylitis	spondylitis	NOUN
dti-3019	417	27	:	:	PUNCT
dti-3019	417	28	a	a	DET
dti-3019	417	29	randomized	randomized	ADJ
dti-3019	417	30	,	,	PUNCT
dti-3019	417	31	controlled	control	VERB
dti-3019	417	32	trial	trial	NOUN
dti-3019	417	33	.	.	PUNCT
dti-3019	418	1	arthritis	arthritis	NOUN
dti-3019	418	2	rheumatol	rheumatol	NOUN
dti-3019	418	3	.	.	PUNCT
dti-3019	419	1	2003;48(11):3230	2003;48(11):3230	NUM
dti-3019	419	2	-	-	SYM
dti-3019	419	3	3236	3236	NUM
dti-3019	419	4	.	.	PUNCT
dti-3019	419	5	35	35	NUM
dti-3019	419	6	.	.	PUNCT
dti-3019	420	1	gatti	gatti	PROPN
dti-3019	420	2	j	j	PROPN
dti-3019	420	3	,	,	PUNCT
dti-3019	420	4	lindstrom	lindstrom	PROPN
dti-3019	420	5	ja	ja	PROPN
dti-3019	420	6	,	,	PUNCT
dti-3019	420	7	beitz	beitz	PROPN
dti-3019	420	8	j.	j.	PROPN
dti-3019	420	9	reconsideration	reconsideration	NOUN
dti-3019	420	10	of	of	ADP
dti-3019	420	11	2008	2008	NUM
dti-3019	420	12	decision	decision	NOUN
dti-3019	420	13	:	:	PUNCT
dti-3019	420	14	food	food	NOUN
dti-3019	420	15	and	and	CCONJ
dti-3019	420	16	drug	drug	PROPN
dti-3019	420	17	administration	administration	NOUN
dti-3019	420	18	approval	approval	NOUN
dti-3019	420	19	of	of	ADP
dti-3019	420	20	etanercept	etanercept	NOUN
dti-3019	420	21	for	for	ADP
dti-3019	420	22	systemic	systemic	ADJ
dti-3019	420	23	treatment	treatment	NOUN
dti-3019	420	24	of	of	ADP
dti-3019	420	25	moderate	moderate	ADJ
dti-3019	420	26	to	to	ADP
dti-3019	420	27	severe	severe	ADJ
dti-3019	420	28	pediatric	pediatric	ADJ
dti-3019	420	29	psoriasis	psoriasis	NOUN
dti-3019	420	30	.	.	PUNCT
dti-3019	421	1	pediatr	pediatr	ADJ
dti-3019	421	2	dermatol	dermatol	NOUN
dti-3019	421	3	.	.	PUNCT
dti-3019	422	1	2018;35(5):688	2018;35(5):688	NUM
dti-3019	422	2	-	-	PUNCT
dti-3019	422	3	689	689	NUM
dti-3019	422	4	.	.	PUNCT
dti-3019	423	1	crossref	crossref	PROPN
dti-3019	423	2	pubmed	pubmed	PROPN
dti-3019	423	3	36	36	NUM
dti-3019	423	4	.	.	PUNCT
dti-3019	424	1	nathan	nathan	PROPN
dti-3019	424	2	mewton	mewton	PROPN
dti-3019	424	3	,	,	PUNCT
dti-3019	424	4	françois	françois	PROPN
dti-3019	424	5	roubille	roubille	NOUN
dti-3019	424	6	,	,	PUNCT
dti-3019	424	7	didier	didier	PROPN
dti-3019	424	8	bresson	bresson	PROPN
dti-3019	424	9	et	et	PROPN
dti-3019	424	10	al	al	PROPN
dti-3019	424	11	.	.	PUNCT
dti-3019	425	1	“	"	PUNCT
dti-3019	425	2	effect	effect	NOUN
dti-3019	425	3	of	of	ADP
dti-3019	425	4	colchicine	colchicine	PROPN
dti-3019	425	5	on	on	ADP
dti-3019	425	6	myocardial	myocardial	ADJ
dti-3019	425	7	injury	injury	NOUN
dti-3019	425	8	in	in	ADP
dti-3019	425	9	acute	acute	ADJ
dti-3019	425	10	myocardial	myocardial	ADJ
dti-3019	425	11	infarction	infarction	NOUN
dti-3019	425	12	”	"	PUNCT
dti-3019	425	13	.	.	PUNCT
dti-3019	426	1	circulation	circulation	NOUN
dti-3019	426	2	,	,	PUNCT
dti-3019	426	3	vol	vol	NOUN
dti-3019	426	4	.	.	PUNCT
dti-3019	427	1	144	144	NUM
dti-3019	427	2	,	,	PUNCT
dti-3019	427	3	no	no	INTJ
dti-3019	427	4	.	.	NOUN
dti-3019	427	5	11	11	NUM
dti-3019	427	6	,	,	PUNCT
dti-3019	427	7	859–869	859–869	NUM
dti-3019	427	8	,	,	PUNCT
dti-3019	427	9	2021	2021	NUM
dti-3019	427	10	.	.	PUNCT
dti-3019	428	1	37	37	NUM
dti-3019	428	2	.	.	PUNCT
dti-3019	429	1	shah	shah	PROPN
dti-3019	429	2	b	b	PROPN
dti-3019	429	3	,	,	PUNCT
dti-3019	429	4	pillinger	pillinger	NOUN
dti-3019	429	5	m	m	PROPN
dti-3019	429	6	,	,	PUNCT
dti-3019	429	7	zhong	zhong	PROPN
dti-3019	429	8	h	h	PROPN
dti-3019	429	9	,	,	PUNCT
dti-3019	429	10	et	et	PROPN
dti-3019	429	11	al	al	PROPN
dti-3019	429	12	.	.	PUNCT
dti-3019	429	13	effects	effect	NOUN
dti-3019	429	14	of	of	ADP
dti-3019	429	15	acute	acute	PROPN
dti-3019	429	16	colchicine	colchicine	PROPN
dti-3019	429	17	administration	administration	PROPN
dti-3019	429	18	prior	prior	ADV
dti-3019	429	19	to	to	ADP
dti-3019	429	20	percutaneous	percutaneous	ADJ
dti-3019	429	21	coronary	coronary	ADJ
dti-3019	429	22	intervention	intervention	NOUN
dti-3019	429	23	:	:	PUNCT
dti-3019	429	24	colchicine	colchicine	NOUN
dti-3019	429	25	-	-	PUNCT
dti-3019	429	26	pci	pci	PROPN
dti-3019	429	27	randomized	randomized	ADJ
dti-3019	429	28	trial	trial	NOUN
dti-3019	429	29	.	.	PUNCT
dti-3019	430	1	circ	circ	PROPN
dti-3019	430	2	cardiovasc	cardiovasc	PROPN
dti-3019	430	3	interv	interv	VERB
dti-3019	430	4	.	.	PUNCT
dti-3019	431	1	2020;13(4):e008717	2020;13(4):e008717	NUM
dti-3019	431	2	.	.	PUNCT
dti-3019	432	1	crossref	crossref	PROPN
dti-3019	432	2	pubmed	pubmed	PROPN
dti-3019	432	3	38	38	NUM
dti-3019	432	4	.	.	PUNCT
dti-3019	433	1	tardif	tardif	PROPN
dti-3019	433	2	j	j	PROPN
dti-3019	433	3	-	-	PUNCT
dti-3019	433	4	c	c	PROPN
dti-3019	433	5	,	,	PUNCT
dti-3019	433	6	kouz	kouz	PROPN
dti-3019	433	7	s	s	PART
dti-3019	433	8	,	,	PUNCT
dti-3019	433	9	waters	water	NOUN
dti-3019	433	10	dd	dd	VERB
dti-3019	433	11	,	,	PUNCT
dti-3019	434	1	et	et	PROPN
dti-3019	434	2	al	al	PROPN
dti-3019	434	3	.	.	PROPN
dti-3019	434	4	efficacy	efficacy	NOUN
dti-3019	434	5	and	and	CCONJ
dti-3019	434	6	safety	safety	NOUN
dti-3019	434	7	of	of	ADP
dti-3019	434	8	lowdose	lowdose	ADJ
dti-3019	434	9	colchicine	colchicine	PROPN
dti-3019	434	10	after	after	ADP
dti-3019	434	11	myocardial	myocardial	ADJ
dti-3019	434	12	infarction	infarction	NOUN
dti-3019	434	13	.	.	PUNCT
dti-3019	435	1	n	n	CCONJ
dti-3019	435	2	engl	engl	PROPN
dti-3019	435	3	j	j	PROPN
dti-3019	435	4	med	med	PROPN
dti-3019	435	5	.	.	PUNCT
dti-3019	436	1	2019;381(26):2497	2019;381(26):2497	NUM
dti-3019	436	2	-	-	SYM
dti-3019	436	3	2505	2505	NUM
dti-3019	436	4	.	.	PUNCT
dti-3019	437	1	39	39	NUM
dti-3019	437	2	.	.	PUNCT
dti-3019	438	1	tong	tong	PROPN
dti-3019	438	2	dc	dc	PROPN
dti-3019	438	3	,	,	PUNCT
dti-3019	438	4	quinn	quinn	PROPN
dti-3019	438	5	s	s	PART
dti-3019	438	6	,	,	PUNCT
dti-3019	438	7	nasis	nasis	NOUN
dti-3019	438	8	a	a	PRON
dti-3019	438	9	,	,	PUNCT
dti-3019	438	10	et	et	PROPN
dti-3019	438	11	al	al	PROPN
dti-3019	438	12	.	.	PROPN
dti-3019	438	13	colchicine	colchicine	PROPN
dti-3019	438	14	in	in	ADP
dti-3019	438	15	patients	patient	NOUN
dti-3019	438	16	with	with	ADP
dti-3019	438	17	acute	acute	ADJ
dti-3019	438	18	coronary	coronary	ADJ
dti-3019	438	19	syndrome	syndrome	NOUN
dti-3019	438	20	:	:	PUNCT
dti-3019	438	21	the	the	DET
dti-3019	438	22	australian	australian	ADJ
dti-3019	438	23	cops	cop	NOUN
dti-3019	438	24	randomized	randomize	VERB
dti-3019	438	25	clinical	clinical	ADJ
dti-3019	438	26	trial	trial	NOUN
dti-3019	438	27	.	.	PUNCT
dti-3019	439	1	circulation	circulation	NOUN
dti-3019	439	2	.	.	PUNCT
dti-3019	440	1	2020;142(20):1890	2020;142(20):1890	NUM
dti-3019	440	2	-	-	SYM
dti-3019	440	3	1900	1900	NUM
dti-3019	440	4	.	.	PUNCT
dti-3019	441	1	40	40	NUM
dti-3019	441	2	.	.	PUNCT
dti-3019	442	1	mewton	mewton	PROPN
dti-3019	442	2	n	n	PROPN
dti-3019	442	3	,	,	PUNCT
dti-3019	442	4	roubille	roubille	NOUN
dti-3019	442	5	f	f	PROPN
dti-3019	442	6	,	,	PUNCT
dti-3019	442	7	bresson	bresson	PROPN
dti-3019	442	8	d	d	PROPN
dti-3019	442	9	,	,	PUNCT
dti-3019	442	10	et	et	PROPN
dti-3019	442	11	al	al	PROPN
dti-3019	442	12	.	.	PROPN
dti-3019	442	13	effect	effect	NOUN
dti-3019	442	14	of	of	ADP
dti-3019	442	15	colchicine	colchicine	PROPN
dti-3019	442	16	on	on	ADP
dti-3019	442	17	myocardial	myocardial	ADJ
dti-3019	442	18	injury	injury	NOUN
dti-3019	442	19	in	in	ADP
dti-3019	442	20	acute	acute	ADJ
dti-3019	442	21	myocardial	myocardial	ADJ
dti-3019	442	22	infarction	infarction	NOUN
dti-3019	442	23	.	.	PUNCT
dti-3019	443	1	circulation	circulation	NOUN
dti-3019	443	2	.	.	PUNCT
dti-3019	444	1	2021;144(11):859	2021;144(11):859	PROPN
dti-3019	444	2	-	-	PUNCT
dti-3019	444	3	869	869	NUM
dti-3019	444	4	.	.	PUNCT
dti-3019	445	1	crossref	crossref	PROPN
dti-3019	445	2	pubmed	pubmed	PROPN
dti-3019	445	3	41	41	NUM
dti-3019	445	4	.	.	PUNCT
dti-3019	446	1	spada	spada	PROPN
dti-3019	446	2	a	a	PROPN
dti-3019	446	3	,	,	PUNCT
dti-3019	446	4	emami	emami	PROPN
dti-3019	446	5	j	j	PROPN
dti-3019	446	6	,	,	PUNCT
dti-3019	446	7	sanaee	sanaee	PROPN
dti-3019	447	1	f	f	AUX
dti-3019	447	2	,	,	PUNCT
dti-3019	447	3	et	et	PROPN
dti-3019	447	4	al	al	PROPN
dti-3019	447	5	.	.	PROPN
dti-3019	447	6	design	design	NOUN
dti-3019	447	7	and	and	CCONJ
dti-3019	447	8	evaluation	evaluation	NOUN
dti-3019	447	9	of	of	ADP
dti-3019	447	10	albumin	albumin	ADJ
dti-3019	447	11	nanoparticles	nanoparticle	NOUN
dti-3019	447	12	for	for	ADP
dti-3019	447	13	the	the	DET
dti-3019	447	14	delivery	delivery	NOUN
dti-3019	447	15	of	of	ADP
dti-3019	447	16	a	a	DET
dti-3019	447	17	novel	novel	ADJ
dti-3019	447	18	β	β	NOUN
dti-3019	447	19	-	-	PUNCT
dti-3019	447	20	tubulin	tubulin	NOUN
dti-3019	447	21	polymerization	polymerization	NOUN
dti-3019	447	22	inhibitor	inhibitor	NOUN
dti-3019	447	23	.	.	PUNCT
dti-3019	448	1	j	j	PROPN
dti-3019	448	2	pharm	pharm	PROPN
dti-3019	448	3	pharm	pharm	PROPN
dti-3019	448	4	sci	sci	PROPN
dti-3019	448	5	.	.	PUNCT
dti-3019	448	6	2021;24:344	2021;24:344	PROPN
dti-3019	448	7	-	-	PUNCT
dti-3019	448	8	362	362	NUM
dti-3019	448	9	.	.	PUNCT
dti-3019	449	1	crossref	crossref	PROPN
dti-3019	449	2	pubmed	pubmed	PROPN
dti-3019	449	3	42	42	NUM
dti-3019	449	4	.	.	PUNCT
dti-3019	450	1	kaddoura	kaddoura	PROPN
dti-3019	450	2	m	m	PROPN
dti-3019	450	3	,	,	PUNCT
dti-3019	450	4	alibrahim	alibrahim	PROPN
dti-3019	450	5	m	m	PROPN
dti-3019	450	6	,	,	PUNCT
dti-3019	450	7	hijazi	hijazi	PROPN
dti-3019	450	8	g	g	PROPN
dti-3019	450	9	,	,	PUNCT
dti-3019	450	10	et	et	PROPN
dti-3019	450	11	al	al	PROPN
dti-3019	450	12	.	.	PUNCT
dti-3019	451	1	covid-19	covid-19	PROPN
dti-3019	451	2	therapeutic	therapeutic	ADJ
dti-3019	451	3	options	option	NOUN
dti-3019	451	4	under	under	ADP
dti-3019	451	5	investigation	investigation	NOUN
dti-3019	451	6	.	.	PUNCT
dti-3019	452	1	vol	vol	NOUN
dti-3019	452	2	11	11	NUM
dti-3019	452	3	.	.	PUNCT
dti-3019	453	1	in	in	ADP
dti-3019	453	2	uckun	uckun	PROPN
dti-3019	453	3	fmm	fmm	PROPN
dti-3019	453	4	.	.	PUNCT
dti-3019	453	5	frontiers	frontier	NOUN
dti-3019	453	6	in	in	ADP
dti-3019	453	7	pharmacology	pharmacology	NOUN
dti-3019	453	8	;	;	PUNCT
dti-3019	453	9	2020	2020	NUM
dti-3019	453	10	.	.	PUNCT
dti-3019	454	1	43	43	NUM
dti-3019	454	2	.	.	PUNCT
dti-3019	455	1	ge	ge	PROPN
dti-3019	455	2	p	p	PROPN
dti-3019	455	3	,	,	PUNCT
dti-3019	455	4	fu	fu	PROPN
dti-3019	455	5	y	y	PROPN
dti-3019	455	6	,	,	PUNCT
dti-3019	455	7	qi	qi	PROPN
dti-3019	455	8	s	s	PROPN
dti-3019	455	9	,	,	PUNCT
dti-3019	455	10	et	et	PROPN
dti-3019	455	11	al	al	PROPN
dti-3019	455	12	.	.	PROPN
dti-3019	455	13	colchicine	colchicine	PROPN
dti-3019	455	14	for	for	ADP
dti-3019	455	15	prevention	prevention	NOUN
dti-3019	455	16	of	of	ADP
dti-3019	455	17	post	post	ADJ
dti-3019	455	18	operative	operative	ADJ
dti-3019	455	19	atrial	atrial	ADJ
dti-3019	455	20	fibrillation	fibrillation	NOUN
dti-3019	455	21	:	:	PUNCT
dti-3019	455	22	meta	meta	ADJ
dti-3019	455	23	-	-	PUNCT
dti-3019	455	24	analysis	analysis	NOUN
dti-3019	455	25	of	of	ADP
dti-3019	455	26	randomized	randomized	ADJ
dti-3019	455	27	controlled	control	VERB
dti-3019	455	28	trials	trial	NOUN
dti-3019	455	29	.	.	PUNCT
dti-3019	456	1	vol	vol	NOUN
dti-3019	456	2	9	9	NUM
dti-3019	456	3	.	.	PUNCT
dti-3019	457	1	front	front	PROPN
dti-3019	457	2	cardiovasc	cardiovasc	PROPN
dti-3019	457	3	med	me	VERB
dti-3019	457	4	.	.	PUNCT
dti-3019	458	1	2022;9:1032116	2022;9:1032116	PROPN
dti-3019	458	2	.	.	PUNCT
dti-3019	459	1	44	44	NUM
dti-3019	459	2	.	.	PUNCT
dti-3019	460	1	akrami	akrami	PROPN
dti-3019	460	2	m	m	PROPN
dti-3019	460	3	,	,	PUNCT
dti-3019	460	4	izadpanah	izadpanah	PROPN
dti-3019	460	5	p	p	X
dti-3019	460	6	,	,	PUNCT
dti-3019	460	7	bazrafshan	bazrafshan	NOUN
dti-3019	460	8	m	m	PROPN
dti-3019	460	9	,	,	PUNCT
dti-3019	460	10	et	et	PROPN
dti-3019	460	11	al	al	PROPN
dti-3019	460	12	.	.	PUNCT
dti-3019	460	13	effects	effect	NOUN
dti-3019	460	14	of	of	ADP
dti-3019	460	15	colchicine	colchicine	NOUN
dti-3019	460	16	on	on	ADP
dti-3019	460	17	major	major	ADJ
dti-3019	460	18	adverse	adverse	ADJ
dti-3019	460	19	cardiac	cardiac	ADJ
dti-3019	460	20	events	event	NOUN
dti-3019	460	21	in	in	ADP
dti-3019	460	22	next	next	ADJ
dti-3019	460	23	6	6	NUM
dti-3019	460	24	-	-	PUNCT
dti-3019	460	25	month	month	NOUN
dti-3019	460	26	period	period	NOUN
dti-3019	460	27	after	after	ADP
dti-3019	460	28	acute	acute	ADJ
dti-3019	460	29	coronary	coronary	ADJ
dti-3019	460	30	syndrome	syndrome	NOUN
dti-3019	460	31	occurrence	occurrence	NOUN
dti-3019	460	32	;	;	PUNCT
dti-3019	460	33	a	a	DET
dti-3019	460	34	randomized	randomized	ADJ
dti-3019	460	35	placebocontrol	placebocontrol	NOUN
dti-3019	460	36	trial	trial	NOUN
dti-3019	460	37	.	.	PUNCT
dti-3019	461	1	bmc	bmc	PROPN
dti-3019	461	2	cardiovasc	cardiovasc	PROPN
dti-3019	461	3	disord	disord	PROPN
dti-3019	461	4	.	.	PUNCT
dti-3019	462	1	2021;21(1):583	2021;21(1):583	NOUN
dti-3019	462	2	.	.	PUNCT
dti-3019	463	1	crossref	crossref	PROPN
dti-3019	463	2	pubmed	pubmed	PROPN
dti-3019	463	3	45	45	NUM
dti-3019	463	4	.	.	PUNCT
dti-3019	464	1	meyer	meyer	PROPN
dti-3019	464	2	-	-	PUNCT
dti-3019	464	3	lindemann	lindemann	PROPN
dti-3019	464	4	u	u	PROPN
dti-3019	464	5	,	,	PUNCT
dti-3019	464	6	mauersberger	mauersberger	PROPN
dti-3019	464	7	c	c	NOUN
dti-3019	464	8	,	,	PUNCT
dti-3019	464	9	schmidt	schmidt	PROPN
dti-3019	464	10	a	a	X
dti-3019	464	11	,	,	PUNCT
dti-3019	464	12	et	et	PROPN
dti-3019	464	13	al	al	PROPN
dti-3019	464	14	.	.	PROPN
dti-3019	464	15	colchicine	colchicine	PROPN
dti-3019	464	16	impacts	impact	VERB
dti-3019	464	17	leukocyte	leukocyte	NOUN
dti-3019	464	18	trafficking	trafficking	NOUN
dti-3019	464	19	in	in	ADP
dti-3019	464	20	atherosclerosis	atherosclerosis	NOUN
dti-3019	464	21	and	and	CCONJ
dti-3019	464	22	reduces	reduce	VERB
dti-3019	464	23	vascular	vascular	ADJ
dti-3019	464	24	inflammation	inflammation	NOUN
dti-3019	464	25	.	.	PUNCT
dti-3019	465	1	front	front	ADJ
dti-3019	465	2	immunol	immunol	NOUN
dti-3019	465	3	.	.	PUNCT
dti-3019	466	1	2022;13:898690	2022;13:898690	NUM
dti-3019	466	2	.	.	PROPN
dti-3019	466	3	46	46	NUM
dti-3019	466	4	.	.	PUNCT
dti-3019	467	1	huang	huang	PROPN
dti-3019	467	2	w	w	PROPN
dti-3019	467	3	,	,	PUNCT
dti-3019	467	4	wang	wang	PROPN
dti-3019	467	5	y	y	PROPN
dti-3019	467	6	,	,	PUNCT
dti-3019	467	7	tian	tian	PROPN
dti-3019	467	8	w	w	PROPN
dti-3019	467	9	,	,	PUNCT
dti-3019	467	10	et	et	PROPN
dti-3019	467	11	al	al	PROPN
dti-3019	467	12	.	.	PROPN
dti-3019	467	13	biosynthesis	biosynthesis	VERB
dti-3019	467	14	investigations	investigation	NOUN
dti-3019	467	15	of	of	ADP
dti-3019	467	16	terpenoid	terpenoid	NOUN
dti-3019	467	17	,	,	PUNCT
dti-3019	467	18	alkaloid	alkaloid	NOUN
dti-3019	467	19	,	,	PUNCT
dti-3019	467	20	and	and	CCONJ
dti-3019	467	21	flavonoid	flavonoid	PROPN
dti-3019	467	22	antimicrobial	antimicrobial	ADJ
dti-3019	467	23	agents	agent	NOUN
dti-3019	467	24	derived	derive	VERB
dti-3019	467	25	from	from	ADP
dti-3019	467	26	medicinal	medicinal	ADJ
dti-3019	467	27	plants	plant	NOUN
dti-3019	467	28	.	.	PUNCT
dti-3019	468	1	antibiotics	antibiotic	NOUN
dti-3019	468	2	(	(	PUNCT
dti-3019	468	3	basel	basel	PROPN
dti-3019	468	4	)	)	PUNCT
dti-3019	468	5	.	.	PUNCT
dti-3019	469	1	2022;11(10):1380	2022;11(10):1380	X
dti-3019	469	2	.	.	PUNCT
dti-3019	470	1	crossref	crossref	PROPN
dti-3019	470	2	pubmed	pubmed	PROPN
dti-3019	470	3	47	47	NUM
dti-3019	470	4	.	.	PUNCT
dti-3019	471	1	zhang	zhang	PROPN
dti-3019	471	2	f	f	X
dti-3019	471	3	-	-	PUNCT
dti-3019	471	4	s	s	PROPN
dti-3019	471	5	,	,	PUNCT
dti-3019	471	6	he	he	PRON
dti-3019	471	7	q	q	NOUN
dti-3019	471	8	-	-	PUNCT
dti-3019	471	9	z	z	NOUN
dti-3019	471	10	,	,	PUNCT
dti-3019	471	11	qin	qin	PROPN
dti-3019	471	12	ch	ch	PROPN
dti-3019	471	13	,	,	PUNCT
dti-3019	471	14	little	little	ADJ
dti-3019	471	15	pj	pj	PROPN
dti-3019	471	16	,	,	PUNCT
dti-3019	471	17	weng	weng	PROPN
dti-3019	471	18	jp	jp	PROPN
dti-3019	471	19	,	,	PUNCT
dti-3019	471	20	xu	xu	PROPN
dti-3019	471	21	sw	sw	PROPN
dti-3019	471	22	.	.	PUNCT
dti-3019	472	1	therapeutic	therapeutic	ADJ
dti-3019	472	2	potential	potential	NOUN
dti-3019	472	3	of	of	ADP
dti-3019	472	4	colchicine	colchicine	NOUN
dti-3019	472	5	in	in	ADP
dti-3019	472	6	cardiovascular	cardiovascular	ADJ
dti-3019	472	7	medicine	medicine	NOUN
dti-3019	472	8	:	:	PUNCT
dti-3019	472	9	a	a	DET
dti-3019	472	10	pharmacological	pharmacological	ADJ
dti-3019	472	11	review	review	NOUN
dti-3019	472	12	.	.	PUNCT
dti-3019	473	1	acta	acta	PROPN
dti-3019	473	2	pharmacol	pharmacol	PROPN
dti-3019	473	3	sin	sin	NOUN
dti-3019	473	4	.	.	PUNCT
dti-3019	474	1	2022;43(9):2173	2022;43(9):2173	NUM
dti-3019	474	2	-	-	PUNCT
dti-3019	474	3	2190	2190	NUM
dti-3019	474	4	.	.	PUNCT
dti-3019	475	1	crossref	crossref	PROPN
dti-3019	475	2	pubmed	pubmed	PROPN
dti-3019	475	3	48	48	NUM
dti-3019	475	4	.	.	PUNCT
dti-3019	476	1	moreira	moreira	PROPN
dti-3019	476	2	dm	dm	PROPN
dti-3019	476	3	,	,	PUNCT
dti-3019	476	4	vieira	vieira	PROPN
dti-3019	476	5	jl	jl	PROPN
dti-3019	476	6	,	,	PUNCT
dti-3019	476	7	gottschall	gottschall	PROPN
dti-3019	476	8	ca	ca	NOUN
dti-3019	476	9	.	.	PUNCT
dti-3019	477	1	the	the	DET
dti-3019	477	2	effects	effect	NOUN
dti-3019	477	3	of	of	ADP
dti-3019	477	4	methotrexate	methotrexate	NOUN
dti-3019	477	5	therapy	therapy	NOUN
dti-3019	477	6	on	on	ADP
dti-3019	477	7	the	the	DET
dti-3019	477	8	physical	physical	ADJ
dti-3019	477	9	capacity	capacity	NOUN
dti-3019	477	10	of	of	ADP
dti-3019	477	11	patients	patient	NOUN
dti-3019	477	12	with	with	ADP
dti-3019	477	13	ischemic	ischemic	ADJ
dti-3019	477	14	heart	heart	NOUN
dti-3019	477	15	failure	failure	NOUN
dti-3019	477	16	:	:	PUNCT
dti-3019	477	17	a	a	DET
dti-3019	477	18	randomized	randomized	ADJ
dti-3019	477	19	double	double	ADJ
dti-3019	477	20	-	-	PUNCT
dti-3019	477	21	blind	blind	ADJ
dti-3019	477	22	,	,	PUNCT
dti-3019	477	23	placebo	placebo	NOUN
dti-3019	477	24	-	-	PUNCT
dti-3019	477	25	controlled	control	VERB
dti-3019	477	26	trial	trial	NOUN
dti-3019	477	27	(	(	PUNCT
dti-3019	477	28	metis	metis	NOUN
dti-3019	477	29	trial	trial	NOUN
dti-3019	477	30	)	)	PUNCT
dti-3019	477	31	.	.	PUNCT
dti-3019	478	1	j	j	PROPN
dti-3019	478	2	card	card	NOUN
dti-3019	478	3	fail	fail	VERB
dti-3019	478	4	.	.	PUNCT
dti-3019	479	1	2009;15(10):828834	2009;15(10):828834	X
dti-3019	479	2	.	.	PUNCT
dti-3019	479	3	crossref	crossref	PROPN
dti-3019	479	4	pubmed	pubmed	PROPN
dti-3019	479	5	49	49	NUM
dti-3019	479	6	.	.	PUNCT
dti-3019	480	1	moreira	moreira	PROPN
dti-3019	480	2	dm	dm	PROPN
dti-3019	480	3	,	,	PUNCT
dti-3019	480	4	lueneberg	lueneberg	PROPN
dti-3019	480	5	me	i	PRON
dti-3019	480	6	,	,	PUNCT
dti-3019	480	7	da	da	PROPN
dti-3019	480	8	silva	silva	PROPN
dti-3019	480	9	rl	rl	PROPN
dti-3019	480	10	,	,	PUNCT
dti-3019	480	11	fattah	fattah	PROPN
dti-3019	480	12	t	t	PROPN
dti-3019	480	13	,	,	PUNCT
dti-3019	480	14	gottschall	gottschall	PROPN
dti-3019	480	15	cam	cam	PROPN
dti-3019	480	16	.	.	PUNCT
dti-3019	481	1	methotrexate	methotrexate	VERB
dti-3019	481	2	therapy	therapy	NOUN
dti-3019	481	3	in	in	ADP
dti-3019	481	4	st	st	PROPN
dti-3019	481	5	-	-	PUNCT
dti-3019	481	6	segment	segment	NOUN
dti-3019	481	7	elevation	elevation	NOUN
dti-3019	481	8	myocardial	myocardial	ADJ
dti-3019	481	9	infarctions	infarction	NOUN
dti-3019	481	10	:	:	PUNCT
dti-3019	481	11	a	a	DET
dti-3019	481	12	randomized	randomized	ADJ
dti-3019	481	13	double	double	ADJ
dti-3019	481	14	-	-	PUNCT
dti-3019	481	15	blind	blind	ADJ
dti-3019	481	16	,	,	PUNCT
dti-3019	481	17	placebo	placebo	NOUN
dti-3019	481	18	controlled	control	VERB
dti-3019	481	19	trial	trial	NOUN
dti-3019	481	20	(	(	PUNCT
dti-3019	481	21	tethys	tethy	NOUN
dti-3019	481	22	trial	trial	NOUN
dti-3019	481	23	)	)	PUNCT
dti-3019	481	24	.	.	PUNCT
dti-3019	482	1	j	j	PROPN
dti-3019	482	2	cardiovasc	cardiovasc	PROPN
dti-3019	482	3	pharmacol	pharmacol	VERB
dti-3019	482	4	ther	ther	ADV
dti-3019	482	5	.	.	PUNCT
dti-3019	483	1	2017;22(6):538	2017;22(6):538	NUM
dti-3019	483	2	-	-	SYM
dti-3019	483	3	545	545	NUM
dti-3019	483	4	.	.	PUNCT
dti-3019	484	1	crossref	crossref	PROPN
dti-3019	484	2	pubmed	pubmed	PROPN
dti-3019	484	3	50	50	NUM
dti-3019	484	4	.	.	PUNCT
dti-3019	485	1	ridker	ridker	PROPN
dti-3019	485	2	pm	pm	PROPN
dti-3019	485	3	,	,	PUNCT
dti-3019	485	4	everett	everett	PROPN
dti-3019	485	5	bm	bm	PROPN
dti-3019	485	6	,	,	PUNCT
dti-3019	485	7	pradhan	pradhan	PROPN
dti-3019	485	8	a	a	PROPN
dti-3019	485	9	,	,	PUNCT
dti-3019	485	10	et	et	PROPN
dti-3019	485	11	al	al	PROPN
dti-3019	485	12	;	;	PUNCT
dti-3019	485	13	cirt	cirt	NOUN
dti-3019	485	14	investigators	investigator	NOUN
dti-3019	485	15	.	.	PUNCT
dti-3019	486	1	low	low	ADJ
dti-3019	486	2	-	-	PUNCT
dti-3019	486	3	dose	dose	NOUN
dti-3019	486	4	methotrexate	methotrexate	NOUN
dti-3019	486	5	for	for	ADP
dti-3019	486	6	the	the	DET
dti-3019	486	7	prevention	prevention	NOUN
dti-3019	486	8	of	of	ADP
dti-3019	486	9	atherosclerotic	atherosclerotic	ADJ
dti-3019	486	10	events	event	NOUN
dti-3019	486	11	.	.	PUNCT
dti-3019	487	1	n	n	PRON
dti-3019	487	2	engl	engl	PROPN
dti-3019	487	3	j	j	PROPN
dti-3019	487	4	med	med	PROPN
dti-3019	487	5	.	.	PUNCT
dti-3019	488	1	2019;380(8):752	2019;380(8):752	NUM
dti-3019	488	2	-	-	SYM
dti-3019	488	3	762	762	NUM
dti-3019	488	4	.	.	PUNCT
dti-3019	489	1	crossref	crossref	PROPN
dti-3019	489	2	pubmed	pubmed	PROPN
dti-3019	489	3	51	51	NUM
dti-3019	489	4	.	.	PUNCT
dti-3019	490	1	borel	borel	PROPN
dti-3019	490	2	jf	jf	PROPN
dti-3019	490	3	.	.	PROPN
dti-3019	490	4	comparative	comparative	ADJ
dti-3019	490	5	study	study	NOUN
dti-3019	490	6	of	of	ADP
dti-3019	490	7	in	in	ADP
dti-3019	490	8	vitro	vitro	X
dti-3019	490	9	and	and	CCONJ
dti-3019	490	10	in	in	ADP
dti-3019	490	11	vivo	vivo	ADJ
dti-3019	490	12	drug	drug	NOUN
dti-3019	490	13	effects	effect	NOUN
dti-3019	490	14	on	on	ADP
dti-3019	490	15	cell	cell	NOUN
dti-3019	490	16	-	-	PUNCT
dti-3019	490	17	mediated	mediate	VERB
dti-3019	490	18	cytotoxicity	cytotoxicity	NOUN
dti-3019	490	19	.	.	PUNCT
dti-3019	491	1	immunology	immunology	NOUN
dti-3019	491	2	.	.	PUNCT
dti-3019	492	1	1976;31(4):631641	1976;31(4):631641	PROPN
dti-3019	492	2	.	.	PUNCT
dti-3019	493	1	pubmed	pubmed	PROPN
dti-3019	493	2	52	52	NUM
dti-3019	493	3	.	.	PUNCT
dti-3019	494	1	tedesco	tedesco	PROPN
dti-3019	494	2	d	d	PROPN
dti-3019	494	3	,	,	PUNCT
dti-3019	494	4	haragsim	haragsim	PROPN
dti-3019	494	5	l.	l.	PROPN
dti-3019	494	6	cyclosporine	cyclosporine	PROPN
dti-3019	494	7	:	:	PUNCT
dti-3019	494	8	a	a	DET
dti-3019	494	9	review	review	NOUN
dti-3019	494	10	.	.	PUNCT
dti-3019	495	1	j	j	PROPN
dti-3019	495	2	transplant	transplant	PROPN
dti-3019	495	3	.	.	PUNCT
dti-3019	496	1	2012;2012:230386	2012;2012:230386	NUM
dti-3019	496	2	.	.	X
dti-3019	497	1	53	53	NUM
dti-3019	497	2	.	.	PUNCT
dti-3019	498	1	lim	lim	PROPN
dti-3019	498	2	sw	sw	PROPN
dti-3019	498	3	,	,	PUNCT
dti-3019	498	4	doh	doh	PROPN
dti-3019	498	5	kc	kc	PROPN
dti-3019	498	6	,	,	PUNCT
dti-3019	498	7	jin	jin	PROPN
dti-3019	498	8	l	l	PROPN
dti-3019	498	9	,	,	PUNCT
dti-3019	498	10	et	et	PROPN
dti-3019	498	11	al	al	PROPN
dti-3019	498	12	.	.	PROPN
dti-3019	498	13	oral	oral	PROPN
dti-3019	498	14	administration	administration	PROPN
dti-3019	498	15	of	of	ADP
dti-3019	498	16	ginseng	ginseng	NOUN
dti-3019	498	17	ameliorates	ameliorate	VERB
dti-3019	498	18	cyclosporine	cyclosporine	ADJ
dti-3019	498	19	-	-	PUNCT
dti-3019	498	20	induced	induce	VERB
dti-3019	498	21	pancreatic	pancreatic	ADJ
dti-3019	498	22	injury	injury	NOUN
dti-3019	498	23	in	in	ADP
dti-3019	498	24	an	an	DET
dti-3019	498	25	experimental	experimental	ADJ
dti-3019	498	26	mouse	mouse	NOUN
dti-3019	498	27	model	model	NOUN
dti-3019	498	28	.	.	PUNCT
dti-3019	499	1	plos	plos	PROPN
dti-3019	499	2	one	one	NUM
dti-3019	499	3	.	.	PUNCT
dti-3019	500	1	2013;8(8):e72685	2013;8(8):e72685	NUM
dti-3019	500	2	.	.	PUNCT
dti-3019	501	1	crossref	crossref	PROPN
dti-3019	501	2	pubmed	pubmed	PROPN
dti-3019	501	3	54	54	NUM
dti-3019	501	4	.	.	PUNCT
dti-3019	502	1	kern	kern	PROPN
dti-3019	502	2	g	g	PROPN
dti-3019	502	3	,	,	PUNCT
dti-3019	502	4	mair	mair	PROPN
dti-3019	502	5	sm	sm	PROPN
dti-3019	502	6	,	,	PUNCT
dti-3019	502	7	noppert	noppert	NOUN
dti-3019	502	8	sj	sj	PROPN
dti-3019	502	9	,	,	PUNCT
dti-3019	502	10	et	et	PROPN
dti-3019	502	11	al	al	PROPN
dti-3019	502	12	.	.	PUNCT
dti-3019	503	1	tacrolimus	tacrolimus	PROPN
dti-3019	503	2	increases	increase	VERB
dti-3019	503	3	nox4	nox4	PROPN
dti-3019	503	4	expression	expression	NOUN
dti-3019	503	5	in	in	ADP
dti-3019	503	6	human	human	ADJ
dti-3019	503	7	renal	renal	ADJ
dti-3019	503	8	fibroblasts	fibroblast	NOUN
dti-3019	503	9	and	and	CCONJ
dti-3019	503	10	induces	induce	VERB
dti-3019	503	11	fibrosisrelated	fibrosisrelated	ADJ
dti-3019	503	12	genes	gene	NOUN
dti-3019	503	13	by	by	ADP
dti-3019	503	14	aberrant	aberrant	ADJ
dti-3019	503	15	tgf	tgf	PROPN
dti-3019	503	16	-	-	PUNCT
dti-3019	503	17	beta	beta	NOUN
dti-3019	503	18	receptor	receptor	NOUN
dti-3019	503	19	signalling	signal	VERB
dti-3019	503	20	.	.	PUNCT
dti-3019	504	1	plos	plos	PROPN
dti-3019	504	2	one	one	NUM
dti-3019	504	3	.	.	PUNCT
dti-3019	505	1	2014;9(5):e96377	2014;9(5):e96377	NOUN
dti-3019	505	2	.	.	PUNCT
dti-3019	506	1	crossref	crossref	PROPN
dti-3019	506	2	pubmed	pubmed	PROPN
dti-3019	506	3	55	55	NUM
dti-3019	506	4	.	.	PUNCT
dti-3019	507	1	thorat	thorat	NOUN
dti-3019	507	2	a	a	NOUN
dti-3019	507	3	,	,	PUNCT
dti-3019	507	4	chou	chou	PROPN
dti-3019	507	5	h	h	PROPN
dti-3019	507	6	-	-	PUNCT
dti-3019	507	7	s	s	PROPN
dti-3019	507	8	,	,	PUNCT
dti-3019	507	9	lee	lee	PROPN
dti-3019	507	10	c	c	PROPN
dti-3019	507	11	-	-	PUNCT
dti-3019	507	12	f	f	PROPN
dti-3019	507	13	,	,	PUNCT
dti-3019	507	14	et	et	PROPN
dti-3019	507	15	al	al	PROPN
dti-3019	507	16	.	.	PUNCT
dti-3019	507	17	effects	effect	NOUN
dti-3019	507	18	of	of	ADP
dti-3019	507	19	converting	convert	VERB
dti-3019	507	20	tacrolimus	tacrolimus	NOUN
dti-3019	507	21	formulation	formulation	NOUN
dti-3019	507	22	from	from	ADP
dti-3019	507	23	twice	twice	ADV
dti-3019	507	24	-	-	PUNCT
dti-3019	507	25	daily	daily	NOUN
dti-3019	507	26	to	to	ADP
dti-3019	507	27	once	once	ADV
dti-3019	507	28	-	-	PUNCT
dti-3019	507	29	daily	daily	ADJ
dti-3019	507	30	in	in	ADP
dti-3019	507	31	liver	liver	NOUN
dti-3019	507	32	transplantation	transplantation	NOUN
dti-3019	507	33	recipients	recipient	NOUN
dti-3019	507	34	.	.	PUNCT
dti-3019	507	35	biomed	biome	VERB
dti-3019	507	36	res	re	NOUN
dti-3019	507	37	int	int	NOUN
dti-3019	507	38	.	.	PUNCT
dti-3019	508	1	2014;2014:265658	2014;2014:265658	NUM
dti-3019	508	2	.	.	X
dti-3019	509	1	56	56	NUM
dti-3019	509	2	.	.	PUNCT
dti-3019	510	1	abdelkader	abdelkader	PROPN
dti-3019	510	2	m	m	PROPN
dti-3019	510	3	,	,	PUNCT
dti-3019	510	4	hilal	hilal	PROPN
dti-3019	510	5	m	m	PROPN
dti-3019	510	6	,	,	PUNCT
dti-3019	510	7	torky	torky	PROPN
dti-3019	510	8	ar	ar	PROPN
dti-3019	510	9	,	,	PUNCT
dti-3019	510	10	elsayed	elsaye	VERB
dti-3019	510	11	h	h	NOUN
dti-3019	510	12	,	,	PUNCT
dti-3019	510	13	allam	allam	PROPN
dti-3019	510	14	w.	w.	PROPN
dti-3019	510	15	experimental	experimental	PROPN
dti-3019	510	16	study	study	NOUN
dti-3019	510	17	of	of	ADP
dti-3019	510	18	renal	renal	ADJ
dti-3019	510	19	toxicity	toxicity	NOUN
dti-3019	510	20	of	of	ADP
dti-3019	510	21	cyclosporine	cyclosporine	NOUN
dti-3019	510	22	and	and	CCONJ
dti-3019	510	23	the	the	DET
dti-3019	510	24	ameliorative	ameliorative	ADJ
dti-3019	510	25	effect	effect	NOUN
dti-3019	510	26	of	of	ADP
dti-3019	510	27	n	n	CCONJ
dti-3019	510	28	-	-	PUNCT
dti-3019	510	29	acetylcysteine	acetylcysteine	NOUN
dti-3019	510	30	in	in	ADP
dti-3019	510	31	albino	albino	NOUN
dti-3019	510	32	rat	rat	NOUN
dti-3019	510	33	.	.	PROPN
dti-3019	510	34	ain	ain	PROPN
dti-3019	510	35	shams	shams	PROPN
dti-3019	510	36	j	j	PROPN
dti-3019	510	37	forensic	forensic	ADJ
dti-3019	510	38	med	med	PROPN
dti-3019	510	39	clin	clin	PROPN
dti-3019	510	40	toxicol	toxicol	PROPN
dti-3019	510	41	.	.	PUNCT
dti-3019	511	1	2021;37(2):8	2021;37(2):8	NUM
dti-3019	511	2	-	-	SYM
dti-3019	511	3	15	15	NUM
dti-3019	511	4	.	.	PUNCT
dti-3019	512	1	crossref	crossref	PROPN
dti-3019	512	2	57	57	NUM
dti-3019	512	3	.	.	PUNCT
dti-3019	513	1	cung	cung	PROPN
dti-3019	513	2	t	t	PROPN
dti-3019	513	3	-	-	PUNCT
dti-3019	513	4	t	t	PROPN
dti-3019	513	5	,	,	PUNCT
dti-3019	513	6	morel	morel	NOUN
dti-3019	513	7	o	o	PROPN
dti-3019	513	8	,	,	PUNCT
dti-3019	513	9	cayla	cayla	NOUN
dti-3019	513	10	g	g	PROPN
dti-3019	513	11	,	,	PUNCT
dti-3019	513	12	et	et	PROPN
dti-3019	513	13	al	al	PROPN
dti-3019	513	14	.	.	PROPN
dti-3019	513	15	cyclosporine	cyclosporine	PROPN
dti-3019	513	16	before	before	SCONJ
dti-3019	513	17	pci	pci	PROPN
dti-3019	513	18	in	in	ADP
dti-3019	513	19	patients	patient	NOUN
dti-3019	513	20	with	with	ADP
dti-3019	513	21	acute	acute	ADJ
dti-3019	513	22	myocardial	myocardial	ADJ
dti-3019	513	23	infarction	infarction	NOUN
dti-3019	513	24	.	.	PUNCT
dti-3019	514	1	n	n	CCONJ
dti-3019	514	2	engl	engl	PROPN
dti-3019	514	3	j	j	PROPN
dti-3019	514	4	med	med	PROPN
dti-3019	514	5	.	.	PUNCT
dti-3019	515	1	2015;373(11):1021	2015;373(11):1021	X
dti-3019	515	2	-	-	SYM
dti-3019	515	3	1031	1031	NUM
dti-3019	515	4	.	.	PUNCT
dti-3019	516	1	crossref	crossref	PROPN
dti-3019	516	2	pubmed	pubmed	PROPN
dti-3019	516	3	58	58	NUM
dti-3019	516	4	.	.	PUNCT
dti-3019	517	1	ottani	ottani	PROPN
dti-3019	517	2	f	f	PROPN
dti-3019	517	3	,	,	PUNCT
dti-3019	517	4	latini	latini	PROPN
dti-3019	517	5	r	r	NOUN
dti-3019	517	6	,	,	PUNCT
dti-3019	517	7	staszewsky	staszewsky	ADJ
dti-3019	517	8	l	l	NOUN
dti-3019	517	9	,	,	PUNCT
dti-3019	517	10	et	et	PROPN
dti-3019	517	11	al	al	PROPN
dti-3019	517	12	;	;	PUNCT
dti-3019	517	13	cycle	cycle	NOUN
dti-3019	517	14	investigators	investigator	NOUN
dti-3019	517	15	.	.	PUNCT
dti-3019	518	1	cyclosporine	cyclosporine	VERB
dti-3019	518	2	a	a	PRON
dti-3019	518	3	in	in	ADP
dti-3019	518	4	reperfused	reperfuse	VERB
dti-3019	518	5	myocardial	myocardial	ADJ
dti-3019	518	6	infarction	infarction	NOUN
dti-3019	518	7	:	:	PUNCT
dti-3019	518	8	the	the	DET
dti-3019	518	9	multicenter	multicenter	NOUN
dti-3019	518	10	,	,	PUNCT
dti-3019	518	11	controlled	control	VERB
dti-3019	518	12	,	,	PUNCT
dti-3019	518	13	open	open	ADJ
dti-3019	518	14	-	-	PUNCT
dti-3019	518	15	label	label	NOUN
dti-3019	518	16	cycle	cycle	NOUN
dti-3019	518	17	trial	trial	NOUN
dti-3019	518	18	.	.	PUNCT
dti-3019	519	1	j	j	PROPN
dti-3019	519	2	am	be	AUX
dti-3019	519	3	coll	coll	PROPN
dti-3019	519	4	cardiol	cardiol	NOUN
dti-3019	519	5	.	.	PUNCT
dti-3019	520	1	2016;67(4):365	2016;67(4):365	NUM
dti-3019	520	2	-	-	SYM
dti-3019	520	3	374	374	NUM
dti-3019	520	4	.	.	PUNCT
dti-3019	521	1	crossref	crossref	PROPN
dti-3019	521	2	pubmed	pubmed	PROPN
dti-3019	521	3	59	59	NUM
dti-3019	521	4	.	.	PUNCT
dti-3019	522	1	elgendy	elgendy	PROPN
dti-3019	522	2	a	a	X
dti-3019	522	3	,	,	PUNCT
dti-3019	522	4	alshawadfy	alshawadfy	PROPN
dti-3019	522	5	e	e	NOUN
dti-3019	522	6	,	,	PUNCT
dti-3019	522	7	altaweel	altaweel	PROPN
dti-3019	522	8	a	a	X
dti-3019	522	9	,	,	PUNCT
dti-3019	522	10	elsaidi	elsaidi	VERB
dti-3019	522	11	a.	a.	NOUN
dti-3019	522	12	cardiovascular	cardiovascular	ADJ
dti-3019	522	13	and	and	CCONJ
dti-3019	522	14	metabolic	metabolic	NOUN
dti-3019	522	15	comorbidities	comorbiditie	NOUN
dti-3019	522	16	of	of	ADP
dti-3019	522	17	psoriasis	psoriasis	NOUN
dti-3019	522	18	.	.	PUNCT
dti-3019	523	1	dermatol	dermatol	NOUN
dti-3019	523	2	case	case	NOUN
dti-3019	523	3	rep	rep	PROPN
dti-3019	523	4	.	.	PROPN
dti-3019	523	5	2016;1(1):1	2016;1(1):1	PROPN
dti-3019	523	6	-	-	PUNCT
dti-3019	523	7	9	9	NUM
dti-3019	523	8	.	.	PUNCT
dti-3019	524	1	crossref	crossref	PROPN
dti-3019	524	2	60	60	NUM
dti-3019	524	3	.	.	PUNCT
dti-3019	525	1	sakamoto	sakamoto	PROPN
dti-3019	525	2	h	h	PROPN
dti-3019	525	3	,	,	PUNCT
dti-3019	525	4	kurabayashi	kurabayashi	PROPN
dti-3019	525	5	m.	m.	NOUN
dti-3019	525	6	cardiovascular	cardiovascular	ADJ
dti-3019	525	7	effects	effect	NOUN
dti-3019	525	8	of	of	ADP
dti-3019	525	9	an	an	DET
dti-3019	525	10	immunosuppressive	immunosuppressive	ADJ
dti-3019	525	11	agent	agent	NOUN
dti-3019	525	12	cyclosporin	cyclosporin	NOUN
dti-3019	525	13	a.	a.	PROPN
dti-3019	525	14	int	int	PROPN
dti-3019	526	1	j	j	PROPN
dti-3019	526	2	immunopathol	immunopathol	PROPN
dti-3019	526	3	pharmacol	pharmacol	PROPN
dti-3019	526	4	.	.	PUNCT
dti-3019	527	1	2000;15(2):75	2000;15(2):75	PROPN
dti-3019	527	2	-	-	SYM
dti-3019	527	3	79	79	NUM
dti-3019	527	4	.	.	PUNCT
dti-3019	528	1	crossref	crossref	PROPN
dti-3019	528	2	pubmed	pubmed	PROPN
dti-3019	528	3	61	61	NUM
dti-3019	528	4	.	.	PUNCT
dti-3019	529	1	grupper	grupper	PROPN
dti-3019	529	2	a	a	PROPN
dti-3019	529	3	,	,	PUNCT
dti-3019	529	4	shashar	shashar	PROPN
dti-3019	529	5	m	m	PROPN
dti-3019	529	6	,	,	PUNCT
dti-3019	529	7	bahry	bahry	PROPN
dti-3019	529	8	d	d	PROPN
dti-3019	529	9	,	,	PUNCT
dti-3019	529	10	et	et	PROPN
dti-3019	529	11	al	al	PROPN
dti-3019	529	12	.	.	PROPN
dti-3019	530	1	cyclosporine	cyclosporine	PROPN
dti-3019	530	2	attenuates	attenuate	NOUN
dti-3019	530	3	arginine	arginine	NOUN
dti-3019	530	4	transport	transport	NOUN
dti-3019	530	5	,	,	PUNCT
dti-3019	530	6	in	in	ADP
dti-3019	530	7	human	human	ADJ
dti-3019	530	8	endothelial	endothelial	ADJ
dti-3019	530	9	cells	cell	NOUN
dti-3019	530	10	,	,	PUNCT
dti-3019	530	11	through	through	ADP
dti-3019	530	12	modulation	modulation	NOUN
dti-3019	530	13	of	of	ADP
dti-3019	530	14	cationic	cationic	ADJ
dti-3019	530	15	amino	amino	NOUN
dti-3019	530	16	acid	acid	NOUN
dti-3019	530	17	transporter-1	transporter-1	PROPN
dti-3019	530	18	.	.	PUNCT
dti-3019	530	19	am	be	AUX
dti-3019	530	20	j	j	PROPN
dti-3019	530	21	nephrol	nephrol	NOUN
dti-3019	530	22	.	.	PUNCT
dti-3019	531	1	2013;37(6):613	2013;37(6):613	NUM
dti-3019	531	2	-	-	SYM
dti-3019	531	3	619	619	NUM
dti-3019	531	4	.	.	PUNCT
dti-3019	532	1	crossref	crossref	PROPN
dti-3019	532	2	pubmed	pubmed	PROPN
dti-3019	532	3	62	62	NUM
dti-3019	532	4	.	.	PUNCT
dti-3019	533	1	michael	michael	PROPN
dti-3019	533	2	aa	aa	PROPN
dti-3019	533	3	,	,	PUNCT
dti-3019	533	4	balakrishnan	balakrishnan	PROPN
dti-3019	533	5	p	p	NOUN
dti-3019	533	6	,	,	PUNCT
dti-3019	533	7	velusamy	velusamy	ADJ
dti-3019	533	8	t.	t.	NOUN
dti-3019	533	9	drug	drug	NOUN
dti-3019	533	10	repurposing	repurpose	VERB
dti-3019	533	11	for	for	ADP
dti-3019	533	12	hematological	hematological	ADJ
dti-3019	533	13	malignancies	malignancy	NOUN
dti-3019	533	14	.	.	PUNCT
dti-3019	534	1	in	in	ADP
dti-3019	534	2	sobti	sobti	PROPN
dti-3019	534	3	rc	rc	PROPN
dti-3019	534	4	,	,	PUNCT
dti-3019	534	5	lal	lal	PROPN
dti-3019	534	6	sk	sk	PROPN
dti-3019	534	7	,	,	PUNCT
dti-3019	534	8	goyal	goyal	PROPN
dti-3019	534	9	rk	rk	PROPN
dti-3019	534	10	,	,	PUNCT
dti-3019	534	11	eds	ed	NOUN
dti-3019	534	12	.	.	PUNCT
dti-3019	535	1	drug	drug	NOUN
dti-3019	535	2	repurposing	repurpose	VERB
dti-3019	535	3	for	for	ADP
dti-3019	535	4	emerging	emerge	VERB
dti-3019	535	5	infectious	infectious	ADJ
dti-3019	535	6	diseases	disease	NOUN
dti-3019	535	7	and	and	CCONJ
dti-3019	535	8	cancer	cancer	NOUN
dti-3019	535	9	,	,	PUNCT
dti-3019	535	10	singapore	singapore	PROPN
dti-3019	535	11	,	,	PUNCT
dti-3019	535	12	springer	springer	NOUN
dti-3019	535	13	;	;	PUNCT
dti-3019	535	14	2023:217	2023:217	NUM
dti-3019	535	15	-	-	SYM
dti-3019	535	16	252	252	NUM
dti-3019	535	17	.	.	PUNCT
dti-3019	536	1	crossref	crossref	PROPN
dti-3019	536	2	63	63	NUM
dti-3019	536	3	.	.	PUNCT
dti-3019	537	1	ioakeim	ioakeim	NOUN
dti-3019	537	2	-	-	PUNCT
dti-3019	537	3	skoufa	skoufa	PROPN
dti-3019	537	4	i	i	PROPN
dti-3019	537	5	,	,	PUNCT
dti-3019	537	6	tobajas	tobajas	PROPN
dti-3019	537	7	-	-	PUNCT
dti-3019	537	8	ramos	ramos	PROPN
dti-3019	537	9	n	n	PROPN
dti-3019	537	10	,	,	PUNCT
dti-3019	537	11	menditto	menditto	NOUN
dti-3019	537	12	e	e	NOUN
dti-3019	537	13	,	,	PUNCT
dti-3019	537	14	et	et	PROPN
dti-3019	537	15	al	al	PROPN
dti-3019	537	16	.	.	PROPN
dti-3019	538	1	drug	drug	NOUN
dti-3019	538	2	repurposing	repurpose	VERB
dti-3019	538	3	in	in	ADP
dti-3019	538	4	oncology	oncology	NOUN
dti-3019	538	5	:	:	PUNCT
dti-3019	538	6	a	a	DET
dti-3019	538	7	systematic	systematic	ADJ
dti-3019	538	8	review	review	NOUN
dti-3019	538	9	of	of	ADP
dti-3019	538	10	randomized	randomized	ADJ
dti-3019	538	11	controlled	control	VERB
dti-3019	538	12	clinical	clinical	ADJ
dti-3019	538	13	trials	trial	NOUN
dti-3019	538	14	.	.	PUNCT
dti-3019	539	1	cancers	cancer	NOUN
dti-3019	539	2	(	(	PUNCT
dti-3019	539	3	basel	basel	PROPN
dti-3019	539	4	)	)	PUNCT
dti-3019	539	5	.	.	PUNCT
dti-3019	540	1	2023;15(11):2972	2023;15(11):2972	NUM
dti-3019	540	2	.	.	PROPN
dti-3019	540	3	crossref	crossref	PROPN
dti-3019	540	4	pubmed	pubmed	PROPN
dti-3019	540	5	64	64	NUM
dti-3019	540	6	.	.	PUNCT
dti-3019	541	1	issa	issa	PROPN
dti-3019	541	2	j	j	PROPN
dti-3019	541	3	-	-	PROPN
dti-3019	541	4	p	p	PROPN
dti-3019	541	5	,	,	PUNCT
dti-3019	541	6	garcia	garcia	PROPN
dti-3019	541	7	-	-	PUNCT
dti-3019	541	8	manero	manero	PROPN
dti-3019	541	9	g	g	PROPN
dti-3019	541	10	,	,	PUNCT
dti-3019	541	11	huang	huang	PROPN
dti-3019	541	12	x	x	PROPN
dti-3019	541	13	,	,	PUNCT
dti-3019	541	14	et	et	PROPN
dti-3019	541	15	al	al	PROPN
dti-3019	541	16	.	.	PROPN
dti-3019	541	17	results	result	NOUN
dti-3019	541	18	of	of	ADP
dti-3019	541	19	phase	phase	NOUN
dti-3019	541	20	2	2	NUM
dti-3019	541	21	randomized	randomized	ADJ
dti-3019	541	22	study	study	NOUN
dti-3019	541	23	of	of	ADP
dti-3019	541	24	low	low	ADJ
dti-3019	541	25	-	-	PUNCT
dti-3019	541	26	dose	dose	NOUN
dti-3019	541	27	decitabine	decitabine	NOUN
dti-3019	541	28	with	with	ADP
dti-3019	541	29	or	or	CCONJ
dti-3019	541	30	without	without	ADP
dti-3019	541	31	valproic	valproic	ADJ
dti-3019	541	32	acid	acid	NOUN
dti-3019	541	33	in	in	ADP
dti-3019	541	34	patients	patient	NOUN
dti-3019	541	35	with	with	ADP
dti-3019	541	36	myelodysplastic	myelodysplastic	ADJ
dti-3019	541	37	syndrome	syndrome	NOUN
dti-3019	541	38	and	and	CCONJ
dti-3019	541	39	acute	acute	ADJ
dti-3019	541	40	myelogenous	myelogenous	ADJ
dti-3019	541	41	leukemia	leukemia	NOUN
dti-3019	541	42	.	.	PUNCT
dti-3019	542	1	cancer	cancer	NOUN
dti-3019	542	2	.	.	PUNCT
dti-3019	543	1	2015;121(4):556	2015;121(4):556	NUM
dti-3019	543	2	-	-	SYM
dti-3019	543	3	561	561	NUM
dti-3019	543	4	.	.	PUNCT
dti-3019	544	1	crossref	crossref	PROPN
dti-3019	544	2	pubmed	pubmed	PROPN
dti-3019	544	3	65	65	NUM
dti-3019	544	4	.	.	PUNCT
dti-3019	545	1	lübbert	lübbert	PROPN
dti-3019	545	2	m	m	PROPN
dti-3019	545	3	,	,	PUNCT
dti-3019	545	4	grishina	grishina	PROPN
dti-3019	545	5	o	o	NOUN
dti-3019	545	6	,	,	PUNCT
dti-3019	545	7	schmoor	schmoor	PROPN
dti-3019	545	8	c	c	NOUN
dti-3019	545	9	,	,	PUNCT
dti-3019	545	10	et	et	PROPN
dti-3019	545	11	al	al	PROPN
dti-3019	545	12	.	.	PROPN
dti-3019	545	13	results	result	NOUN
dti-3019	545	14	of	of	ADP
dti-3019	545	15	the	the	DET
dti-3019	545	16	randomized	randomized	ADJ
dti-3019	545	17	phase	phase	NOUN
dti-3019	545	18	ii	ii	PROPN
dti-3019	545	19	study	study	NOUN
dti-3019	545	20	decider	decider	NOUN
dti-3019	545	21	(	(	PUNCT
dti-3019	545	22	amlsg	amlsg	PROPN
dti-3019	545	23	14	14	NUM
dti-3019	545	24	-	-	SYM
dti-3019	545	25	09	09	NUM
dti-3019	545	26	)	)	PUNCT
dti-3019	545	27	comparing	compare	VERB
dti-3019	545	28	decitabine	decitabine	NOUN
dti-3019	545	29	(	(	PUNCT
dti-3019	545	30	dac	dac	PROPN
dti-3019	545	31	)	)	PUNCT
dti-3019	545	32	with	with	ADP
dti-3019	545	33	or	or	CCONJ
dti-3019	545	34	without	without	ADP
dti-3019	545	35	valproic	valproic	ADJ
dti-3019	545	36	acid	acid	NOUN
dti-3019	545	37	(	(	PUNCT
dti-3019	545	38	vpa	vpa	PROPN
dti-3019	545	39	)	)	PUNCT
dti-3019	545	40	and	and	CCONJ
dti-3019	545	41	with	with	ADP
dti-3019	545	42	or	or	CCONJ
dti-3019	545	43	without	without	ADP
dti-3019	545	44	all	all	PRON
dti-3019	545	45	-	-	PUNCT
dti-3019	545	46	trans	trans	PROPN
dti-3019	545	47	retinoic	retinoic	PROPN
dti-3019	545	48	acid	acid	PROPN
dti-3019	545	49	(	(	PUNCT
dti-3019	545	50	atra	atra	NOUN
dti-3019	545	51	)	)	PUNCT
dti-3019	545	52	add	add	NOUN
dti-3019	545	53	-	-	PUNCT
dti-3019	545	54	on	on	ADP
dti-3019	545	55	in	in	ADP
dti-3019	545	56	newly	newly	ADV
dti-3019	545	57	diagnosed	diagnose	VERB
dti-3019	545	58	elderly	elderly	ADJ
dti-3019	545	59	non	non	ADJ
dti-3019	545	60	-	-	ADJ
dti-3019	545	61	fit	fit	ADJ
dti-3019	545	62	aml	aml	NOUN
dti-3019	545	63	patients	patient	NOUN
dti-3019	545	64	.	.	PUNCT
dti-3019	546	1	blood	blood	NOUN
dti-3019	546	2	.	.	PUNCT
dti-3019	547	1	2016;128(22):589	2016;128(22):589	NUM
dti-3019	547	2	.	.	PUNCT
dti-3019	548	1	crossref	crossref	PROPN
dti-3019	548	2	66	66	NUM
dti-3019	548	3	.	.	PUNCT
dti-3019	549	1	tassara	tassara	PROPN
dti-3019	549	2	m	m	PROPN
dti-3019	549	3	,	,	PUNCT
dti-3019	549	4	döhner	döhner	ADJ
dti-3019	549	5	k	k	NOUN
dti-3019	549	6	,	,	PUNCT
dti-3019	549	7	brossart	brossart	PROPN
dti-3019	549	8	p	p	NOUN
dti-3019	549	9	,	,	PUNCT
dti-3019	549	10	et	et	PROPN
dti-3019	549	11	al	al	PROPN
dti-3019	549	12	.	.	PUNCT
dti-3019	549	13	valproic	valproic	ADJ
dti-3019	549	14	acid	acid	NOUN
dti-3019	549	15	in	in	ADP
dti-3019	549	16	combination	combination	NOUN
dti-3019	549	17	with	with	ADP
dti-3019	549	18	all	all	DET
dti-3019	549	19	-	-	PUNCT
dti-3019	549	20	trans	trans	PROPN
dti-3019	549	21	retinoic	retinoic	NOUN
dti-3019	549	22	acid	acid	PROPN
dti-3019	549	23	and	and	CCONJ
dti-3019	549	24	intensive	intensive	ADJ
dti-3019	549	25	therapy	therapy	NOUN
dti-3019	549	26	for	for	ADP
dti-3019	549	27	acute	acute	ADJ
dti-3019	549	28	myeloid	myeloid	NOUN
dti-3019	549	29	leukemia	leukemia	NOUN
dti-3019	549	30	in	in	ADP
dti-3019	549	31	older	old	ADJ
dti-3019	549	32	patients	patient	NOUN
dti-3019	549	33	.	.	PUNCT
dti-3019	550	1	blood	blood	NOUN
dti-3019	550	2	.	.	PUNCT
dti-3019	551	1	2014;123(26):40274036	2014;123(26):40274036	X
dti-3019	551	2	.	.	PUNCT
dti-3019	551	3	crossref	crossref	PROPN
dti-3019	551	4	pubmed	pubmed	PROPN
dti-3019	551	5	67	67	NUM
dti-3019	551	6	.	.	PUNCT
dti-3019	552	1	wojcicki	wojcicki	PROPN
dti-3019	552	2	av	av	PROPN
dti-3019	552	3	,	,	PUNCT
dti-3019	552	4	kadapakkam	kadapakkam	PROPN
dti-3019	552	5	m	m	PROPN
dti-3019	552	6	,	,	PUNCT
dti-3019	552	7	frymoyer	frymoyer	NOUN
dti-3019	552	8	a	a	NOUN
dti-3019	552	9	,	,	PUNCT
dti-3019	552	10	lacayo	lacayo	NOUN
dti-3019	552	11	n	n	CCONJ
dti-3019	552	12	,	,	PUNCT
dti-3019	552	13	chae	chae	PROPN
dti-3019	552	14	hd	hd	PROPN
dti-3019	552	15	,	,	PUNCT
dti-3019	552	16	sakamoto	sakamoto	PROPN
dti-3019	552	17	km	km	PROPN
dti-3019	552	18	.	.	PUNCT
dti-3019	553	1	repurposing	repurpose	VERB
dti-3019	553	2	drugs	drug	NOUN
dti-3019	553	3	for	for	ADP
dti-3019	553	4	acute	acute	ADJ
dti-3019	553	5	myeloid	myeloid	ADJ
dti-3019	553	6	leukemia	leukemia	NOUN
dti-3019	553	7	:	:	PUNCT
dti-3019	553	8	a	a	DET
dti-3019	553	9	worthy	worthy	ADJ
dti-3019	553	10	cause	cause	NOUN
dti-3019	553	11	or	or	CCONJ
dti-3019	553	12	a	a	DET
dti-3019	553	13	futile	futile	ADJ
dti-3019	553	14	pursuit	pursuit	NOUN
dti-3019	553	15	?	?	PUNCT
dti-3019	554	1	cancers	cancer	NOUN
dti-3019	554	2	(	(	PUNCT
dti-3019	554	3	basel	basel	PROPN
dti-3019	554	4	)	)	PUNCT
dti-3019	554	5	.	.	PUNCT
dti-3019	555	1	2020;12(2):441	2020;12(2):441	NUM
dti-3019	555	2	.	.	PUNCT
dti-3019	556	1	crossref	crossref	PROPN
dti-3019	556	2	pubmed	pubmed	PROPN
dti-3019	556	3	68	68	NUM
dti-3019	556	4	.	.	PUNCT
dti-3019	557	1	zong	zong	PROPN
dti-3019	557	2	n	n	CCONJ
dti-3019	557	3	,	,	PUNCT
dti-3019	557	4	chowdhury	chowdhury	PROPN
dti-3019	557	5	s	s	PROPN
dti-3019	557	6	,	,	PUNCT
dti-3019	557	7	zhou	zhou	PROPN
dti-3019	557	8	s	s	PROPN
dti-3019	557	9	,	,	PUNCT
dti-3019	557	10	et	et	PROPN
dti-3019	557	11	al	al	PROPN
dti-3019	557	12	.	.	PUNCT
dti-3019	557	13	artificial	artificial	ADJ
dti-3019	557	14	intelligence	intelligence	NOUN
dti-3019	557	15	-	-	PUNCT
dti-3019	557	16	based	base	VERB
dti-3019	557	17	efficacy	efficacy	NOUN
dti-3019	557	18	prediction	prediction	NOUN
dti-3019	557	19	of	of	ADP
dti-3019	557	20	phase	phase	NOUN
dti-3019	557	21	3	3	NUM
dti-3019	557	22	clinical	clinical	ADJ
dti-3019	557	23	trial	trial	NOUN
dti-3019	557	24	for	for	ADP
dti-3019	557	25	repurposing	repurpose	VERB
dti-3019	557	26	heart	heart	NOUN
dti-3019	557	27	failure	failure	NOUN
dti-3019	557	28	therapies	therapy	NOUN
dti-3019	557	29	.	.	PUNCT
dti-3019	558	1	medrxiv	medrxiv	PROPN
dti-3019	558	2	,	,	PUNCT
dti-3019	558	3	2023:2023.05.25.23290531	2023:2023.05.25.23290531	NUM
dti-3019	558	4	.	.	PUNCT
dti-3019	559	1	https://doi.org/10.1111/pde.13557	https://doi.org/10.1111/pde.13557	AUX
dti-3019	559	2	https://www.ncbi.nlm.nih.gov/pubmed/30066378	https://www.ncbi.nlm.nih.gov/pubmed/30066378	X
dti-3019	559	3	https://doi.org/10.1161/circinterventions.119.008717	https://doi.org/10.1161/circinterventions.119.008717	PROPN
dti-3019	559	4	https://www.ncbi.nlm.nih.gov/pubmed/32295417	https://www.ncbi.nlm.nih.gov/pubmed/32295417	PUNCT
dti-3019	559	5	https://doi.org/10.1161/circulationaha.121.056177	https://doi.org/10.1161/circulationaha.121.056177	PROPN
dti-3019	559	6	https://www.ncbi.nlm.nih.gov/pubmed/34420373	https://www.ncbi.nlm.nih.gov/pubmed/34420373	NUM
dti-3019	559	7	https://doi.org/10.18433/jpps31877	https://doi.org/10.18433/jpps31877	NOUN
dti-3019	559	8	https://www.ncbi.nlm.nih.gov/pubmed/34224665	https://www.ncbi.nlm.nih.gov/pubmed/34224665	NUM
dti-3019	559	9	https://doi.org/10.1186/s12872-021-02393-9	https://doi.org/10.1186/s12872-021-02393-9	NUM
dti-3019	559	10	https://www.ncbi.nlm.nih.gov/pubmed/34876021	https://www.ncbi.nlm.nih.gov/pubmed/34876021	NUM
dti-3019	559	11	https://doi.org/10.3390/antibiotics11101380	https://doi.org/10.3390/antibiotics11101380	NOUN
dti-3019	559	12	https://www.ncbi.nlm.nih.gov/pubmed/36290037	https://www.ncbi.nlm.nih.gov/pubmed/36290037	NUM
dti-3019	559	13	https://doi.org/10.1038/s41401-021-00835-w	https://doi.org/10.1038/s41401-021-00835-w	NOUN
dti-3019	559	14	https://www.ncbi.nlm.nih.gov/pubmed/35046517	https://www.ncbi.nlm.nih.gov/pubmed/35046517	PUNCT
dti-3019	559	15	https://doi.org/10.1016/j.cardfail.2009.06.439	https://doi.org/10.1016/j.cardfail.2009.06.439	PROPN
dti-3019	559	16	https://www.ncbi.nlm.nih.gov/pubmed/19944358	https://www.ncbi.nlm.nih.gov/pubmed/19944358	PROPN
dti-3019	559	17	https://doi.org/10.1177/1074248417699884	https://doi.org/10.1177/1074248417699884	SYM
dti-3019	559	18	https://www.ncbi.nlm.nih.gov/pubmed/28325070	https://www.ncbi.nlm.nih.gov/pubmed/28325070	NUM
dti-3019	559	19	https://doi.org/10.1056/nejmoa1809798	https://doi.org/10.1056/nejmoa1809798	NOUN
dti-3019	559	20	https://www.ncbi.nlm.nih.gov/pubmed/30415610	https://www.ncbi.nlm.nih.gov/pubmed/30415610	X
dti-3019	560	1	https://www.ncbi.nlm.nih.gov/pubmed/824198	https://www.ncbi.nlm.nih.gov/pubmed/824198	PRON
dti-3019	560	2	https://doi.org/10.1371/journal.pone.0072685	https://doi.org/10.1371/journal.pone.0072685	ADJ
dti-3019	560	3	https://www.ncbi.nlm.nih.gov/pubmed/24009697	https://www.ncbi.nlm.nih.gov/pubmed/24009697	PUNCT
dti-3019	560	4	https://doi.org/10.1371/journal.pone.0096377	https://doi.org/10.1371/journal.pone.0096377	NOUN
dti-3019	560	5	https://www.ncbi.nlm.nih.gov/pubmed/24816588	https://www.ncbi.nlm.nih.gov/pubmed/24816588	X
dti-3019	561	1	https://doi.org/10.21608/ajfm.2021.174400	https://doi.org/10.21608/ajfm.2021.174400	PROPN
dti-3019	561	2	https://doi.org/10.1056/nejmoa1505489	https://doi.org/10.1056/nejmoa1505489	NOUN
dti-3019	561	3	https://www.ncbi.nlm.nih.gov/pubmed/26321103	https://www.ncbi.nlm.nih.gov/pubmed/26321103	NUM
dti-3019	561	4	https://doi.org/10.1016/j.jacc.2015.10.081	https://doi.org/10.1016/j.jacc.2015.10.081	PROPN
dti-3019	561	5	https://www.ncbi.nlm.nih.gov/pubmed/26821623	https://www.ncbi.nlm.nih.gov/pubmed/26821623	NUM
dti-3019	561	6	https://doi.org/10.35248/2684-124x.16.1.106	https://doi.org/10.35248/2684-124x.16.1.106	NOUN
dti-3019	561	7	https://doi.org/10.1177/039463200201500201	https://doi.org/10.1177/039463200201500201	NOUN
dti-3019	561	8	https://www.ncbi.nlm.nih.gov/pubmed/12590868	https://www.ncbi.nlm.nih.gov/pubmed/12590868	PRON
dti-3019	561	9	https://doi.org/10.1159/000350614	https://doi.org/10.1159/000350614	X
dti-3019	561	10	https://www.ncbi.nlm.nih.gov/pubmed/23796541	https://www.ncbi.nlm.nih.gov/pubmed/23796541	X
dti-3019	561	11	https://doi.org/10.1007/978-981-19-5399-6_11	https://doi.org/10.1007/978-981-19-5399-6_11	X
dti-3019	561	12	https://doi.org/10.3390/cancers15112972	https://doi.org/10.3390/cancers15112972	PROPN
dti-3019	561	13	https://www.ncbi.nlm.nih.gov/pubmed/37296934	https://www.ncbi.nlm.nih.gov/pubmed/37296934	X
dti-3019	561	14	https://doi.org/10.1002/cncr.29085	https://doi.org/10.1002/cncr.29085	NOUN
dti-3019	561	15	https://www.ncbi.nlm.nih.gov/pubmed/25336333	https://www.ncbi.nlm.nih.gov/pubmed/25336333	NUM
dti-3019	561	16	https://doi.org/10.1182/blood.v128.22.589.589	https://doi.org/10.1182/blood.v128.22.589.589	PROPN
dti-3019	561	17	https://doi.org/10.1182/blood-2013-12-546283	https://doi.org/10.1182/blood-2013-12-546283	NUM
dti-3019	561	18	https://www.ncbi.nlm.nih.gov/pubmed/24797300	https://www.ncbi.nlm.nih.gov/pubmed/24797300	NUM
dti-3019	561	19	https://doi.org/10.3390/cancers12020441	https://doi.org/10.3390/cancers12020441	NOUN
dti-3019	561	20	https://www.ncbi.nlm.nih.gov/pubmed/32069925	https://www.ncbi.nlm.nih.gov/pubmed/32069925	ADP
dti-3019	561	21	the	the	DET
dti-3019	561	22	dark	dark	ADJ
dti-3019	561	23	side	side	NOUN
dti-3019	561	24	of	of	ADP
dti-3019	561	25	drug	drug	NOUN
dti-3019	561	26	repurposing18	repurposing18	NOUN
dti-3019	561	27	©	©	ADP
dti-3019	561	28	2024	2024	NUM
dti-3019	561	29	the	the	DET
dti-3019	561	30	authors	author	NOUN
dti-3019	561	31	.	.	PUNCT
dti-3019	562	1	drug	drug	NOUN
dti-3019	562	2	target	target	NOUN
dti-3019	562	3	insights	insight	NOUN
dti-3019	562	4	issn	issn	VERB
dti-3019	562	5	1177	1177	NUM
dti-3019	562	6	-	-	SYM
dti-3019	562	7	3928	3928	NUM
dti-3019	562	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-3019	562	9	69	69	NUM
dti-3019	562	10	.	.	PUNCT
dti-3019	563	1	turner	turner	PROPN
dti-3019	563	2	n	n	PROPN
dti-3019	563	3	,	,	PUNCT
dti-3019	563	4	zeng	zeng	PROPN
dti-3019	563	5	x	x	PROPN
dti-3019	563	6	-	-	PROPN
dti-3019	563	7	y	y	PROPN
dti-3019	563	8	,	,	PUNCT
dti-3019	563	9	osborne	osborne	PROPN
dti-3019	563	10	b	b	PROPN
dti-3019	563	11	,	,	PUNCT
dti-3019	563	12	rogers	rogers	PROPN
dti-3019	563	13	s	s	PROPN
dti-3019	563	14	,	,	PUNCT
dti-3019	563	15	ye	ye	PROPN
dti-3019	563	16	j	j	NOUN
dti-3019	563	17	-	-	PUNCT
dti-3019	563	18	m.	m.	NOUN
dti-3019	563	19	repurposing	repurpose	VERB
dti-3019	563	20	drugs	drug	NOUN
dti-3019	563	21	to	to	PART
dti-3019	563	22	target	target	VERB
dti-3019	563	23	the	the	DET
dti-3019	563	24	diabetes	diabetes	NOUN
dti-3019	563	25	epidemic	epidemic	NOUN
dti-3019	563	26	.	.	PUNCT
dti-3019	564	1	trends	trend	NOUN
dti-3019	564	2	pharmacol	pharmacol	PROPN
dti-3019	564	3	sci	sci	PROPN
dti-3019	564	4	.	.	PUNCT
dti-3019	565	1	2016;37(5):379	2016;37(5):379	NUM
dti-3019	565	2	-	-	PUNCT
dti-3019	565	3	389	389	NUM
dti-3019	565	4	.	.	PUNCT
dti-3019	566	1	crossref	crossref	PROPN
dti-3019	566	2	pubmed	pubmed	PROPN
dti-3019	566	3	70	70	PROPN
dti-3019	566	4	.	.	PUNCT
dti-3019	567	1	mandrup	mandrup	NOUN
dti-3019	567	2	-	-	PUNCT
dti-3019	567	3	poulsen	poulsen	NOUN
dti-3019	567	4	t.	t.	PROPN
dti-3019	567	5	perspective	perspective	NOUN
dti-3019	567	6	:	:	PUNCT
dti-3019	567	7	testing	testing	NOUN
dti-3019	567	8	failures	failure	NOUN
dti-3019	567	9	.	.	PUNCT
dti-3019	568	1	nature	nature	NOUN
dti-3019	568	2	.	.	PUNCT
dti-3019	569	1	2012;485(7398):s17	2012;485(7398):s17	NUM
dti-3019	569	2	.	.	PUNCT
dti-3019	570	1	crossref	crossref	PROPN
dti-3019	570	2	pubmed	pubmed	PROPN
dti-3019	570	3	71	71	NUM
dti-3019	570	4	.	.	PUNCT
dti-3019	571	1	mantik	mantik	PROPN
dti-3019	571	2	kek	kek	PROPN
dti-3019	571	3	,	,	PUNCT
dti-3019	571	4	kim	kim	PROPN
dti-3019	571	5	s	s	PROPN
dti-3019	571	6	,	,	PUNCT
dti-3019	571	7	gu	gu	NOUN
dti-3019	571	8	b	b	PROPN
dti-3019	571	9	,	,	PUNCT
dti-3019	571	10	et	et	PROPN
dti-3019	571	11	al	al	PROPN
dti-3019	571	12	.	.	PUNCT
dti-3019	572	1	repositioning	reposition	VERB
dti-3019	572	2	of	of	ADP
dti-3019	572	3	anti	anti	ADJ
dti-3019	572	4	-	-	ADJ
dti-3019	572	5	diabetic	diabetic	ADJ
dti-3019	572	6	drugs	drug	NOUN
dti-3019	572	7	against	against	ADP
dti-3019	572	8	dementia	dementia	NOUN
dti-3019	572	9	:	:	PUNCT
dti-3019	572	10	insight	insight	NOUN
dti-3019	572	11	from	from	ADP
dti-3019	572	12	molecular	molecular	ADJ
dti-3019	572	13	perspectives	perspective	NOUN
dti-3019	572	14	to	to	ADP
dti-3019	572	15	clinical	clinical	ADJ
dti-3019	572	16	trials	trial	NOUN
dti-3019	572	17	.	.	PUNCT
dti-3019	573	1	int	int	PROPN
dti-3019	573	2	j	j	PROPN
dti-3019	573	3	mol	mol	ADP
dti-3019	573	4	sci	sci	PROPN
dti-3019	573	5	.	.	PUNCT
dti-3019	574	1	2023;24(14):11450	2023;24(14):11450	X
dti-3019	574	2	.	.	PUNCT
dti-3019	574	3	crossref	crossref	PROPN
dti-3019	574	4	pubmed	pubmed	PROPN
dti-3019	574	5	72	72	NUM
dti-3019	574	6	.	.	PUNCT
dti-3019	575	1	pathak	pathak	PROPN
dti-3019	575	2	k	k	PROPN
dti-3019	575	3	,	,	PUNCT
dti-3019	575	4	pathak	pathak	PROPN
dti-3019	575	5	mp	mp	PROPN
dti-3019	575	6	,	,	PUNCT
dti-3019	575	7	saikia	saikia	ADJ
dti-3019	575	8	r	r	PROPN
dti-3019	575	9	,	,	PUNCT
dti-3019	575	10	et	et	PROPN
dti-3019	575	11	al	al	PROPN
dti-3019	575	12	.	.	PUNCT
dti-3019	576	1	therapeutic	therapeutic	ADJ
dti-3019	576	2	repurposing	repurposing	NOUN
dti-3019	576	3	of	of	ADP
dti-3019	576	4	antidiabetic	antidiabetic	ADJ
dti-3019	576	5	drugs	drug	NOUN
dti-3019	576	6	in	in	ADP
dti-3019	576	7	diabetes	diabetes	NOUN
dti-3019	576	8	-	-	PUNCT
dti-3019	576	9	associated	associate	VERB
dti-3019	576	10	comorbidities	comorbiditie	NOUN
dti-3019	576	11	.	.	PUNCT
dti-3019	577	1	curr	curr	PROPN
dti-3019	577	2	drug	drug	PROPN
dti-3019	577	3	ther	ther	PROPN
dti-3019	577	4	.	.	PUNCT
dti-3019	578	1	2024;19(2):178	2024;19(2):178	NUM
dti-3019	578	2	-	-	PUNCT
dti-3019	578	3	194	194	NUM
dti-3019	578	4	.	.	PUNCT
dti-3019	579	1	73	73	NUM
dti-3019	579	2	.	.	PUNCT
dti-3019	580	1	haddad	haddad	PROPN
dti-3019	580	2	f	f	PROPN
dti-3019	580	3	,	,	PUNCT
dti-3019	580	4	dokmak	dokmak	PROPN
dti-3019	580	5	g	g	PROPN
dti-3019	580	6	,	,	PUNCT
dti-3019	580	7	bader	bader	PROPN
dti-3019	580	8	m	m	PROPN
dti-3019	580	9	,	,	PUNCT
dti-3019	580	10	karaman	karaman	PROPN
dti-3019	580	11	r.	r.	PROPN
dti-3019	580	12	a	a	DET
dti-3019	580	13	comprehensive	comprehensive	ADJ
dti-3019	580	14	review	review	NOUN
dti-3019	580	15	on	on	ADP
dti-3019	580	16	weight	weight	NOUN
dti-3019	580	17	loss	loss	NOUN
dti-3019	580	18	associated	associate	VERB
dti-3019	580	19	with	with	ADP
dti-3019	580	20	anti	anti	ADJ
dti-3019	580	21	-	-	ADJ
dti-3019	580	22	diabetic	diabetic	ADJ
dti-3019	580	23	medications	medication	NOUN
dti-3019	580	24	.	.	PUNCT
dti-3019	581	1	life	life	NOUN
dti-3019	581	2	(	(	PUNCT
dti-3019	581	3	basel	basel	PROPN
dti-3019	581	4	)	)	PUNCT
dti-3019	581	5	.	.	PUNCT
dti-3019	582	1	2023;13(4):1012	2023;13(4):1012	NUM
dti-3019	582	2	.	.	PUNCT
dti-3019	583	1	crossref	crossref	PROPN
dti-3019	583	2	pubmed	pubmed	PROPN
dti-3019	583	3	74	74	NUM
dti-3019	583	4	.	.	PUNCT
dti-3019	584	1	gussow	gussow	PROPN
dti-3019	584	2	l.	l.	PROPN
dti-3019	584	3	more	more	ADJ
dti-3019	584	4	questions	question	NOUN
dti-3019	584	5	than	than	ADP
dti-3019	584	6	answers	answer	NOUN
dti-3019	584	7	about	about	ADP
dti-3019	584	8	injectable	injectable	ADJ
dti-3019	584	9	weight	weight	NOUN
dti-3019	584	10	loss	loss	NOUN
dti-3019	584	11	drugs	drug	NOUN
dti-3019	584	12	.	.	PUNCT
dti-3019	585	1	emerg	emerg	PROPN
dti-3019	585	2	med	med	PROPN
dti-3019	585	3	news	news	PROPN
dti-3019	585	4	.	.	PUNCT
dti-3019	586	1	2023;45(7):10	2023;45(7):10	X
dti-3019	586	2	.	.	PUNCT
dti-3019	586	3	crossref	crossref	PROPN
dti-3019	586	4	75	75	NUM
dti-3019	586	5	.	.	PUNCT
dti-3019	587	1	natsheh	natsheh	PROPN
dti-3019	587	2	iy	iy	PROPN
dti-3019	587	3	,	,	PUNCT
dti-3019	587	4	elkhader	elkhader	PROPN
dti-3019	587	5	mt	mt	PROPN
dti-3019	587	6	,	,	PUNCT
dti-3019	587	7	al	al	PROPN
dti-3019	587	8	-	-	PUNCT
dti-3019	587	9	bakheit	bakheit	PROPN
dti-3019	587	10	aa	aa	NOUN
dti-3019	587	11	,	,	PUNCT
dti-3019	587	12	et	et	PROPN
dti-3019	587	13	al	al	PROPN
dti-3019	587	14	.	.	PROPN
dti-3019	587	15	inhibition	inhibition	NOUN
dti-3019	587	16	of	of	ADP
dti-3019	587	17	acinetobacter	acinetobacter	ADJ
dti-3019	587	18	baumannii	baumannii	ADJ
dti-3019	587	19	biofilm	biofilm	NOUN
dti-3019	587	20	formation	formation	NOUN
dti-3019	587	21	using	use	VERB
dti-3019	587	22	different	different	ADJ
dti-3019	587	23	treatments	treatment	NOUN
dti-3019	587	24	of	of	ADP
dti-3019	587	25	silica	silica	NOUN
dti-3019	587	26	nanoparticles	nanoparticle	NOUN
dti-3019	587	27	.	.	PUNCT
dti-3019	588	1	antibiotics	antibiotic	NOUN
dti-3019	588	2	(	(	PUNCT
dti-3019	588	3	basel	basel	PROPN
dti-3019	588	4	)	)	PUNCT
dti-3019	588	5	.	.	PUNCT
dti-3019	589	1	2023	2023	NUM
dti-3019	589	2	;	;	PUNCT
dti-3019	589	3	12(9):1365	12(9):1365	NUM
dti-3019	589	4	.	.	PUNCT
dti-3019	590	1	crossref	crossref	PROPN
dti-3019	590	2	pubmed	pubmed	PROPN
dti-3019	590	3	76	76	PROPN
dti-3019	590	4	.	.	PUNCT
dti-3019	591	1	wang	wang	PROPN
dti-3019	591	2	y	y	PROPN
dti-3019	591	3	,	,	PUNCT
dti-3019	591	4	lu	lu	PROPN
dti-3019	591	5	j	j	PROPN
dti-3019	591	6	,	,	PUNCT
dti-3019	591	7	engelstädter	engelstädter	PROPN
dti-3019	591	8	j	j	PROPN
dti-3019	591	9	,	,	PUNCT
dti-3019	591	10	et	et	PROPN
dti-3019	591	11	al	al	PROPN
dti-3019	591	12	.	.	PUNCT
dti-3019	592	1	non	non	ADJ
dti-3019	592	2	-	-	ADJ
dti-3019	592	3	antibiotic	antibiotic	ADJ
dti-3019	592	4	pharmaceuticals	pharmaceutical	NOUN
dti-3019	592	5	enhance	enhance	VERB
dti-3019	592	6	the	the	DET
dti-3019	592	7	transmission	transmission	NOUN
dti-3019	592	8	of	of	ADP
dti-3019	592	9	exogenous	exogenous	ADJ
dti-3019	592	10	antibiotic	antibiotic	ADJ
dti-3019	592	11	resistance	resistance	NOUN
dti-3019	592	12	genes	gene	NOUN
dti-3019	592	13	through	through	ADP
dti-3019	592	14	bacterial	bacterial	ADJ
dti-3019	592	15	transformation	transformation	NOUN
dti-3019	592	16	.	.	PUNCT
dti-3019	593	1	isme	isme	PROPN
dti-3019	593	2	j.	j.	PROPN
dti-3019	593	3	2020;14(8):2179	2020;14(8):2179	PROPN
dti-3019	593	4	-	-	PUNCT
dti-3019	593	5	2196	2196	NUM
dti-3019	593	6	.	.	PUNCT
dti-3019	594	1	crossref	crossref	PROPN
dti-3019	594	2	pubmed	pubmed	PROPN
dti-3019	594	3	77	77	NUM
dti-3019	594	4	.	.	PUNCT
dti-3019	595	1	stevenson	stevenson	PROPN
dti-3019	595	2	c	c	PROPN
dti-3019	595	3	,	,	PUNCT
dti-3019	595	4	hall	hall	PROPN
dti-3019	595	5	jp	jp	PROPN
dti-3019	595	6	,	,	PUNCT
dti-3019	595	7	harrison	harrison	PROPN
dti-3019	595	8	e	e	PROPN
dti-3019	595	9	,	,	PUNCT
dti-3019	595	10	wood	wood	NOUN
dti-3019	595	11	a	a	PRON
dti-3019	595	12	,	,	PUNCT
dti-3019	595	13	brockhurst	brockhurst	PROPN
dti-3019	595	14	ma	ma	PROPN
dti-3019	595	15	.	.	PROPN
dti-3019	595	16	gene	gene	NOUN
dti-3019	595	17	mobility	mobility	NOUN
dti-3019	595	18	promotes	promote	VERB
dti-3019	595	19	the	the	DET
dti-3019	595	20	spread	spread	NOUN
dti-3019	595	21	of	of	ADP
dti-3019	595	22	resistance	resistance	NOUN
dti-3019	595	23	in	in	ADP
dti-3019	595	24	bacterial	bacterial	ADJ
dti-3019	595	25	populations	population	NOUN
dti-3019	595	26	.	.	PUNCT
dti-3019	596	1	isme	isme	PROPN
dti-3019	596	2	j.	j.	PROPN
dti-3019	596	3	2017;11(8):1930	2017;11(8):1930	PROPN
dti-3019	596	4	-	-	SYM
dti-3019	596	5	1932	1932	NUM
dti-3019	596	6	.	.	PUNCT
dti-3019	597	1	crossref	crossref	PROPN
dti-3019	597	2	pubmed	pubmed	PROPN
dti-3019	597	3	78	78	NUM
dti-3019	597	4	.	.	PUNCT
dti-3019	598	1	gillings	gilling	NOUN
dti-3019	598	2	mr	mr	PROPN
dti-3019	598	3	,	,	PUNCT
dti-3019	598	4	gaze	gaze	NOUN
dti-3019	598	5	wh	wh	PROPN
dti-3019	598	6	,	,	PUNCT
dti-3019	598	7	pruden	pruden	VERB
dti-3019	598	8	a	a	PRON
dti-3019	598	9	,	,	PUNCT
dti-3019	598	10	et	et	PROPN
dti-3019	598	11	al	al	PROPN
dti-3019	598	12	.	.	PUNCT
dti-3019	599	1	using	use	VERB
dti-3019	599	2	the	the	DET
dti-3019	599	3	class	class	NOUN
dti-3019	599	4	1	1	NUM
dti-3019	599	5	integron	integron	NOUN
dti-3019	599	6	-	-	PUNCT
dti-3019	599	7	integrase	integrase	NOUN
dti-3019	599	8	gene	gene	NOUN
dti-3019	599	9	as	as	ADP
dti-3019	599	10	a	a	DET
dti-3019	599	11	proxy	proxy	NOUN
dti-3019	599	12	for	for	ADP
dti-3019	599	13	anthropogenic	anthropogenic	ADJ
dti-3019	599	14	pollution	pollution	NOUN
dti-3019	599	15	.	.	PUNCT
dti-3019	600	1	isme	isme	PROPN
dti-3019	600	2	j.	j.	PROPN
dti-3019	600	3	2015;9(6):1269	2015;9(6):1269	PROPN
dti-3019	600	4	-	-	PROPN
dti-3019	600	5	1279	1279	NUM
dti-3019	600	6	.	.	PUNCT
dti-3019	600	7	79	79	NUM
dti-3019	600	8	.	.	PUNCT
dti-3019	601	1	chawla	chawla	PROPN
dti-3019	601	2	m	m	PROPN
dti-3019	601	3	,	,	PUNCT
dti-3019	601	4	verma	verma	PROPN
dti-3019	601	5	j	j	PROPN
dti-3019	601	6	,	,	PUNCT
dti-3019	601	7	gupta	gupta	PROPN
dti-3019	601	8	r	r	PROPN
dti-3019	601	9	,	,	PUNCT
dti-3019	601	10	das	das	PROPN
dti-3019	601	11	b.	b.	PROPN
dti-3019	601	12	antibiotic	antibiotic	ADJ
dti-3019	601	13	potentiators	potentiator	NOUN
dti-3019	601	14	against	against	ADP
dti-3019	601	15	multidrug	multidrug	NOUN
dti-3019	601	16	-	-	PUNCT
dti-3019	601	17	resistant	resistant	ADJ
dti-3019	601	18	bacteria	bacteria	NOUN
dti-3019	601	19	:	:	PUNCT
dti-3019	601	20	discovery	discovery	NOUN
dti-3019	601	21	,	,	PUNCT
dti-3019	601	22	development	development	NOUN
dti-3019	601	23	,	,	PUNCT
dti-3019	601	24	and	and	CCONJ
dti-3019	601	25	clinical	clinical	ADJ
dti-3019	601	26	relevance	relevance	NOUN
dti-3019	601	27	.	.	PUNCT
dti-3019	602	1	front	front	ADJ
dti-3019	602	2	microbiol	microbiol	NOUN
dti-3019	602	3	.	.	PUNCT
dti-3019	603	1	2022;13(887251	2022;13(887251	NUM
dti-3019	603	2	):	):	PUNCT
dti-3019	603	3	887251	887251	NUM
dti-3019	603	4	.	.	PUNCT
dti-3019	604	1	crossref	crossref	PROPN
dti-3019	604	2	pubmed	pubmed	PROPN
dti-3019	604	3	80	80	NUM
dti-3019	604	4	.	.	PUNCT
dti-3019	605	1	cunningham	cunningham	PROPN
dti-3019	605	2	sa	sa	PROPN
dti-3019	605	3	,	,	PUNCT
dti-3019	605	4	rodriguez	rodriguez	PROPN
dti-3019	605	5	c	c	PROPN
dti-3019	605	6	,	,	PUNCT
dti-3019	605	7	woerther	woerther	ADJ
dti-3019	605	8	p	p	NOUN
dti-3019	605	9	-	-	PUNCT
dti-3019	605	10	l	l	NOUN
dti-3019	605	11	,	,	PUNCT
dti-3019	605	12	et	et	PROPN
dti-3019	605	13	al	al	PROPN
dti-3019	605	14	.	.	PROPN
dti-3019	606	1	in	in	ADP
dti-3019	606	2	vivo	vivo	ADJ
dti-3019	606	3	emergence	emergence	NOUN
dti-3019	606	4	of	of	ADP
dti-3019	606	5	dual	dual	ADJ
dti-3019	606	6	resistance	resistance	NOUN
dti-3019	606	7	to	to	PART
dti-3019	606	8	rifampin	rifampin	VERB
dti-3019	606	9	and	and	CCONJ
dti-3019	606	10	levofloxacin	levofloxacin	NOUN
dti-3019	606	11	in	in	ADP
dti-3019	606	12	osteoarticular	osteoarticular	ADJ
dti-3019	606	13	cutibacterium	cutibacterium	ADJ
dti-3019	606	14	avidum	avidum	NOUN
dti-3019	606	15	.	.	PUNCT
dti-3019	607	1	microbiol	microbiol	PROPN
dti-3019	607	2	spectr	spectr	PROPN
dti-3019	607	3	.	.	PUNCT
dti-3019	608	1	2023;11(4):e0368722	2023;11(4):e0368722	NUM
dti-3019	608	2	.	.	NOUN
dti-3019	608	3	81	81	NUM
dti-3019	608	4	.	.	PUNCT
dti-3019	609	1	dulyayangkul	dulyayangkul	PROPN
dti-3019	609	2	p	p	PROPN
dti-3019	609	3	,	,	PUNCT
dti-3019	609	4	calvopiña	calvopiña	ADJ
dti-3019	609	5	k	k	PROPN
dti-3019	609	6	,	,	PUNCT
dti-3019	609	7	heesom	heesom	INTJ
dti-3019	609	8	kj	kj	PROPN
dti-3019	609	9	,	,	PUNCT
dti-3019	609	10	avison	avison	PROPN
dti-3019	609	11	mb	mb	PROPN
dti-3019	609	12	.	.	PROPN
dti-3019	609	13	novel	novel	ADJ
dti-3019	609	14	mechanisms	mechanism	NOUN
dti-3019	609	15	of	of	ADP
dti-3019	609	16	efflux	efflux	NOUN
dti-3019	609	17	-	-	PUNCT
dti-3019	609	18	mediated	mediate	VERB
dti-3019	609	19	levofloxacin	levofloxacin	NOUN
dti-3019	609	20	resistance	resistance	NOUN
dti-3019	609	21	and	and	CCONJ
dti-3019	609	22	reduced	reduce	VERB
dti-3019	609	23	amikacin	amikacin	PROPN
dti-3019	609	24	susceptibility	susceptibility	NOUN
dti-3019	609	25	in	in	ADP
dti-3019	609	26	stenotrophomonas	stenotrophomona	NOUN
dti-3019	609	27	maltophilia	maltophilia	PROPN
dti-3019	609	28	.	.	PUNCT
dti-3019	610	1	antimicrob	antimicrob	PROPN
dti-3019	610	2	agents	agents	PROPN
dti-3019	610	3	chemother	chemother	PROPN
dti-3019	610	4	.	.	PUNCT
dti-3019	611	1	2020;65(1):e01284	2020;65(1):e01284	NUM
dti-3019	611	2	-	-	SYM
dti-3019	611	3	20	20	NUM
dti-3019	611	4	.	.	PUNCT
dti-3019	612	1	crossref	crossref	PROPN
dti-3019	612	2	pubmed	pubmed	PROPN
dti-3019	612	3	82	82	NUM
dti-3019	612	4	.	.	PUNCT
dti-3019	613	1	zając	zając	PROPN
dti-3019	613	2	om	om	PROPN
dti-3019	613	3	,	,	PUNCT
dti-3019	613	4	tyski	tyski	NOUN
dti-3019	613	5	s	s	PROPN
dti-3019	613	6	,	,	PUNCT
dti-3019	613	7	laudy	laudy	PROPN
dti-3019	613	8	ae	ae	PROPN
dti-3019	613	9	.	.	PUNCT
dti-3019	614	1	the	the	DET
dti-3019	614	2	contribution	contribution	NOUN
dti-3019	614	3	of	of	ADP
dti-3019	614	4	efflux	efflux	NOUN
dti-3019	614	5	systems	system	NOUN
dti-3019	614	6	to	to	ADP
dti-3019	614	7	levofloxacin	levofloxacin	PROPN
dti-3019	614	8	resistance	resistance	NOUN
dti-3019	614	9	in	in	ADP
dti-3019	614	10	stenotrophomonas	stenotrophomonas	PROPN
dti-3019	614	11	maltophilia	maltophilia	VERB
dti-3019	614	12	clinical	clinical	ADJ
dti-3019	614	13	strains	strain	NOUN
dti-3019	614	14	isolated	isolate	VERB
dti-3019	614	15	in	in	ADP
dti-3019	614	16	warsaw	warsaw	PROPN
dti-3019	614	17	,	,	PUNCT
dti-3019	614	18	poland	poland	PROPN
dti-3019	614	19	.	.	PUNCT
dti-3019	615	1	biology	biology	NOUN
dti-3019	615	2	(	(	PUNCT
dti-3019	615	3	basel	basel	PROPN
dti-3019	615	4	)	)	PUNCT
dti-3019	615	5	.	.	PUNCT
dti-3019	616	1	2022;11(7):1044	2022;11(7):1044	PROPN
dti-3019	616	2	.	.	PUNCT
dti-3019	617	1	crossref	crossref	PROPN
dti-3019	617	2	pubmed	pubmed	PROPN
dti-3019	617	3	83	83	NUM
dti-3019	617	4	.	.	PUNCT
dti-3019	618	1	ramdhani	ramdhani	PROPN
dti-3019	618	2	d	d	NOUN
dti-3019	618	3	,	,	PUNCT
dti-3019	618	4	azizah	azizah	PROPN
dti-3019	618	5	sn	sn	PROPN
dti-3019	618	6	,	,	PUNCT
dti-3019	618	7	kusuma	kusuma	PROPN
dti-3019	618	8	saf	saf	PROPN
dti-3019	618	9	,	,	PUNCT
dti-3019	618	10	sediana	sediana	PROPN
dti-3019	618	11	d.	d.	PROPN
dti-3019	618	12	antibiotic	antibiotic	PROPN
dti-3019	618	13	resistance	resistance	NOUN
dti-3019	618	14	:	:	PUNCT
dti-3019	618	15	evaluation	evaluation	NOUN
dti-3019	618	16	of	of	ADP
dti-3019	618	17	levofloxacin	levofloxacin	NOUN
dti-3019	618	18	treatment	treatment	NOUN
dti-3019	618	19	in	in	ADP
dti-3019	618	20	acute	acute	ADJ
dti-3019	618	21	respiratory	respiratory	ADJ
dti-3019	618	22	tract	tract	NOUN
dti-3019	618	23	infections	infection	NOUN
dti-3019	618	24	cases	case	NOUN
dti-3019	618	25	at	at	ADP
dti-3019	618	26	the	the	DET
dti-3019	618	27	tasikmalaya	tasikmalaya	NOUN
dti-3019	618	28	city	city	PROPN
dti-3019	618	29	health	health	PROPN
dti-3019	618	30	center	center	PROPN
dti-3019	618	31	,	,	PUNCT
dti-3019	618	32	indonesia	indonesia	PROPN
dti-3019	618	33	.	.	PUNCT
dti-3019	619	1	j	j	PROPN
dti-3019	619	2	adv	adv	PROPN
dti-3019	619	3	pharm	pharm	PROPN
dti-3019	619	4	technol	technol	NOUN
dti-3019	619	5	res	re	NOUN
dti-3019	619	6	.	.	PUNCT
dti-3019	620	1	2020;11(3):113116	2020;11(3):113116	NUM
dti-3019	620	2	.	.	PUNCT
dti-3019	621	1	crossref	crossref	PROPN
dti-3019	621	2	pubmed	pubmed	PROPN
dti-3019	621	3	84	84	NUM
dti-3019	621	4	.	.	PUNCT
dti-3019	622	1	trespalacios	trespalacio	NOUN
dti-3019	622	2	-	-	PUNCT
dti-3019	622	3	rangél	rangél	PROPN
dti-3019	622	4	aa	aa	PROPN
dti-3019	622	5	,	,	PUNCT
dti-3019	622	6	otero	otero	PROPN
dti-3019	622	7	w	w	PROPN
dti-3019	622	8	,	,	PUNCT
dti-3019	622	9	arévalo	arévalo	NOUN
dti-3019	622	10	-	-	PUNCT
dti-3019	622	11	galvis	galvis	VERB
dti-3019	622	12	a	a	PRON
dti-3019	622	13	,	,	PUNCT
dti-3019	622	14	poutoupiñales	poutoupiñale	NOUN
dti-3019	622	15	ra	ra	PROPN
dti-3019	622	16	,	,	PUNCT
dti-3019	622	17	rimbara	rimbara	NOUN
dti-3019	622	18	e	e	PROPN
dti-3019	622	19	,	,	PUNCT
dti-3019	622	20	graham	graham	PROPN
dti-3019	622	21	dy	dy	PROPN
dti-3019	622	22	.	.	PROPN
dti-3019	623	1	surveillance	surveillance	NOUN
dti-3019	623	2	of	of	ADP
dti-3019	623	3	levofloxacin	levofloxacin	PROPN
dti-3019	623	4	resistance	resistance	NOUN
dti-3019	623	5	in	in	ADP
dti-3019	623	6	helicobacter	helicobacter	NOUN
dti-3019	623	7	pylori	pylori	NOUN
dti-3019	623	8	isolates	isolate	NOUN
dti-3019	623	9	in	in	ADP
dti-3019	623	10	bogotá	bogotá	NOUN
dti-3019	623	11	-	-	PUNCT
dti-3019	623	12	colombia	colombia	PROPN
dti-3019	623	13	(	(	PUNCT
dti-3019	623	14	2009	2009	NUM
dti-3019	623	15	-	-	SYM
dti-3019	623	16	2014	2014	NUM
dti-3019	623	17	)	)	PUNCT
dti-3019	623	18	.	.	PUNCT
dti-3019	624	1	plos	plos	PROPN
dti-3019	624	2	one	one	NUM
dti-3019	624	3	.	.	PUNCT
dti-3019	625	1	2016;11(7):e0160007	2016;11(7):e0160007	NUM
dti-3019	625	2	.	.	PUNCT
dti-3019	625	3	crossref	crossref	PROPN
dti-3019	625	4	pubmed	pubmed	PROPN
dti-3019	625	5	85	85	NUM
dti-3019	625	6	.	.	PUNCT
dti-3019	626	1	abdelaal	abdelaal	PROPN
dti-3019	626	2	am	be	AUX
dti-3019	626	3	,	,	PUNCT
dti-3019	626	4	mahmood	mahmood	PROPN
dti-3019	626	5	ss	ss	PROPN
dti-3019	626	6	.	.	PUNCT
dti-3019	627	1	the	the	DET
dti-3019	627	2	role	role	NOUN
dti-3019	627	3	of	of	ADP
dti-3019	627	4	efflux	efflux	NOUN
dti-3019	627	5	pump	pump	NOUN
dti-3019	627	6	adej	adej	ADJ
dti-3019	627	7	gene	gene	NOUN
dti-3019	627	8	in	in	ADP
dti-3019	627	9	levofloxacin	levofloxacin	PROPN
dti-3019	627	10	resistance	resistance	NOUN
dti-3019	627	11	among	among	ADP
dti-3019	627	12	a.	a.	NOUN
dti-3019	627	13	baumannii	baumannii	PROPN
dti-3019	627	14	.	.	PUNCT
dti-3019	628	1	syst	syst	PROPN
dti-3019	628	2	rev	rev	PROPN
dti-3019	628	3	pharm	pharm	PROPN
dti-3019	628	4	.	.	PUNCT
dti-3019	629	1	2020;11(10):1105	2020;11(10):1105	NUM
dti-3019	629	2	-	-	PROPN
dti-3019	629	3	1110	1110	NUM
dti-3019	629	4	.	.	PUNCT
dti-3019	630	1	86	86	NUM
dti-3019	630	2	.	.	PUNCT
dti-3019	631	1	asaduzzaman	asaduzzaman	PROPN
dti-3019	631	2	m	m	PROPN
dti-3019	631	3	,	,	PUNCT
dti-3019	631	4	hasan	hasan	PROPN
dti-3019	631	5	mz	mz	PROPN
dti-3019	631	6	,	,	PUNCT
dti-3019	631	7	khatun	khatun	PROPN
dti-3019	631	8	m	m	PROPN
dti-3019	631	9	,	,	PUNCT
dti-3019	631	10	et	et	PROPN
dti-3019	631	11	al	al	PROPN
dti-3019	631	12	.	.	PROPN
dti-3019	631	13	resistance	resistance	NOUN
dti-3019	631	14	pattern	pattern	NOUN
dti-3019	631	15	of	of	ADP
dti-3019	631	16	levofloxacin	levofloxacin	NOUN
dti-3019	631	17	against	against	ADP
dti-3019	631	18	uropathogens	uropathogen	NOUN
dti-3019	631	19	causing	cause	VERB
dti-3019	631	20	urinary	urinary	ADJ
dti-3019	631	21	tract	tract	NOUN
dti-3019	631	22	infection	infection	NOUN
dti-3019	631	23	in	in	ADP
dti-3019	631	24	selected	select	VERB
dti-3019	631	25	areas	area	NOUN
dti-3019	631	26	of	of	ADP
dti-3019	631	27	dhaka	dhaka	PROPN
dti-3019	631	28	city	city	PROPN
dti-3019	631	29	.	.	PUNCT
dti-3019	632	1	bangladesh	bangladesh	PROPN
dti-3019	632	2	j	j	PROPN
dti-3019	632	3	biol	biol	PROPN
dti-3019	632	4	agric	agric	PROPN
dti-3019	632	5	healthc	healthc	PROPN
dti-3019	632	6	.	.	PUNCT
dti-3019	633	1	2018;8(4):74	2018;8(4):74	NUM
dti-3019	633	2	-	-	SYM
dti-3019	633	3	81	81	NUM
dti-3019	633	4	.	.	PUNCT
dti-3019	634	1	87	87	NUM
dti-3019	634	2	.	.	PUNCT
dti-3019	635	1	iskhakova	iskhakova	PROPN
dti-3019	635	2	khi	khi	PROPN
dti-3019	635	3	.	.	PUNCT
dti-3019	636	1	antibiotic	antibiotic	ADJ
dti-3019	636	2	sensitivity	sensitivity	NOUN
dti-3019	636	3	of	of	ADP
dti-3019	636	4	nonfermenting	nonfermenting	ADJ
dti-3019	636	5	gramnegative	gramnegative	ADJ
dti-3019	636	6	bacteria	bacteria	NOUN
dti-3019	636	7	.	.	PUNCT
dti-3019	637	1	antibiotiki	antibiotiki	PROPN
dti-3019	637	2	i	i	PRON
dti-3019	637	3	khimioterapiia	khimioterapiia	VERB
dti-3019	637	4	.	.	PUNCT
dti-3019	638	1	1988;33(11	1988;33(11	NUM
dti-3019	638	2	):	):	PUNCT
dti-3019	638	3	823	823	NUM
dti-3019	638	4	-	-	SYM
dti-3019	638	5	827	827	NUM
dti-3019	638	6	.	.	PUNCT
dti-3019	638	7	88	88	NUM
dti-3019	638	8	.	.	PUNCT
dti-3019	639	1	rolinson	rolinson	PROPN
dti-3019	639	2	gn	gn	PROPN
dti-3019	639	3	.	.	PROPN
dti-3019	640	1	bacterial	bacterial	ADJ
dti-3019	640	2	resistance	resistance	NOUN
dti-3019	640	3	to	to	ADP
dti-3019	640	4	penicillins	penicillin	NOUN
dti-3019	640	5	and	and	CCONJ
dti-3019	640	6	cephalosporins	cephalosporin	NOUN
dti-3019	640	7	.	.	PUNCT
dti-3019	641	1	proc	proc	NOUN
dti-3019	641	2	r	r	PROPN
dti-3019	641	3	soc	soc	NOUN
dti-3019	641	4	lond	lond	PROPN
dti-3019	641	5	,	,	PUNCT
dti-3019	641	6	b.	b.	PROPN
dti-3019	641	7	1971;179(1057):403	1971;179(1057):403	PROPN
dti-3019	641	8	-	-	SYM
dti-3019	641	9	410	410	NUM
dti-3019	641	10	.	.	PUNCT
dti-3019	642	1	crossref	crossref	PROPN
dti-3019	642	2	pubmed	pubmed	PROPN
dti-3019	642	3	89	89	NUM
dti-3019	642	4	.	.	PUNCT
dti-3019	643	1	lachmajer	lachmajer	NOUN
dti-3019	643	2	-	-	PUNCT
dti-3019	643	3	lutoslawska	lutoslawska	PROPN
dti-3019	643	4	m	m	PROPN
dti-3019	643	5	,	,	PUNCT
dti-3019	643	6	bobrowski	bobrowski	PROPN
dti-3019	643	7	m.	m.	NOUN
dti-3019	643	8	resistance	resistance	NOUN
dti-3019	643	9	to	to	ADP
dti-3019	643	10	betalactam	betalactam	NOUN
dti-3019	643	11	antibiotics	antibiotic	NOUN
dti-3019	643	12	proteus	proteus	NOUN
dti-3019	643	13	strains	strain	VERB
dti-3019	643	14	.	.	PUNCT
dti-3019	644	1	acta	acta	PROPN
dti-3019	644	2	microbiol	microbiol	PROPN
dti-3019	644	3	pol	pol	PROPN
dti-3019	644	4	a.	a.	NOUN
dti-3019	644	5	1975;8(3):141	1975;8(3):141	PROPN
dti-3019	644	6	-	-	SYM
dti-3019	644	7	149	149	NUM
dti-3019	644	8	.	.	PUNCT
dti-3019	645	1	pubmed	pubmed	PROPN
dti-3019	645	2	90	90	NUM
dti-3019	645	3	.	.	PUNCT
dti-3019	646	1	chow	chow	PROPN
dti-3019	646	2	aw	aw	INTJ
dti-3019	646	3	,	,	PUNCT
dti-3019	646	4	patten	patten	ADJ
dti-3019	646	5	v	v	NOUN
dti-3019	646	6	,	,	PUNCT
dti-3019	646	7	guze	guze	ADJ
dti-3019	646	8	lb	lb	PROPN
dti-3019	646	9	.	.	PROPN
dti-3019	646	10	comparative	comparative	ADJ
dti-3019	646	11	susceptibility	susceptibility	NOUN
dti-3019	646	12	of	of	ADP
dti-3019	646	13	anaerobic	anaerobic	ADJ
dti-3019	646	14	bacteria	bacteria	NOUN
dti-3019	646	15	to	to	ADP
dti-3019	646	16	minocycline	minocycline	NOUN
dti-3019	646	17	,	,	PUNCT
dti-3019	646	18	doxycycline	doxycycline	NOUN
dti-3019	646	19	,	,	PUNCT
dti-3019	646	20	and	and	CCONJ
dti-3019	646	21	tetracycline	tetracycline	NOUN
dti-3019	646	22	.	.	PUNCT
dti-3019	647	1	antimicrob	antimicrob	PROPN
dti-3019	647	2	agents	agents	PROPN
dti-3019	647	3	chemother	chemother	PROPN
dti-3019	647	4	.	.	PUNCT
dti-3019	648	1	1975;7(1):46	1975;7(1):46	NUM
dti-3019	648	2	-	-	SYM
dti-3019	648	3	49	49	NUM
dti-3019	648	4	.	.	PUNCT
dti-3019	649	1	crossref	crossref	PROPN
dti-3019	649	2	pubmed	pubmed	PROPN
dti-3019	649	3	91	91	PROPN
dti-3019	649	4	.	.	PUNCT
dti-3019	650	1	larsen	larsen	PROPN
dti-3019	650	2	t.	t.	PROPN
dti-3019	650	3	occurrence	occurrence	PROPN
dti-3019	650	4	of	of	ADP
dti-3019	650	5	doxycycline	doxycycline	NOUN
dti-3019	650	6	resistant	resistant	ADJ
dti-3019	650	7	bacteria	bacteria	NOUN
dti-3019	650	8	in	in	ADP
dti-3019	650	9	the	the	DET
dti-3019	650	10	oral	oral	ADJ
dti-3019	650	11	cavity	cavity	NOUN
dti-3019	650	12	after	after	ADP
dti-3019	650	13	local	local	ADJ
dti-3019	650	14	administration	administration	NOUN
dti-3019	650	15	of	of	ADP
dti-3019	650	16	doxycycline	doxycycline	NOUN
dti-3019	650	17	in	in	ADP
dti-3019	650	18	patients	patient	NOUN
dti-3019	650	19	with	with	ADP
dti-3019	650	20	periodontal	periodontal	ADJ
dti-3019	650	21	disease	disease	NOUN
dti-3019	650	22	.	.	PUNCT
dti-3019	651	1	scand	scand	PROPN
dti-3019	651	2	j	j	PROPN
dti-3019	651	3	infect	infect	PROPN
dti-3019	651	4	dis	dis	PROPN
dti-3019	651	5	.	.	PUNCT
dti-3019	652	1	1991;23(1):89	1991;23(1):89	PROPN
dti-3019	652	2	-	-	SYM
dti-3019	652	3	95	95	NUM
dti-3019	652	4	.	.	PUNCT
dti-3019	653	1	crossref	crossref	PROPN
dti-3019	653	2	pubmed	pubmed	PROPN
dti-3019	653	3	92	92	NUM
dti-3019	653	4	.	.	PUNCT
dti-3019	654	1	eliopulos	eliopulos	PROPN
dti-3019	654	2	n	n	CCONJ
dti-3019	654	3	,	,	PUNCT
dti-3019	654	4	alsina	alsina	PROPN
dti-3019	654	5	l	l	PROPN
dti-3019	654	6	,	,	PUNCT
dti-3019	654	7	diana	diana	PROPN
dti-3019	654	8	l	l	PROPN
dti-3019	654	9	,	,	PUNCT
dti-3019	654	10	brandl	brandl	PROPN
dti-3019	654	11	s.	s.	PROPN
dti-3019	654	12	multiple	multiple	ADJ
dti-3019	654	13	antimicrobial	antimicrobial	ADJ
dti-3019	654	14	resistance	resistance	NOUN
dti-3019	654	15	in	in	ADP
dti-3019	654	16	enterobacteriaceae	enterobacteriaceae	PROPN
dti-3019	654	17	isolated	isolate	VERB
dti-3019	654	18	from	from	ADP
dti-3019	654	19	a	a	DET
dti-3019	654	20	sea	sea	NOUN
dti-3019	654	21	lion	lion	NOUN
dti-3019	654	22	(	(	PUNCT
dti-3019	654	23	otaria	otaria	NOUN
dti-3019	654	24	flavescens	flavescen	VERB
dti-3019	654	25	)	)	PUNCT
dti-3019	654	26	specimen	speciman	NOUN
dti-3019	654	27	from	from	ADP
dti-3019	654	28	isla	isla	PROPN
dti-3019	654	29	de	de	PROPN
dti-3019	654	30	lobos	lobos	PROPN
dti-3019	654	31	,	,	PUNCT
dti-3019	654	32	uruguay	uruguay	PROPN
dti-3019	654	33	:	:	PUNCT
dti-3019	654	34	a	a	DET
dti-3019	654	35	case	case	NOUN
dti-3019	654	36	report	report	NOUN
dti-3019	654	37	.	.	PUNCT
dti-3019	655	1	brazilian	brazilian	ADJ
dti-3019	655	2	j	j	PROPN
dti-3019	655	3	animal	animal	NOUN
dti-3019	655	4	environ	environ	NOUN
dti-3019	655	5	res	re	NOUN
dti-3019	655	6	.	.	PUNCT
dti-3019	656	1	2022;5(4):3477	2022;5(4):3477	NUM
dti-3019	656	2	-	-	SYM
dti-3019	656	3	3486	3486	NUM
dti-3019	656	4	.	.	PUNCT
dti-3019	657	1	crossref	crossref	NOUN
dti-3019	657	2	93	93	NUM
dti-3019	657	3	.	.	PUNCT
dti-3019	658	1	belousoff	belousoff	PROPN
dti-3019	658	2	mj	mj	PROPN
dti-3019	658	3	,	,	PUNCT
dti-3019	658	4	venugopal	venugopal	PROPN
dti-3019	658	5	h	h	PROPN
dti-3019	658	6	,	,	PUNCT
dti-3019	658	7	wright	wright	PROPN
dti-3019	658	8	a	a	PROPN
dti-3019	658	9	,	,	PUNCT
dti-3019	658	10	et	et	PROPN
dti-3019	658	11	al	al	PROPN
dti-3019	658	12	.	.	PUNCT
dti-3019	658	13	cryoem	cryoem	PROPN
dti-3019	658	14	-	-	PUNCT
dti-3019	658	15	guided	guide	VERB
dti-3019	658	16	development	development	NOUN
dti-3019	658	17	of	of	ADP
dti-3019	658	18	antibiotics	antibiotic	NOUN
dti-3019	658	19	for	for	ADP
dti-3019	658	20	drug	drug	NOUN
dti-3019	658	21	-	-	PUNCT
dti-3019	658	22	resistant	resistant	ADJ
dti-3019	658	23	bacteria	bacteria	NOUN
dti-3019	658	24	.	.	PUNCT
dti-3019	659	1	chemmedchem	chemmedchem	PROPN
dti-3019	659	2	.	.	PUNCT
dti-3019	660	1	2019;14(5):527	2019;14(5):527	NUM
dti-3019	660	2	-	-	SYM
dti-3019	660	3	531	531	NUM
dti-3019	660	4	.	.	PUNCT
dti-3019	661	1	crossref	crossref	PROPN
dti-3019	661	2	pubmed	pubmed	PROPN
dti-3019	661	3	94	94	PROPN
dti-3019	661	4	.	.	PUNCT
dti-3019	662	1	richardson	richardson	PROPN
dti-3019	662	2	ll	ll	PROPN
dti-3019	662	3	.	.	PUNCT
dti-3019	663	1	alternating	alternate	VERB
dti-3019	663	2	antibiotics	antibiotic	NOUN
dti-3019	663	3	render	render	VERB
dti-3019	663	4	resistant	resistant	ADJ
dti-3019	663	5	bacteria	bacteria	NOUN
dti-3019	663	6	beatable	beatable	ADJ
dti-3019	663	7	.	.	PUNCT
dti-3019	664	1	plos	plos	PROPN
dti-3019	664	2	biol	biol	PROPN
dti-3019	664	3	.	.	PUNCT
dti-3019	665	1	2015;13(4):e1002105	2015;13(4):e1002105	X
dti-3019	665	2	.	.	PROPN
dti-3019	666	1	95	95	NUM
dti-3019	666	2	.	.	PUNCT
dti-3019	667	1	o’neill	o’neill	INTJ
dti-3019	667	2	j.	j.	PROPN
dti-3019	667	3	antimicrobial	antimicrobial	PROPN
dti-3019	667	4	resistance	resistance	NOUN
dti-3019	667	5	:	:	PUNCT
dti-3019	667	6	tackling	tackle	VERB
dti-3019	667	7	a	a	DET
dti-3019	667	8	crisis	crisis	NOUN
dti-3019	667	9	for	for	ADP
dti-3019	667	10	the	the	DET
dti-3019	667	11	health	health	NOUN
dti-3019	667	12	and	and	CCONJ
dti-3019	667	13	wealth	wealth	NOUN
dti-3019	667	14	of	of	ADP
dti-3019	667	15	nations	nation	NOUN
dti-3019	667	16	.	.	PUNCT
dti-3019	668	1	in	in	ADP
dti-3019	668	2	review	review	NOUN
dti-3019	668	3	on	on	ADP
dti-3019	668	4	antimicrobial	antimicrobial	ADJ
dti-3019	668	5	resistance	resistance	NOUN
dti-3019	668	6	.	.	PUNCT
dti-3019	669	1	london	london	PROPN
dti-3019	669	2	:	:	PUNCT
dti-3019	669	3	wellcome	wellcome	PROPN
dti-3019	669	4	trust	trust	PROPN
dti-3019	669	5	;	;	PUNCT
dti-3019	669	6	2014	2014	NUM
dti-3019	669	7	.	.	PUNCT
dti-3019	670	1	96	96	NUM
dti-3019	670	2	.	.	PUNCT
dti-3019	671	1	song	song	PROPN
dti-3019	671	2	m	m	PROPN
dti-3019	671	3	,	,	PUNCT
dti-3019	671	4	wu	wu	PROPN
dti-3019	671	5	h	h	PROPN
dti-3019	671	6	,	,	PUNCT
dti-3019	671	7	wu	wu	PROPN
dti-3019	671	8	s	s	PROPN
dti-3019	671	9	,	,	PUNCT
dti-3019	671	10	et	et	PROPN
dti-3019	671	11	al	al	PROPN
dti-3019	671	12	.	.	PUNCT
dti-3019	672	1	antibiotic	antibiotic	ADJ
dti-3019	672	2	drug	drug	NOUN
dti-3019	672	3	levofloxacin	levofloxacin	PROPN
dti-3019	672	4	inhibits	inhibit	VERB
dti-3019	672	5	proliferation	proliferation	NOUN
dti-3019	672	6	and	and	CCONJ
dti-3019	672	7	induces	induce	VERB
dti-3019	672	8	apoptosis	apoptosis	NOUN
dti-3019	672	9	of	of	ADP
dti-3019	672	10	lung	lung	NOUN
dti-3019	672	11	cancer	cancer	NOUN
dti-3019	672	12	cells	cell	NOUN
dti-3019	672	13	through	through	ADP
dti-3019	672	14	inducing	induce	VERB
dti-3019	672	15	mitochondrial	mitochondrial	ADJ
dti-3019	672	16	dysfunction	dysfunction	NOUN
dti-3019	672	17	and	and	CCONJ
dti-3019	672	18	oxidative	oxidative	ADJ
dti-3019	672	19	damage	damage	NOUN
dti-3019	672	20	.	.	PUNCT
dti-3019	673	1	biomed	biome	VERB
dti-3019	673	2	pharmacother	pharmacother	ADJ
dti-3019	673	3	.	.	PUNCT
dti-3019	674	1	2016;84:1137	2016;84:1137	NUM
dti-3019	674	2	-	-	SYM
dti-3019	674	3	1143	1143	NUM
dti-3019	674	4	.	.	PUNCT
dti-3019	675	1	crossref	crossref	PROPN
dti-3019	675	2	pubmed	pubmed	PROPN
dti-3019	675	3	97	97	NUM
dti-3019	675	4	.	.	PUNCT
dti-3019	676	1	alsalahat	alsalahat	PROPN
dti-3019	676	2	i	i	PRON
dti-3019	676	3	,	,	PUNCT
dti-3019	676	4	al	al	PROPN
dti-3019	676	5	-	-	PUNCT
dti-3019	676	6	majdoub	majdoub	PROPN
dti-3019	676	7	zm	zm	PROPN
dti-3019	676	8	,	,	PUNCT
dti-3019	676	9	taha	taha	PROPN
dti-3019	676	10	mo	mo	PROPN
dti-3019	676	11	,	,	PUNCT
dti-3019	676	12	et	et	PROPN
dti-3019	676	13	al	al	PROPN
dti-3019	676	14	.	.	PROPN
dti-3019	677	1	inhibition	inhibition	NOUN
dti-3019	677	2	of	of	ADP
dti-3019	677	3	aggregation	aggregation	NOUN
dti-3019	677	4	of	of	ADP
dti-3019	677	5	amyloid	amyloid	NOUN
dti-3019	677	6	-	-	PUNCT
dti-3019	677	7	β	β	NOUN
dti-3019	677	8	through	through	ADP
dti-3019	677	9	covalent	covalent	NOUN
dti-3019	677	10	modification	modification	NOUN
dti-3019	677	11	with	with	ADP
dti-3019	677	12	benzylpenicillin	benzylpenicillin	NOUN
dti-3019	677	13	;	;	PUNCT
dti-3019	677	14	potential	potential	ADJ
dti-3019	677	15	relevance	relevance	NOUN
dti-3019	677	16	to	to	ADP
dti-3019	677	17	alzheimer	alzheimer	PROPN
dti-3019	677	18	’s	’s	PART
dti-3019	677	19	disease	disease	NOUN
dti-3019	677	20	.	.	PUNCT
dti-3019	678	1	biochem	biochem	PROPN
dti-3019	678	2	biophys	biophys	PROPN
dti-3019	678	3	rep	rep	PROPN
dti-3019	678	4	.	.	PROPN
dti-3019	678	5	2021;26:100943	2021;26:100943	NUM
dti-3019	678	6	.	.	PUNCT
dti-3019	679	1	crossref	crossref	PROPN
dti-3019	679	2	pubmed	pubmed	PROPN
dti-3019	679	3	98	98	PROPN
dti-3019	679	4	.	.	PUNCT
dti-3019	680	1	khan	khan	PROPN
dti-3019	680	2	an	an	PROPN
dti-3019	680	3	,	,	PUNCT
dti-3019	680	4	qureshi	qureshi	PROPN
dti-3019	680	5	ia	ia	PROPN
dti-3019	680	6	,	,	PUNCT
dti-3019	680	7	khan	khan	PROPN
dti-3019	680	8	uk	uk	PROPN
dti-3019	680	9	,	,	PUNCT
dti-3019	680	10	uversky	uversky	ADJ
dti-3019	680	11	vn	vn	PROPN
dti-3019	680	12	,	,	PUNCT
dti-3019	680	13	khan	khan	PROPN
dti-3019	680	14	rh	rh	PROPN
dti-3019	680	15	.	.	PROPN
dti-3019	680	16	inhibition	inhibition	NOUN
dti-3019	680	17	and	and	CCONJ
dti-3019	680	18	disruption	disruption	NOUN
dti-3019	680	19	of	of	ADP
dti-3019	680	20	amyloid	amyloid	NOUN
dti-3019	680	21	formation	formation	NOUN
dti-3019	680	22	by	by	ADP
dti-3019	680	23	the	the	DET
dti-3019	680	24	antibiotic	antibiotic	ADJ
dti-3019	680	25	levofloxacin	levofloxacin	NOUN
dti-3019	680	26	:	:	PUNCT
dti-3019	680	27	a	a	DET
dti-3019	680	28	new	new	ADJ
dti-3019	680	29	direction	direction	NOUN
dti-3019	680	30	for	for	ADP
dti-3019	680	31	antibiotics	antibiotic	NOUN
dti-3019	680	32	in	in	ADP
dti-3019	680	33	an	an	DET
dti-3019	680	34	era	era	NOUN
dti-3019	680	35	of	of	ADP
dti-3019	680	36	multi	multi	ADJ
dti-3019	680	37	-	-	ADJ
dti-3019	680	38	drug	drug	ADJ
dti-3019	680	39	resistance	resistance	NOUN
dti-3019	680	40	.	.	PUNCT
dti-3019	681	1	arch	arch	ADJ
dti-3019	681	2	biochem	biochem	PROPN
dti-3019	681	3	biophys	biophy	NOUN
dti-3019	681	4	.	.	PUNCT
dti-3019	682	1	2021;714:109077	2021;714:109077	NUM
dti-3019	682	2	.	.	PUNCT
dti-3019	683	1	crossref	crossref	PROPN
dti-3019	683	2	pubmed	pubmed	PROPN
dti-3019	683	3	99	99	NUM
dti-3019	683	4	.	.	PUNCT
dti-3019	684	1	lanckohr	lanckohr	PROPN
dti-3019	684	2	c	c	PROPN
dti-3019	684	3	,	,	PUNCT
dti-3019	684	4	bracht	bracht	PROPN
dti-3019	684	5	h.	h.	PROPN
dti-3019	684	6	antimicrobial	antimicrobial	ADJ
dti-3019	684	7	stewardship	stewardship	NOUN
dti-3019	684	8	.	.	PUNCT
dti-3019	685	1	curr	curr	PROPN
dti-3019	685	2	opin	opin	PROPN
dti-3019	685	3	crit	crit	NOUN
dti-3019	685	4	care	care	NOUN
dti-3019	685	5	.	.	PUNCT
dti-3019	686	1	2022;28(5):551	2022;28(5):551	NUM
dti-3019	686	2	-	-	SYM
dti-3019	686	3	556	556	NUM
dti-3019	686	4	.	.	PUNCT
dti-3019	687	1	crossref	crossref	PROPN
dti-3019	687	2	pubmed	pubmed	PROPN
dti-3019	687	3	100	100	NUM
dti-3019	687	4	.	.	PUNCT
dti-3019	688	1	rangapriya	rangapriya	PROPN
dti-3019	688	2	m	m	PROPN
dti-3019	688	3	,	,	PUNCT
dti-3019	688	4	lorance	lorance	NOUN
dti-3019	688	5	a	a	PRON
dti-3019	688	6	,	,	PUNCT
dti-3019	688	7	varghese	varghese	PROPN
dti-3019	688	8	am	am	PROPN
dti-3019	688	9	,	,	PUNCT
dti-3019	688	10	hanif	hanif	PROPN
dti-3019	688	11	a	a	PRON
dti-3019	688	12	,	,	PUNCT
dti-3019	688	13	aruna	aruna	PROPN
dti-3019	688	14	s.	s.	PROPN
dti-3019	688	15	awareness	awareness	PROPN
dti-3019	688	16	and	and	CCONJ
dti-3019	688	17	perception	perception	NOUN
dti-3019	688	18	on	on	ADP
dti-3019	688	19	antibiotics	antibiotic	NOUN
dti-3019	688	20	and	and	CCONJ
dti-3019	688	21	antimicrobial	antimicrobial	ADJ
dti-3019	688	22	resistance	resistance	NOUN
dti-3019	688	23	:	:	PUNCT
dti-3019	688	24	a	a	DET
dti-3019	688	25	questionnaire	questionnaire	NOUN
dti-3019	688	26	based	base	VERB
dti-3019	688	27	study	study	NOUN
dti-3019	688	28	.	.	PUNCT
dti-3019	689	1	int	int	PROPN
dti-3019	689	2	j	j	PROPN
dti-3019	689	3	pharm	pharm	PROPN
dti-3019	689	4	sci	sci	PROPN
dti-3019	689	5	rev	rev	PROPN
dti-3019	689	6	res	re	NOUN
dti-3019	689	7	.	.	PUNCT
dti-3019	690	1	2020;65(1):27	2020;65(1):27	NUM
dti-3019	690	2	-	-	SYM
dti-3019	690	3	32	32	NUM
dti-3019	690	4	.	.	PUNCT
dti-3019	691	1	crossref	crossref	PROPN
dti-3019	691	2	101	101	NUM
dti-3019	691	3	.	.	PUNCT
dti-3019	692	1	xiang	xiang	PROPN
dti-3019	692	2	l	l	PROPN
dti-3019	692	3	,	,	PUNCT
dti-3019	692	4	akakuru	akakuru	X
dti-3019	692	5	ou	ou	NOUN
dti-3019	692	6	,	,	PUNCT
dti-3019	692	7	xu	xu	PROPN
dti-3019	693	1	c	c	X
dti-3019	693	2	,	,	PUNCT
dti-3019	693	3	wu	wu	PROPN
dti-3019	693	4	a.	a.	NOUN
dti-3019	693	5	harnessing	harness	VERB
dti-3019	693	6	the	the	DET
dti-3019	693	7	intriguing	intriguing	ADJ
dti-3019	693	8	properties	property	NOUN
dti-3019	693	9	of	of	ADP
dti-3019	693	10	magnetic	magnetic	ADJ
dti-3019	693	11	nanoparticles	nanoparticle	NOUN
dti-3019	693	12	to	to	PART
dti-3019	693	13	detect	detect	VERB
dti-3019	693	14	and	and	CCONJ
dti-3019	693	15	treat	treat	VERB
dti-3019	693	16	bacterial	bacterial	ADJ
dti-3019	693	17	infections	infection	NOUN
dti-3019	693	18	.	.	PUNCT
dti-3019	694	1	magnetochemistry	magnetochemistry	NOUN
dti-3019	694	2	.	.	PUNCT
dti-3019	695	1	2021;7(8):112	2021;7(8):112	X
dti-3019	695	2	.	.	PUNCT
dti-3019	696	1	crossref	crossref	PROPN
dti-3019	696	2	102	102	NUM
dti-3019	696	3	.	.	PUNCT
dti-3019	697	1	zhu	zhu	PROPN
dti-3019	697	2	d	d	PROPN
dti-3019	697	3	,	,	PUNCT
dti-3019	697	4	li	li	PROPN
dti-3019	697	5	q	q	PROPN
dti-3019	697	6	,	,	PUNCT
dti-3019	697	7	shen	shen	PROPN
dti-3019	697	8	y	y	PROPN
dti-3019	697	9	,	,	PUNCT
dti-3019	697	10	zhang	zhang	PROPN
dti-3019	697	11	q.	q.	PROPN
dti-3019	697	12	risk	risk	NOUN
dti-3019	697	13	factors	factor	NOUN
dti-3019	697	14	for	for	ADP
dti-3019	697	15	quinolone	quinolone	NOUN
dti-3019	697	16	-	-	PUNCT
dti-3019	697	17	resistant	resistant	ADJ
dti-3019	697	18	escherichia	escherichia	NOUN
dti-3019	697	19	coli	coli	NOUN
dti-3019	697	20	infection	infection	NOUN
dti-3019	697	21	:	:	PUNCT
dti-3019	697	22	a	a	DET
dti-3019	697	23	systematic	systematic	ADJ
dti-3019	697	24	review	review	NOUN
dti-3019	697	25	and	and	CCONJ
dti-3019	697	26	metaanalysis	metaanalysis	NOUN
dti-3019	697	27	.	.	PUNCT
dti-3019	698	1	antimicrob	antimicrob	PROPN
dti-3019	698	2	resist	resist	VERB
dti-3019	698	3	infect	infect	ADJ
dti-3019	698	4	control	control	NOUN
dti-3019	698	5	.	.	PUNCT
dti-3019	699	1	2020;9:11	2020;9:11	PROPN
dti-3019	699	2	.	.	PUNCT
dti-3019	700	1	103	103	NUM
dti-3019	700	2	.	.	PUNCT
dti-3019	701	1	bird	bird	PROPN
dti-3019	701	2	sb	sb	PROPN
dti-3019	701	3	,	,	PUNCT
dti-3019	701	4	orr	orr	PROPN
dti-3019	701	5	pg	pg	PROPN
dti-3019	701	6	,	,	PUNCT
dti-3019	701	7	mazzola	mazzola	PROPN
dti-3019	701	8	jl	jl	PROPN
dti-3019	701	9	,	,	PUNCT
dti-3019	701	10	brush	brush	PROPN
dti-3019	701	11	de	de	PROPN
dti-3019	701	12	,	,	PUNCT
dti-3019	701	13	boyer	boyer	PROPN
dti-3019	701	14	ew	ew	AUX
dti-3019	701	15	.	.	PROPN
dti-3019	701	16	levofloxacinrelated	levofloxacinrelate	VERB
dti-3019	701	17	seizure	seizure	NOUN
dti-3019	701	18	activity	activity	NOUN
dti-3019	701	19	in	in	ADP
dti-3019	701	20	a	a	DET
dti-3019	701	21	patient	patient	NOUN
dti-3019	701	22	with	with	ADP
dti-3019	701	23	alzheimer	alzheimer	PROPN
dti-3019	701	24	’s	’s	PART
dti-3019	701	25	disease	disease	NOUN
dti-3019	701	26	:	:	PUNCT
dti-3019	702	1	assessment	assessment	NOUN
dti-3019	702	2	of	of	ADP
dti-3019	702	3	potential	potential	ADJ
dti-3019	702	4	risk	risk	NOUN
dti-3019	702	5	factors	factor	NOUN
dti-3019	702	6	.	.	PUNCT
dti-3019	703	1	j	j	PROPN
dti-3019	703	2	clin	clin	PROPN
dti-3019	703	3	psychopharmacol	psychopharmacol	PROPN
dti-3019	703	4	.	.	PUNCT
dti-3019	704	1	2005;25(3):287	2005;25(3):287	NUM
dti-3019	704	2	-	-	SYM
dti-3019	704	3	288	288	NUM
dti-3019	704	4	.	.	PUNCT
dti-3019	705	1	crossref	crossref	PROPN
dti-3019	705	2	pubmed	pubmed	PROPN
dti-3019	705	3	104	104	PROPN
dti-3019	705	4	.	.	PUNCT
dti-3019	706	1	doulberis	doulberis	PROPN
dti-3019	706	2	m	m	PROPN
dti-3019	706	3	,	,	PUNCT
dti-3019	706	4	kotronis	kotronis	PROPN
dti-3019	706	5	g	g	NOUN
dti-3019	706	6	,	,	PUNCT
dti-3019	706	7	gialamprinou	gialamprinou	NOUN
dti-3019	706	8	d	d	NOUN
dti-3019	706	9	,	,	PUNCT
dti-3019	707	1	et	et	PROPN
dti-3019	707	2	al	al	PROPN
dti-3019	707	3	.	.	PROPN
dti-3019	707	4	alzheimer	alzheimer	PROPN
dti-3019	707	5	’s	’s	PART
dti-3019	707	6	disease	disease	NOUN
dti-3019	707	7	and	and	CCONJ
dti-3019	707	8	gastrointestinal	gastrointestinal	ADJ
dti-3019	707	9	microbiota	microbiota	NOUN
dti-3019	707	10	;	;	PUNCT
dti-3019	707	11	impact	impact	NOUN
dti-3019	707	12	of	of	ADP
dti-3019	707	13	helicobacter	helicobacter	NOUN
dti-3019	707	14	pylori	pylori	NOUN
dti-3019	707	15	infection	infection	NOUN
dti-3019	707	16	involvement	involvement	NOUN
dti-3019	707	17	.	.	PUNCT
dti-3019	708	1	int	int	PROPN
dti-3019	708	2	j	j	PROPN
dti-3019	708	3	neurosci	neurosci	PROPN
dti-3019	708	4	.	.	PUNCT
dti-3019	709	1	2021;131(3):289301	2021;131(3):289301	NUM
dti-3019	709	2	.	.	PUNCT
dti-3019	710	1	crossref	crossref	PROPN
dti-3019	710	2	pubmed	pubmed	PROPN
dti-3019	710	3	105	105	PROPN
dti-3019	710	4	.	.	PUNCT
dti-3019	711	1	mehrotra	mehrotra	PROPN
dti-3019	711	2	t	t	PROPN
dti-3019	711	3	,	,	PUNCT
dti-3019	711	4	devi	devi	PROPN
dti-3019	711	5	tb	tb	PROPN
dti-3019	711	6	,	,	PUNCT
dti-3019	711	7	kumar	kumar	PROPN
dti-3019	711	8	s	s	PROPN
dti-3019	711	9	,	,	PUNCT
dti-3019	711	10	et	et	PROPN
dti-3019	711	11	al	al	PROPN
dti-3019	711	12	.	.	PROPN
dti-3019	711	13	antimicrobial	antimicrobial	ADJ
dti-3019	711	14	resistance	resistance	NOUN
dti-3019	711	15	and	and	CCONJ
dti-3019	711	16	virulence	virulence	NOUN
dti-3019	711	17	in	in	ADP
dti-3019	711	18	helicobacter	helicobacter	NOUN
dti-3019	711	19	pylori	pylori	NOUN
dti-3019	711	20	:	:	PUNCT
dti-3019	711	21	genomic	genomic	ADJ
dti-3019	711	22	insights	insight	NOUN
dti-3019	711	23	.	.	PUNCT
dti-3019	712	1	genomics	genomic	NOUN
dti-3019	712	2	.	.	PUNCT
dti-3019	713	1	2021;113(6):3951	2021;113(6):3951	NUM
dti-3019	713	2	-	-	SYM
dti-3019	713	3	3966	3966	NUM
dti-3019	713	4	.	.	PUNCT
dti-3019	714	1	crossref	crossref	PROPN
dti-3019	714	2	pubmed	pubmed	PROPN
dti-3019	714	3	https://doi.org/10.1016/j.tips.2016.01.007	https://doi.org/10.1016/j.tips.2016.01.007	VERB
dti-3019	714	4	https://www.ncbi.nlm.nih.gov/pubmed/26900045	https://www.ncbi.nlm.nih.gov/pubmed/26900045	ADV
dti-3019	714	5	https://doi.org/10.1038/485s17a	https://doi.org/10.1038/485s17a	PROPN
dti-3019	714	6	https://www.ncbi.nlm.nih.gov/pubmed/22616101	https://www.ncbi.nlm.nih.gov/pubmed/22616101	NUM
dti-3019	714	7	https://doi.org/10.3390/ijms241411450	https://doi.org/10.3390/ijms241411450	ADJ
dti-3019	714	8	https://www.ncbi.nlm.nih.gov/pubmed/37511207	https://www.ncbi.nlm.nih.gov/pubmed/37511207	X
dti-3019	714	9	https://doi.org/10.3390/life13041012	https://doi.org/10.3390/life13041012	NOUN
dti-3019	714	10	https://www.ncbi.nlm.nih.gov/pubmed/37109541	https://www.ncbi.nlm.nih.gov/pubmed/37109541	NUM
dti-3019	714	11	https://doi.org/10.1097/01.eem.0000945404.71459.8a	https://doi.org/10.1097/01.eem.0000945404.71459.8a	NOUN
dti-3019	714	12	https://doi.org/10.3390/antibiotics12091365	https://doi.org/10.3390/antibiotics12091365	VERB
dti-3019	714	13	https://www.ncbi.nlm.nih.gov/pubmed/37760662	https://www.ncbi.nlm.nih.gov/pubmed/37760662	X
dti-3019	714	14	https://doi.org/10.1038/s41396-020-0679-2	https://doi.org/10.1038/s41396-020-0679-2	NUM
dti-3019	714	15	https://www.ncbi.nlm.nih.gov/pubmed/32424247	https://www.ncbi.nlm.nih.gov/pubmed/32424247	PRON
dti-3019	714	16	https://doi.org/10.1038/ismej.2017.42	https://doi.org/10.1038/ismej.2017.42	NOUN
dti-3019	714	17	https://www.ncbi.nlm.nih.gov/pubmed/28362724	https://www.ncbi.nlm.nih.gov/pubmed/28362724	NUM
dti-3019	714	18	https://doi.org/10.3389/fmicb.2022.887251	https://doi.org/10.3389/fmicb.2022.887251	PROPN
dti-3019	714	19	https://www.ncbi.nlm.nih.gov/pubmed/35847117	https://www.ncbi.nlm.nih.gov/pubmed/35847117	PROPN
dti-3019	714	20	https://doi.org/10.1128/aac.01284-20	https://doi.org/10.1128/aac.01284-20	PROPN
dti-3019	714	21	https://www.ncbi.nlm.nih.gov/pubmed/33139281	https://www.ncbi.nlm.nih.gov/pubmed/33139281	PROPN
dti-3019	714	22	https://doi.org/10.3390/biology11071044	https://doi.org/10.3390/biology11071044	PROPN
dti-3019	714	23	https://www.ncbi.nlm.nih.gov/pubmed/36101423	https://www.ncbi.nlm.nih.gov/pubmed/36101423	X
dti-3019	714	24	https://doi.org/10.4103/japtr.japtr_17_20	https://doi.org/10.4103/japtr.japtr_17_20	VERB
dti-3019	714	25	https://www.ncbi.nlm.nih.gov/pubmed/33102193	https://www.ncbi.nlm.nih.gov/pubmed/33102193	PRON
dti-3019	714	26	https://doi.org/10.1371/journal.pone.0160007	https://doi.org/10.1371/journal.pone.0160007	VERB
dti-3019	714	27	https://www.ncbi.nlm.nih.gov/pubmed/27454429	https://www.ncbi.nlm.nih.gov/pubmed/27454429	PROPN
dti-3019	714	28	https://doi.org/10.1098/rspb.1971.0105	https://doi.org/10.1098/rspb.1971.0105	PROPN
dti-3019	714	29	https://www.ncbi.nlm.nih.gov/pubmed/4401418	https://www.ncbi.nlm.nih.gov/pubmed/4401418	NUM
dti-3019	714	30	https://www.ncbi.nlm.nih.gov/pubmed/1103580	https://www.ncbi.nlm.nih.gov/pubmed/1103580	PROPN
dti-3019	714	31	https://doi.org/10.1128/aac.7.1.46	https://doi.org/10.1128/aac.7.1.46	PROPN
dti-3019	714	32	https://www.ncbi.nlm.nih.gov/pubmed/1137358	https://www.ncbi.nlm.nih.gov/pubmed/1137358	NOUN
dti-3019	714	33	https://doi.org/10.3109/00365549109023379	https://doi.org/10.3109/00365549109023379	PROPN
dti-3019	714	34	https://www.ncbi.nlm.nih.gov/pubmed/2028232	https://www.ncbi.nlm.nih.gov/pubmed/2028232	X
dti-3019	714	35	https://doi.org/10.34188/bjaerv5n4-001	https://doi.org/10.34188/bjaerv5n4-001	PROPN
dti-3019	714	36	https://doi.org/10.1002/cmdc.201900042	https://doi.org/10.1002/cmdc.201900042	PRON
dti-3019	714	37	https://www.ncbi.nlm.nih.gov/pubmed/30667174	https://www.ncbi.nlm.nih.gov/pubmed/30667174	PROPN
dti-3019	714	38	https://doi.org/10.1016/j.biopha.2016.10.034	https://doi.org/10.1016/j.biopha.2016.10.034	NOUN
dti-3019	714	39	https://www.ncbi.nlm.nih.gov/pubmed/27780143	https://www.ncbi.nlm.nih.gov/pubmed/27780143	NOUN
dti-3019	714	40	https://doi.org/10.1016/j.bbrep.2021.100943	https://doi.org/10.1016/j.bbrep.2021.100943	PROPN
dti-3019	714	41	https://www.ncbi.nlm.nih.gov/pubmed/33778168	https://www.ncbi.nlm.nih.gov/pubmed/33778168	NUM
dti-3019	714	42	https://doi.org/10.1016/j.abb.2021.109077	https://doi.org/10.1016/j.abb.2021.109077	PROPN
dti-3019	714	43	https://www.ncbi.nlm.nih.gov/pubmed/34728171	https://www.ncbi.nlm.nih.gov/pubmed/34728171	NUM
dti-3019	714	44	https://doi.org/10.1097/mcc.0000000000000967	https://doi.org/10.1097/mcc.0000000000000967	PROPN
dti-3019	714	45	https://www.ncbi.nlm.nih.gov/pubmed/35942707	https://www.ncbi.nlm.nih.gov/pubmed/35942707	NUM
dti-3019	715	1	https://doi.org/10.47583/ijpsrr.2020.v65i01.003	https://doi.org/10.47583/ijpsrr.2020.v65i01.003	PROPN
dti-3019	715	2	https://doi.org/10.3390/magnetochemistry7080112	https://doi.org/10.3390/magnetochemistry7080112	PROPN
dti-3019	715	3	https://doi.org/10.1097/01.jcp.0000162811.15066.8e	https://doi.org/10.1097/01.jcp.0000162811.15066.8e	NOUN
dti-3019	715	4	https://www.ncbi.nlm.nih.gov/pubmed/15876916	https://www.ncbi.nlm.nih.gov/pubmed/15876916	NUM
dti-3019	715	5	https://doi.org/10.1080/00207454.2020.1738432	https://doi.org/10.1080/00207454.2020.1738432	NOUN
dti-3019	716	1	https://www.ncbi.nlm.nih.gov/pubmed/32125206	https://www.ncbi.nlm.nih.gov/pubmed/32125206	X
dti-3019	716	2	https://doi.org/10.1016/j.ygeno.2021.10.002	https://doi.org/10.1016/j.ygeno.2021.10.002	NOUN
dti-3019	717	1	https://www.ncbi.nlm.nih.gov/pubmed/34619341	https://www.ncbi.nlm.nih.gov/pubmed/34619341	NUM
dti-3019	717	2	natsheh	natsheh	NOUN
dti-3019	717	3	et	et	PROPN
dti-3019	717	4	al	al	PROPN
dti-3019	717	5	drug	drug	PROPN
dti-3019	717	6	target	target	NOUN
dti-3019	717	7	insights	insight	NOUN
dti-3019	717	8	2024	2024	NUM
dti-3019	717	9	;	;	PUNCT
dti-3019	717	10	18	18	NUM
dti-3019	717	11	:	:	SYM
dti-3019	717	12	19	19	NUM
dti-3019	717	13	©	©	PROPN
dti-3019	717	14	2024	2024	NUM
dti-3019	717	15	the	the	DET
dti-3019	717	16	authors	author	NOUN
dti-3019	717	17	.	.	PUNCT
dti-3019	718	1	published	publish	VERB
dti-3019	718	2	by	by	ADP
dti-3019	718	3	aboutscience	aboutscience	NOUN
dti-3019	718	4	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-3019	718	5	106	106	NUM
dti-3019	718	6	.	.	PUNCT
dti-3019	719	1	howard	howard	PROPN
dti-3019	719	2	r	r	PROPN
dti-3019	719	3	,	,	PUNCT
dti-3019	719	4	zubko	zubko	NOUN
dti-3019	719	5	o	o	NOUN
dti-3019	719	6	,	,	PUNCT
dti-3019	719	7	bradley	bradley	PROPN
dti-3019	719	8	r	r	PROPN
dti-3019	719	9	,	,	PUNCT
dti-3019	719	10	et	et	PROPN
dti-3019	719	11	al	al	PROPN
dti-3019	719	12	;	;	PUNCT
dti-3019	719	13	minocycline	minocycline	NOUN
dti-3019	719	14	in	in	ADP
dti-3019	719	15	alzheimer	alzheimer	PROPN
dti-3019	719	16	disease	disease	PROPN
dti-3019	719	17	efficacy	efficacy	NOUN
dti-3019	719	18	(	(	PUNCT
dti-3019	719	19	made	make	VERB
dti-3019	719	20	)	)	PUNCT
dti-3019	719	21	trialist	trialist	NOUN
dti-3019	719	22	group	group	NOUN
dti-3019	719	23	.	.	PUNCT
dti-3019	720	1	minocycline	minocycline	PROPN
dti-3019	720	2	at	at	ADP
dti-3019	720	3	2	2	NUM
dti-3019	720	4	different	different	ADJ
dti-3019	720	5	dosages	dosage	NOUN
dti-3019	720	6	vs	vs	ADP
dti-3019	720	7	placebo	placebo	NOUN
dti-3019	720	8	for	for	ADP
dti-3019	720	9	patients	patient	NOUN
dti-3019	720	10	with	with	ADP
dti-3019	720	11	mild	mild	ADJ
dti-3019	720	12	alzheimer	alzheimer	NOUN
dti-3019	720	13	disease	disease	NOUN
dti-3019	720	14	:	:	PUNCT
dti-3019	720	15	a	a	DET
dti-3019	720	16	randomized	randomized	ADJ
dti-3019	720	17	clinical	clinical	ADJ
dti-3019	720	18	trial	trial	NOUN
dti-3019	720	19	.	.	PUNCT
dti-3019	721	1	jama	jama	PROPN
dti-3019	721	2	neurol	neurol	PROPN
dti-3019	721	3	.	.	PUNCT
dti-3019	722	1	2020;77(2):164	2020;77(2):164	NUM
dti-3019	722	2	-	-	PUNCT
dti-3019	722	3	174	174	NUM
dti-3019	722	4	.	.	PUNCT
dti-3019	723	1	crossref	crossref	PROPN
dti-3019	723	2	pubmed	pubmed	PROPN
dti-3019	723	3	107	107	PROPN
dti-3019	723	4	.	.	PUNCT
dti-3019	724	1	gandra	gandra	PROPN
dti-3019	724	2	s	s	PROPN
dti-3019	724	3	,	,	PUNCT
dti-3019	724	4	mojica	mojica	PROPN
dti-3019	724	5	n	n	NUM
dti-3019	724	6	,	,	PUNCT
dti-3019	724	7	klein	klein	PROPN
dti-3019	724	8	ey	ey	PROPN
dti-3019	724	9	,	,	PUNCT
dti-3019	724	10	et	et	PROPN
dti-3019	724	11	al	al	PROPN
dti-3019	724	12	.	.	PUNCT
dti-3019	724	13	trends	trend	NOUN
dti-3019	724	14	in	in	ADP
dti-3019	724	15	antibiotic	antibiotic	ADJ
dti-3019	724	16	resistance	resistance	NOUN
dti-3019	724	17	among	among	ADP
dti-3019	724	18	major	major	ADJ
dti-3019	724	19	bacterial	bacterial	ADJ
dti-3019	724	20	pathogens	pathogen	NOUN
dti-3019	724	21	isolated	isolate	VERB
dti-3019	724	22	from	from	ADP
dti-3019	724	23	blood	blood	NOUN
dti-3019	724	24	cultures	culture	NOUN
dti-3019	724	25	tested	test	VERB
dti-3019	724	26	at	at	ADP
dti-3019	724	27	a	a	DET
dti-3019	724	28	large	large	ADJ
dti-3019	724	29	private	private	ADJ
dti-3019	724	30	laboratory	laboratory	NOUN
dti-3019	724	31	network	network	NOUN
dti-3019	724	32	in	in	ADP
dti-3019	724	33	india	india	PROPN
dti-3019	724	34	,	,	PUNCT
dti-3019	724	35	2008	2008	NUM
dti-3019	724	36	-	-	SYM
dti-3019	724	37	2014	2014	NUM
dti-3019	724	38	.	.	PUNCT
dti-3019	725	1	int	int	NOUN
dti-3019	725	2	j	j	PROPN
dti-3019	725	3	infect	infect	VERB
dti-3019	725	4	dis	dis	PROPN
dti-3019	725	5	.	.	PUNCT
dti-3019	726	1	2016;50(50):75	2016;50(50):75	NUM
dti-3019	726	2	-	-	SYM
dti-3019	726	3	82	82	NUM
dti-3019	726	4	.	.	PUNCT
dti-3019	727	1	crossref	crossref	PROPN
dti-3019	727	2	pubmed	pubmed	PROPN
dti-3019	727	3	108	108	NUM
dti-3019	727	4	.	.	PUNCT
dti-3019	728	1	narendrakumar	narendrakumar	PROPN
dti-3019	728	2	l	l	PROPN
dti-3019	728	3	,	,	PUNCT
dti-3019	728	4	chandrika	chandrika	PROPN
dti-3019	728	5	sk	sk	VERB
dti-3019	728	6	,	,	PUNCT
dti-3019	728	7	thomas	thomas	PROPN
dti-3019	728	8	s.	s.	PROPN
dti-3019	728	9	adaptive	adaptive	PROPN
dti-3019	728	10	laboratory	laboratory	PROPN
dti-3019	728	11	evolution	evolution	NOUN
dti-3019	728	12	of	of	ADP
dti-3019	728	13	vibrio	vibrio	ADJ
dti-3019	728	14	cholerae	cholerae	NOUN
dti-3019	728	15	to	to	PART
dti-3019	728	16	doxycycline	doxycycline	VERB
dti-3019	728	17	associated	associate	VERB
dti-3019	728	18	with	with	ADP
dti-3019	728	19	spontaneous	spontaneous	ADJ
dti-3019	728	20	mutation	mutation	NOUN
dti-3019	728	21	.	.	PUNCT
dti-3019	729	1	int	int	NOUN
dti-3019	729	2	j	j	PROPN
dti-3019	729	3	antimicrob	antimicrob	PROPN
dti-3019	729	4	agents	agent	NOUN
dti-3019	729	5	.	.	PUNCT
dti-3019	730	1	2020;56(3):106097	2020;56(3):106097	NUM
dti-3019	730	2	.	.	PUNCT
dti-3019	731	1	crossref	crossref	PROPN
dti-3019	731	2	pubmed	pubmed	PROPN
dti-3019	731	3	109	109	NUM
dti-3019	731	4	.	.	PUNCT
dti-3019	732	1	kotwani	kotwani	PROPN
dti-3019	732	2	a	a	PROPN
dti-3019	732	3	,	,	PUNCT
dti-3019	732	4	joshi	joshi	PROPN
dti-3019	732	5	j	j	PROPN
dti-3019	732	6	,	,	PUNCT
dti-3019	732	7	lamkang	lamkang	PROPN
dti-3019	732	8	as	as	ADP
dti-3019	732	9	.	.	PUNCT
dti-3019	732	10	over	over	ADP
dti-3019	732	11	-	-	PUNCT
dti-3019	732	12	the	the	DET
dti-3019	732	13	-	-	PUNCT
dti-3019	732	14	counter	counter	NOUN
dti-3019	732	15	sale	sale	NOUN
dti-3019	732	16	of	of	ADP
dti-3019	732	17	antibiotics	antibiotic	NOUN
dti-3019	732	18	in	in	ADP
dti-3019	732	19	india	india	PROPN
dti-3019	732	20	:	:	PUNCT
dti-3019	732	21	a	a	DET
dti-3019	732	22	qualitative	qualitative	ADJ
dti-3019	732	23	study	study	NOUN
dti-3019	732	24	of	of	ADP
dti-3019	732	25	providers	provider	NOUN
dti-3019	732	26	’	'	PUNCT
dti-3019	732	27	perspectives	perspective	NOUN
dti-3019	732	28	across	across	ADP
dti-3019	732	29	two	two	NUM
dti-3019	732	30	states	state	NOUN
dti-3019	732	31	.	.	PUNCT
dti-3019	733	1	antibiotics	antibiotic	NOUN
dti-3019	733	2	(	(	PUNCT
dti-3019	733	3	basel	basel	PROPN
dti-3019	733	4	)	)	PUNCT
dti-3019	733	5	.	.	PUNCT
dti-3019	734	1	2021;10(9):1123	2021;10(9):1123	NOUN
dti-3019	734	2	.	.	PUNCT
dti-3019	735	1	crossref	crossref	PROPN
dti-3019	735	2	pubmed	pubmed	PROPN
dti-3019	735	3	110	110	NUM
dti-3019	735	4	.	.	PUNCT
dti-3019	736	1	fair	fair	PROPN
dti-3019	736	2	rj	rj	PROPN
dti-3019	736	3	,	,	PUNCT
dti-3019	736	4	tor	tor	PROPN
dti-3019	736	5	y.	y.	NOUN
dti-3019	736	6	antibiotics	antibiotic	NOUN
dti-3019	736	7	and	and	CCONJ
dti-3019	736	8	bacterial	bacterial	ADJ
dti-3019	736	9	resistance	resistance	NOUN
dti-3019	736	10	in	in	ADP
dti-3019	736	11	the	the	DET
dti-3019	736	12	21st	21st	ADJ
dti-3019	736	13	century	century	NOUN
dti-3019	736	14	.	.	PUNCT
dti-3019	737	1	perspect	perspect	NOUN
dti-3019	737	2	.	.	PUNCT
dti-3019	738	1	medicin	medicin	PROPN
dti-3019	738	2	chem	chem	PROPN
dti-3019	738	3	;	;	PUNCT
dti-3019	738	4	2014;6:25	2014;6:25	NOUN
dti-3019	738	5	-	-	SYM
dti-3019	738	6	64	64	NUM
dti-3019	738	7	.	.	NOUN
dti-3019	738	8	111	111	NUM
dti-3019	738	9	.	.	PUNCT
dti-3019	739	1	yacouba	yacouba	PROPN
dti-3019	739	2	a	a	PRON
dti-3019	739	3	,	,	PUNCT
dti-3019	739	4	olowo	olowo	PROPN
dti-3019	739	5	-	-	PUNCT
dti-3019	739	6	okere	okere	VERB
dti-3019	739	7	a	a	DET
dti-3019	739	8	,	,	PUNCT
dti-3019	739	9	yunusa	yunusa	NOUN
dti-3019	739	10	i.	i.	NOUN
dti-3019	739	11	repurposing	repurposing	NOUN
dti-3019	739	12	of	of	ADP
dti-3019	739	13	antibiotics	antibiotic	NOUN
dti-3019	739	14	for	for	ADP
dti-3019	739	15	clinical	clinical	ADJ
dti-3019	739	16	management	management	NOUN
dti-3019	739	17	of	of	ADP
dti-3019	739	18	covid-19	covid-19	PROPN
dti-3019	739	19	:	:	PUNCT
dti-3019	739	20	a	a	DET
dti-3019	739	21	narrative	narrative	NOUN
dti-3019	739	22	review	review	NOUN
dti-3019	739	23	.	.	PUNCT
dti-3019	740	1	ann	ann	PROPN
dti-3019	740	2	clin	clin	PROPN
dti-3019	740	3	microbiol	microbiol	PROPN
dti-3019	740	4	antimicrob	antimicrob	PROPN
dti-3019	740	5	.	.	PUNCT
dti-3019	741	1	2021;20(1):37	2021;20(1):37	NUM
dti-3019	741	2	-	-	SYM
dti-3019	741	3	38	38	NUM
dti-3019	741	4	.	.	PUNCT
dti-3019	742	1	crossref	crossref	PROPN
dti-3019	742	2	pubmed	pubmed	PROPN
dti-3019	742	3	112	112	NUM
dti-3019	742	4	.	.	PUNCT
dti-3019	743	1	burns	burns	PROPN
dti-3019	743	2	al	al	PROPN
dti-3019	743	3	,	,	PUNCT
dti-3019	743	4	sleebs	sleebs	NOUN
dti-3019	743	5	be	be	AUX
dti-3019	743	6	,	,	PUNCT
dti-3019	743	7	gancheva	gancheva	PROPN
dti-3019	743	8	m	m	PROPN
dti-3019	743	9	,	,	PUNCT
dti-3019	743	10	et	et	PROPN
dti-3019	743	11	al	al	PROPN
dti-3019	743	12	.	.	PUNCT
dti-3019	744	1	targeting	target	VERB
dti-3019	744	2	malaria	malaria	NOUN
dti-3019	744	3	parasites	parasite	NOUN
dti-3019	744	4	with	with	ADP
dti-3019	744	5	novel	novel	ADJ
dti-3019	744	6	derivatives	derivative	NOUN
dti-3019	744	7	of	of	ADP
dti-3019	744	8	azithromycin	azithromycin	NOUN
dti-3019	744	9	.	.	PUNCT
dti-3019	745	1	front	front	ADJ
dti-3019	745	2	cell	cell	NOUN
dti-3019	745	3	infect	infect	VERB
dti-3019	745	4	microbiol	microbiol	NOUN
dti-3019	745	5	.	.	PUNCT
dti-3019	746	1	2022;12:1063407	2022;12:1063407	X
dti-3019	746	2	.	.	PUNCT
dti-3019	746	3	crossref	crossref	PROPN
dti-3019	746	4	pubmed	pubmed	PROPN
dti-3019	746	5	113	113	NUM
dti-3019	746	6	.	.	PUNCT
dti-3019	747	1	burns	burns	PROPN
dti-3019	747	2	al	al	PROPN
dti-3019	747	3	,	,	PUNCT
dti-3019	747	4	sleebs	sleebs	NOUN
dti-3019	747	5	be	be	VERB
dti-3019	747	6	,	,	PUNCT
dti-3019	747	7	siddiqui	siddiqui	NOUN
dti-3019	747	8	g	g	PROPN
dti-3019	747	9	,	,	PUNCT
dti-3019	747	10	et	et	PROPN
dti-3019	747	11	al	al	PROPN
dti-3019	747	12	.	.	PUNCT
dti-3019	748	1	retargeting	retargete	VERB
dti-3019	748	2	azithromycin	azithromycin	NOUN
dti-3019	748	3	analogues	analogue	NOUN
dti-3019	748	4	to	to	PART
dti-3019	748	5	have	have	VERB
dti-3019	748	6	dual	dual	ADJ
dti-3019	748	7	-	-	PUNCT
dti-3019	748	8	modality	modality	NOUN
dti-3019	748	9	antimalarial	antimalarial	ADJ
dti-3019	748	10	activity	activity	NOUN
dti-3019	748	11	.	.	PUNCT
dti-3019	749	1	bmc	bmc	ADJ
dti-3019	749	2	biol.2020;18:1	biol.2020;18:1	PROPN
dti-3019	749	3	-	-	PUNCT
dti-3019	749	4	23	23	NUM
dti-3019	749	5	.	.	PUNCT
dti-3019	749	6	114	114	NUM
dti-3019	749	7	.	.	PUNCT
dti-3019	750	1	gore	gore	PROPN
dti-3019	750	2	-	-	PUNCT
dti-3019	750	3	langton	langton	PROPN
dti-3019	750	4	gr	gr	PROPN
dti-3019	750	5	,	,	PUNCT
dti-3019	750	6	cairns	cairns	PROPN
dti-3019	750	7	m	m	PROPN
dti-3019	750	8	,	,	PUNCT
dti-3019	750	9	compaoré	compaoré	PROPN
dti-3019	750	10	yd	yd	PROPN
dti-3019	750	11	,	,	PUNCT
dti-3019	750	12	et	et	PROPN
dti-3019	750	13	al	al	PROPN
dti-3019	750	14	.	.	PROPN
dti-3019	750	15	effect	effect	NOUN
dti-3019	750	16	of	of	ADP
dti-3019	750	17	adding	add	VERB
dti-3019	750	18	azithromycin	azithromycin	PROPN
dti-3019	750	19	to	to	ADP
dti-3019	750	20	the	the	DET
dti-3019	750	21	antimalarials	antimalarial	NOUN
dti-3019	750	22	used	use	VERB
dti-3019	750	23	for	for	ADP
dti-3019	750	24	seasonal	seasonal	ADJ
dti-3019	750	25	malaria	malaria	NOUN
dti-3019	750	26	chemoprevention	chemoprevention	NOUN
dti-3019	750	27	on	on	ADP
dti-3019	750	28	the	the	DET
dti-3019	750	29	nutritional	nutritional	ADJ
dti-3019	750	30	status	status	NOUN
dti-3019	750	31	of	of	ADP
dti-3019	750	32	african	african	ADJ
dti-3019	750	33	children	child	NOUN
dti-3019	750	34	.	.	PUNCT
dti-3019	751	1	trop	trop	PROPN
dti-3019	751	2	med	med	ADJ
dti-3019	751	3	int	int	PROPN
dti-3019	751	4	health	health	NOUN
dti-3019	751	5	.	.	PUNCT
dti-3019	752	1	2020;25(6):740	2020;25(6):740	NOUN
dti-3019	752	2	-	-	PUNCT
dti-3019	752	3	750	750	NUM
dti-3019	752	4	.	.	PUNCT
dti-3019	752	5	115	115	NUM
dti-3019	752	6	.	.	PUNCT
dti-3019	753	1	peric	peric	PROPN
dti-3019	753	2	m	m	PROPN
dti-3019	753	3	,	,	PUNCT
dti-3019	753	4	pešić	pešić	PROPN
dti-3019	753	5	d	d	PROPN
dti-3019	753	6	,	,	PUNCT
dti-3019	753	7	alihodžić	alihodžić	NOUN
dti-3019	753	8	s	s	PART
dti-3019	753	9	,	,	PUNCT
dti-3019	753	10	et	et	PROPN
dti-3019	753	11	al	al	PROPN
dti-3019	753	12	.	.	PUNCT
dti-3019	754	1	a	a	DET
dti-3019	754	2	novel	novel	ADJ
dti-3019	754	3	class	class	NOUN
dti-3019	754	4	of	of	ADP
dti-3019	754	5	fast	fast	ADV
dti-3019	754	6	-	-	PUNCT
dti-3019	754	7	acting	act	VERB
dti-3019	754	8	antimalarial	antimalarial	ADJ
dti-3019	754	9	agents	agent	NOUN
dti-3019	754	10	:	:	PUNCT
dti-3019	754	11	substituted	substitute	VERB
dti-3019	754	12	15	15	NUM
dti-3019	754	13	-	-	PUNCT
dti-3019	754	14	membered	membere	VERB
dti-3019	754	15	azalides	azalide	NOUN
dti-3019	754	16	.	.	PUNCT
dti-3019	755	1	br	br	PROPN
dti-3019	755	2	j	j	PROPN
dti-3019	755	3	pharmacol	pharmacol	PROPN
dti-3019	755	4	.	.	PUNCT
dti-3019	756	1	2021;178(2):363	2021;178(2):363	NUM
dti-3019	756	2	-	-	SYM
dti-3019	756	3	377	377	NUM
dti-3019	756	4	.	.	PUNCT
dti-3019	757	1	crossref	crossref	PROPN
dti-3019	757	2	pubmed	pubmed	PROPN
dti-3019	757	3	116	116	PROPN
dti-3019	757	4	.	.	PUNCT
dti-3019	758	1	advani	advani	PROPN
dti-3019	758	2	d	d	PROPN
dti-3019	758	3	,	,	PUNCT
dti-3019	758	4	kumar	kumar	PROPN
dti-3019	758	5	p.	p.	PROPN
dti-3019	758	6	therapeutic	therapeutic	ADJ
dti-3019	758	7	targeting	targeting	NOUN
dti-3019	758	8	of	of	ADP
dti-3019	758	9	repurposed	repurpose	VERB
dti-3019	758	10	anticancer	anticancer	NOUN
dti-3019	758	11	drugs	drug	NOUN
dti-3019	758	12	in	in	ADP
dti-3019	758	13	alzheimer	alzheimer	PROPN
dti-3019	758	14	’s	’s	PART
dti-3019	758	15	disease	disease	NOUN
dti-3019	758	16	:	:	PUNCT
dti-3019	758	17	using	use	VERB
dti-3019	758	18	the	the	DET
dti-3019	758	19	multiomics	multiomics	NOUN
dti-3019	758	20	approach	approach	NOUN
dti-3019	758	21	.	.	PUNCT
dti-3019	759	1	acs	acs	PROPN
dti-3019	759	2	omega	omega	NOUN
dti-3019	759	3	.	.	PUNCT
dti-3019	760	1	2021;6(21):13870	2021;6(21):13870	NUM
dti-3019	760	2	-	-	SYM
dti-3019	760	3	13887	13887	NUM
dti-3019	760	4	.	.	PUNCT
dti-3019	761	1	crossref	crossref	PROPN
dti-3019	761	2	pubmed	pubmed	PROPN
dti-3019	761	3	117	117	PROPN
dti-3019	761	4	.	.	PUNCT
dti-3019	762	1	tímár	tímár	PROPN
dti-3019	762	2	j	j	PROPN
dti-3019	762	3	,	,	PUNCT
dti-3019	762	4	ladányi	ladányi	PROPN
dti-3019	762	5	a	a	X
dti-3019	762	6	,	,	PUNCT
dti-3019	762	7	forster	forster	PROPN
dti-3019	762	8	-	-	PUNCT
dti-3019	762	9	horváth	horváth	PROPN
dti-3019	762	10	c	c	PROPN
dti-3019	762	11	,	,	PUNCT
dti-3019	762	12	et	et	PROPN
dti-3019	762	13	al	al	PROPN
dti-3019	762	14	.	.	PROPN
dti-3019	763	1	neoadjuvant	neoadjuvant	ADJ
dti-3019	763	2	immunotherapy	immunotherapy	NOUN
dti-3019	763	3	of	of	ADP
dti-3019	763	4	oral	oral	ADJ
dti-3019	763	5	squamous	squamous	ADJ
dti-3019	763	6	cell	cell	NOUN
dti-3019	763	7	carcinoma	carcinoma	NOUN
dti-3019	763	8	modulates	modulate	VERB
dti-3019	763	9	intratumoral	intratumoral	ADJ
dti-3019	763	10	cd4	cd4	PROPN
dti-3019	763	11	/	/	SYM
dti-3019	763	12	cd8	cd8	PROPN
dti-3019	763	13	ratio	ratio	NOUN
dti-3019	763	14	and	and	CCONJ
dti-3019	763	15	tumor	tumor	NOUN
dti-3019	763	16	microenvironment	microenvironment	NOUN
dti-3019	763	17	:	:	PUNCT
dti-3019	763	18	a	a	DET
dti-3019	763	19	multicenter	multicenter	ADJ
dti-3019	763	20	phase	phase	NOUN
dti-3019	763	21	ii	ii	NOUN
dti-3019	763	22	clinical	clinical	ADJ
dti-3019	763	23	trial	trial	NOUN
dti-3019	763	24	.	.	PUNCT
dti-3019	764	1	j	j	PROPN
dti-3019	764	2	clin	clin	PROPN
dti-3019	764	3	oncol	oncol	PROPN
dti-3019	764	4	.	.	PUNCT
dti-3019	765	1	2005;23(15):3421	2005;23(15):3421	X
dti-3019	765	2	-	-	SYM
dti-3019	765	3	3432	3432	NUM
dti-3019	765	4	.	.	PUNCT
dti-3019	766	1	crossref	crossref	PROPN
dti-3019	766	2	pubmed	pubmed	PROPN
dti-3019	766	3	118	118	NUM
dti-3019	766	4	.	.	PUNCT
dti-3019	767	1	avershina	avershina	PROPN
dti-3019	767	2	e	e	PROPN
dti-3019	767	3	,	,	PUNCT
dti-3019	767	4	shapovalova	shapovalova	PROPN
dti-3019	767	5	v	v	PROPN
dti-3019	767	6	,	,	PUNCT
dti-3019	767	7	shipulin	shipulin	PROPN
dti-3019	767	8	g.	g.	PROPN
dti-3019	767	9	fighting	fight	VERB
dti-3019	767	10	antibiotic	antibiotic	ADJ
dti-3019	767	11	resistance	resistance	NOUN
dti-3019	767	12	in	in	ADP
dti-3019	767	13	hospital	hospital	NOUN
dti-3019	767	14	-	-	PUNCT
dti-3019	767	15	acquired	acquire	VERB
dti-3019	767	16	infections	infection	NOUN
dti-3019	767	17	:	:	PUNCT
dti-3019	767	18	current	current	ADJ
dti-3019	767	19	state	state	NOUN
dti-3019	767	20	and	and	CCONJ
dti-3019	767	21	emerging	emerge	VERB
dti-3019	767	22	technologies	technology	NOUN
dti-3019	767	23	in	in	ADP
dti-3019	767	24	disease	disease	NOUN
dti-3019	767	25	prevention	prevention	NOUN
dti-3019	767	26	,	,	PUNCT
dti-3019	767	27	diagnostics	diagnostic	NOUN
dti-3019	767	28	and	and	CCONJ
dti-3019	767	29	therapy	therapy	NOUN
dti-3019	767	30	.	.	PUNCT
dti-3019	768	1	front	front	PROPN
dti-3019	768	2	microbiol	microbiol	PROPN
dti-3019	768	3	.	.	PUNCT
dti-3019	769	1	2021;12:2044	2021;12:2044	NUM
dti-3019	769	2	.	.	PROPN
dti-3019	769	3	119	119	NUM
dti-3019	769	4	.	.	PUNCT
dti-3019	770	1	tyers	tyers	PROPN
dti-3019	770	2	m	m	PROPN
dti-3019	770	3	,	,	PUNCT
dti-3019	770	4	wright	wright	PROPN
dti-3019	770	5	gd	gd	PROPN
dti-3019	770	6	.	.	PUNCT
dti-3019	770	7	drug	drug	NOUN
dti-3019	770	8	combinations	combination	NOUN
dti-3019	770	9	:	:	PUNCT
dti-3019	770	10	a	a	DET
dti-3019	770	11	strategy	strategy	NOUN
dti-3019	770	12	to	to	PART
dti-3019	770	13	extend	extend	VERB
dti-3019	770	14	the	the	DET
dti-3019	770	15	life	life	NOUN
dti-3019	770	16	of	of	ADP
dti-3019	770	17	antibiotics	antibiotic	NOUN
dti-3019	770	18	in	in	ADP
dti-3019	770	19	the	the	DET
dti-3019	770	20	21st	21st	ADJ
dti-3019	770	21	century	century	NOUN
dti-3019	770	22	.	.	PUNCT
dti-3019	771	1	nat	nat	PROPN
dti-3019	771	2	rev	rev	PROPN
dti-3019	771	3	microbiol	microbiol	PROPN
dti-3019	771	4	.	.	PUNCT
dti-3019	772	1	2019;17(3):141	2019;17(3):141	NUM
dti-3019	772	2	-	-	SYM
dti-3019	772	3	155	155	NUM
dti-3019	772	4	.	.	PUNCT
dti-3019	773	1	crossref	crossref	PROPN
dti-3019	773	2	pubmed	pubmed	PROPN
dti-3019	773	3	120	120	NUM
dti-3019	773	4	.	.	PUNCT
dti-3019	774	1	hartkoorn	hartkoorn	PROPN
dti-3019	774	2	rc	rc	PROPN
dti-3019	774	3	,	,	PUNCT
dti-3019	774	4	sala	sala	PROPN
dti-3019	774	5	c	c	PROPN
dti-3019	774	6	,	,	PUNCT
dti-3019	774	7	neres	neres	PROPN
dti-3019	774	8	j	j	PROPN
dti-3019	774	9	,	,	PUNCT
dti-3019	774	10	et	et	PROPN
dti-3019	774	11	al	al	PROPN
dti-3019	774	12	.	.	PROPN
dti-3019	774	13	towards	towards	ADP
dti-3019	774	14	a	a	DET
dti-3019	774	15	new	new	ADJ
dti-3019	774	16	tuberculosis	tuberculosis	NOUN
dti-3019	774	17	drug	drug	NOUN
dti-3019	774	18	:	:	PUNCT
dti-3019	774	19	pyridomycin	pyridomycin	ADJ
dti-3019	774	20	-	-	PUNCT
dti-3019	774	21	nature	nature	NOUN
dti-3019	774	22	’s	’s	PART
dti-3019	774	23	isoniazid	isoniazid	NOUN
dti-3019	774	24	.	.	PUNCT
dti-3019	775	1	embo	embo	NOUN
dti-3019	775	2	mol	mol	ADP
dti-3019	775	3	med	med	PROPN
dti-3019	775	4	.	.	PUNCT
dti-3019	776	1	2012;4(10):1032	2012;4(10):1032	NUM
dti-3019	776	2	-	-	SYM
dti-3019	776	3	1042	1042	NUM
dti-3019	776	4	.	.	PUNCT
dti-3019	777	1	121	121	NUM
dti-3019	777	2	.	.	PUNCT
dti-3019	778	1	diacon	diacon	PROPN
dti-3019	778	2	ah	ah	INTJ
dti-3019	778	3	,	,	PUNCT
dti-3019	778	4	dawson	dawson	PROPN
dti-3019	778	5	r	r	PROPN
dti-3019	778	6	,	,	PUNCT
dti-3019	778	7	groote	groote	NOUN
dti-3019	778	8	-	-	PUNCT
dti-3019	778	9	bidlingmaier	bidlingmaier	NOUN
dti-3019	778	10	f	f	NOUN
dti-3019	778	11	,	,	PUNCT
dti-3019	778	12	et	et	PROPN
dti-3019	778	13	al	al	PROPN
dti-3019	778	14	.	.	PUNCT
dti-3019	778	15	bactericidal	bactericidal	ADJ
dti-3019	778	16	activity	activity	NOUN
dti-3019	778	17	of	of	ADP
dti-3019	778	18	pyrazinamide	pyrazinamide	NOUN
dti-3019	778	19	and	and	CCONJ
dti-3019	778	20	clofazimine	clofazimine	ADJ
dti-3019	778	21	alone	alone	ADV
dti-3019	778	22	and	and	CCONJ
dti-3019	778	23	in	in	ADP
dti-3019	778	24	combinations	combination	NOUN
dti-3019	778	25	with	with	ADP
dti-3019	778	26	pretomanid	pretomanid	ADJ
dti-3019	778	27	and	and	CCONJ
dti-3019	778	28	bedaquiline	bedaquiline	NOUN
dti-3019	778	29	.	.	PUNCT
dti-3019	779	1	am	be	AUX
dti-3019	779	2	j	j	PROPN
dti-3019	779	3	respir	respir	NOUN
dti-3019	779	4	crit	crit	PROPN
dti-3019	779	5	care	care	NOUN
dti-3019	779	6	med	me	VERB
dti-3019	779	7	.	.	PUNCT
dti-3019	780	1	2015;191(8):943	2015;191(8):943	NUM
dti-3019	780	2	-	-	SYM
dti-3019	780	3	953	953	NUM
dti-3019	780	4	.	.	PUNCT
dti-3019	781	1	122	122	NUM
dti-3019	781	2	.	.	PUNCT
dti-3019	782	1	weng	weng	PROPN
dti-3019	782	2	h	h	PROPN
dti-3019	782	3	-	-	PUNCT
dti-3019	782	4	b	b	PROPN
dti-3019	782	5	,	,	PUNCT
dti-3019	782	6	chen	chen	PROPN
dti-3019	782	7	h	h	PROPN
dti-3019	782	8	-	-	PUNCT
dti-3019	782	9	x	x	PROPN
dti-3019	782	10	,	,	PUNCT
dti-3019	782	11	wang	wang	PROPN
dti-3019	782	12	m	m	PROPN
dti-3019	782	13	-	-	PROPN
dti-3019	782	14	w.	w.	PROPN
dti-3019	782	15	innovation	innovation	NOUN
dti-3019	782	16	in	in	ADP
dti-3019	782	17	neglected	neglect	VERB
dti-3019	782	18	tropical	tropical	ADJ
dti-3019	782	19	disease	disease	NOUN
dti-3019	782	20	drug	drug	NOUN
dti-3019	782	21	discovery	discovery	NOUN
dti-3019	782	22	and	and	CCONJ
dti-3019	782	23	development	development	NOUN
dti-3019	782	24	.	.	PUNCT
dti-3019	783	1	infect	infect	VERB
dti-3019	783	2	dis	dis	PROPN
dti-3019	783	3	poverty	poverty	NOUN
dti-3019	783	4	.	.	PUNCT
dti-3019	784	1	2018;7(1):67	2018;7(1):67	X
dti-3019	784	2	.	.	X
dti-3019	784	3	crossref	crossref	PROPN
dti-3019	784	4	pubmed	pubmed	PROPN
dti-3019	784	5	123	123	NUM
dti-3019	784	6	.	.	PUNCT
dti-3019	785	1	lauring	laure	VERB
dti-3019	785	2	as	as	ADP
dti-3019	785	3	,	,	PUNCT
dti-3019	785	4	andino	andino	PROPN
dti-3019	785	5	r.	r.	PROPN
dti-3019	785	6	quasispecies	quasispecies	PROPN
dti-3019	785	7	theory	theory	NOUN
dti-3019	785	8	and	and	CCONJ
dti-3019	785	9	the	the	DET
dti-3019	785	10	behavior	behavior	NOUN
dti-3019	785	11	of	of	ADP
dti-3019	785	12	rna	rna	NOUN
dti-3019	785	13	viruses	virus	NOUN
dti-3019	785	14	.	.	PUNCT
dti-3019	786	1	plos	plos	PROPN
dti-3019	786	2	pathog	pathog	PROPN
dti-3019	786	3	.	.	PUNCT
dti-3019	787	1	2010;6(7):e1001005	2010;6(7):e1001005	NUM
dti-3019	787	2	.	.	PUNCT
dti-3019	788	1	crossref	crossref	PROPN
dti-3019	788	2	pubmed	pubmed	PROPN
dti-3019	788	3	124	124	NUM
dti-3019	788	4	.	.	PUNCT
dti-3019	789	1	ventola	ventola	PROPN
dti-3019	789	2	cl	cl	PROPN
dti-3019	789	3	.	.	PUNCT
dti-3019	790	1	the	the	DET
dti-3019	790	2	antibiotic	antibiotic	ADJ
dti-3019	790	3	resistance	resistance	NOUN
dti-3019	790	4	crisis	crisis	NOUN
dti-3019	790	5	:	:	PUNCT
dti-3019	790	6	part	part	NOUN
dti-3019	790	7	1	1	NUM
dti-3019	790	8	:	:	PUNCT
dti-3019	790	9	causes	cause	NOUN
dti-3019	790	10	and	and	CCONJ
dti-3019	790	11	threats	threat	NOUN
dti-3019	790	12	.	.	PUNCT
dti-3019	791	1	p&t	p&t	PROPN
dti-3019	791	2	.	.	PUNCT
dti-3019	792	1	2015;40(4):277	2015;40(4):277	PROPN
dti-3019	792	2	-	-	PUNCT
dti-3019	792	3	283	283	NUM
dti-3019	792	4	.	.	PUNCT
dti-3019	793	1	pubmed	pubmed	PROPN
dti-3019	793	2	125	125	NUM
dti-3019	793	3	.	.	PUNCT
dti-3019	794	1	scherf	scherf	PROPN
dti-3019	794	2	a	a	DET
dti-3019	794	3	,	,	PUNCT
dti-3019	794	4	lopez	lopez	NOUN
dti-3019	794	5	-	-	PUNCT
dti-3019	794	6	rubio	rubio	PROPN
dti-3019	794	7	jj	jj	PROPN
dti-3019	794	8	,	,	PUNCT
dti-3019	794	9	riviere	riviere	PROPN
dti-3019	794	10	l.	l.	PROPN
dti-3019	794	11	antigenic	antigenic	ADJ
dti-3019	794	12	variation	variation	NOUN
dti-3019	794	13	in	in	ADP
dti-3019	794	14	plasmodium	plasmodium	NOUN
dti-3019	794	15	falciparum	falciparum	NOUN
dti-3019	794	16	.	.	PUNCT
dti-3019	795	1	annu	annu	PROPN
dti-3019	795	2	rev	rev	VERB
dti-3019	795	3	microbiol	microbiol	PROPN
dti-3019	795	4	.	.	PUNCT
dti-3019	796	1	2008;62:445	2008;62:445	NOUN
dti-3019	796	2	-	-	PUNCT
dti-3019	796	3	470	470	NUM
dti-3019	796	4	.	.	PUNCT
dti-3019	797	1	126	126	NUM
dti-3019	797	2	.	.	PUNCT
dti-3019	798	1	gomez	gomez	PROPN
dti-3019	798	2	je	je	PROPN
dti-3019	798	3	,	,	PUNCT
dti-3019	798	4	mckinney	mckinney	PROPN
dti-3019	798	5	jd	jd	PROPN
dti-3019	798	6	.	.	PROPN
dti-3019	798	7	m.	m.	NOUN
dti-3019	798	8	tuberculosis	tuberculosis	NOUN
dti-3019	798	9	persistence	persistence	NOUN
dti-3019	798	10	,	,	PUNCT
dti-3019	798	11	latency	latency	NOUN
dti-3019	798	12	,	,	PUNCT
dti-3019	798	13	and	and	CCONJ
dti-3019	798	14	drug	drug	NOUN
dti-3019	798	15	tolerance	tolerance	NOUN
dti-3019	798	16	.	.	PUNCT
dti-3019	799	1	tuberculosis	tuberculosis	NOUN
dti-3019	799	2	(	(	PUNCT
dti-3019	799	3	edinb	edinb	NOUN
dti-3019	799	4	)	)	PUNCT
dti-3019	799	5	.	.	PUNCT
dti-3019	800	1	2004;84(1	2004;84(1	NUM
dti-3019	800	2	-	-	SYM
dti-3019	800	3	2):29	2):29	NUM
dti-3019	800	4	-	-	PUNCT
dti-3019	800	5	44	44	NUM
dti-3019	800	6	.	.	PUNCT
dti-3019	801	1	crossref	crossref	PROPN
dti-3019	801	2	pubmed	pubmed	PROPN
dti-3019	801	3	127	127	NUM
dti-3019	801	4	.	.	PUNCT
dti-3019	802	1	barrett	barrett	PROPN
dti-3019	802	2	mp	mp	PROPN
dti-3019	802	3	,	,	PUNCT
dti-3019	802	4	kyle	kyle	PROPN
dti-3019	802	5	de	de	PROPN
dti-3019	802	6	,	,	PUNCT
dti-3019	802	7	sibley	sibley	PROPN
dti-3019	802	8	ld	ld	PROPN
dti-3019	802	9	,	,	PUNCT
dti-3019	802	10	radke	radke	PROPN
dti-3019	802	11	jb	jb	PROPN
dti-3019	802	12	,	,	PUNCT
dti-3019	802	13	tarleton	tarleton	PROPN
dti-3019	802	14	rl	rl	PROPN
dti-3019	802	15	.	.	PROPN
dti-3019	802	16	protozoan	protozoan	NOUN
dti-3019	802	17	persister	persister	NOUN
dti-3019	802	18	-	-	PUNCT
dti-3019	802	19	like	like	ADJ
dti-3019	802	20	cells	cell	NOUN
dti-3019	802	21	and	and	CCONJ
dti-3019	802	22	drug	drug	NOUN
dti-3019	802	23	treatment	treatment	NOUN
dti-3019	802	24	failure	failure	NOUN
dti-3019	802	25	.	.	PUNCT
dti-3019	803	1	nat	nat	PROPN
dti-3019	803	2	rev	rev	PROPN
dti-3019	803	3	microbiol	microbiol	PROPN
dti-3019	803	4	.	.	PUNCT
dti-3019	804	1	2019;17(10):607	2019;17(10):607	PROPN
dti-3019	804	2	-	-	PUNCT
dti-3019	804	3	620	620	PROPN
dti-3019	804	4	.	.	PUNCT
dti-3019	805	1	crossref	crossref	PROPN
dti-3019	805	2	pubmed	pubmed	PROPN
dti-3019	805	3	128	128	NUM
dti-3019	805	4	.	.	PUNCT
dti-3019	805	5	donlan	donlan	PROPN
dti-3019	805	6	rm	rm	PROPN
dti-3019	805	7	.	.	PROPN
dti-3019	805	8	biofilms	biofilm	NOUN
dti-3019	805	9	and	and	CCONJ
dti-3019	805	10	device	device	NOUN
dti-3019	805	11	-	-	PUNCT
dti-3019	805	12	associated	associate	VERB
dti-3019	805	13	infections	infection	NOUN
dti-3019	805	14	.	.	PUNCT
dti-3019	806	1	emerg	emerg	PROPN
dti-3019	806	2	infect	infect	PROPN
dti-3019	806	3	dis	dis	PROPN
dti-3019	806	4	.	.	PUNCT
dti-3019	807	1	2001;7(2):277	2001;7(2):277	NUM
dti-3019	807	2	-	-	SYM
dti-3019	807	3	281	281	NUM
dti-3019	807	4	.	.	PUNCT
dti-3019	808	1	crossref	crossref	PROPN
dti-3019	808	2	pubmed	pubmed	PROPN
dti-3019	808	3	129	129	NUM
dti-3019	808	4	.	.	PUNCT
dti-3019	809	1	hay	hay	PROPN
dti-3019	809	2	m	m	PROPN
dti-3019	809	3	,	,	PUNCT
dti-3019	809	4	thomas	thomas	PROPN
dti-3019	809	5	dw	dw	PROPN
dti-3019	809	6	,	,	PUNCT
dti-3019	809	7	craighead	craighead	PROPN
dti-3019	809	8	jl	jl	PROPN
dti-3019	809	9	,	,	PUNCT
dti-3019	809	10	economides	economide	VERB
dti-3019	809	11	c	c	PROPN
dti-3019	809	12	,	,	PUNCT
dti-3019	809	13	rosenthal	rosenthal	PROPN
dti-3019	809	14	j.	j.	PROPN
dti-3019	809	15	clinical	clinical	PROPN
dti-3019	809	16	development	development	NOUN
dti-3019	809	17	success	success	NOUN
dti-3019	809	18	rates	rate	NOUN
dti-3019	809	19	for	for	ADP
dti-3019	809	20	investigational	investigational	ADJ
dti-3019	809	21	drugs	drug	NOUN
dti-3019	809	22	.	.	PUNCT
dti-3019	810	1	nat	nat	PROPN
dti-3019	810	2	biotechnol	biotechnol	NOUN
dti-3019	810	3	.	.	PUNCT
dti-3019	811	1	2014;32(1):40	2014;32(1):40	NUM
dti-3019	811	2	-	-	SYM
dti-3019	811	3	51	51	NUM
dti-3019	811	4	.	.	PUNCT
dti-3019	812	1	crossref	crossref	PROPN
dti-3019	812	2	pubmed	pubmed	PROPN
dti-3019	812	3	130	130	NUM
dti-3019	812	4	.	.	PUNCT
dti-3019	813	1	ginsberg	ginsberg	PROPN
dti-3019	813	2	am	be	AUX
dti-3019	813	3	,	,	PUNCT
dti-3019	813	4	spigelman	spigelman	ADJ
dti-3019	813	5	m.	m.	NOUN
dti-3019	813	6	challenges	challenge	NOUN
dti-3019	813	7	in	in	ADP
dti-3019	813	8	tuberculosis	tuberculosis	NOUN
dti-3019	813	9	drug	drug	NOUN
dti-3019	813	10	research	research	NOUN
dti-3019	813	11	and	and	CCONJ
dti-3019	813	12	development	development	NOUN
dti-3019	813	13	.	.	PUNCT
dti-3019	814	1	nat	nat	PROPN
dti-3019	814	2	med	med	PROPN
dti-3019	814	3	.	.	PUNCT
dti-3019	815	1	2007;13(3):290	2007;13(3):290	NUM
dti-3019	815	2	-	-	PUNCT
dti-3019	815	3	294	294	NUM
dti-3019	815	4	.	.	PUNCT
dti-3019	816	1	crossref	crossref	PROPN
dti-3019	816	2	pubmed	pubmed	PROPN
dti-3019	816	3	131	131	PROPN
dti-3019	816	4	.	.	PUNCT
dti-3019	817	1	takuadina	takuadina	PROPN
dti-3019	817	2	ai	ai	VERB
dti-3019	817	3	,	,	PUNCT
dti-3019	817	4	pazylkhan	pazylkhan	ADP
dti-3019	817	5	np	np	INTJ
dti-3019	817	6	,	,	PUNCT
dti-3019	817	7	iskakov	iskakov	PROPN
dti-3019	817	8	kt	kt	PROPN
dti-3019	817	9	.	.	PROPN
dti-3019	817	10	mathematical	mathematical	ADJ
dti-3019	817	11	modeling	modeling	NOUN
dti-3019	817	12	of	of	ADP
dti-3019	817	13	infectious	infectious	ADJ
dti-3019	817	14	diseases	disease	NOUN
dti-3019	817	15	on	on	ADP
dti-3019	817	16	the	the	DET
dti-3019	817	17	example	example	NOUN
dti-3019	817	18	of	of	ADP
dti-3019	817	19	astana	astana	PROPN
dti-3019	817	20	city	city	PROPN
dti-3019	817	21	.	.	PUNCT
dti-3019	818	1	sci	sci	PROPN
dti-3019	818	2	educ	educ	PROPN
dti-3019	818	3	.	.	PUNCT
dti-3019	819	1	2023;71	2023;71	NUM
dti-3019	819	2	.	.	PUNCT
dti-3019	820	1	132	132	NUM
dti-3019	820	2	.	.	PUNCT
dti-3019	821	1	jiménez	jiménez	NOUN
dti-3019	821	2	-	-	PUNCT
dti-3019	821	3	díaz	díaz	PROPN
dti-3019	821	4	mb	mb	NOUN
dti-3019	821	5	,	,	PUNCT
dti-3019	821	6	mulet	mulet	PROPN
dti-3019	821	7	t	t	PROPN
dti-3019	821	8	,	,	PUNCT
dti-3019	821	9	viera	viera	PROPN
dti-3019	821	10	s	s	PROPN
dti-3019	821	11	,	,	PUNCT
dti-3019	821	12	et	et	PROPN
dti-3019	821	13	al	al	PROPN
dti-3019	821	14	.	.	PROPN
dti-3019	821	15	improved	improve	VERB
dti-3019	821	16	murine	murine	ADJ
dti-3019	821	17	model	model	NOUN
dti-3019	821	18	of	of	ADP
dti-3019	821	19	malaria	malaria	NOUN
dti-3019	821	20	using	use	VERB
dti-3019	821	21	plasmodium	plasmodium	NOUN
dti-3019	821	22	falciparum	falciparum	ADP
dti-3019	821	23	competent	competent	ADJ
dti-3019	821	24	strains	strain	NOUN
dti-3019	821	25	and	and	CCONJ
dti-3019	821	26	non	non	ADJ
dti-3019	821	27	-	-	ADJ
dti-3019	821	28	myelodepleted	myelodepleted	ADJ
dti-3019	821	29	nod	nod	PROPN
dti-3019	821	30	-	-	PUNCT
dti-3019	821	31	scid	scid	PROPN
dti-3019	821	32	il2rgammanull	il2rgammanull	PROPN
dti-3019	821	33	mice	mouse	NOUN
dti-3019	821	34	engrafted	engraft	VERB
dti-3019	821	35	with	with	ADP
dti-3019	821	36	human	human	ADJ
dti-3019	821	37	erythrocytes	erythrocyte	NOUN
dti-3019	821	38	.	.	PUNCT
dti-3019	822	1	antimicrob	antimicrob	PROPN
dti-3019	822	2	agents	agents	PROPN
dti-3019	822	3	chemother	chemother	PROPN
dti-3019	822	4	.	.	PUNCT
dti-3019	823	1	2009;53(10):4533	2009;53(10):4533	NUM
dti-3019	823	2	-	-	SYM
dti-3019	823	3	4536	4536	NUM
dti-3019	823	4	.	.	PUNCT
dti-3019	824	1	crossref	crossref	PROPN
dti-3019	824	2	pubmed	pubmed	PROPN
dti-3019	824	3	133	133	NUM
dti-3019	824	4	.	.	PUNCT
dti-3019	825	1	aguilar	aguilar	PROPN
dti-3019	825	2	c	c	PROPN
dti-3019	825	3	,	,	PUNCT
dti-3019	825	4	alves	alves	PROPN
dti-3019	825	5	da	da	PROPN
dti-3019	825	6	silva	silva	PROPN
dti-3019	825	7	m	m	PROPN
dti-3019	825	8	,	,	PUNCT
dti-3019	825	9	saraiva	saraiva	PROPN
dti-3019	825	10	m	m	PROPN
dti-3019	825	11	,	,	PUNCT
dti-3019	825	12	et	et	PROPN
dti-3019	825	13	al	al	PROPN
dti-3019	825	14	.	.	PROPN
dti-3019	825	15	organoids	organoid	NOUN
dti-3019	825	16	as	as	ADP
dti-3019	825	17	host	host	NOUN
dti-3019	825	18	models	model	NOUN
dti-3019	825	19	for	for	ADP
dti-3019	825	20	infection	infection	NOUN
dti-3019	825	21	biology	biology	NOUN
dti-3019	825	22	–	–	PUNCT
dti-3019	825	23	a	a	DET
dti-3019	825	24	review	review	NOUN
dti-3019	825	25	of	of	ADP
dti-3019	825	26	methods	method	NOUN
dti-3019	825	27	.	.	PUNCT
dti-3019	826	1	exp	exp	NOUN
dti-3019	826	2	mol	mol	ADP
dti-3019	826	3	med	med	PROPN
dti-3019	826	4	.	.	PUNCT
dti-3019	827	1	2021;53(10):1471	2021;53(10):1471	PROPN
dti-3019	827	2	-	-	SYM
dti-3019	827	3	1482	1482	NUM
dti-3019	827	4	.	.	PUNCT
dti-3019	828	1	pubmed	pubmed	PROPN
dti-3019	828	2	134	134	NUM
dti-3019	828	3	.	.	PUNCT
dti-3019	829	1	mihaljevic	mihaljevic	PROPN
dti-3019	829	2	jr	jr	PROPN
dti-3019	829	3	,	,	PUNCT
dti-3019	829	4	borkovec	borkovec	PROPN
dti-3019	829	5	s	s	PART
dti-3019	829	6	,	,	PUNCT
dti-3019	829	7	ratnavale	ratnavale	PROPN
dti-3019	829	8	s	s	PROPN
dti-3019	829	9	,	,	PUNCT
dti-3019	829	10	et	et	PROPN
dti-3019	829	11	al	al	PROPN
dti-3019	829	12	.	.	PROPN
dti-3019	829	13	sparsemodr	sparsemodr	VERB
dti-3019	829	14	:	:	PUNCT
dti-3019	829	15	rapidly	rapidly	ADV
dti-3019	829	16	simulate	simulate	VERB
dti-3019	829	17	spatially	spatially	ADV
dti-3019	829	18	explicit	explicit	ADJ
dti-3019	829	19	and	and	CCONJ
dti-3019	829	20	stochastic	stochastic	ADJ
dti-3019	829	21	models	model	NOUN
dti-3019	829	22	of	of	ADP
dti-3019	829	23	covid19	covid19	NOUN
dti-3019	829	24	and	and	CCONJ
dti-3019	829	25	other	other	ADJ
dti-3019	829	26	infectious	infectious	ADJ
dti-3019	829	27	diseases	disease	NOUN
dti-3019	829	28	.	.	PUNCT
dti-3019	830	1	biol	biol	ADJ
dti-3019	830	2	methods	method	NOUN
dti-3019	830	3	protocols	protocol	NOUN
dti-3019	830	4	.	.	PUNCT
dti-3019	831	1	2022;7(1):bpac022	2022;7(1):bpac022	NUM
dti-3019	831	2	.	.	PUNCT
dti-3019	832	1	135	135	NUM
dti-3019	832	2	.	.	PUNCT
dti-3019	833	1	blutt	blutt	PROPN
dti-3019	833	2	se	se	PROPN
dti-3019	833	3	,	,	PUNCT
dti-3019	833	4	estes	estes	PROPN
dti-3019	833	5	mk	mk	PROPN
dti-3019	833	6	.	.	PUNCT
dti-3019	833	7	organoid	organoid	PROPN
dti-3019	833	8	models	model	NOUN
dti-3019	833	9	for	for	ADP
dti-3019	833	10	infectious	infectious	ADJ
dti-3019	833	11	disease	disease	NOUN
dti-3019	833	12	.	.	PUNCT
dti-3019	834	1	annu	annu	PROPN
dti-3019	834	2	rev	rev	VERB
dti-3019	834	3	med	med	PROPN
dti-3019	834	4	.	.	PUNCT
dti-3019	835	1	2022;73(1):167	2022;73(1):167	NUM
dti-3019	835	2	-	-	PUNCT
dti-3019	835	3	182	182	NUM
dti-3019	835	4	.	.	PUNCT
dti-3019	836	1	crossref	crossref	PROPN
dti-3019	836	2	pubmed	pubmed	PROPN
dti-3019	836	3	136	136	NUM
dti-3019	836	4	.	.	PUNCT
dti-3019	837	1	smith	smith	PROPN
dti-3019	837	2	gc	gc	PROPN
dti-3019	837	3	,	,	PUNCT
dti-3019	837	4	kao	kao	PROPN
dti-3019	837	5	rr	rr	PROPN
dti-3019	837	6	,	,	PUNCT
dti-3019	837	7	walker	walker	PROPN
dti-3019	837	8	m.	m.	PROPN
dti-3019	837	9	infectious	infectious	ADJ
dti-3019	837	10	disease	disease	NOUN
dti-3019	837	11	modelling	model	VERB
dti-3019	837	12	to	to	PART
dti-3019	837	13	inform	inform	VERB
dti-3019	837	14	policy	policy	NOUN
dti-3019	837	15	.	.	PUNCT
dti-3019	838	1	rev	rev	VERB
dti-3019	838	2	sci	sci	PROPN
dti-3019	838	3	tech	tech	PROPN
dti-3019	838	4	.	.	PUNCT
dti-3019	839	1	2023;42:173	2023;42:173	NUM
dti-3019	839	2	-	-	SYM
dti-3019	839	3	179	179	NUM
dti-3019	839	4	.	.	PUNCT
dti-3019	840	1	crossref	crossref	PROPN
dti-3019	840	2	pubmed	pubmed	PROPN
dti-3019	840	3	137	137	NUM
dti-3019	840	4	.	.	PUNCT
dti-3019	841	1	anna	anna	PROPN
dti-3019	841	2	pgs	pgs	PROPN
dti-3019	841	3	,	,	PUNCT
dti-3019	841	4	henrique	henrique	PROPN
dti-3019	841	5	dos	do	VERB
dti-3019	841	6	santos	santos	PROPN
dti-3019	841	7	m	m	PROPN
dti-3019	841	8	,	,	PUNCT
dti-3019	841	9	banerjee	banerjee	PROPN
dti-3019	841	10	a.	a.	NOUN
dti-3019	841	11	a	a	DET
dti-3019	841	12	statistical	statistical	ADJ
dti-3019	841	13	examination	examination	NOUN
dti-3019	841	14	of	of	ADP
dti-3019	841	15	distinct	distinct	ADJ
dti-3019	841	16	characteristics	characteristic	NOUN
dti-3019	841	17	influencing	influence	VERB
dti-3019	841	18	the	the	DET
dti-3019	841	19	performance	performance	NOUN
dti-3019	841	20	of	of	ADP
dti-3019	841	21	vector	vector	NOUN
dti-3019	841	22	-	-	PUNCT
dti-3019	841	23	borne	bear	VERB
dti-3019	841	24	epidemiological	epidemiological	ADJ
dti-3019	841	25	agent	agent	NOUN
dti-3019	841	26	-	-	PUNCT
dti-3019	841	27	based	base	VERB
dti-3019	841	28	simulation	simulation	NOUN
dti-3019	841	29	models	model	NOUN
dti-3019	841	30	.	.	PUNCT
dti-3019	842	1	modelling	modelling	NOUN
dti-3019	842	2	.	.	PUNCT
dti-3019	843	1	2021;2(2):166	2021;2(2):166	X
dti-3019	843	2	-	-	SYM
dti-3019	843	3	196	196	NUM
dti-3019	843	4	.	.	PUNCT
dti-3019	844	1	crossref	crossref	PROPN
dti-3019	844	2	138	138	NUM
dti-3019	844	3	.	.	PUNCT
dti-3019	845	1	raja	raja	PROPN
dti-3019	845	2	d.	d.	PROPN
dti-3019	845	3	the	the	DET
dti-3019	845	4	power	power	NOUN
dti-3019	845	5	of	of	ADP
dti-3019	845	6	epidemiological	epidemiological	ADJ
dti-3019	845	7	modelling	modelling	NOUN
dti-3019	845	8	in	in	ADP
dti-3019	845	9	understanding	understanding	NOUN
dti-3019	845	10	and	and	CCONJ
dti-3019	845	11	managing	manage	VERB
dti-3019	845	12	infectious	infectious	ADJ
dti-3019	845	13	diseases	disease	NOUN
dti-3019	845	14	.	.	PUNCT
dti-3019	846	1	chettinad	chettinad	PROPN
dti-3019	846	2	health	health	PROPN
dti-3019	846	3	city	city	PROPN
dti-3019	846	4	med	med	PROPN
dti-3019	846	5	j	j	PROPN
dti-3019	846	6	(	(	PUNCT
dti-3019	846	7	e-2278	e-2278	PROPN
dti-3019	846	8	-	-	PUNCT
dti-3019	846	9	2044	2044	NUM
dti-3019	846	10	&	&	CCONJ
dti-3019	846	11	p-2277	p-2277	PROPN
dti-3019	846	12	-	-	PUNCT
dti-3019	846	13	8845	8845	NUM
dti-3019	846	14	)	)	PUNCT
dti-3019	846	15	,	,	PUNCT
dti-3019	846	16	2023;12(1):1	2023;12(1):1	NUM
dti-3019	846	17	-	-	SYM
dti-3019	846	18	2	2	NUM
dti-3019	846	19	.	.	NOUN
dti-3019	846	20	139	139	NUM
dti-3019	846	21	.	.	PUNCT
dti-3019	847	1	rong	rong	PROPN
dti-3019	847	2	n	n	CCONJ
dti-3019	847	3	,	,	PUNCT
dti-3019	847	4	liu	liu	PROPN
dti-3019	847	5	j.	j.	PROPN
dti-3019	847	6	development	development	PROPN
dti-3019	847	7	of	of	ADP
dti-3019	847	8	animal	animal	NOUN
dti-3019	847	9	models	model	NOUN
dti-3019	847	10	for	for	ADP
dti-3019	847	11	emerging	emerge	VERB
dti-3019	847	12	infectious	infectious	ADJ
dti-3019	847	13	diseases	disease	NOUN
dti-3019	847	14	by	by	ADP
dti-3019	847	15	breaking	break	VERB
dti-3019	847	16	the	the	DET
dti-3019	847	17	barrier	barrier	NOUN
dti-3019	847	18	of	of	ADP
dti-3019	847	19	species	specie	NOUN
dti-3019	847	20	susceptibility	susceptibility	NOUN
dti-3019	847	21	to	to	ADP
dti-3019	847	22	human	human	ADJ
dti-3019	847	23	pathogens	pathogen	NOUN
dti-3019	847	24	.	.	PUNCT
dti-3019	848	1	emerg	emerg	PROPN
dti-3019	848	2	microbes	microbe	NOUN
dti-3019	848	3	infections	infection	NOUN
dti-3019	848	4	.	.	PUNCT
dti-3019	849	1	2023;12(1):2178242	2023;12(1):2178242	NOUN
dti-3019	849	2	.	.	PUNCT
dti-3019	850	1	140	140	NUM
dti-3019	850	2	.	.	PUNCT
dti-3019	851	1	fitzpatrick	fitzpatrick	PROPN
dti-3019	851	2	mc	mc	PROPN
dti-3019	851	3	,	,	PUNCT
dti-3019	851	4	bauch	bauch	PROPN
dti-3019	851	5	ct	ct	PROPN
dti-3019	851	6	,	,	PUNCT
dti-3019	851	7	townsend	townsend	PROPN
dti-3019	851	8	jp	jp	PROPN
dti-3019	851	9	,	,	PUNCT
dti-3019	851	10	galvani	galvani	PROPN
dti-3019	851	11	ap	ap	PROPN
dti-3019	851	12	.	.	PUNCT
dti-3019	852	1	modelling	model	VERB
dti-3019	852	2	microbial	microbial	ADJ
dti-3019	852	3	infection	infection	NOUN
dti-3019	852	4	to	to	PART
dti-3019	852	5	address	address	VERB
dti-3019	852	6	global	global	ADJ
dti-3019	852	7	health	health	NOUN
dti-3019	852	8	challenges	challenge	NOUN
dti-3019	852	9	.	.	PUNCT
dti-3019	853	1	nat	nat	PROPN
dti-3019	853	2	microbiol	microbiol	PROPN
dti-3019	853	3	.	.	PUNCT
dti-3019	854	1	2019;4(10):1612	2019;4(10):1612	NUM
dti-3019	854	2	-	-	PUNCT
dti-3019	854	3	1619	1619	NUM
dti-3019	854	4	.	.	PUNCT
dti-3019	855	1	crossref	crossref	PROPN
dti-3019	855	2	pubmed	pubmed	PROPN
dti-3019	855	3	141	141	NUM
dti-3019	855	4	.	.	PUNCT
dti-3019	856	1	cartelle	cartelle	VERB
dti-3019	856	2	gestal	gestal	PROPN
dti-3019	856	3	m	m	PROPN
dti-3019	856	4	,	,	PUNCT
dti-3019	856	5	dedloff	dedloff	PROPN
dti-3019	856	6	mr	mr	PROPN
dti-3019	856	7	,	,	PUNCT
dti-3019	856	8	torres	torres	PROPN
dti-3019	856	9	-	-	PUNCT
dti-3019	856	10	sangiao	sangiao	PROPN
dti-3019	856	11	e.	e.	PROPN
dti-3019	856	12	computational	computational	PROPN
dti-3019	856	13	health	health	PROPN
dti-3019	856	14	engineering	engineering	NOUN
dti-3019	856	15	applied	apply	VERB
dti-3019	856	16	to	to	AUX
dti-3019	856	17	model	model	VERB
dti-3019	856	18	infectious	infectious	ADJ
dti-3019	856	19	diseases	disease	NOUN
dti-3019	856	20	and	and	CCONJ
dti-3019	856	21	antimicrobial	antimicrobial	ADJ
dti-3019	856	22	resistance	resistance	NOUN
dti-3019	856	23	spread	spread	NOUN
dti-3019	856	24	.	.	PUNCT
dti-3019	857	1	appl	appl	PROPN
dti-3019	857	2	sci	sci	PROPN
dti-3019	857	3	(	(	PUNCT
dti-3019	857	4	basel	basel	PROPN
dti-3019	857	5	)	)	PUNCT
dti-3019	857	6	.	.	PUNCT
dti-3019	858	1	2019;9(12):2486	2019;9(12):2486	NUM
dti-3019	858	2	.	.	PUNCT
dti-3019	859	1	crossref	crossref	PROPN
dti-3019	859	2	142	142	NUM
dti-3019	859	3	.	.	PUNCT
dti-3019	860	1	legrand	legrand	PROPN
dti-3019	860	2	n	n	CCONJ
dti-3019	860	3	,	,	PUNCT
dti-3019	860	4	ploss	ploss	NOUN
dti-3019	860	5	a	a	X
dti-3019	860	6	,	,	PUNCT
dti-3019	860	7	balling	ball	VERB
dti-3019	860	8	r	r	NOUN
dti-3019	860	9	,	,	PUNCT
dti-3019	860	10	et	et	PROPN
dti-3019	860	11	al	al	PROPN
dti-3019	860	12	.	.	PROPN
dti-3019	861	1	humanized	humanize	VERB
dti-3019	861	2	mice	mouse	NOUN
dti-3019	861	3	for	for	ADP
dti-3019	861	4	modeling	model	VERB
dti-3019	861	5	human	human	ADJ
dti-3019	861	6	infectious	infectious	ADJ
dti-3019	861	7	disease	disease	NOUN
dti-3019	861	8	:	:	PUNCT
dti-3019	861	9	challenges	challenge	NOUN
dti-3019	861	10	,	,	PUNCT
dti-3019	861	11	progress	progress	NOUN
dti-3019	861	12	,	,	PUNCT
dti-3019	861	13	and	and	CCONJ
dti-3019	861	14	outlook	outlook	NOUN
dti-3019	861	15	.	.	PUNCT
dti-3019	862	1	cell	cell	NOUN
dti-3019	862	2	host	host	NOUN
dti-3019	862	3	microbe	microbe	PROPN
dti-3019	862	4	2009;6(1):5	2009;6(1):5	PROPN
dti-3019	862	5	-	-	SYM
dti-3019	862	6	9	9	NUM
dti-3019	862	7	.	.	NOUN
dti-3019	862	8	143	143	NUM
dti-3019	862	9	.	.	PUNCT
dti-3019	863	1	swearengen	swearengen	PROPN
dti-3019	863	2	jr	jr	PROPN
dti-3019	863	3	.	.	PROPN
dti-3019	864	1	choosing	choose	VERB
dti-3019	864	2	the	the	DET
dti-3019	864	3	right	right	ADJ
dti-3019	864	4	animal	animal	NOUN
dti-3019	864	5	model	model	NOUN
dti-3019	864	6	for	for	ADP
dti-3019	864	7	infectious	infectious	ADJ
dti-3019	864	8	disease	disease	NOUN
dti-3019	864	9	research	research	NOUN
dti-3019	864	10	.	.	PUNCT
dti-3019	865	1	animal	animal	NOUN
dti-3019	865	2	model	model	NOUN
dti-3019	865	3	exp	exp	NOUN
dti-3019	865	4	med	med	PROPN
dti-3019	865	5	.	.	PUNCT
dti-3019	866	1	2018;1(2):100	2018;1(2):100	NUM
dti-3019	866	2	-	-	SYM
dti-3019	866	3	108	108	NUM
dti-3019	866	4	.	.	PUNCT
dti-3019	867	1	crossref	crossref	PROPN
dti-3019	867	2	pubmed	pubmed	PROPN
dti-3019	867	3	https://doi.org/10.1001/jamaneurol.2019.3762	https://doi.org/10.1001/jamaneurol.2019.3762	PROPN
dti-3019	867	4	https://www.ncbi.nlm.nih.gov/pubmed/31738372	https://www.ncbi.nlm.nih.gov/pubmed/31738372	NUM
dti-3019	867	5	https://doi.org/10.1016/j.ijid.2016.08.002	https://doi.org/10.1016/j.ijid.2016.08.002	PROPN
dti-3019	867	6	https://www.ncbi.nlm.nih.gov/pubmed/27522002	https://www.ncbi.nlm.nih.gov/pubmed/27522002	X
dti-3019	867	7	https://doi.org/10.1016/j.ijantimicag.2020.106097	https://doi.org/10.1016/j.ijantimicag.2020.106097	PROPN
dti-3019	867	8	https://www.ncbi.nlm.nih.gov/pubmed/32697966	https://www.ncbi.nlm.nih.gov/pubmed/32697966	NUM
dti-3019	867	9	https://doi.org/10.3390/antibiotics10091123	https://doi.org/10.3390/antibiotics10091123	NOUN
dti-3019	867	10	https://www.ncbi.nlm.nih.gov/pubmed/34572705	https://www.ncbi.nlm.nih.gov/pubmed/34572705	NUM
dti-3019	867	11	https://doi.org/10.1186/s12941-021-00444-9	https://doi.org/10.1186/s12941-021-00444-9	NUM
dti-3019	867	12	https://www.ncbi.nlm.nih.gov/pubmed/34020659	https://www.ncbi.nlm.nih.gov/pubmed/34020659	NUM
dti-3019	867	13	https://doi.org/10.3389/fcimb.2022.1063407	https://doi.org/10.3389/fcimb.2022.1063407	PROPN
dti-3019	867	14	https://www.ncbi.nlm.nih.gov/pubmed/36530422	https://www.ncbi.nlm.nih.gov/pubmed/36530422	ADP
dti-3019	867	15	https://doi.org/10.1111/bph.15292	https://doi.org/10.1111/bph.15292	NOUN
dti-3019	867	16	https://www.ncbi.nlm.nih.gov/pubmed/33085774	https://www.ncbi.nlm.nih.gov/pubmed/33085774	PRON
dti-3019	867	17	https://doi.org/10.1021/acsomega.1c01526	https://doi.org/10.1021/acsomega.1c01526	VERB
dti-3019	867	18	https://www.ncbi.nlm.nih.gov/pubmed/34095679	https://www.ncbi.nlm.nih.gov/pubmed/34095679	NUM
dti-3019	867	19	https://doi.org/10.1200/jco.2005.06.005	https://doi.org/10.1200/jco.2005.06.005	NUM
dti-3019	867	20	https://www.ncbi.nlm.nih.gov/pubmed/15908653	https://www.ncbi.nlm.nih.gov/pubmed/15908653	X
dti-3019	867	21	https://doi.org/10.1038/s41579-018-0141-x	https://doi.org/10.1038/s41579-018-0141-x	PROPN
dti-3019	867	22	https://www.ncbi.nlm.nih.gov/pubmed/30683887	https://www.ncbi.nlm.nih.gov/pubmed/30683887	PROPN
dti-3019	867	23	https://doi.org/10.1186/s40249-018-0444-1	https://doi.org/10.1186/s40249-018-0444-1	NUM
dti-3019	867	24	https://www.ncbi.nlm.nih.gov/pubmed/29950174	https://www.ncbi.nlm.nih.gov/pubmed/29950174	NUM
dti-3019	867	25	https://doi.org/10.1371/journal.ppat.1001005	https://doi.org/10.1371/journal.ppat.1001005	NOUN
dti-3019	867	26	https://www.ncbi.nlm.nih.gov/pubmed/20661479	https://www.ncbi.nlm.nih.gov/pubmed/20661479	NUM
dti-3019	867	27	https://www.ncbi.nlm.nih.gov/pubmed/25859123	https://www.ncbi.nlm.nih.gov/pubmed/25859123	PROPN
dti-3019	867	28	https://doi.org/10.1016/j.tube.2003.08.003	https://doi.org/10.1016/j.tube.2003.08.003	PROPN
dti-3019	867	29	https://www.ncbi.nlm.nih.gov/pubmed/14670344	https://www.ncbi.nlm.nih.gov/pubmed/14670344	ADP
dti-3019	867	30	https://doi.org/10.1038/s41579-019-0238-x	https://doi.org/10.1038/s41579-019-0238-x	PROPN
dti-3019	867	31	https://www.ncbi.nlm.nih.gov/pubmed/31444481	https://www.ncbi.nlm.nih.gov/pubmed/31444481	NUM
dti-3019	867	32	https://doi.org/10.3201/eid0702.010226	https://doi.org/10.3201/eid0702.010226	PRON
dti-3019	867	33	https://www.ncbi.nlm.nih.gov/pubmed/11294723	https://www.ncbi.nlm.nih.gov/pubmed/11294723	NUM
dti-3019	867	34	https://doi.org/10.1038/nbt.2786	https://doi.org/10.1038/nbt.2786	NOUN
dti-3019	867	35	https://www.ncbi.nlm.nih.gov/pubmed/24406927	https://www.ncbi.nlm.nih.gov/pubmed/24406927	PROPN
dti-3019	867	36	https://doi.org/10.1038/nm0307-290	https://doi.org/10.1038/nm0307-290	PROPN
dti-3019	867	37	https://www.ncbi.nlm.nih.gov/pubmed/17342142	https://www.ncbi.nlm.nih.gov/pubmed/17342142	PROPN
dti-3019	867	38	https://doi.org/10.1128/aac.00519-09	https://doi.org/10.1128/aac.00519-09	PROPN
dti-3019	867	39	https://www.ncbi.nlm.nih.gov/pubmed/19596869	https://www.ncbi.nlm.nih.gov/pubmed/19596869	PROPN
dti-3019	867	40	https://www.ncbi.nlm.nih.gov/pubmed/34663936	https://www.ncbi.nlm.nih.gov/pubmed/34663936	NUM
dti-3019	867	41	https://doi.org/10.1146/annurev-med-042320-023055	https://doi.org/10.1146/annurev-med-042320-023055	NOUN
dti-3019	867	42	https://www.ncbi.nlm.nih.gov/pubmed/34644153	https://www.ncbi.nlm.nih.gov/pubmed/34644153	PUNCT
dti-3019	867	43	https://doi.org/10.20506/rst.42.3360	https://doi.org/10.20506/rst.42.3360	PROPN
dti-3019	867	44	https://www.ncbi.nlm.nih.gov/pubmed/37232307	https://www.ncbi.nlm.nih.gov/pubmed/37232307	X
dti-3019	867	45	https://doi.org/10.3390/modelling2020009	https://doi.org/10.3390/modelling2020009	PROPN
dti-3019	867	46	https://doi.org/10.1038/s41564-019-0565-8	https://doi.org/10.1038/s41564-019-0565-8	NUM
dti-3019	867	47	https://www.ncbi.nlm.nih.gov/pubmed/31541212	https://www.ncbi.nlm.nih.gov/pubmed/31541212	X
dti-3019	867	48	https://doi.org/10.3390/app9122486	https://doi.org/10.3390/app9122486	PROPN
dti-3019	867	49	https://doi.org/10.1002/ame2.12020	https://doi.org/10.1002/ame2.12020	X
dti-3019	867	50	https://www.ncbi.nlm.nih.gov/pubmed/30891554	https://www.ncbi.nlm.nih.gov/pubmed/30891554	PRON